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Abstract
This work is primarily concerned with the expression, purification, and 
characterisation of aspartic proteases from three retroviruses of the lentivirus 
subgroup, specifically the Human Immunodeficiency Viruses types 1 and 2, and the 
Simian Immunodeficiency Virus isolated from the African Green Monkey (HIV-1 PR, 
HIV-2 PR, S I V agm PR respectively). These viruses cause immunodeficiency 
syndromes within their respective hosts, and understanding their molecular biology 
would facilitate development of Acquired Immunodeficiency Syndrome (AIDS) 
treatments in man. The proteases are essential to viral maturation and infection; and 
are of great interest with respect to the development of new antivirals.
This thesis describes attempts to develop improved methods for the over-expression 
and purification of these cytotoxic proteins for use in structural and biochemical 
studies. The development of a system for expression and purification of active, 
crystallisable HIV-1 PR is described, followed by a preliminary analysis o f two 
compounds intended to act as irreversible “suicide inhibitors” of HIV-1 PR. The 
expression, purification, crystallisation, and preliminary crystallographic data for the 
native HIV-2 PR using the same expression system are also reported.
Mutagenesis of the HIV-2 protease is described, whereby the conserved active site 
aspartic acids of the native homodimer were changed to histidine and cysteine, with 
the intention of modifying the enzyme’s mechanism, whilst maintaining its native 
substrate specificity and overall structure.
Finally the production of an insoluble, non-toxic, histidine tagged fusion of mutant
E.coli Uracil DNA Glycosylase (UDG) and the S I V agm PR is reported. This was 
intended to produce high levels o f a non-toxic fusion protein, allow one-step affinity 
purification, and provide native soluble protease following autocatalytic cleavage 
from the fusion protein. The effects o f protease toxicity and codon usage on yields are 
discussed in light o f the results presented.
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Abbreviations
The table below defines the abbreviations used in this text. Note that abbreviations for 
chemical elements were as designated by international convention, whilst SI (System 
International) symbols were used for abbreviation of physical units. The conventional 
single and three letter codes for amino acids have both been used. Many commonly 
used scientific abbreviations (such as DNA, RNA) are not listed here since it was 
assumed that these would not require explaination. In any case each abbreviation is 
follwed by an explaination at point of first use within the text. Note that genes are 
typed in lower case, whilst proteins are typed in upper case (eg. tat and TAT).
Table of abbreviations.
AI Angiotensin I CypA Cyclophilin A
AII Angiotensin II DAN DiazoAcetyl Norleucine methyl ester
AGM African Green Monkey ddw Double Distilled Water
AIDS Acquired Immuno Deficiency DIQ Decahydro-IsoQuinoline
Syndrome DMS DiMethylSilane
Amp Ampicillin DM SO DiMethylSulphOxide
APS Ammonium PerSuIphate dNTPs deoxy-N ucleotide-T ri Phosphates
ARC AIDS Related Complex DTNB 5,5'-dithio-bis(2-nitrobenzoic acid)
ARV-2
ATP
AIDS-associated retrovirus-2 
Adenosine TriPhosphate
DTT
(Ellman’s reagent) 
DiThioThreitol
AUC Analytical Ultra Centrifugation
EDTA EthyleneDiamineTetra Acetate
AZT Azidothymidine
EF-TU-GTP complex
Elongation Factor -  Temoerture
B-TrCP [betaj-transducin repeat-containing 
protein
Unstable: Guanosine 5'-Triphosphate 
complex
Bg Background EIAV Equinelnfectious Aneamia Virus
CA Capsid protein EMBL European Molecular Biology Laboratory
CCP4 Suite o f Crystallographic programs EPNP 1,2-Epoxy-3-(p-nitrophenoxy) propane
CD Circular Dichroism ER Endoplasmic Reticulum
CD4+ Receptor found on surface o f  T cells FDA Federal Drugs Administration
CDC Centres for Disease Control FPLC Fast Protein Liquid Chromatography ™
Chlor Chloramphenicol
Bg (s) figure (s)
Chpt Chapter Frag Fragment
CIP C alf Intestinal Phosphatase GCG Genetics Computer Group
CIAP C alf Intestinal Alkaline Phosphatase (Bioinformatics software package)
CPM Counts Per Minute gP glycol protein (eg. gp41 or gp l20)
CTL Cytotoxic T-Lymphocyte GST Glutathione S-Transferase
CTD C-Terminal Domain HIC Hydrophobic Interaction Chromatograph
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H is-tag Histidine tag NRTI Nucleoside / Nucleotide Reverse
HIV Human Immuno Deficiency Virus Transcriptase Inhibitor
HLA Human Leukocyte Antigen OD 280 Optical Density at A,=280 nm
HTLV-III Human T-cell Lymphotropic Virus III O D 600 Optical Density at X= 600 nm
IEC Ion Exchange Chromatography ORF Open Reading Frame
ILL Insitut Laue-Langevin PAGE Poly-Acrylamide Gel Electrophoresis
IMAC Immobilised Metal Afinity PBMC Peripheral Blood Mononuclear Cells
Chromatography PBS Phosphate Buffered Saline
IN Integrase PCR Polymerase Chain Reaction
IPTG Isopropyl P-d-thiogalactoside PDB Protein Data Base
IR Infra Red (spectroscopy) PEG Poly Ethylene Glycol
IUBM B International Union o f  Biochemistry and Pfu Pyrococcus furiosus
Kcat
Km 
lac I
Molecular Biology  
Rate constant
Michaelis-Menton constant 
Gene encoding the lac repressor
PHA
PMA
PMSF
PR
Phytohemaglutanin 
Phorbol-12-myristate-13-acetate 
Phenyl methyl sulfonyl fluoride 
Protease
lac Iq lac I “quantity” mutant
QSB Quick Screen Buffer
LAV Lymphadenopathy-Associated Virus
RCF Relative Centrifugal Force
LB
LBHB
LTR
Luria Broth
Low-Barrier Hydrogen Bond 
Long Terminal Repeat
REV
RIL
Regulator o f Expression o f Viral proteins
E.coli strain encoding tRNA for rare 
codons o f Arg, Iso and Leu.
MA Matrix protein RPM Revolutions Per Minute
M BP Maltose Binding Protein RT Reverse Transcriptase
MES 2-Morpholino-Ethane Sulfonic acid SDS Sodium Dodecyl Sulphate
2M E 2-MercaptoEthanol SEC Size Exclusion Chromatography
MHCI Major Histocompatibility Complex I SI Suicide Inhibitor
M HR Major Homology Region SIV Simian Immunodeficiency Virus
M IP Mono Isopropyl-Phosphate SOB Buffered E.coli growth medium
MK MegaKaryocytes SP1 Specificity protein 1 (a zinc finger
MS Mass Spectroscopy
transcription factor).
M W CO Molecular Weight Cut-Off 
M wt Molecular Weight 
NC NucleoCapsid 
NEB New  England Biolabs 
NEF Negative Factor 
NF-kB Nuclear Factor-kB 
Ni-NTA Nickel Nitrilotriacetic acid 
NM R Nuclear Magnetic Resonance 
(spectroscopy)
NNRTI Non-NRTI
SPA Scintillation Proximity Assay
SRS Synchrotron Radiation Source
SSHB Short Strong Hydrogen Bond
Sta Statine
SU Surface envelope protein
T4 Lymphocytes aka T-helper or CD4+ cells
T7 Promoter from Bacteriophage T7
TAR Trans-Activating Response element
TAT Tran sacti vator prote in
Taq Thermus aquaticus
TB Transformation Buffer
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TBE Tris Borate EDTA
T B P TATA-box binding protein
TE Tris EDTA
TEM ED  NNN'N'Tetramethyl-1,2-ethanediamine 
TM  Transmembrane protein
T m Melting temperature
Trc Hybrid o f  Trp and Lac promoters
Tris Tris Hydroxymethylaminoethane
Trp Promoter from E.coli Tryptophan operon
TW EEN (Tween 20) Registered Trademark 
U Uracil
UDG Uracil DNA Glycosylase
UF Ultra Filtration
UN AIDS United Nations AIDS program
UV Ultra Violet
Vent trademark o f thermophilic DNA 
polymerase
vis visible
VPR Viral Protein R
VPU Viral Protein U
VPX Viral Protein X
VIF Viral Infectivity Factor
Vmax Maximum velocity
W HO World Health Organisation
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Chapter One: General Introduction.
The Human Immunodeficiency Virus (HIV) (Gallo, Wong-Staal et al. 1988) is the 
etiological agent of the Acquired Immunodeficiency Syndrome (AIDS) (Weiss, 
Hollander et al. 1985; Gallo and Montagnier 1988), a disease that has evolved into a 
world-wide public health problem (Barre-sinoussi, Chermann et al. 1983; Gallo, 
Salahuddin et al. 1984; Pinching and Weiss 1986). The need to develop effective 
therapeutic agents against the virus is well recognised and a brief summary of the 
retroviral life cycle is provided in this chapter to allow an appreciation of the potential 
targets. As this project began all licenced drugs for the treatment of AIDS were based 
on nucleoside analogues, targeting the enzyme Reverse Transcriptase (RT) (Mitsuya, 
Yarchoan et al. 1990). The drug of choice was Zidovudine (AZT), first approved by 
the US Food and Drug Administration (FDA) for treatment of AIDS in 1987. There 
are now thirteen NRTI (Nuceloside / Nucleotide Reverse Transcriptase Inhibitor) 
formulations, and three NNRTI (Non-NRTI) compounds approved by the FDA 
(Federal Drugs Administration) and commercially available. However, toxicities 
associated with AZT (Richman, Fischl et al. 1987) and the demonstration of AZT 
resistant strains of virus (Larder, Darby et al. 1989; Larder and Kemp 1989; Boucher, 
O'Sullivan et al. 1992) - problems also encountered with later anti-RT drugs - led 
researchers to focus on other potential antiviral targets. The most promising of these 
alternatives appeared to be the viral aspartic protease (PR) (Wlodawer, Miller et al. 
1989) encoded by the pol open reading frame (Fauci 1988) of HIV, which is essential 
for the proteolytic processing of both the gag and the gag-pol polyprotein precursors 
during replication (Kramer, Schaber et al. 1986; Debouck, Gorniak et al. 1987; 
Graves, Lim et al. 1988; Le Grice, Mills et al. 1988; Mous, Heimer et al. 1988; 
Seelmeier, Schmidt et al. 1988). Inactivation of this protease, by biochemical or 
genetic means, results in the production of immature, non-infectious virions (Kohl, 
Emini et al. 1988; Peng, Ho et al. 1989). This project aimed to contribute towards an 
increased understanding of the structures, mechanisms and inhibition of the retroviral 
proteases derived from HIV-1, HIV-2 and S I V agm- There are now five PR inhibitors 
commercially available, all developed by means of rational drug design strategies 
(reviewed in Ren and Lien 1998; Ren and Lien 2001). Such strategies were only 
possible once high resolution three dimensional structural solutions had been obtained 
for these proteases and their inhibitor complexes. A major aim of this project was to
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obtain such data for the HIV-2 PR apoenzyme, a task that proved intractable. 
Structural studies demand high levels of the target protein but the retroviral proteases 
are notoriously difficult to express from recombinant protein expression systems. 
Early structural successes relied variously on synthetic protein (Schneider, J. and S.
B. Kent 1988; Wlodawer, Miller et al. 1989) or expression on a very large scale 
(approximately 3000 litre fermentations) (Danley, Geoghegan, et al. 1989; Lapatto, 
Blundell et al. 1989; Darke, Leu, et al. 1989; McKeever, Navia et al. 1989). This 
project intended to address the problem by development of strategies for SIVAgm PR 
overexpression in bacteria. It resulted in the construction of a new bacterial 
expression system able to produce the retroviral protease as a non-toxic and inactive 
fusion protein, which can be converted to a soluble and fully functional protease once 
extracted from the bacterial cell. Development of this system has shed further light on 
the probable causes o f low protease expression in bacteria and other expression 
systems.
A collaboration with an organic chemist produced compounds, which successfully 
inhibited HIV-1 PR. These compounds had been designed using a three dimensional 
computer model of the protease based on available structural data, and were intended 
either to disrupt dimerisation or to permanently block the protease active site. Their 
efficacy and mode of action was investigated using HIV-1 PR expressed in bacteria 
and purified to homogeneity for this purpose.
Mutants of HIV-2 PR were successfully made which allowed the creation of a 
heterodimeric PR having an active site intended to simulate that of a cysteine protease 
(Papain).
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Aims o f this study.
• To establish in house methods of large scale expression and purification for each 
of the proteases, or optimise them if already in existence (HIV-1), such that 
sufficient protein could be obtained to allow pursuit of the further aims.
• To attempt crystallographic studies of HIV-2 protease with a view to solving its 
structure, thus facilitating the rational design of protease inhibitors.
• To attempt the mutagenesis of the HIV-2 protease active site such that its 
mechanism of action might be altered (from that of an aspartate protease to that of 
papain), perhaps furthering our understanding of proteolytic mechanisms in 
general.
• To attempt crystallographic studies of S I V agm, protease with a view to solving its 
structure.
• To determine the efficacy of novel protease inhibitors designed to bind covalently 
to the active site of HIV-1 protease.
As will be seen, an overexpression and purification system for both HIV-1 PR 
(chapter 3) and HIV-2 PR (Chapter 4) was established. Sufficient HIV-1 PR was 
available to allow a preliminary study of two rationally designed protease inhibitors 
(Chapter 3). The HIV-2 PR apoenzyme was crystallised and some data collected 
(Chapter 4). However, no structural solution was possible from the available data and 
the collection of an entire data set was prevented by the rapid degradation of crystals 
on their exposure to X-rays.
Mutagenesis of the HIV-2 PR active site was carried out (Chapter 5) both to study the 
effect loss of activity might have on protease expression, and to create a heterodimeric 
mutant protease which was predicted to show proteolytic activity by virtue of a 
pseudo-papain active site.
Following the publication of an HIV-2 PR structure (Tong, Pav et al. 1993; Chen, Li 
et al. 1994), attention was turned to S I V agm- An examination of conventional 
methods for S I V agm protease expression and purification was made (Chapter 6), 
which resulted in the development of a novel expression system for this protease
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(Chapter 7 ). The purified S I V agm was characterised and efforts to crystallise it were 
made. Structures of SIV protease were subsequently published by other groups 
(Wilderspin and Sugrue 1994; Rose, Craik et al 1996) though not from the African 
Green Monkey serotype.
As a consequence of work on both the H IV -2  P R  mutants and S I V agm expression 
system a revised view of the factors effecting bacterial expression of retroviral 
proteases was proposed and investigated, and suggestions made for future work 
(Chapter 8).
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AIDS is a global health problem .
AIDS (Acquired Immune Deficiency Syndrome) was first discovered as a new 
disease in the USA, by the Centres for Disease Control (CDC) in 1981 (Sellers 1982). 
In 1983/84 French (Barre-sinoussi, Chermann et al. 1983) and American (Gallo, 
Salahuddin et al. 1984; Wong-Staal, Hahn et al. 1984) investigators (lead by 
Montagnier and Gallo respectively) identified the retrovirus now known as HIV 
(Human Immunodeficiency Virus) and confirmed it as the etiological agent of AIDS 
(Goedert and Gallo 1985). HIV was initially referred to by one of a number of names 
including Lymphadenopathy-Associated Virus (LAV), Human T-cell Lymphotropic 
Virus III (HTLV-III), and AIDS-associated Retrovirus-2 (ARV-2) until a consensus 
was reached (Biberfeld, Brown et al. 1987; Gallo, Wong-Staal et al. 1988). The virus 
was first successfully cultured in 1987 (Article: Nature, News 1987), there were two 
serotypes and each was shown to induce AIDS (Essex and Kanki 1988) (Marlink, 
R icardo al. 1988).
In this chapter I will outline the lifecycle, structure and genomic organisation of HIV. 
In doing so aspects of its molecular biology will be introduced, their roles in viral 
infectivity discussed, and the possibility of targeting AIDS therapies against them 
considered. My intentions are first to provide a general overview of HIV research, and 
second to give an insight into the area of protease research in particular. It is not my 
intention to deal with AIDS per se, its distribution, or any related diseases - other than 
as an initial justification for the study of HIV, and in order to illustrate the ways in 
which HIV affects its host. In addition the importance of CD4+ T-lymphocytes (T4 
cells, or T-helper cells) to the normal functioning of the immune system will be 
assumed to be prior knowledge, and is amply covered in the text of Riott’s Essential 
Immunology (Roitt and Delves 2001). It is also worth noting that for the purposes of 
this chapter no distinction will be made between HIV-1 and HIV-2, and the term 
‘HIV’ will be used to include both serotypes, unless one serotype is specifically 
stipulated.
On its recognition in 1981, AIDS was seen to be typified by outbreaks of Kaposi’s 
Sarcoma, and Pneumocystis carinii in previously healthy homosexual men. By mid- 
1988 100 000 cases of AIDS had been reported to the World Health Organisation 
(WHO) from 136 countries, and it was estimated that 500 000 to 1 million people 
were infected by HIV. Dr. J. Mann, head of the WHO special program on AIDS at
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that time, considered that the HIV infected population worldwide might actually 
number 5 to 10 million, while the director of the CDC Dr. James Curran, claimed that 
one new case o f AIDS was being diagnosed every 14 minutes. Since that time the 
global epidemic has continued to grow, and in the years between 1997 and 2003 the 
number of new infections has been estimated at approximately 5 million per year 
worldwide. At the end of 2004 it is expected that approximately 28 million AIDS 
deaths will have been reported worldwide since the outbreak of the epeidemic1.
Initially the majority of reported infections occurred in the USA, yet AIDS is global. 
Thousands of cases have been reported in Europe, but the greatest incidence is now in 
Africa (particularly sub-Saharan Africa) where only a fraction of cases are reported to 
the WHO. Figures for 2003 from the WHO and UNAIDS suggest that there are 
between 34 and 46 million people currently living with the infection (although some 
estimates are as high as 60 million), of whom 60-70% (25-28 million) are in sub- 
Saharan Africa, and about 10-20% (4-8 million) are in southern Asia. Throughout the 
world, more epicentres are emerging where there had previously been very few cases 
of HIV, such as in China, Russia or the Ukraine. With the cost of treatment currently 
estimated at around $10 000 (£6250) per patient per annum the majority of infections 
in Asia and Africa go untreated. This combined with poor education and a lack of 
appropriate preventative measures has ensured that levels of infection continue to rise. 
A total of 14 million children are estimated to have been orphaned through AIDS, and 
in 16 countries south of the Sahara, 10% or more of 15 to 49 year olds have become 
infected with HIV. The highest incidence is in Botswana, where one adult in three 
carries the virus, and two-thirds of all boys now aged 15 will die prematurely of 
AIDS. In South Africa, where a fifth, and in Zimbabwe, where a quarter of all adults 
have become infected, AIDS will kill half of all 15-year olds.
The effect in areas worst hit has been social and economic catastrophe. In Zambia, 
1300 teachers died in the first ten months of 1998, equivalent to two-thirds of all the
1 Figures herein are based on the most recent available data from UNAIDS (UNAIDS 
AIDS Epidemic Update 2003). UNAIDS/WHO publish updated country estimates 
biannually. The next update will be released in advance of the International AIDS 
Conference, to be held this year in Bangkok (11-16 July 2004). Until then, the country 
estimates available are from end 2001 (published in the “Report on the Global 
HIV/AIDS Epidemic 2002”). The most recent regional and global estimates were 
published in the “AIDS Epidemic Update, December 2003”.
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country’s newly qualified teachers. In Zimbabwe AIDS infections and related deaths 
have resulted in a 61% reduction in rural maize production. Across the South African 
mining industry an average of 25% of mine workers are infected. Recently Zambia’s 
largest cement company reported a 15-fold increase in the number of workers taking 
leave in order to attend funerals. These and other anecdotes are reminiscent of a 
plague-infested Europe in the middle ages. In the absence of preventative measures or 
affordable treament the situation will presumably worsen, and have a knock on effect 
on the societies worst hit as labour shortages plus a break down in social and 
governmental administration take their toll.
HIV infection is spread by sexual contact, by infected blood or blood products, and 
perinatally by mother to child. It can damage organs directly, but its crippling effect 
on the immune system also allows the development of opportunistic infections - 
which account for up to 90% of deaths from AIDS (AIDS being the final stage of 
HIV infection -  see fig. 1, ‘Progression through stages of HIV infection’). HIV 
impairs immune function through its elimination of T-lymphocytes and macrophages 
(representing the cell-mediated arm of the immune system). Cytotoxic T lymphocytes 
(CTLs) provide a highly effective anti-viral defense mechanism, and can detect virus- 
infected cells (by recognition of viral peptides presented at the cell surface within the 
HLA class I binding cleft) and kill them. These cells are effective against HIV 
infection in the short to medium term (Ogg, Jin et al 1998; Schmitz, Kuroda et al. 
1999), but ultimately cannot control infection. These cells are known to carry the 
CD4+ receptor (discussed later, see ‘Fusion and entry’) and as illustrated in figure 1, 
declining CD4+ cell numbers can be correlated with progression of the syndrome 
(although some immune dysfunction may be present before CD4+ cell numbers are 
seen to decline, so that there may be some other mechanism involved).
A healthy person has approximately 1000 CD4+ cells per ml of blood. This number 
drops by 40 to 80 cells per ml each year in an HIV infected individual. Once the level 
has fallen below 200 to 400 cells per ml, many of the opportunistic infections 
associated with ‘AIDS Related Complex’ (ARC) appear. The major killers are 
Pneumocystis carinii, Crytococcal meningitis, and toxoplasmosis. These account for 
50 to 70% of deaths. The risk o f P. carinii increases greatly once the CD4+ cell count 
drops below 200 per ml, and risk of the others increases when the count falls below 
100 per ml. Evasion of the CTL response by HIV has been the subject of investigation
22
(Phillips, Rowland-Jones et al. 1991; Evans, O'Connor et al. 1999) and the positive 
selection of mutations within the viral sequences encoding the CTL-recognised 
epitopes may be responsible. These mutations significantly reduce the ability of CTLs 
to kill infected cells.
Figure 1. Progression through stages of HIV infection.
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NATURAL COURSE OF HIV INFECTION in a typical untreated patient begins with 
a sharp rise of virus in the blood (orange line) and a consequent drop in CD4 T  cells 
(blue line), the immune cells most damaged by HIV. The immune system soon recovers 
somewhat, however, and keeps HIV levels fairly steady for several years. Eventually, 
though, the virus gains the upper hand. AIDS is diagnosed when the CD4 T cell level 
drops below 200 cells per cubic millimeter of blood or when opportunistic infections 
(reflecting failed immunity) arise, whichever happens first.
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The point at which CD4+ count dips below 400 cells per ml is marked by the onset of 
ARC, and is coincident with an equivalent titre of viral particles. Shortly after this 
point the viral titre increases unabated as the CD4+ count plummets towards the 200 
cells per ml mark, where AIDS is officially diagnosed. The chronic phase (Fig. 1) was 
first thought to represent a period of viral latency during, since infected persons did 
not necessarily present any obvious symptoms of disease. However, the measurement 
of viral load and CD4+ cell count indicated that this might not be the case. As the 
work described in this thesis began (1992) the mechanism behind the observed decay
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in CD4+ count was not clear, and it has since been the subject of extensive research. 
This area o f study has impinged on, and benefited from, developments in drug design 
- especially advances in protease inhibitor design between 1992 and 1997. 
Consequently it will be considered here to provide a backdrop to the work of this 
thesis, and to demonstrate the contribution made to the understanding of viral / host 
interaction, and to AIDS therapy in general, by the development of protease 
inhibitors.
By 1993 it had been demonstrated that increased HIV-1 load correlated with a 
reduction in CD4+ lymphocyte levels and consequent disease progression (Weiss 
1993; Wain-Hobson 1993). The importance of viral replication to the disease state 
was clear (Wei, Gosh et al 1995 and references therein), however, little was known 
about the kinetics of viral and CD4+ lymphocyte turnover in vivo because sufficiently 
potent antiviral compounds had not been available and because methods for 
quantification of virus had been inadequate.
Two studies (Ho, Neumann, et al 1995; Wei, Gosh et a l 1995) were able to 
overcome these difficulties and shed light on the problem by exploiting new more 
potent antiviral compounds and more sensitive assays for viral RNA. The compounds 
in question were the protease inhibitors ABT-538 (Kempf, Marsh et al 1995) and L- 
735,524 (Vacca, Dorsey et al 1994; Dorsey, Levin et al 1994), and the reverse 
transcriptase inhibitor nevirapine (Merluzzi, Hargrave et a l 1990).
The clinical trial of the protease inhibitor ABT-538 (Markowitz, Mo et al 1995) 
provided an opportunity for Ho et al to determine what steady state (if any) existed 
between viral and CD4+ lymphocyte turnovers in vivo by disrupting that state. Prior to 
and during the treatment of trial patients CD4+ lymphocyte counts and HIV-1 levels 
were monitored, and the findings reported in Nature (Ho, Neumann et al 1995). The 
results suggested that approximately half the plasma virions turned-over every two 
days -  inferring that HIV-1 replication in vivo must be high. Furthermore, on average 
the entire population of CD4+ lymphocytes was seen to be turning over every fifteen 
days in patients prior to treatment and thus before disruption of any steady state. Since 
on treatment CD4+ counts were seen to rise they concluded that the depletion of 
CD4+ cells during AIDS could be attributed to CD4+ cell destruction by HIV-1. They 
estimated that in an infected patient approximately 109 CD4+ cells are destroyed and
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replenished daily, and commented that this was close to the number of HIV-1 RNA 
expressing lymphocytes calculated to be present in the body by in situ PCR and 
hybridisation experiments (Embretson, Zupancic et al. 1993; Haase 1994).
Wei et al. (Wei, Gosh et al. 1995) also used clinical trials on ABT-538 to study the 
kinetics o f viral production and clearance, but additionally employed the results of 
trials on L-735,524, and nevirapine as well (see review of HIV protease inhibitors, 
this chapter). Besides measuring viral load changes by PCR analysis of plasma borne 
viral RNA, they also quantified changes in the viral genotype and phenotype by 
employing automated DNA sequencing and an in situ assay of reverse transcriptase 
function. Their results concurred with those of Ho et al., and they concluded that the 
majority of circulating plasma virus was derived from “continuous rounds of de novo 
infection, replication and cell turnover, and not from cells that produce virus 
chronically or are latently infected and become activated” (Wei, Gosh et al. 1995). 
They also calculated that in order for steady-state levels of the virus to be maintained
o
the total viral population must be replaced daily (i.e. something like 1.1 x 10 virions 
per day), whilst CD4+ cells were turned over at a rate of about 2 x 109 cells per day. 
Remarkably their clinical trials also showed that wild type virus was almost 
completely replaced by drug resistant virus in the plasma within 14 days.
In summing up Ho et al. (Ho, Neumann et al. 1995) famously used a “sink” analogy 
to emphasise that the CD4+ depletion seen at later stages of infection was due to virus 
production finally outstripping the rate at which CD4+ cells could be replenished. The 
period of supposed ‘latency’ between initial infection and the onset of AIDS was in 
fact shown to be a period of extreme, yet finely balanced, activity on behalf of both 
virus and host. A dynamic ‘steady-state’ in which viral production and clearance, and 
CD4+ cell infection and replenishment were balanced had lately been anticipated 
(Nowak, Anderson et al. 1991; Coffin 1992; Wain-Hobson 1993) but the coincidently 
published works of Ho, Wei and respective co-workers confirmed the departure from 
earliest thinking, which had supposed that the virus lay ‘dormant’ (hence lentivirus or 
slow virus) for many years until ‘awakened’ by some extracellular stimulus to the 
host cells, or more recently that HIV specific CD8 T-lymphocytes were responsible 
for maintaining a low viral load and thus allowing a long period of asymptomatic 
infection (Buseyne and Riviere 1993; Pantaleo, Demarest et al. 1994). Importantly 
Wei et al. also pointed the way to the future therapeutic strategy of combinatorial
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therapy, since they demonstrated that the virus could very quickly develop resistance 
to compounds delivered individually.
The papers provoked a flurry of comments and replies (Wain-Hobson 1995; Nowak et 
al. 1995; Mosier 1995; Bukrinsky, Manogue et al. 1995; Phillips, Sabin et al. 1995; 
Ascher, Sheppard et al. 1995; Michie 1995; Buianouckas 1995; Weber and Galpin 
1995; Cohen 1995; James 1995; Coffin 1995; Levy, Ramachandran et al. 1996), not 
all in agreement (Duesberg and Bialy 1995). Duesberg and Bialy considered that the 
mathematical models were flawed, and that in any case the results merely confirmed 
that HIV was a passenger virus rather than the causal agent of AIDS. Despite this 
further study reiterated and refined the initial findings (Perelson, Neumann et al. 
1996). Overall these results had revitalised belief that a patient’s immune system 
might recover if HIV reproduction could be stopped long enough, even though the 
virus could not be completely eradicated. They had also validated the use of small, 
rapid clinical trials and the employment of PCR based measurements of plasma borne 
viral RNA to measure viral titres in vivo, and they had emphasised the importance of 
combinatorial therapy.
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The retrovirus family
HIV and SIV are members of the family of viruses known as the Retroviridae, thus 
they are retroviruses. The defining characteristic of this family is a genome 
comprising RNA which is reverse transcribed to DNA by viral reverse transcriptase. 
Retroviridae are currently divided into seven genera, including the Lentiviruses. This 
genus incorporates retroviruses with complex genomes and cone shaped capsid core 
particles, enveloped by a lipid bi-layer derived from their host’s cell membrane. The 
Lentiviruses are subdivided into five species - the Visna Virus, the Equine Infectious 
Anemia Virus (EIAV), the Feline Immunodeficiency Virus (FIV), the Simian 
Immunodeficiency Virus (SIV), and the Human Immunodeficiency Virus (HIV) - 
based on their respective hosts (these being ovine / caprine and bovine, equine, feline, 
and primate).
Figure 2. The Retroviridae
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The molecular biology of HIV.
In order to understand the significance of retroviral proteases in the lifecycles of HIV 
and SIV it is helpful to have knowledge of the viral biology. In this section the 
molecular and structural biology of HIV is outlined. HIV is described, but a general 
appreciation of both HIV and SIV biology can be obtained, since they are essentially 
very similar.
In general the retroviral lifecycle (fig. 3) can be broken down into the following five 
stages
1. Fusion and entry.
2. Pro viral synthesis and integration.
3. Pro viral transcription and translation.
4. Assembly.
5. Budding and maturation.
Stages 1 and 2 comprise the early phase, while stages 3,4 and 5 make up the late 
phase. The stages of the lifecycle will be considered in detail, but first the structure of 
the mature virion will be briefly described.
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Figure 3. The retroviral life cycle.
The retroviral lifecycle comprises five stages:-
1. Fusion and entry.
2. Proviral synthesis and integration.
3. Proviral transcription and translation.
4. Assembly.
5. Budding and maturation.
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Structure of the mature virion.
The mature virion (Fig. 4) has a lipid bi-layer envelope, approximately 100 nm in 
diameter, forming an icosohedral, sphere-like structure. The lipid envelope is acquired 
during budding of the virion from the host cell. Since it was once part of the host cell 
membrane it contains a number of host cell membrane proteins. These include major 
histocompatibility antigens, actin, and ubiquitin (Arthur, Bess et al. 1992). In addition 
numerous ‘spikes’ are visible in electron micrographs protruding from the membrane 
surface. Each consists o f two noncovalently associated envelope glycoprotein (gp) 
subunits - the 345 amino acid, 41 kilo Dalton (kD) transmembrane glycoprotein gp41 
(or TM) which provides an anchor for the 515 amino acid, 120 kD surface 
glycoprotein, gpl20 (or SU). The gpl20 and gp41 subunits are encoded by the HIV 
env gene, and are initially synthesised as a precursor called gpl60. Following its 
synthesis gpl60 is directed into the host cell secretory pathway for transport to the 
cell surface. Whilst within the secretory pathway it is modified by glycosylation, and 
proteolytically processed into the mature gpl20 and gp41 subunits (SU and TM) 
(Willey, Bonifacino et al. 1988; Earl, Moss et al. 1991; Haseltine 1991). The host cell 
protease responsible for this cleaveage has not yet been identified, however, if the 
processing event is prevented the viral surface glycoprotein is incapable of mediating 
membrane fusion (Kowalski, Potz et al. 1987; McCune, Rabin et al. 1988; Haseltine 
1991) making it a target for antiviral therapy. Both envelope glycoproteins are 
involved in entry o f the host cell, gpl20 being especially important as it interacts with 
the CD4+ receptor carried by T4 cells (Lifson, Feinberg et al. 1986; Schnittman, Lane 
et al. 1988).
Lining the inner surface of the lipid membrane are 2000 copies2 of the matrix protein 
p i7 (or MA). Within the matrix, at the centre of the particle is the capsid - 
constructed from 2000 copies2 of the p24 (or CA) capsid protein.
The capsid encases two molecules of the unspliced viral genomic RNA (HIV is 
diploid), which is stabilised by approximately 2000 copies2 of the nucleocapsid 
protein p7 (or NC). Also within the capsid are the virally encoded enzymes required 
for replication - reverse transcriptase (RT), integrase (IN), and protease (PR) - plus 
three auxiliary proteins - NEF, VIF, and VPR. There are three additional auxiliary
2 Estimate based on calculations by Forster, Mulloy and Nermut 2000.
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proteins encoded by the genome - REV, TAT, and VPU - but these are apparently not 
packaged within the virion. The presence of the six auxiliary proteins is a 
characteristic of both the HIV and SIV groups, distinguishing them from the other 
retroviruses. VPU is found exclusively in HIV-1 and no homologues have been 
described in other primate lentiviruses (Schubert, Bour, et al. 1996) other than the 
HIV-1 related S IV cpz isolated from chimpanzees (Huet, Cheynier, et al. 1990). For a 
review of HIV-1 related accessory proteins see Emerman and Malim (Emerman and 
Malim 1998). An additional auxiliary protein, VPX, is absent in HIV-1 but present in 
HIV-2 and members of the SIV group. The VPR and VPX proteins are homologous. 
It is probable that the vpx gene within HIV-2 arose by duplication of an ancestral vpr 
gene. Evolutionary distance analysis has shown that both genes were well conserved 
when compared with viral regulatory genes, and indicated that the duplication 
occurred at approximately the same time as the HIV-2 group and the other primate 
lentivirus groups diverged from a common ancestor (Tristem, Marshall, et al 1992).
The integrated HIV proviral genome (Fig. 5) is double stranded DNA, 10 kilobases 
(kb) long, consisting of two flanking ‘Long Terminal Repeat’ regions (LTRS)3 plus 
three main coding sequences, gag, pol, and env. The LTRS contain regulatory 
sequences for HIV replication, whilst gag, pol and env encode the core proteins, the 
viral enzymes (eg. reverse transcriptase, protease and integrase), and the envelope 
glycoproteins (gpl20 and gp41) respectively.
3 Discussed in section entitled Proviral synthesis and integration, this chapter.
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Figure 4. The mature virion.
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Figure 5. The HIV genome.
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Figure 4 (above) illustrates the basic structural organisation of the mature virion, with 
the host derived lipid bilayer embedded with gp41/gpl20 complexes and surrounding 
the matrix and capsid structures. Matrix, capsid and nucleocapsid proteins are 
coloured yellow, red and blue respectively, as are the corresponding genes encoding 
them shown in figure 5 (above) -  a genomic organisation schematic for HIV-1. HIV-2 
and SIV are essentially the same, but incorporate an additional auxiliary protein, 
VPX, which is homologous to VPR (which they also possess). VPU is found 
exclusively in HIV-1.
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Fusion and entry.
Once a viral particle has entered the body and encountered a potential host cell, 
adsorption and entry may occur. Cells (predominantly T4 lymphocytes, but also 
monocytes, macrophages and some neural cells) expressing the CD4+ antigen (a 60 
kD glycoprotein) are all potential hosts. Dalgleish et a l (1984) (Dalgleish, Beverley et 
a l 1984) have demonstrated the dependance of HIV on the CD4+ antigen for 
infection, and it is known to be a high affinity receptor for gp l20 - their interaction 
triggering an entry mechanism. The sequential interaction o f gpl20, with CD4 and a 
chemokine receptor on the cell surface initiates fusion of the viral and cellular 
membranes. Parts of the gpl20 bind to the CD4+ receptor, and to a group of 
chemokine receptors (Kwong, Wyatt et al 1998) that are essential co factors 
(Clapham and Weiss 1997). There are seven of these G-coupled proteins, and they are 
normally responsible for mobilising intracellular calcium and inducing leukocyte 
chemotaxis. Viral entry is not possible in their absence thus their physiological 
ligands are able to inhibit viral entry by competing with HIV for their receptor (Bleul, 
Farzan et al 1996; Choe, Farzan et al 1996; Oberlin, Amara et al 1996; Clapham 
and Weiss 1997). It may therefor prove possible to block infection using ligand 
derivatives which bind these receptors but do not activate the chemokine signalling 
pathways (Clapham and Weiss 1997). These interactions are considered further in the 
Appendix (General Introduction -  supplementary information; “The interaction of 
HIV envelope glycoproteins with CD4 and Chemokine receptors facilitates the viral 
entry process” page 328).
A conformational change within the gp41 subunit is illicited by the interaction 
between CD4+ and gpl20. Each gp41 contains two ‘heptad repeat’ sequences 
(consensus motifs predicted to be hydrophobic alpha-helices), and crystallographic 
studies have shown that these two heptad repeat domains form a helical bundle 
containing a trimer of each domain (Chan, Fass et a l 1997; Tan, Liu et al 1997; 
Weissenhorn, Dessen et al 1997). It is suggested that these bundles have a role in the 
conformational changes essential for membrane fusion (Dubay, Roberts et al 1992; 
Wild, Dubay et al 1994). It may thus be that the HIV fusion mechanism is similar to 
the ‘spring-loaded’ mechanism proposed for the influenza virus whereby 
hemaglutinin changes from a loop to an extended coiled-coil and in the process moves 
a ‘fusion peptide’ into a position such that membrane fusion can occur (Carr and Kim
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1993; Bullough, Hughson et al. 1994). Compounds able to prevent the fusion process 
have been discovered based on the C and N-terminals of the central trimer (Wild, Oas 
et al. 1992; Jiang, Lin et al. 1993; Wild, Dubay et al. 1994; Wild, Shugars et al. 1994; 
Lu, Blacklow et al. 1995) and it is probable that these act by interaction with the gp41 
helical bundle preventing it from adopting its fiisogenic conformation (Judice, Tom et 
al. 1997; Tan, Liu et al. 1997; Shu, Liu et al. 2000). Jiang and Debnath have reviewed 
the development of inhibitors targeting gp41 (Jiang and Debnath 2000).
Fusion of the viral and cellular membranes results in entry of the viral core into the 
host cell cytoplasm. Capsid breakdown then allows viral enzymes access to their 
respective substrates. It also releases the viral RNA genome, and this must then be 
reverse transcribed prior to its integration into the host cell genome.
Proviral synthesis and integration
Reverse Transcriptase, RT, (an RNA dependant DNA polymerase, characteristic of 
retroviruses) uses the viral RNA as a template for the synthesis o f double stranded 
‘proviral’ DNA. RT is present in HIV as a heterodimer with its two polypeptides, p66 
and p51, being 66 kD (560 residues) and 51 kD (440 residues) respectively. These 
share a common N-terminus, and the 51 kD form appears to be derived from the 66 
kD form by proteolytic cleavage of approximately 130 amino acids from the C- 
terminus. Both have an N-terminal polymerase domain consisting of four subunits 
(called fingers, palm, thumb, and connection). Both the 66 kD form, and a 15 kD 
polypeptide derived from its C-terminus display an RNase H activity. There is a 
‘tether region’ in between the polymerase and RNase H domains of the 66 kD 
polypeptide.
Reverse transcription requires that a lysine tRNA primer anneals to a primer binding 
site near the 5' end of the viral RNA genome (Oude Essink, Das et al. 1996). The 
lysine tRNA primer is incorporated into virions during their assembly (Oude Essink, 
Das et al. 1996; Huang, Wang et al. 1997) and can be extended by several nucleotides 
while within the particle (Huang, Wang et al. 1997), however, the majority of reverse 
transcription probably occurs in the host cytoplasm following uncoating. RT moves 
from 3' to 5', each RNA base enters its binding site, and a complementary nucleotide 
is incorporated into the growing DNA chain that sits in the enzyme's primer binding 
groove. The result is a hybrid DNA / RNA molecule. The RNase H activity derived
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from the p66 C-terminus digests the RNA strand of the hybrid DNA / RNA molecule. 
Cellular DNA polymerases then replace the RNA strand with a second DNA strand.
Since inception of this project the structure of RT has been solved (Kohlstaedt, Wang 
et al. 1992; Jacobo-Molina, Ding et al. 1993; Esnouf, Ren et al. 1995; Ren, Esnouf et 
al 1995; Ren, Esnouf et al. 1995; Rodgers, Gamblin et al. 1995; Hsiou, Ding et al.
1996). During synthesis of the linear, double stranded DNA ‘provirus’ the Long 
Terminal Repeat (LTR) sequences flanking the coding regions of the genome are 
formed. Retroviral RNA has a sequence of 30-60 base pairs (bp) designated ‘R’ 
(redundant) at the extreme 5' and 3' ends. Each of the two R regions has an adjacent 
‘U’ (unique) sequence, these are U5' and U3\ The U5' (80-120 bp) precedes the gag 
gene and the U3' (200-1200 bp) follows the env gene (see fig. 5). During DNA 
production a series of template switches by RT repeats the U3-R-U5' sequence at 
each end of the new DNA strand forming the LTR's. Retroviral LTR’s are 280-1300 
bases long depending on the virus - in HIV each LTR is 634 bp long. They are 
essential for integration - the process whereby viral DNA is translocated into the host 
cell nucleus and incorporated into its genome. They allow circularisation of viral 
DNA, giving two types of covalently closed, supercoiled molecules. The first type 
incorporates one LTR, the second two tandem copies. The second type is thought to 
be the precursor to the integrated provirus, and is probably formed by ligation of the 
blunt ends o f the linear molecule. A novel sequence at the junction between the two 
LTR's called the ‘circle junction’ is probably the substrate for the viral endonuclease, 
‘integrase’ (IN). This enzyme is encoded by the 3' end of the pol gene and seems to 
cut both the host and viral DNA, giving staggered ends. Probably the short end of the 
viral DNA covalently joins to the protruding end of the host DNA, whilst DNA repair 
synthesis fills in the host DNA and removes the non-hydrogen bonded terminal viral 
dinucleotide sequences. This mechanism explains the observed deletion of LTR 
terminal dinucleotide sequences and the short duplication of host DNA flanking the 
integrated provirus. If the terminal dinucleotide sequences (TT/AA) are recognition 
sites for integration, their loss renders the process irreversible, explaining the stability 
of the integrated provirus. The site of integration within the host genome appears to 
be random, though DNA exposed during replication, actively transcribed regions, 
nicks, gaps and other modifications have been suggested as possible targets. A 
preference for kinked or distorted DNA has been shown in vitro (Miller, Bor et al.
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1995), and this may indicate the involvement of nucleosomes as integration sites. It 
may be that interaction with cellular DNA binding proteins guides IN to specific sites. 
Much of the viral DNA remains unintegrated in the cytoplasm - an unusual 
characteristic o f HIV, and one that may be a factor in its cytopathic effect.
It has been observed that there are similarities between retroviral proviruses and 
transposons (Finnegan 1981; Hehlmann, Brack-Werner et al 1988), they are 
structurally related (Majors, Swanstrom et a l 1981), and it is even possible that 
retroviruses evolved from transposons (Flavell 1981; Shimotohno and Temin 1981; 
Finnegan 1983; 1992). Models for the molecular aspects of retroviral integration have 
been based on knowledge of transposases (Polard and Chandler 1995; Capy, Vitalis et 
al 1996; Haren, Ton-Hoang et al 1999), which are structurally similar to retroviral 
integrases (Rice, Craigie et al 1996).
IN is packaged within the viral particle as a Gag-Pol precursor. PR releases the active 
IN from the precursor by proteolysis, either during or after the budding process. It has 
288 residues, three functional domains - the N-terminal zinc finger-like domain, the 
central catalytic domain, and the C-terminal domain. NMR structures of the N and C 
terminal domains were solved individually (Lodi, Ernst et al 1995; Cai, Zheng et al 
1997; Cai, Huang et al 1998). However, the catalytic domain exhibited poor 
solubility, limiting any structural analysis until a more soluble mutant (having a single 
change -  F185K) was made which enabled a crystal structure to be obtained (Dyda, 
Hickman et al 1994).
As yet the structure of IN in its entirety has not been established, neither is the precise 
mode of IN action clear. The arrangement and interaction of the three domains is not 
yet known, but the fact that each domain has been shown to exist individually in a 
dimeric form suggests that this may be true of IN as a whole. However, there has been 
some suggestion that a tetramer is more likely (Rice, Craigie et al 1996; Cai, Zheng 
e ta l  1997).
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Proviral transcription and translation
A period of dormancy (latency) may follow integration, until a signal (eg. T-cell 
activation) causes transcription of the viral DNA via a promoter located in the 5' LTR. 
In addition to the HIV promoter the 5' LTR contains the regulatory elements for RNA 
polymerase II transcription, and upstream of the start are sites for the binding of 
cellular transcription factors including Nuclear Factor-kB (NF-kB), Specificity 
protein 1 (Spl) and TATA-box binding protein (TBP). These factors may help to 
control the rate of transcription initiation thus their relative abundance in the host cell 
may influence the level of proviral replicative activity. In vitro phytohemaglutanin 
(PHA), phorbal myristate acetate (PMA), and other mitogens, activate T-cells - 
probably via cell surface receptors, protein kinase C, and the secondary messenger 
inositol triphosphate. In this way they mimic the action of an antigen, and stimulate 
the production of the cellular transcription. These in turn induce the production of 
interleukins and their receptors, but also increase LTR directed viral gene expression 
by binding the upstream sites within the LTR. Deletion studies have shown that 
tandemly repeated core elements of the LTR's, function as transcription enhancers 
(expression of the auxiliary proteins TAT and REV is enhanced in this way). Their 
activation ends the proviral latency, and the first viral mRNAs produced are doubly 
spliced and encode TAT, REV and NEF.
Once transcription is underway a full length RNA transcript of approximately 9000 
bp is produced. Nine important regions have been identified within the full-length 
transcript (see fig. 5).
However, even in the presence of the cellular factors described, transcription 
complexes initiated at the 5' LTR are inefficiently elongated. This is overcome by the 
action of the tat (transactivator) gene, which has a positive effect on both its own 
expression and that of other genes by increasing the ability of transcribing 
polymerases to elongate their transcripts. LTR directed gene expression results in 
production of another transactivator called REV (Regulation of Expression of Viral 
proteins). As REV levels increase it has the effect of reducing the frequency of 
splicing so that singly spliced or unspliced transcripts are now transported to the 
cytoplasm so that translation of other viral components can begin, and so that full 
length genomic RNA becomes available for packaging. TAT and REV are examined 
in more detail below.
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TAT
The tat gene encodes a 14 kD (86 residue) protein (TAT) found in the nucleus of 
infected cells. TAT may recruit or activate factors that phosphorylate the RNA 
polymerase II C-terminal domain (CTD), and enhanced phosphorylation of this 
domain is known to occur as the polymerase II changes function from initiation to 
elongation (Parada and Roeder 1996; Yang, Herrmann et al. 1996; Zhou and Sharp 
1996; Cujec, Cho et al. 1997; Garcia-Martinez, Mavankal et al. 1997; Jones 1997). In 
this way TAT increases the production of viral mRNA by about 100 fold. In the 
absence of TAT the polymerase fails to transcribe beyond a few hundred nucleotides, 
presumably because the CTD remains unphosphorylated. Consequently TAT is 
essential for replication and is another target for antivirals. The combined effects of 
TAT and T-cell activation increase LTR directed gene expression by 800 times the 
basal level seen in non-activated cells where tat is not expressed.
Typically transactivators bind DNA sites, however, TAT binds to an RNA hairpin 
loop called TAR (Trans-Activating Response element). TAR is located at the 5' end 
of developing viral transcripts (ie. in the R region of the LTR encoding the 5' leader of 
viral mRNA). An arginine rich region of TAT allows binding to a tri-nucleotide bulge 
in TAR (Bayer, Kraft et al. 1995). TAT protein may stabilise RNA molecules that 
initiate with the LTR TAR sequences. Alternatively it may have a transcription anti­
termination activity, since TAR contains a 24 nucleotide inverted repeat - potentially 
able to form a stable hairpin structure in the mRNA leader and thus terminate 
transcription. Whatever TAT’s mechanism of action it probably regulates viral protein 
expression post-transcriptionally. It may facilitate transport of TAR-containing RNA 
molecules from a compartment in the nucleus (the nucleolus) within which RNA is 
made and spliced, to a subcellular compartment where it is accessible to the 
translational initiation complex. The overall effect of the TAT-TAR positive 
regulatory loop is explosive replication of the virus under favourable conditions. The 
TAT-TAR interaction is stabilised by an as yet unidentified host cell protein, which 
may be encoded by chromosome 12 (Alonso, Cujec et al. 1994).
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REV
The 19 kD REV protein is encoded by sequences overlapping those of TAT but which 
are in a different reading frame. REV is essential for the formation of the long HIV 
transcripts encoding GAG, POL and ENV precursor polypeptides. In cells infected by 
a rev defective HIV genome, levels of GAG, POL and ENV mRNA are depressed, 
whilst normal overall levels o f viral mRNA are maintained by a compensatory 
increase in short, doubly spliced species. This suggests that REV acts by relieving a 
block in GAG and by allowing the formation, but not splicing of, gag pol and env 
precursor mRNA transcripts. Since all viral proteins are cleaved from precursor 
polyproteins encoded by such full-length transcripts, the rev gene is a positive 
regulator of these proteins.
Although REV may simply inhibit the splicing process it appears more likely that it 
targets the nuclear export system. In doing so it may steer the pre-cursor mRNA away 
from the splicing and degradation pathways (its usual fate) allowing its transport from 
the nucleus to the cytoplasm prior to complete splicing (Hope 1997).
Following REV’s activity spliced and genomic length viral mRNA is transported to 
the host cell cytoplasm where its translation results in the GAG and GAG-POL 
polyproteins. These subsequently become localised to the host cell membrane and are 
later processed into their constituent proteins (MA, CA, NC, p6, PR, RT and IN).
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Assembly
In 1968 Maizel et al. and Summers et al. (Maizel and Summers 1968; Summers and 
Maizel 1968) showed that in the polio virus the combined molecular weights of 
protein comprising the virion exceeded the coding capacity of its genome. This lead 
to the realisation that the viral proteins were expressed as a single large precursor 
polypeptide (Holland and Kiehn 1968; Jacobson and Baltimore 1968; Summers and 
Maizel 1968). It was Jacobson and Baltimore who termed the precursor a polyprotein 
(Jacobson and Baltimore 1968). Polyproteins are made by all retroviruses including 
HIV and SIV, and many plus strand RNA viruses. They contain many distinct 
domains which are cleaved proteolytically, either as they are translated (RNA viruses) 
or during virion maturation (Retroviruses).
Many viruses have evolved such that they produce more structural proteins than non- 
structural proteins simply because they need more of the former type. Retroviruses 
produce more GAG and ENV proteins than POL proteins. The ENV proteins are 
derived from subgenomic mRNA species produced by splicing. The GAG polyprotein 
is translated from genome length mRNA, while the POL proteins are also encoded by 
genome length mRNA but translated as a GAG-POL polyprotein. The level of GAG- 
POL polyprotein production is 80-95% lower than that of the GAG polyprotein. This 
is due to two rare translational events -  the suppression of an amber codon (at end of 
gag coding sequence), or frame shifting at the 3' terminal half of the gag coding 
sequence.
Localisation of the GAG and GAG-POL polyproteins to the inner surface of the host 
cell membrane is made possible by the matrix protein MA, located at the N-terminal 
end of the GAG polyprotein. This is an initial stage of the assembly process. At this 
point some of the individual components of the polyproteins will be considered, 
including MA, CA, NC and p6. As previously stated, the enzymes PR, RT and IN are 
incorporated within the GAG-POL polyprotein, and thus also become attached to the 
host cell membrane. However, their involvement in the lifecycle will be considered 
later (see Budding and Maturation, this Chapter page 46).
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MA
MA has an N-terminal myristate group and a number of basic residues (lysines 26, 27 
30 and 32) among the first 50 amino acids of its N-terminal domain. Both are 
involved in an interaction with the host cell membrane. Crystallographic studies have 
revealed that MA exists as a trimer with the basic residues of each monomer 
positioned at what is presumably the membrane-binding surface. It is probable that 
the trimeric structure is of biological significance since mutagenesis of residues 
involved in trimerisation (amino acids 42-77) prevents viral assembly. Probably the 
three myristates penetrate the host cell’s lipid bilayer, while the lysines from each 
monomer interact with the phospholipid head groups at the cytoplasmic surface of the 
membrane. In addition to locating GAG and GAG-POL polyproteins to the host cell 
membrane, MA may also ensure the incorporation of ENV glycoproteins with long 
cytoplasmic tails into viral particles (Freed, Englund et al. 1995; Mammano, Kondo et 
al 1995; Hill, Worthylake et al. 1996; Massiah, Worthy lake et al. 1996).
CA
The other components of the polyproteins are suspended from the membrane beneath 
MA. The first of these is the capsid protein CA, approximately 2000 copies of which 
will eventually form the viral core. CA subunits have been seen to arrange themselves 
in strips within a crystal, possibly a reflection o f their packaging arrangement in vivo.
CA is 231 amino acids long and has two domains - the N-terminal (residues 1-151), 
and the C-terminal (residues 152-231). The structures of both these domains have 
been solved either by crystallography or NMR (Gamble, Vajdos et al. 1996; Gitti, Lee 
et al. 1996; Momany, Kovari et al. 1996; Gamble, Yoo et al. 1997). Mutations of the 
N-terminal domain do not disrupt assembly or budding, but do reduce viral 
infectivity. It may be that this domain is involved in uncoating, and it is known to 
associate with Cyclophilin A (CypA) - probably a cellular chaperone. The N-terminal 
domain exists as a monomer in solution.
The C-terminal domain has an extended strand followed by four alpha helices and 
exists as a dimer in solution. It has a 20 amino acid region that is highly conserved 
throughout retroviral GAG proteins called the Major Homology Region (MHR). This 
region produces a tight fold stabilised by hydrogen bonds between its four most 
conserved residues. It is essential for particle assemby (Srinivasakumar,
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Hammarskjold et al. 1995) and has a possible role in membrane affinity (Ebbets- 
Reed, Scarlata e/a/. 1996).
NC
The third component of the GAG polyprotein is the nucleocapsid protein NC, which 
following maturation is responsible for coating the genomic RNA inside the virion 
core. In coating the RNA it is able to protect it from ribonucleases, and ensure that the 
genome is compact enough for packaging into the core. NC has additional chaperone 
like functions and is involved in promoting tRNALys primer annealing, melting of 
RNA secondary structure, DNA strand exchange during reverse transcription 
(Cameron, Ghosh et a l 1997; Guo, Henderson et al. 1997; Huang, Barchi et al.
1997), and stimulation of integration (Carteau, Batson et al. 1997).
NC is a basic protein of 55 residues and it’s structure has been determined by NMR 
(Morellet, Jullian et al. 1992; Summers, Henderson et al. 1992). It has two zinc finger 
domains (CCHC type zinc fingers), and removal of the zinc by disulphide substituted 
benzamide compounds inhibits viral replication. NC binds non-specifically to single 
stranded nucleic acids, but also binds specifically to the packaging signal v|/, thus 
ensuring that full length genomic RNA becomes incorported into the virion. The zinc 
fingers and the basic residues flanking them are required for the interaction with ij/ 
(Poon, Wu et al. 1996; Schmalzbauer, Strack et al. 1996). The packaging signal \\j 
probably consists o f 3 RNA hairpin loops surrounding a major splice donor site 
(Clever and Pars low 1997; Laughrea, Jette et al. 1997). The first of these hairpins 
includes the ‘kissing loop’ responsible for RNA dimerisation.
p6 and VPR/VPX
Viral protein R (VPR) is an auxiliary protein that is conserved in both HIV-1 and 
HIV-2 (Dedera, Vander Heyden, et al. 1989), it is a 96 amino acid, 15 kD protein that 
increases the rate o f replication and accelerates the cytopathic effect of the virus in T- 
cells by acting in trans to increase levels of viral protein expression (Cohen, 
Terwilliger, et al. 1990). The C-terminal 51 amino acids of GAG make up p6, a 
protein which binds VPR and is involved with the incorporation of VPR during viral 
assembly (Checroune, Yao et al. 1995; Lu, Bennett et al. 1995; Kondo and Gottlinger 
1996) - an alpha-helix at the N-terminal of VPR contains amino acids responsible for 
binding p6. In addition p6 incorporates a sequence of four amino acids (Pro7 Thr8
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Ala9 Pro 10) involved in particle release (Huang, Orenstein et al. 1995). Viral protein 
X (VPX) is a 16 kDa accessory protein, homologous with VPR, expressed in 
cells infected with HIV-2 and most SIV strains (Horton, Spearman et al. 1994). In 
HIV-2 and SIV VPX is necessary for efficient replication in Peripheral Blood 
Mononuclear Cells (PBMC) (Park and Sodroski 1995).
The ENV poly protein (gpl60), VPUf and NEF
Following its translation the env polyprotein (gpl60) undergoes glycosylation within 
the Endoplasmic Reticulum (ER), followed by cleavage into SU (gpl20) and TM 
(gp41). In preparation for budding gp41 and gpl20 must be incorporated into the host 
lipid membrane, creating the outer coat for a new virion. However, the host CD4+ 
receptors are also glycosylated in the ER - consequently the gpl60 or gpl20 and 
CD4+ interact prematurely to form unwanted complexes. These complexes can inhibit 
the formation of the fully functional gp41/gpl20 complex and its translocation to the 
cell membrane. The gpl60/gpl20 must therefore be released from these complexes. 
Auxliary proteins VPU and NEF assist in degradation of CD4+ throughout the host 
cell.
VPU
The auxiliary protein VPU (found only in HIV-1 group virions) assists in the release 
by promoting degradation of CD4+. The degradation of CD4+ is interupted by 
proteasome inhibitors such as lactacystin (Fujita, Omura et al. 1997), and is regulated 
by a cellular kinase - which phosphorylates Ser52 and Ser56 of VPU. If these residues 
are mutated a decrease in CD4+ degradation is observed (Cohen, Subbramanian et al.
1996). It has now been shown that VPU interacts with an F box protein called P- 
Transducin repeat Containing Protein (p-TrCP) in a phosphorylation dependent 
manner (Margottin, Bour et al. 1998; Akari, Bour et al. 2001; Coadou, Gharbi- 
Benarous et al. 2003). In doing so VPU is able to corrupt the ubiquitin pathway and 
directs the p-TrCP to the host’s own CD4+ protein - this is described more fully by 
Yaron et al. (Yaron, Hatzubai et al. 1998). VPU is somehow also able to reduce the 
occurrence of Major Histocompatibility Complex class I (MHCI) proteins on the cell 
surface. This probably prevents cytotoxic T-lymphocytes from recognising that the 
cell has been infected and thus killing it (Kerkau, Bacik et al. 1997).
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VPU is an oligomeric integral membrane phosphoprotein o f 81 amino acids (Cohen, 
Terwilliger, et al. 1988; Strebel, Klimkait, et al. 1988; Strebel, Klimkait, et al. 1989), 
with a transmembrane N-terminal domain (residues 1-24) and a C-terminal 
cytoplasmic tail (residues 25-81). It is probable that the C-terminal tail is involved in 
receptor binding and CD4+ degradation (Willey, Maldarelli et al. 1992; Schubert and 
Strebel 1994), and that located within it are the (serine) phosphorylation sites 
regulating these functions. The N-terminal domain is probably involved in the release 
of particles from the host cell, and also displays non-specific cation channel activity 
(Strebel, Klimkait, et al. 1988; Strebel, Klimkait, et al. 1989; Terwilliger, Cohen, et 
al. 1989; Schubert, Bour, et al. 1996; Ewart, Sutherland et al. 1996). Mutation of this 
domain results in virions with an increased tendancy to remain associated with the 
cell surface, or localised to intracellular membranes.
Although VPU is not essential for virus replication in vitro, its expression enhances 
viral particle release from the host cell in tissue culture systems (Strebel, Klimkait, et 
al. 1988; Strebel, Klimkait, et al. 1989; Terwilliger, Cohen, et al. 1989). In its 
absence viral proteins accumulate within the infected cell as a result of intracellular 
budding, causing increased cytopathicity in vpu-deficient strains (Klimkait, Strebel, et 
al. 1990). Given the absence of vpu from the non-HIV-1 type retroviruses they were 
envisaged to have evolved alternative mechanisms to augment particle release. 
Studies by Bour, Strebel and co-workers have shown that the gpl40 envelope protein 
of H I V -2 rod has VPU-like activity and can enhance particle release (Bour, Schubert, 
et al. 1996; Bour and Strebel 1996). There are similarities between VPU and gpl40 -  
both are integral membrane proteins able to form oligomeric structures, they are 
similarly regulated (since in HIV-1 ENV and VPU are translated from the same 
bicistronic mRNA), and it is probable that they both act in similar subcellular 
compartments (Bour, Schubert, et al. 1996 and references therein). It seems then that 
in the viral groups where VPU is absent its function is carried out by the ENV protein 
gpl40.
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NEF
NEF is an N-terminally myristoylated protein of 206 amino acids, and promotes the 
endocytosis and degradation of CD4+ receptors already at the cell surface. The 
removal o f CD4+ molecules from the surface may be a means of avoiding an immune 
response, but would also be necessary to ensure that no CD4+ receptors will be 
present on the viral outer envelope. Such an occurence would presumably result in 
viral particles attempting to fuse with each other. It probably also helps prevent 
multiple infection of a host cell.
NEF probably interacts with the tail of CD4+ (Mangasarian and Trono 1997), 
presumably via its myristoylated N-terminus. NEF then directs the CD4+ from its 
location at the cell surface or at the golgi, to lysosomes where receptor degradation 
occurs (Mangasarian and Trono 1997) NEF also shares VPU’s ability to downregulate 
the deployment of MHC class I proteins at the cell surface (Le Gall, Heard et al.
1997).
Approximately 70 molecules of NEF are incorporated into each new virion, and these 
are cleaved by PR (at residue 57) during maturation to yield a soluble C-terminal 
fragment (Guatelli 1997). This suggests possible involvement in assembly, maturation 
and entry.
At this stage in development (and as previously described) the GAG polyprotein is 
being synthesised in the ribosomes from unspliced mRNA. A smaller amount of 
GAG-POL precusor proteins are also expressed following a translational frameshift. 
The N-terminal myristoylated MA domain of the GAG and GAG-POL polyproteins, 
besides enabling them to bind directly to the inner surface of the host cell membrane, 
also allows interaction with the cytoplasmic tail of gp41.
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Budding and maturation.
Gag and gag-pol polyproteins migrate to the host cell membrane where they become 
anchored via an N-terminal myristic acid group (Henderson, Krutzsch et al. 1983; 
Mervis, Ahmad et al 1988). Between 1200 and 2000 such polyproteins per new 
particle bind the inner surface of the host membrane. The adjacently anchored 
polyproteins then interact with each other, and electron micrograph observations show 
them apparently aggregating together (Gonda, Wong-Staal et al. 1985). Presumably 
this is at least in part the result of dimer formation between adjacent monomers of 
each component protein. This interaction distorts the host cell membrane, forming a 
bulge. The bulging effect becomes more exaggerated as more polyproteins become 
anchored in the vaccinity, and join the aggregate. Eventually the bulge is an almost 
spherical protruberance from the host cell surface, and finally the sphere is completed 
as the host cell membrane ruptures at the point of maximum distortion. The spherical 
virion buds off from the host cell’s plasma membrane, encapsidating two full-length 
molecules of the unspliced genomic RNA in the process.
Within the newly detached virion the polyproteins are still intact, none of their 
component proteins have been released, the particle is immature and not infectious. 
In order for maturation to occur the active PR must be present (Kohl, Emini et al. 
1988). As adjacent, membrane anchored, viral polyproteins associate or aggregate 
their component proteins may be able to dimerise into their active conformations. 
Among these emerging dimers is the PR, which on becoming an active dimer is now 
able to recognise, bind and cleave the scissile sites between component proteins of 
adjacently aggregated polyproteins. There have been several accounts suggesting that 
once dimerised PR is able to autocatalytically cleave itself from within its gag-pol 
polyprotein (Farmerie, Loeb et al. 1987) (Debouck, Gomiak et al. 1987; Giam and 
Boros 1988) (Krausslich and Wimmer 1988). The first five N-terminal residues of the 
PR (linking PR to the gag encoded half of the polyprotein) serve no known catalytic 
or structural function, and it may be that their sole purpose is to provide the flexible 
linker required to make autocatalysis possible. It has been suggested that these 
residues are sufficiently flexible that the N-terminal scissile site can be manouvered 
into its own active site for cleavage. Mutagenesis of residues at the N-terminal 
cleavage site has been successful in modifying autoproteolytic activity (Rose, Salto et 
al. 1993)
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Once PR is released, either by itself or perhaps by its neighbour, it is able to cleave 
nearby polyproteins into their constituent protein subunits, releasing more PR in the 
process. A cascade of proteolysis consequently ensues, until all the polyproteins are 
processed, and maturation is complete.
The 23 kD protein VIF (Viral Infectivity Factor) is also required at this stage, 
although its mode of action is unclear. Mutants of vif are unable to initiate particle- 
mediated infection, though they are still able to spread cell-to-cell, and infected cells 
may still form syncitia (multi-nucleated giant cells produced by the fusion of infected 
host cells - expressing gpl20 on their surface - with other CD4+ carrying cells). 
Syncitia formation is a major cause of HIV induced cell death. The defect in the vif 
gene mutants is not related to virus adsorption, packaging of RNA, or reverse 
transcription. It may be that VIF is involved in post-translational modification of viral 
proteins.
It is the viral protease (PR), however, which plays the major role in maturation, and 
its activity yields the individual enzymes required later for replication (IN and RT), 
plus the major structural proteins (MA, CA, and NC). During the maturation process 
the structural proteins rearrange and an infectious particle results. If PR activity is 
blocked by mutation or inhibition the maturation process cannot proceed, and the viral 
particles remain non-infectious. Thus PR has long been recognised as a major 
antiviral target. It has consequently been the subject of intense investigation, 
culminating in the widespread clinical use of PR inhibitors today. The next section 
will deal with this enzyme in more detail, and will describe the investigations that 
have put it among the best-understood proteins known.
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An introduction to proteases
Preliminary note
In 1992 when this PhD research project was begun the structure of HIV-1 PR 
apoenzyme had been solved, however, no structure existed for HIV-2 PR, or for an 
SIV PR (SIV is interesting as an animal model for HIV). Inhibitor design was 
predominantly based on non-scissile substrate analogues. No anti-PR drugs had yet 
been launched. The remainder of this introduction will consider the PR field as it 
developed up until 1992, and the questions that were being addressed by researchers 
at that time. Subsequently it will review developments contemporary with this study 
(1992 -  1996), and finally bring the reader up to date with the field. In this way the 
work that follows will be placed in context. At the end of the thesis the General 
Discussion will appraise the work with respect to the PR field as it is today, and 
assess the results in light of current knowledge.
Classification of proteolytic enzymes
Proteolytic enzymes are proteins able to catalyse the cleavage of peptide bonds. These 
enzymes engage either limited or unlimited proteolysis, the former involving the 
cleavage of only one or a limited number of specific peptide bonds within a target 
protein, whilst the latter involves the degradation of the target protein into its 
constituent amino acids. Ubiquitination of a protein is often the first step in a pathway 
involving ATP (Adenosine Tri-Phosphate) driven unlimited proteolysis, and a similar 
process of rapid protein degradation also occurs in the lysosome. Unlimited 
proteolysis is thus a means by which proteins may be removed from circulation and 
broken into their consituent amino acids. Limited proteolysis, by contrast, is often a 
means by which pro-enzymes may be activated, the cleavage of specifically 
recognised peptide bonds leading to release of an active mature protein from a 
formerly inactive precursor. The proteolytic enzymes (peptide bond hydrolases) have 
been classified by the International Union of Biochemistry and Molecular Biology 
(IUBMB) (1984) as peptidases (the term protease is synonymous with peptidase). 
Within the peptidase subclass there are two further groups of enzymes, the 
endopeptidases and the exopeptidases. These cleave bonds within a peptide chain in 
the case of endopeptidases, or sequentially remove residues from the N or C terminal 
ends of the chain in the case of exopeptidases. The term proteinase is synonymous 
with endopeptidase. This thesis deals with retroviral proteases engaging in limited
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proteolysis of viral polyproteins at specifically recognised sites within the target 
protein. They are thus correctly classified as endopeptidases, or proteinases, whilst the 
name currently recommended by the Merops database is HIV retropepsin. However, 
the term protease is so widely applied to these enzymes in the literature that it has 
become almost universally accepted. Protease has therefore been used throughout this 
work in relation to the retroviral enzymes, and is also represented by the shorthand PR 
in that respect.
The endopeptidases / proteinases may be further divided according to their 
mechanisms of action. Four mechanistic classes have been recognised by the IUBMB, 
these being the serine, cysteine, aspartic and metallo proteinases. It is predominantly 
the aspartic proteinases that will be dealt with here, though some mention will be 
made of cysteine proteinases in chapter 5.
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Protease subsite nomenclature
Where protease enzyme subsites or peptide substrates are described in this text the 
nomenclature of Schechter and Berger was used (Schechter and Berger 1967) 
whereby the subsites on the protease are called S and the substrate amino acid 
residues are called P (Fig. 6). Substrate peptide amino acid residues on the N-terminal 
side of the peptide bond are numbered P3, P2, PI, whilst those on the C-terminal side 
are PI', P2', P3' and so on, up to P8 and P8'. The residue numbers increase away from 
the scissile bond, so that the PI and PI' residues are those flanking the bond. The 
corresponding subsites on the protease, interacting with the peptide residues of the 
substrate, are numbered S3, S2, SI, SI', S2', S3', in a similar way - thus 
complementing the nomenclature for the substrate.
Figure 6 The Schecter and Berger nomenclature.
The Schechter and Berger nomenclature
Sci33ile bond
Enzyme
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The retroviral proteases (PR)
Following translation of viral proteins and the assembly of the viral core, the 
membrane coat incorporating SU and TM surrounds the particle, and the virion buds 
from the cell’s surface and is released.
At this stage the particle is not infectious. A number of maturation events must take 
place in the period from assembly to budding, and the exact timing of these events is 
not yet clear. It had already been shown that in several other retroviruses a protease, 
usually encoded by the pol gene, was essential for this maturation process to occur 
(Dickson 1984). Indeed if the protease is absent or inactivated then the maturation 
process cannot be completed, and a non-infectious immature particle results. It was 
also known that the maturation process involves cleavage of the viral polyproteins 
into their constituent subunit proteins. In HIV it was shown by mutational analysis 
that the protease, PR, responsible for this cleavage process is located at the amino 
terminal coding region of the pol gene (Kramer, Schaber et al. 1986). It was clearly a 
potential target for antiviral therapy, especially since it was shown to be responsible 
for the release of structural proteins from the polyprotein encoded by gag, and for the 
release of viral enzymes from the GAG-POL fusion polyprotein (Kramer, Schaber et 
al. 1986; Debouck, Gorniak et al. 1987; Darke, Nutt et al. 1988). This suggested that 
the PR was able to release itself from the GAG-POL fusion polyprotein by 
autoproteolysis (Witte and Baltimore 1978; Crawford and Goff 1985; Katoh, 
Yoshinaka et al. 1985; Farmerie, Loeb et al. 1987; Darke, Nutt et al. 1988).
It was shown that the PR incorporated a single highly conserved triad (Asp-Thr-Gly) 
typical of the aspartyl proteases, and it was conjectured that it might belong to this 
family of enzymes (Toh, Kikuno et al. 1985; Power, Marx et al. 1986). Other 
members of this protease family had already been studied, in particular pepsin 
(produced in the stomach and involved in protein digestion), renin (found in blood 
plasma and involved, in association with angiotensin, in the regulation of blood 
pressure), cathepsin D (a lysosomal enzyme), rhizopuspepsin, endothiapepsin and 
penicillopepsin (isolated from fungi). For further information relating to renin see: 
Appendix; General Introduction -  supplementary information; “The development of 
Renin inhibitors” (page 332).
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Three dimensional crystal structures for endothiapepsin (Cooper, Foundling et al. 
1987) and for penicillopepsin (Hsu, Delbaere et al. 1977) had already been solved.
However, these other mammalian and microbial aspartic proteases were typically in 
excess of 300 amino acids in length, and always had a pair of conserved triads - 
whereas the retroviral enzymes were much shorter and contained just one triad. 
Retroviral proteases were generally observed to have molecular weights in the range 
1 1 - 1 4  kD, whereas the conventional aspartic proteases had molecular weights in the 
range 32 -  36 kD. HIV PR was eventually shown to consist of only 99 amino acids 
(Debouck, Gomiak et al. 1987; Graves, Lim et al. 1988; Nutt, Brady et al. 1988; 
Schneider and Kent 1988), making it the smallest of the retroviral proteases. A 
possible explanation for these discrepancies became apparent when the 11 kD MLV 
protease was shown to run at 22 kD on an analytical size exclusion column, 
suggesting that it was a dimer in solution (Yoshinaka and Luftig 1980). Perhaps this 
was true of all retroviral proteases?
In a conventional aspartic protease the two catalytic triads are brought into opposing 
proximity once the protein is correctly folded, forming the enzyme’s active site. It 
was therefore proposed that the PR sequence represented the equivalent of a single 
domain of a conventional aspartic protease, and that furthermore it was a dimer in its 
active form (Pearl and Taylor 1987). In the dimeric state its catalytic residues would 
be brought together at the interface between the monomers and create an active site. 
Each monomer would contribute one of the two aspartates essential for catalytic 
activity. Pearl and Taylor performed extensive sequence alignments between 
members of the aspartic protease family, and the supposed retroviral aspartic 
proteases. This enabled them to make secondary structure predictions for the 
retroviral sequences, and compare them with the observed secondary structures for 
penicillopepsin and endothiapepsin. They found a close correspondence between the 
predictions and the observed structures, supporting the idea that the retroviral 
proteases were effectively equivalent to single aspartic protease domains. There is a 
difference in length between a retroviral protease and an aspartic domain (the former 
is typically about 20 amino acids shorter than the latter).
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However, this can be explained in two ways: first by differences between the lengths 
of loops joining strands of 6-sheet in the respective proteases; and second by the fact 
that the retroviral proteases lack residues at their C-terminus that are present in other 
aspartic proteases.
Pearl and Taylor also constructed a three-dimensional model from the retroviral 
protease sequences based on the structure of endothiapepsin. They chose to model 
HIV-1 PR in particular, and took into account variations between the loop lengths of 
different enzymes by incorporating the loop lengths predicted for HIV-1 protease. The 
model showed that HIV-1 PR would essentially share the same folds as 
endothiapepsin. When modelled as a monomer the HIV-1 PR lacked the active site 
typical of an aspartic protease. However, a further model having two HIV-1 PR 
monomers, arranged opposite each other by using the twofold axis from the 
endothiapepsin active site, produced a plausible PR active site. In addition this model 
illustrated the presence of a substrate-binding cleft of sufficient size to accept as many 
as six amino acids.
It was later shown experimentally that the active HIV PR was dimeric (Darke, Leu et 
al 1989) and that recombinant HIV PR was active in the dimeric form (Meek, Dayton 
et al 1989). Subsequent cry stallo graphic analyses finally confirmed the validity of the 
Pearl and Taylor models.
In forming its protease by the fusion of two identical monomers the virus is able to 
express an active protease while reducing the RNA required by half. In fact it is now 
clear that many viral proteins are dimeric suggesting that this is a widespread strategy 
for the reduction of genetic material to be packaged into a viral particle. A number of 
observations soon firmly established HIV PR as a member of the aspartic protease 
family. Inhibition of a protease by pepstatin (Morishima, Takita et al 1970; 
Umezawa, Aoyagi et al 1970) is indicative of aspartic proteases. When it was shown 
that pepstatin inhibited HIV-1 PR in vivo this suggested that the protease was a 
member of the aspartyl family (Hansen, Billich et a l 1988; Seelmeier, Schmidt et al 
1988; Darke, Leu et al 1989). HIV PR is also inactivated by diazoacetyl norleucine 
methylester in the presence of Cu2+ - a reaction specific to aspartic proteases. In 
contrast, general protease inhibitors including leupeptin, chymotrypsin, 
phosphoramidone, and E-64 do not inhibit HIV PR even at 1 mM.
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Figure 7 HIV-PR 3D structure, as published in Nature by Navia et al. 1989.
Active
site
Monomers fail to 
interface at their N
and C termini in this 
erroneous structure - 
see text.
Figure 7 (Navia, Fitzgerald et al. 1989) shows a stereo Cot representation of the HIV-1 PR dimer 
(monomers are arbitrarily labelled A and B, and drawn in thin and thick lines respectively). The top 
view is along the dimer’s twofold axis of symmetry, whilst the bottom view shows a rotation of the 
first view by 90° about the vertical axis.
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Confirmation came when mutation of the conserved Asp 25 residue eliminated 
protease activity, just as predicted given it to be the catalytic residue of an aspartyl 
protease (Kohl, Emini et al. 1988; Mous, Heimer et a l 1988; Seelmeier, Schmidt et 
al 1988; Darke, Leu et al 1989). More importantly mutagenesis o f Asp 25 caused the 
generation o f non-infectious viral particles, demonstrating that maturation and host 
infection by the retrovirus are dependant on an active PR (Kohl, Emini et al 1988). 
This clearly established PR as a serious target for antiviral therapy, and confirmed 
that knowledge gained designing inhibitors of other aspartic proteases could be very 
usefully employed against HIV PR.
Soon crystals of HIV-1 PR were grown and preliminary data collected (McKeever, 
Navia et al 1989), and this was swiftly followed by a three dimensional structure for 
HIV-1 PR solved to 3.0 A resolution (Navia, Fitzgerald et al. 1989; Wlodawer, Miller 
et al. 1989; Lapatto, Blundell et al. 1989). It was the first structure of an HIV protein 
to be solved.
The initial structure by Navia et al., as illustrated in figure 7, was the subject of some 
controversy following the publication of rival structures by Wlodawer et al. and 
Lapatto et al. very shortly afterwards. The cause of this controversy was the fact that 
an interaction between the monomers at their N and C termini was seen in the later 
structures (illustrated figs. 8 and 9) but was absent in the earlier one (fig. 7). The main 
dimerization interface is composed of the interdigitated N- and C-terminal portions of 
the protease monomers, which together form a four-stranded antiparallel 13-sheet. The 
later X-ray structures showed that the interface directly involved the N-terminal 
residues 1-4 and C-terminal residues 96-99 of each monomer, whereas the initial 
structure by Navia et al. lacked residues 1 -5 and thus did not reveal the true nature of 
this interaction. This interface region is highly conserved among HIV-1 isolates and 
has since become a target for compounds designed to block the assembly of the 
homodimer or disrupt the dimeric interface, and thus inactivate the enzyme (Boggetto 
and Reboud-Ravaux 2002; Bowman and Chmielewski 2002).
The structural solutions demonstrated that the PR was a symmetrical homodimer, and 
that it was similar in structure to the other aspartyl proteases of the pepsin family 
(Navia, Fitzgerald et al. 1989; Wlodawer, Miller et al. 1989). It was also similar to 
other retroviral proteases, such as the Rous Sarcoma Virus (RSV) protease (Miller,
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Jaskolski et al. 1989). As discussed above, and illustrated in figures 8 and 9, the dimer 
was stabilised by a four-stranded antiparallel B-sheet formed by B-strands at both the 
N- and C-terminal ends. Also, the active site did indeed form at the interface between 
the catalytic triads o f each subunit, as predicted. A pair of ‘flaps’ enclosed the active 
site, each formed by two antiparallel B-strands connected by a B-tum at residues 49- 
52. It was clear from early structural solutions that the position of the flaps differed in 
the presence and absence of complexed inhibitor (Miller, Schneider et al. 1989). In 
the native enzyme the flaps adopt an open conformation (as seen in fig. 7 b), whereas 
in the presence of a bound inhibitor they appear to close down (fig. 8) over the active 
site and substrate binding cleft (Wlodawer and Erickson 1993). Subsequent NMR 
studies have revealed that the flaps are flexible (Nicholson, Yamazaki et al. 1995; 
Yamazaki, Hinck et al. 1996) and therefore able to undergo this conformational 
change. A water molecule (not to be confused with the nucleophilic water which is 
bound between the substrate and the catalytic residues) was frequently observed (fig. 
10) to be involved in hydrogen bond formation between the flaps and a bound 
inhibitor (Wlodawer and Erickson 1993). The hydrogen bonding mediated by this 
water may contribute to distortion of the scissile bond (Pearl 1987; Suguna, Padlan et 
al. 1987) and possibly plays an important role in the mechanism of catalysis (Miller, 
Schneider et al. 1989; Fitzgerald, McKeever et al. 1990; Swain, Miller et al. 1990; 
Jaskolski, Tomasselli et al. 1991; Harrison and Weber 1994). Specific deletion of 
these hydrogen bonds resulted in a dramatic decrease in catalytic activity (Baca and 
Kent 1993). The eukaroytic aspartic proteinases have only a single flap, which 
interacts with the substrate directly rather than via a water molecule. Consequently it 
was considered that designing compounds able to displace the structural water 
molecule might provide the basis for inhibitors specific to the retroviral proteases.
It was eventually shown that careful inhibitor design could achieve displacement of 
this structural water by a carbonyl group (Lam, Jadhav et al. 1994; Lam, Ru et al. 
1996; Wang, Freedberg et al. 1996)4.
4 More recently however, evidence suggests that while this structural water plays a role in inhibitor binding, it is 
not actually involved in the catalytic action of the protease (see Baca and Kent 2000 (Baca and Kent 2000), and 
references therein).
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Figure 8 HIV-1 PR illustration of 3D structure, showing closed flans,
active site with bound inhibitor, and dimerisation domain.
Figure 9 Schematic diagram of dimerisation domain.
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Figure 10 H IV-1 PR  active site with inhibitor.
* Water 301
1 PInhibitor
Figure 10 shows a water molecule (water 301) bound between the enzyme flaps and an inhibitor in the 
protease active site. It may contribute to substrate / inhibitor binding, but probably does not influence 
catalysis. Asps 25 and 125 are shown in green.
Between 1989 and 1993 over 160 crystal-structures of HIV-1 PR and HIV-1 PR 
inhibitor complexes were solved (Wlodawer and Erickson 1993). The information 
derived from these structures was used in the rational development of HIV PR 
inhibitors (considered later in this chapter, page 85 onwards). A recent query revealed 
181 hits from the PDB database when searching “HIV-1 protease” (text search 
settings: full text and match exact word), and of these 160 were accessible, and 21 
were either on hold or being processed (13 of these were dated 2004). Of the 
structures available 13 were deposited in 2002, 4 in 2003, and 6 in 2004, 
demonstrating that structural studies of this protein, its mutants and inhibitors are 
ongoing.
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The focus of attention then turned to the structure of HIV-2 PR, since any drugs 
directed against the proteases should preferably be effective against both serotypes of 
HIV. A structural solution of the HIV-2 PR was thus one of the initial aims of this 
PhD project. In the meantime modelling of HIV-2 PR was being used to enable 
rational drug design in the absence of a structure. HIV-1 and HIV-2 share no more 
than a 60% overall amino-acid identity. Many isolates of both HIV-1 and HIV-2 have 
been sequenced, and their proteases have been compared. Only 41% of the PR amino 
acids are identical between the two serotypes, however, the important structural 
elements are highly conserved. Since most differences are found in the loop regions, 
an accurate model o f HIV-2 PR could be obtained based on the structure of HIV-1 
PR.
With three dimensional models and actual structural data available, researchers were 
able to design inhibitors to specifically target HIV PR. Obvious starting points for 
inhibitor designs were pepstatin analogues and substrate analogues. Inhibitor design 
therefore required an extensive knowledge of the PR recognition / cleavage sites and 
their interactions with the PR substrate binding cleft. Studies had shown that PR is 
able to recognise several cleavage sites within the GAG and GAG-POL polyproteins 
at the junctions between constituent protein subunits (Darke, Nutt et al 1988; Nutt, 
Brady et al. 1988; Schneider and Kent 1988; Darke, Leu et al 1989). Since PR is also 
part of the POL polyprotein, it must achieve its own release from the POL 
polyprotein. This autocatalysis, and its inhibition by mutagenesis of the active site, 
has been demonstrated by the work of Loeb et a l (Loeb, Hutchison et al 1989). In 
the process of extricating itself from the POL polyprotein PR would also free the 
other viral enzymes - RT and IN. Subsequently the unfettered PR could release MA, 
CA, NC and p6 from the GAG polyprotein (fig. 11). Cleavage sites within retroviral 
polyproteins are heterologous, the amino acids surrounding the cleavage sites are 
different from site to site (fig. 12), and even the dipeptide comprising the site itself 
(ie. PI-PL) differs between different sites. Despite this there is a high degree of 
specificity, for example HIV-1 PR will not cleave RSV cleavage sites (Krausslich, 
Ingraham et a l 1989) despite sharing the same scissile bonds in some cases. Mutation 
of polyprotein substrates also disrupts cleavage (Hellen, Krausslich et a l 1989).
The different scissile site amino acid sequences give rise to varying cleavage 
efficiency from site to site. This may influence the order in which proteins are
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released from their polyprotein. While there is no clear recognition sequence, an 
approximate consensus can be perceived (fig. 13), and an algorithm for predicting 
protease sensitive sites has been published (Poorman, Tomasselli et al. 1991).
Figure 11 Cleavage site locations in polvnroteins.
The gag-pol region of HIV, showing junctions at which cleavage occurs.
(B.M. Dunn & J. Kay; 1990; Antiviral Cham. & Chemotherapy 1 (1), 3-8.)
(P17)
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Figure 12 The cleavage site recognition sequences for HIV-1 PR, and
predicted sequences for HIV-1 PR and SIVap.m PR.
* = scissile bond. Predictions were made by sequence alignment. For further information relating to
retroviral cleavage sites see Dunn et al. 1994 (Dunn, Gustchina et al. 1 9 9 4 )  .
HIV—1 known PR cleavage sites (Dunn & Kay 1990).
-P6 —P5 -P4 -P3 -P2 -PI * P'l--P12-P'3-P'4—P ‘5-P'6-
1. -ser-gln-asn-tyr * pro--ile-val-gln-
2. -ala-arg-val-leu * ala--glu-ala-met-
3. -ala-thr-ile-met * met--gln-arg-gly-
4. -pro-gly-asn-phe * leu -gln-ser-arg-
5. -ser-phe-asn-phe * pro--gln-ile-thr-
6. -thr-leu-asn-phe * pro--ile-ser-pro-
7. -ala-glu-thr-phe * tyr--val-asp-gly-
8. -ala-lys-ile-leu * phe--leu-asp-gly-
SIV (AGM) possible PR cleavage sites.
-P6 -P5 -P4 -P3 -P2 -PI * P'1-P'2-P’3-P'4-P*5-P16-
1. "850 -Ser-Gln-Asn-Phe * Pro-Ala-Gln-Gln-
2 . "1325 -Gln-Gly-Pro-Lys-Gln-Pro * Phe-Lys-Asp-Tyr-Val-Asp-
3. "1330 -Val-Asp-Arg-Phe * Tyr-Lys-Ala-Ile-
3. "1401 -Trp-Met-Thr-Glu-Ser-Leu * Leu-Ile-Gln-Asn-Ala-
4. "1750 -Gln-Val-Asn-Phe * Leu-Gly-Tyr-Gly-
5. "1950 -Asp-Arg-Gly-Ile-Phe * Phe-Glu-Leu-Pro-Leu-
6. "2250 -Val-Pro-Arg-Leu-Val-Met * Gly-Gln-Leu-Ser-Gln-Lys-
7. "3500 -Phe-Val-Ser-Thr-Pro * Pro-Leu-Val-Arg-Leu- (p51)
8. "3950 -Ile-Arg-Gln-Val-Leu * Phe-Leu-Glu-Lys-Ile- (p66)
HIV-2 PR possible cleavage sites.
_P5 _p4 -p3 -P2 -PI * P '1-P'2-P'3-P'4-P'5-
1. "830 -Gly-Gly-Asn-Tyr * Pro-Val-Gln-His-
2. "1410 -Pro-Lys-Glu-Pro * Phe-Gln-Ser-Tyr-
3. *1450 -Tyr-Val-Asp-Arg-Phe * Tyr-Lys-Ser-
3. "1505 -Thr-Gln-Thr-Leu * Leu-Val-Gln-Asn-
4. "1850 -Gln-Ala-Gly-Phe * Leu-Gly-Leu-Gly-
5. "1950 -Asn-Arg-Gly-Leu * Ala-Ala-Pro-Gln-
6. "2380 -Thr-Ala-Leu-Gly * Met-Ser-Leu-Asn-
6. "2385 -Ser-Leu-Asn-Leu * Pro-Val-Ala-Lys-
7. "3500 -Phe-Val-Ser-Thr-Pro * Pro-Leu-Val-Arg-Leu-
8. "3950 -Ile-Arg-Gln-Val-Leu * Phe-Leu-Glu-Lys-Ile-
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Figure 13 Common characteristics shared bv the HIV-1 PR cleavage sites.
PROTEASE CLEAVAGE SITES SOME COMMON FACTORS.
Compiled from the data for HIV-1.
I. The consensus sequence :-
(Ser/Thr) - X - Y -Z (Phe/Tyr) * Pro
Where x = small & hydrophobic
y = aromatic or large & hydrophobic 
z = small & hydrophobic
* = Scissile site.
II. Seven amino acids (p4 - p ’3) are required for specific, 
efficient cleavage.
III. All eight scissile sites have an overall hydrophobic 
composition.
A. Residues at positions pi & p ’l are always hydrophobic.
B. Those at p2 & p'2 are generally hydrophobic or uncharged 
polar residues.
C. Charged residues are virtually never present at p2/p4 or 
p ’2 /p14 .
IV. Differences between the sites cleaved by HIV-1 & HIV-2.
A. HIV-2 generally shows broader substrate specificity.
B. HIV-1 able to cope with aromatic & branched residues at 
pi & p'l.
C. HIV-2 less able to cleave substrates with aromatic or 
branched residues at pi & p'l/ prefers substrates with 
small substituents at these points.
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The active site is responsible for cleavage of peptide bonds, but not for the selection 
of the bond to be cleaved. The substrate binding sites flanking the active site 
determine where a substrate is cleaved. These contain hydrophobic pockets that bind 
the side chains of amino acids adjacent to the substrate cleavage site, and thus 
determine both substrate selection and rate of turnover. The two flaps (already 
described) close over the active site primarily to desolvate the bound substrate, but 
may also contribute to substrate recognition (Miller, Schneider et al 1989; Fitzgerald, 
McKeever et a l 1990; Swain, Miller et a l 1990; Jaskolski, Tomasselli et al 1991).
Enzyme kinetics using a variety of assay systems -  for example chromogenic peptides 
such as described by Konvalinka et al (Konvalinka, Strop et al 1990) - began to 
provide a great deal of information concerning the substrate specificities of the HIV 
PRs. This was augmented by the development of models and algorithms to predict 
whether a peptide could be cleaved by the protease or not (Chou 1993; Chou 1993; 
Chou and Zhang 1993; Chou, Zhang et al 1993; Zhang and Chou 1994; Cai, Yu et al 
1998). New substrate analogues were designed with optimised affinity for the 
substrate binding cleft, and the inclusion of a non-scissile bond at the cleavage site to 
create a substrate analogue inhibitor. There were technical difficulties involved, 
however. Firstly, large quantities of pure HIV PR were required for the many assays 
and structural studies involved in inhibitor testing, and HIV PR is not expressed at 
high levels in any conventional expression system. This problem was both 
encountered, and addressed, during the completion of this thesis. Secondly, the 
peptide substrates and inhibitor compounds were necessarily hydrophobic, and thus 
extremely insoluble in aqueous solutions. This made them difficult to use in assays, 
and would also impact upon the bioavailability of any drugs based on them.
Whilst inhibitor development and design will be considered later in this chapter (page 
85 onwards), it is useful to consider some aspects of protease inhibition at this stage. 
Aspartic proteinase activity is unaffected by serine, cysteine or metallo-proteinase 
inhibitors such as PMSF, divalent cations, and EDTA, but are in general sensitive to a 
number of inhibitor classes. Diazo compounds such as diazotyl norleucine methyl 
ester (DAN) react covalently with Asp 215 of porcine pepsin (Rajagopalan, Stein et 
al 1966; Bayliss, Knowles et al 1969), and this reaction is specific for a functional 
active site. Epoxides such as l,2-epoxy-3-(p-nitrophenoxy) propane (EPNP) have 
been shown to inhibit pepsin (Tang 1971), the inhibitor molecules reacting in a 2:1
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mole ratio with the enzyme. A crystal structure of penicillopepsin in complex with 
EPNP (James, Hsu et al 1977) revealed that two EPNP molecules form ester linkages 
with the carboxyl groups of the catalytic aspartate residues. Chymosin, renin, and 
various fungal apsartic proteinases are also inhibited by diazo and epoxy compounds 
(Morihara and Oka 1981). The archetypal aspartic proteinase inhibitor, however, is 
pepstatin, a competitive inhibitor having a central statine residue. The isovaleryl- 
derivative of pepstatin (isovaleryl-Val-Val-Sta-Ala-Sta) is the most commonly used, 
and indeed is generally referred to as “pepstatin”, but it should also be noted that 
other derivatives - acetyl-pepstatin (Ac-Val-Val-Sta-Ala-Sta) and lactoyl-pepstatin 
(Lac-Val-Sta-Ala-Sta) -  have also been reported (Satoi and Murao 1970; Kay, Afting 
et al 1982) and shown to inhibit aspartic proteinases (Valler, Kay et al 1985). 
Although isovaleryl-pepstatin was found to be a relatively poor inhibitor of HIV-1 PR 
(Seelmeier, Schmidt et al 1988; Giam and Boros 1988; Hansen, Billich et al 1988), 
and lactoyl-pepstatin even worse (Richards, Roberts et al 1989), the acetyl derivative 
proved to be a relatively good inhibitor of HIV-1 PR (Richards, Roberts et al 1989). 
The differences between the derivatives in terms of HIV PR inhibition were 
subsequently explained by a prediction that the enzyme’s P4 subsite was only able to 
accommodate a small residue or moiety, such as the acetyl (Weber, Miller et al 
1989).
It is thought that the tetrahedral hydroxy group of the statine acts as a transition state 
analogue of the substrate scissile bond carbonyl group (Marciniszyn, Hartsuck et al 
1976). This introduces another highly specific type of inhibitor, the transition state 
analogue inhibitor, the design of which is reliant on knowledge of the enzyme's 
chemical mechanism.
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Elucidation of the aspartic proteinase mechanism.
The mechanism by which the retroviral aspartic proteases achieve catalysis is 
essentially the same as that employed by the other aspartic proteinases. A complete 
understanding of the aspartic proteinase catalytic mechanism, and more specifically 
that of the retroviral aspartic proteases, would facilitate design of effective HIV PR 
inhibitors. It is generally accepted that the catalysis involves both aspartate residues, 
and probably also the participation of the water molecule observed bound between the 
aspartates in many of the PR crystal structures. However, the precise mechanism of 
aspartic proteinases has been the subject of some controversy.
Early proposals: a covalent enzyme -  substrate intermediate.
It was initially suggested that a covalent enzyme-substrate intermediate might be 
involved. Experiments using pepsin and penicillopepsin were thought to imply a 
covalent acyl-enzyme intermediate (Takahashi, Wang et al. 1974), and the failure of 
free amino acids to exchange with the enzyme-amino acid intermediate supported the 
idea that the intermediate was covalent (Wang and Hofmann 1976). Various workers 
tried to demonstrate the presence of a covalent intermediate, predominantly using 
porcine pepsin and penicillopepsin. There were attempts to trap a covalent 
intermediate (Comish-Bowden, Greenwell et al. 1969), stopped-flow experiments 
(Hofmann and Hodges 1982), cryoenzymological studies (Dunn and Fink 1984;
1 RHofmann, Fink et a l 1984), and Isotope incorporation experiments using H2 O 
(Antonov, Ginodman et al 1978; Antonov, Ginodman et al 1981), but they all failed 
to provide any support for the idea. The isotope incorporation experiments, on the 
contrary, showed that a general base catalysed attack by H20  was more likely 
(Antonov, Ginodman et al 1981). Crystallographic structures of rhizopuspepsin and 
penicillopepsin finally demonstrated that the formation of a covalent acyl- or amoni- 
enzyme intermediate is precluded by steric hindrance (Bott, Subramanian et al 1982; 
James, Sielecki et al 1982). However, crystal structures of aspartic proteinases 
consistently revealed the presence of a water molecule associated with the catalytic 
aspartates.
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Early proposals -  general base assisted nucleophilic attack by water.
The observation of an active site water molecule supported the proposal that catalysis
proceeds via a general base assisted attack by a water molecule and does not involve a 
covalent intermediate (Hofmann, Fink et al. 1984). It was thought possible that the 
observed water molecule could be the required nucleophile.
Early crystallographic studies of aspartic proteinases (Hsu, Delbaere et al. 1977; 
Jenkins, Tickle et al. 1977; Subramanian, Liu et al. 1977; Bott, Subramanian et al. 
1982; Blundell, Sibanda et al. 1983; James and Sielecki 1983; James and Sielecki 
1986) suggested that one of the catalytic aspartate residues - Asp 32 - was ionised 
(residues are numbered according to the system applied to Porcine Pepsin by Tang et 
al. PNAS 1973) while the other - Asp 215 - was protonated, and contemporary 
explanations of the potential mechanism reflected this (James, Hsu et al. 1977; 
Blundell, Jones et al. 1980). Among these, the charge relay mechanism of James et al. 
(James, Hsu et al. 1977) was later discounted because the large conformational 
changes by the enzyme that it required were shown to be unlikely (Pearl and Blundell 
1984).
Higher resolution studies of penicillopepsin (James and Sielecki 1983) and 
endothiapepsin (Pearl and Blundell 1984) suggested that the aspartates were in fact 
equivalent and symmetrical about a local 2-fold axis. The higher resolution data 
showed the active site water molecule to be within hydrogen bonding distance of all 
four of the catalytic carboxyl oxygens (James and Sielecki 1983; Pearl and Blundell 
1984). Also revealed was the close proximity of the carboxyl groups of the catalytic 
aspartates to one another, leading to the assumption that a proton must lie between 
these negatively charged groups since they would otherwise be expected to repel each 
other (Pearl and Blundell 1984). These observations and assumptions depicted a 
symmetrical image of the native active site, and it was suggested that this may 
indicate that an average of possible arrangements (fig. 14) was being observed (Pearl 
and Blundell 1984).
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Figure 14. Possible arrangements of active site water and proton.
Proton bound 
between adjacent 
carboxylates.
Asp 32
Asp 215 Asp 32
Negative 
charge 
delocalised 
onto water.
Asp 32
Figure from Pearl and Blundell 1984.
In this case the proton remains bound between the adjacent carboxylates, whilst the 
negative charge from the adjacent residues is delocalised onto the water. This would 
indicate that the water could potentially be a strong nucleophile, and thus initiate 
peptide bond cleavage.
The mechanisms put foward by Pearl and Blundell, James and Sielecki (James and 
Sielecki 1983; Pearl and Blundell 1984) were based on the structure of 
penicillopepsin in complex with pepstatin (James and Sielecki 1983) and incorporated 
this potentially nucleophilic water molecule.
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The proposals incorporate the following generalised mechanistic steps:
First: Protonation of the substrate carbonyl oxygen, probably by Asp 215
could initiate tetrahedral intermediate formation.
Second: Asp 32 could then abstract a proton from the bound water, and
simultaneously that water could engage the carbonyl carbon in a 
nucleophilic attack - forming a tetrahedral gem-diol intermediate.
Third: Protonation of the peptide nitrogen atom would culminate in C-N bond
cleavage, resulting in the amine and carboxyl products of peptide 
hydrolysis.
A tetrahedral intermediate is also featured in the mechanisms of other protease classes 
(Polgar 1988), and structural evidence supports the existence of a gem-diol tetrahedral 
intermediate during catalysis by aspartic proteinases (Veerapandian, Cooper et al. 
1992). There were however, other aspects of the proposed mechanism that could be 
disputed. In the first step if the enzyme associated proton is H-bonded between the 
two aspartates (as suggested by Pearl and Blundell) and held by a negative charge, it 
cannot readily be transferred to the less basic neutral peptide carbonyl oxygen without 
the prior assistance of the water attack (Polgar 1987). It must be assumed then, that 
protonation and base-catalysed nucleophillic attack are simultaneous processes rather 
than two discrete steps. The source of the proton in step 3 is also uncertain. It may 
potentially derive from the hydroxyl of the tetrahedral intermediate via Asp 215, or 
from bulk solvent. However, Polgar argued that protonation o f the leaving nitrogen of 
the tetrahedral intermediate from bulk solvent (specific acid catalysis) is unlikely 
under the conditions favoured by aspartic proteinases, so that this is eliminated as a 
source of the proton in step 3 (Polgar 1987). Alternatively the proton abstracted from 
the attacking water could be passed between the aspartates to protonate the leaving 
nitrogen of the tetrahedral intermediate (Polgar 1987). Given the high symmetry 
around the two active site carboxyl groups (Pearl and Blundell 1984) it may be that 
the dyad proton is able to bind either carboxyl in the free enzyme. The mechanism 
would then involve two concurrent and symmetrical proton transfers for both the 
formation and breakdown of the tetrahedral intermediate, or ‘push-pull’ catalysis 
(Polgar 1987).
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The scissile C-N bond of the peptide substrate may be distorted by the interaction of 
substrate residues elsewhere binding the active site cleft and enzyme flap residues, a 
phenomenon known as substrate strain (Pearl 1985; Davies 1990). It had previously 
been suggested that the strain imposed by substrate binding to pepsin could contribute 
to peptide bond cleavage (Fruton 1976). The lone pair on the peptide nitrogen is 
ordinarily delocalised across the C-N bond providing it with characteristics akin to a 
double bond. On binding of substrate to the enzyme cleft, interaction of substrate 
residues remote from the scissile bond with their adjacent cleft residues may cause 
distortion of the scissile bond. This may have the effect of reducing nitrogen lone pair 
delocalisation so that reversion to a state more characteristic of a single bond would 
occur. This change in the C-N bond would render it more susceptible to cleavage by 
nucleophillic attack (Pearl 1987).
Subsequently enzyme inhibitor complexes have been interpreted in terms of substrate 
strain (Suguna, Padlan et al. 1987; Jaskolski, Tomasselli et al. 1991). However, 
crystallographic studies of HIV-1 and SIV proteases complexed with both substrate 
and the hydrolysis products of that substrate have allowed modeling of the substrate 
enzyme complex (Rose, Craik et al. 1996). The resultant models lack any strain in the 
scissile peptide bond, and indicate the bond would not actually be deformed on 
substrate binding (Rose, Craik et al. 1996).
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Figure 15 The catalytic mechanism of aspartic proteinases as proposed by 
L.H. Pearl 1987.
Adapted from figures within: Pearl L.H., 1987, FEBS Letters, Vol. 214, no. 1, pp. 8-12
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This figure illustrates the steps in a proposed mechanism for aspartic proteinases, based on 
penicillopepsin, which incorporated the possibility that the scissile C-N bond is put under 
strain as the substrate interacts with remote substrate cleft and flap residues.
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Mechanisms with particular relevance to the retroviral proteases are proposed.
As structural and kinetic data for the retroviral proteases and their complexes with
inhibitors became more prevalent, consideration of the mechanism with specific 
respect to retroviral proteases became possible. Detailed potential mechanisms, 
specific for the HIV protease, have been described taking into account all the 
available structural and kinetic data available at the time (Lin, Lin et al 1994; Meek, 
Rodriguez et a l 1994). Each of these involves the nucleophilic attack by the bound 
water and the formation of a tetrahedral intermediate. They are also both referred to 
by the BRENDA protease database (a “comprehensive enzyme information system” 
to be found at http://brenda.bc.uni.koeln.de) as the references of choice when wishing 
to understand the HIV PR mechanism. Consequently they have been included here 
(figs. 16 and 17) as alternate mechanism proposals contemporary with the work 
described in this thesis, and as the basis for most further developments in attempting 
to establish the absolute mechanism.
Figure 16 Catalytic mechanism of HIV-1 PR proposed by Meek et al. 1994.
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Proposed chemical mechanism for HIV-1 protease-catalysed peptidolysis of: 
Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2 
based on crystallographic data, previous kinetic results, and the present isotopes effects data.
Figure taken from Meek T.D., Rodriguez E.J., and Angeles T.S., 1994, 
Methods in Enzymology, Vol. 241, pp 127-156
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Figure 17 Catalytic mechanism of HIV-1 PR pronosed bv Lin et al. 1994.
Nc - ^
0 O-
001 0O1
->
Asp125 Asp25
EH‘S
+S
Asp125 Asp25
<r
-p
Asp125 Asp25
EH"
Asp125 Asp25
EP
Proposed mechanism o f hydrolysis o f HIV-1 protease.
In the free enzyme, EH‘, two active site aspartyl groups (Asp-25 and A sp-125) are assumed to 
share a proton and a water molecule. The negative charge is assigned to the water oxygen. The 
enzyme-substrate complex is presented as EH‘S, three protons in the active site are marked HA, 
Hb, and He respectively. The transition state and the enzyme-product complex are marked ET 
and EP respectively.
Figure taken from Lin X-L, Lin Z-Z, and Tang J, 1994,
Methods in Enzymology, Vol. 241, pp 195-224
The mechanism described by Lin et al. is essentially that of the eukaryotic aspartic 
proteinases as described by Davies in 1990 (Davies 1990). It differs in that the 
retroviral enzyme is a dimer of identical subunits (whereas the eukaryotic enzymes 
are monomeric and asymetrical), and this confers upon the native active site a 
symmetry of both structure and charge distribution which is absent in the eukaryotes. 
However, the initial state (EH) adopted by Lin et al. is actually reminiscent of the 
symmetry proposed by Pearl (Pearl 1987) when describing the general mechanism of 
aspartic proteinases based on work involving the microbial enzyme endothiapepsin 
(fig. 15). Essentially both could be describing a situation in which a hydronium 
(H30 +) ion is effectively shared between the negatively charged carboxyls of the 
catalytic aspartates. In the process the charge from the carboxyls becomes transferred 
to the oxygen of the hydronium ion. On binding of the substrate this symmetry is lost 
in both mechanisms (figs. 15 and 17).
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Investigation o f the proton transfers involved in catalysis.
The investigations thus far considered have established the role of a water molecule in 
the attack and hydration of the peptide bond in addition to the formation of a 
tetrahedral intermediate. The consensus of the many mechanisms proposed is that 
reaction procedes by means of acid-base catalysis, in which a wate- "u cule disrupts 
the peptide bond hybridisation by engaging in a nucleophilic attack on the substrate 
carbonyl carbon. This nucleophilic attack results in the formation of a gem-diol 
tetrahedral intermediate in place of the carbonyl group, and the rearrangement of the 
amide nitrogen hybridisation from sp2 to sp3, i.e. the nitrogen lone pair ceases to be 
delocalised across the peptide bond. The next stage involves protonation of the 
nitrogen, and proton release from the gem-diol, with resultant break down of the 
peptide bond. However, precisely how the proton exchanges implicit in these steps 
procede is unclear. The possible permutations in terms of proton transfer have lead to 
a plethora of suggestions with respect to this aspect of the mechanism, and they are 
yet to be defined absolutely.
Crystallographic and molecular dynamic studies have since focused on this problem. 
Since the rational design of inhibitors to maximise their interaction with the catalytic 
aspartate carboxyls requires accurate information about the ionisation states and pKa 
values of these carboxyl groups, both in the free enzyme and during the catalytic 
process.
Theoretically the catalytic Asp dyad of the free enzyme can adopt one of three 
protonation states, these being deprotonated, monoprotonated or diprotonated. In 
addition any of these states could be adopted as catalysis progresses. Which of these 
states is prevalent at any given point in the reaction must be determined to fully 
understand the proton exchanges inherent in the mechanism. However, since protons 
cannot be visualised via the electron density maps employed to determine protein 
structures following X-ray crystallographic analysis, this information has proved 
difficult to obtain. Consequently the protonation states of the aspartate carboxyls have 
been inferred from other available structural and biochemical information, such as the 
proximity of the carboxyls to each, rather than from direct observations. Furthermore, 
molecular dynamic studies have predicted varying aspartyl protonation states 
dependant on the external pH and on interactions between the carboxyl groups and 
any bound compound (Harte and Beveridge 1994). This has meant that questions
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concerning the nature of proton transfers occuring during catalysis, and thus an 
understanding of the precise mechanism, have not been resolved by the numerous 
crystallographic studies. It has become possible to elucidate protonation states by 
means of NMR spectroscopy. However, NMR measurements are made in solution, 
consequently the dynamic nature of proton transfer makes the elucidation of an 
enzyme’s protonation state at any given point in the hydrolysis process extremely 
difficult. Nevertheless, NMR studies of HIV-1 PR free enzyme and inhibitor 
complexes have shown that various protonation states can exist, supporting the 
molecular dynamic predictions. NMR studies of an HIV-1 PR complex with a two 
fold symmetric inhibitor demonstrated that Asp25 and Asp25' (aka Asp 125) carboxyls 
are both protonated over the pH range 2.2 - 7.0 (Yamazaki, Nicholson et al. 1994). 
Alternatively a separate NMR study on a complex with an asymmetric inhibitor 
showed that Asp25 was protonated, whereas Asp25' (Asp 125) was not (Wang, 
Freedberg et al 1996). These studies support the notion that the prevailing catalytic 
carboxyl proto nation states are dependent upon the specific interactions involved 
between them and a given inhibitor. Ultimately, neutron diffraction studies are better 
suited to the investigation of enzyme protonation states, consequently this technique 
and its application to the study of aspartic proteinases is considered later in this 
chapter (See Future mechanistic investigations; Neutron diffraction, page 81).
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Figure 18 Illustration of the catalytic carboxyl protonation states considered 
in ab initio dynamic studies by Piana et al.
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Figure taken from:
Piana, S. and Carloni, P (2000) Proteins: Structure. Function, and Genetics. 39:26-36.
The deprotonated free enzyme state has already been considered by Pearl and 
Blundell who concluded that the close proximity of the catalytic carboxyls meant that 
they would be expected to repel each other unless a proton lay between them (Pearl 
and Blundell 1984). This supposition has recently been supported by an ab initio 
dynamic study (Piana and Carloni 2000) of the free HIV-1 protease which concluded 
that in the unprotonated state (fig. 18 Conformation A) the aspartyl groups would 
repel each other to such an extent that they would be forced to adopt a highly 
distorted conformation which would be very unstable, and has not been observed 
experimentally. The same study also investigated the possible active site 
conformations that may be adopted by the free HIV-1 PR in the monoprotonated 
state. These are characterised by their differing water and proton positions (fig. 18
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Conformations B and C). Conformation B has been shown to prevail in the free 
eukaryotic aspartic proteinases (Beveridge and Heywood 1993). It is also reminiscent 
of the free enzyme state proposed by Meek et al. (Meek, Rodriguez et al. 1994), 
differing by a rotation about the Cp-Cy bond of the protonated Asp. However, Piana 
and Carloni (Piana and Carloni 2000) concluded that for HIV PR conformation C (fig. 
18) is more stable than conformation B - the reverse of the situation prevailing in the 
eukaryotic aspartic proteinases (Beveridge and Heywood 1993). This result is 
supportive of earlier suggestions that a proton is located between the adjacent 
oxygens of the Asp carboxyl groups (Pearl and Blundell 1984), and that the 
coordinated water molecule makes hydrogen bonds with both the carboxyl side chains 
of the catalytic dyad (Pearl 1987) rather than with only one as later suggested by 
Meek et al. It also concurs with the crystallographic observations concerning the 
location of the coordinated water and proximity of the carboxyl groups. The various 
conformations observed by NMR studies of enzyme inhibitor complexes can be 
explained by the influence on the free-state exerted by the binding of a given 
inhibitor.
The puzzle remaining concerns the precise means by which the leaving nitrogen of 
the C-N bond is protonated, and the peptide bond broken. The nucleophilic attack on 
the carbonyl carbon results in gem-diol tetrahedral intermediate formation, and causes 
the amide nitrogen to change its hybridisation from sp2 to sp3. The diol subsequently 
releases a proton, whilst the nitrogen gains one. The diol most likely donates its 
proton to an aspartate, but the nitrogen could receive a proton either from an active 
site carboxyl group or from a nearby water molecule (Veerapandian, Cooper et al. 
1992). Difluoroketone inhibitors (-CO-CF2-) readily become hydrated (-C(OH)2-CFi) 
and thus mimic the hydroxyls of a gem-diol intermediate. The structure of HIV-1 
protease in complex with an inhibitor containing a central difluoroketone in a gem- 
diol form has been used to mimic a substrate peptide bond following its hybridisation 
collapse, in order to ascertain the means by which the leaving nitrogen is protonated 
(Silva, R.E. et al. 1995; Silva, Cachau et al. 1996).
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A two step substrate binding process (fig. 19) has been suggested which would 
involve conformational change on the part of the substrate itself (Silva, Cachau et al. 
1996), in the mode described by Furfine et al. (Furfine, D'Souza et al. 1992). In this 
scenario only half the substrate binds optimally to the enzyme cleft in the first 
instance. The reaction procedes by means of nucleophilic attack on the carbonyl 
carbon from the bound water (fig. 19 I), a gem-diol tetrahedral intermediate is formed, 
(fig. 19 II) and the peptide bond is hydrolysed - just as predicted by previous 
mechanistic proposals (fig. 19 IV). In the process a proton translocation occurs, so 
that the previously charged aspartate becomes protonated and vice versa (fig. 19 III). 
Additionally the changes wrought on the hybridisation state of the amide nitrogen 
allow rotation about the C-N bond (fig. 19 II). As a result the substrate adopts a 
second conformation in which the remainder of its residues can now bind the enzyme 
cleft optimally (fig. 19 III). The amide nitrogen's lone pair is consequently presented 
towards the newly protonated aspartate carboxyl, and is thus able to accept the proton 
(fig. 19 III). Simultaneously one of the gem-diol hydroxyls donates a proton (fig. 19 
III) to the recently charged aspartate (towards which both the hydroxyls of the diol are 
orientated). The proton exchange described results in rupture of the peptide bond and 
regeneration of the initial protonation state of the enzyme (fig. 19 IV and I).
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Figure 19 Proposed mechanism involving two-step binding process and 
conformational change by the substrate.
Catalytic mechanism of HIV-1 Protease 
as proposed by Silva et al 1996
i l lTV
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Figure taken from:
Silva A.M., Cachau R.E., Sham H.L, Erickson J.W., 1996, J. Mol. Biol., 255, pp. 321-346
Key:
Arrows; Red arrows indicate rotation, yellow arrows indicate electron transfer.
Spheres; Oxygen is red, Hydrogen is white, Carbon is green, Nitrogen is dark blue.
I Nucleophilic attack by water.
II Tetrahedral intermediate formed, rotation occurs about C-N bond.
III Substrate adopts second conformation, amide lone pair accepts a proton, proton exchange 
occurs between gem-diol hydroxyl and charged aspartate.
IV Peptide bond broken, initial enzyme protonation state regenerated.
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Structural studies have shown that protonation of the leaving nitrogen by the nearest 
aspartate is procluded by the likely distance (4 A) between them (Rose, Craik et al. 
1996). Protonation of the nitrogen from bulk solvent has also been rejected as unlikely 
under the pH conditions favoured by the enzyme (Polgar 1987). A conformational 
change in the substrate via the two step binding mechanism proposed by Silva et al. 
would overcome these objections by allowing the nitrogen to come into close 
proximity with a protonated aspartate. It would therefore seem a plausible proposal. 
However, structure based modeling of the substrate enzyme complex has not 
produced any evidence of this conformational change (Rose, Craik et al. 1996). On 
substrate binding the same study suggests that the substrate carbonyl enters a position 
within hydrogen bonding distance of the protonated apartate, and causes displacement 
of the coordinated water which adopts a position in close proximity to the carbonyl 
carbon, and hydrogen bonded to the other aspartate (Rose, Craik et al. 1996). The 
close proximity of the water to the carbonyl carbon at this early stage suggests that 
nucleophilic attack may commence immediately the substrate is bound (Rose, Craik et 
al. 1996). The results therefore support the notion of Polgar that proton abstraction 
and nucleophilic attack probably occur concurrently (Polgar 1987).
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Overview of the aspartic proteinase mechanism.
The various proposals discussed above are here distilled into an overall view of the 
most likely mechanism. It is probable that the free enzyme active site exists in a 
symmetrical state with the pair of catalytic aspartates adopting a monoprotonated state 
with the proton deployed between the two carboxyls (bound to one, and hydrogen 
bonded to the other - or vice versa) acting as a buffer between the two repellant 
groups. A water molecule is symmetrically coordinated by hydrogen bonds to both 
aspartates. On approach and binding of a substrate, the water is displaced and 
rotations about the Cp-Ca bonds of the aspartates are induced, in conjunction with a 
series of proton tranfers, brought about by the proximity of the 5-negative substrate 
carbonyl oxygen. The subsequent rearrangement to form the Michaelis complex 
allows the water to mount a nucleophilic attack on the delta positive carbonyl carbon. 
In the process a gem-diol tetrahedral intermediate is formed as a proton is transferred 
to the substrate carbonyl oxygen from the nearest aspartate, and a proton is abstracted 
from the water by the opposing aspartate, nearest the peptide bond. Rotation about the 
Cp-Ca bond of the asapartate abstracting the proton allows this proton to be 
positioned between the opposing catalytic residues, but at the same time shifts the 
unprotonated oxygen of that carboxyl into proximity with the tetrahedral intermediate. 
The peptide nitrogen is protonated by one of the gem-diol hydroxyls, and the peptide 
bond breaks, releasing the products. The active site reverts to its free state, a new 
coordinated water molecule having been provided from the bulk solvent. The 
symmetry of the active site allows either aspartate to be protonated initially, and thus 
allows an asymmetrical substrate to be processed in either of two orientations - 
provided there is no conflict in terms of interaction with the substrate binding pockets. 
This explains why protonation states have been seen to vary according to the inhibitor 
complex studied, and the efficacy of symmetrical inhibitors.
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Future mechanistic investigations.
The quest for an absolute answer to the mechanism question continues, using super 
computers and techniques such as ab initio Hartree-Fock theory to calculate reaction 
profiles for small, critical, portions of the enzyme substrate complex. As discussed, 
the major issues remaining to be elucidated concern aspects of protonation and proton 
transfer. High resolution X-ray diffraction may provide a solution, but a technique 
that is ideally suited to the task is Neutron Diffraction.
Neutron Diffraction
Neutron diffraction is the phenomenon associated with the interference processes 
which occur when neutrons are scattered by the atomic nuclei within a sample -  just 
as X-ray diffraction involves the scattering of X-rays by atomic electrons. Electrons, 
Neutrons and X-rays each have distinct properties that suit each to specific purposes. 
Their interaction with matter decreases in the order Electrons > X-rays > Neutrons. 
Most electron diffraction is performed with high energy electrons whose wavelengths 
are orders of magnitude smaller than the inter-planar spacing in most crystals. 
Electrons are charged, light particles and their penetration into solids is very limited. 
Since electrons exhibit a strong interaction with matter electron diffraction is 
essentially a surface technique. In contrast, X-ray and Neutron diffraction techniques 
are well suited to structural investigations. Neutrons are neutral particles each with 
spin 1/2, a magnetic moment of 1.9132 nuclear magnetons, and a half-life of 
approximately 888 s. Having a magnetic moment causes them to be sensitive to 
magnetic ordering within a solid.
Relative to X-ray diffraction, Neutron diffraction is a fairly new technique - the first 
neutron diffraction analysis of a protein structure was completed by Schoenbom in 
1969 on myoglobin (Schoenbom 1969), and it is still quite uncommon. This is largely 
because it requires the generation of high thermal-neutron fluxes (a thermal neutron is 
defined as a neutron possessing a kinetic energy of about 0.025 eV). These can only 
be obtained from steady state nuclear reactors or from particle accelerators called 
spallation sources. Further details concerning source of high thermal-neutron fluxes, 
and background information on neutron diffraction can be found in the Appendix 
(Appendix: General Introduction - supplementary information; Neutron Diffraction, 
page 334).
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Although X-ray diffraction has certain advantages over neutron diffraction - one being 
the much higher intensity of the sources available (the greater intensity of X-ray 
sources allows the use of smaller crystals and facilitates solution of the phase 
problem) - the principle distinction between X-ray and Neutron diffraction involves 
the location of hydrogen atoms. Since X-rays are scattered by the atomic electron 
cloud, atoms with fewer electrons scatter X-rays less effectively. Hydrogen atoms can 
therefore only be detected by high precision experiments -  impossible in the case of 
macro molecular crystallography. It is also difficult to distinguish neighbouring atoms 
of the same row of the periodic table and impossible to distinguish between different 
isotopes of the same element. Hydrogen represents half of all the atoms in a typical 
protein, yet a survey of the PDB revealed that only one percent of proteins crystallise 
well enough to provide sufficient resolution to detect hydrogen atoms using 
synchrotron X-ray beams.
The greatest advantage of neutron diffraction over X-ray diffraction is its ability to 
establish the exact position of hydrogen atoms. Since neutron beams interact more 
strongly with nuclei than do x-rays, neutron diffraction is more useful than x-ray 
diffraction for determining proton positions. As a result, neutron diffraction can 
provide data concerning the hydrogen bonds or protonation states of histidine and 
acidic residues -  as demonstrated with lysozyme (Mason, Bentley and McIntyre 
1984), the conformations of methyl groups, the solvent structure of the protein, and 
the degree of protection of particular hydrogen atoms within the structure.
Neutron diffraction is particularly useful when applied to the elucidation of enzyme 
mechanisms. The best currently accepted mechanisms are largely based on X-ray 
images of inhibitor structures, but the active-site hydrogen atoms cannot be 
definitively located by current X-ray analyses, leaving an incomplete picture of 
enzyme catalysis. For example, Myoglobin was studied by neutron diffraction to 
compare similarities in the modes of CO (Hanson and Schoenbom 1981) and O2 
(Phillips and Schoenbom 1981) binding. The imidazole of His64 (E7) was only found 
to be protonated when O2 was bound. However, Trypsin provides the most prominent 
example o f this application to date. The mechanism of the catalytic triad of serine 
proteases was finally solved by a neutron diffraction experiment on Mono-Iso-propyl- 
Phosphate (MIP) inhibited trypsin, which mimics the real enzyme-substrate 
intermediate (Kossiakoff and Spencer 1981). Kossiakoff and Spencer performed a
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neutron structure analysis at a resolution of 2.2 A on bovine trypsin covalently 
inhibited by the transition-state analogue MIP. The unique ability of neutron 
diffraction to locate hydrogen atoms allowed the protonation states of the catalytic site 
residues (Asp 102 and His57) to be determined. It was demonstrated that the proton of 
the catalytic site resided on the imidazole of His57 and not on the carboxylate of 
Asp 102. Since the bound MIP group mimicked the tetrahedral intermediate structure, 
the observed protonation states represented those prevailing at the most crucial stage 
in hydrolysis. This resolved a much debated mechanistic issue by showing 
conclusively that the catalytic base in the transition state of the reaction is His57, not 
Aspl02, improving understanding of the serine protease hydrolysis mechanism. The 
findings were later confirmed by 15N labelled NMR studies (Bachovchin 1985). 
Kossiakoff and Spencer also completed a detailed examination of the stereochemical 
interaction between the catalytic groups, identifying their specific mechanistic roles. It 
transpired that in addition to functioning as the catalytic group, His57 could guide the 
attacking water toward the acyl group during deacylation. Other aspects of protein 
structure which are observable only by neutron diffraction analysis were also 
elucidated, including orientation of well-ordered amide side chains (made possible by 
the large scattering difference between nitrogen and oxygen atoms), the location and 
orientation of water molecules, and the hydrogen exchange properties of the protein. 
This example reveals the versatility of neutron diffraction when applied to the study 
of biomolecules, and neutron diffraction has been used to gain insight into many 
aspects of protein dynamics.
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As we have seen, neutron diffraction clarified the serine protease mechanism, and 
may therefore be applied to similar mechanistic issues remaining to be resolved for 
the retroviral aspartic proteases. The difficulty in obtaining large enough crystals has 
until recently prevented successful neutron diffraction analysis of aspartic proteases. 
However, the development in recent years of the neutron Laue technique at the Intitut 
Laue-Langevin (ILL), and the European Molecular Biology Laboratory (EMBL) at 
Grenoble, has to some extent abrogated this problem. A neutron diffraction structure 
of the fungal aspartic protease endothiapepsin (Cooper and Myles 2000) is currently 
the largest protein solved by neutron diffraction methods, and has enabled the 
positions of the catalytic hydrogens to be established. It also represents the nearest 
analogy to the protonation states of the retroviral protease catalytic residues during 
hydrolysis. It is likely that similar experiments on retroviral protease crystals will 
eventually reveal the precise nature of their mechanism.
Coates et al (Coates, Erskine, et al. 2001) collected high-resolution neutron 
diffraction data from crystals of the fungal aspartic proteinase endothiapepsin bound 
to a transition state analogue (H261). The functional groups at the catalytic centre had 
clearly undergone H-D exchange despite being buried by the inhibitor occupying the 
active site cleft. Crucially the data provided convincing evidence that Asp215 is 
protonated and that Asp32 is the negatively charged residue in the transition state 
complex. This analysis agreed with data used to propose an earlier mechanism for the 
enzyme (Veerapandian, Cooper, et al 1992). However, the results also suggested that 
the hydrogen bonds between Asp32 and the hydroxyl of the transition state isostere 
are short - less than 2.6 A -  and thus possibly a particular type of hydrogen bond 
called a Low-Barrier Hydrogen Bond (LBHB). A brief summary of the LBHB 
concept can be found in the Appendix (Appendix: General Introduction - 
supplementary information; Low Barrier Hydrogen Bonds, page 339).
It has been proposed that LBHBs have an important effect in the catalytic mechanisms 
of a number of enzymes, including citrate synthase and serine proteinases. In serine 
proteases the formation of a LBHB follows steric compression resulting from the 
binding of the inhibitor. It is likely that a similar phenomenon occurs in aspartic 
proteases on inhibitor binding. The neutron diffraction data collected by Coates et al 
strongly supports the position that Asp215 is protonated in the transition state, while 
their suggestion that a LBHB forms between Asp32 and the inhibitor hydroxyl would
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account for delocalisation of the neutron density between these two groups. A 
subsequent 1.37 A resolution crystal structure of endothiapepsin in complex with the 
gem-diol inhibitor PD-135,040 corroborated the previous endothiapepsin gem-diol 
inhibitor complex structures on which earlier catalytic mechanisms had been based. 
However, the increased resolution over previous structures also confirmed the 
presence of several short hydrogen bonds within the active site. Neutron diffraction 
studies of endothiapepsin are thus providing a valuable insight into the mechanism of 
aspartic proteases generally, and may finally answer the remaining questions in this 
field. Ultimately this will enable improvements in aspartic protease inhibitor design, 
and subsequent developments in HIV therapy.
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HIV protease inhibitors.
Since the recognition of HIV PR as an essential component in the viral maturation 
process, and thus as a therapeutic target, a huge research effort has been applied to 
determine the enzyme’s structural and mechanistic characteristics, and subsequently 
identify means by which the protease function may be blocked in vivo. Some aspects 
of protease inhibition have been briefly considered already, but it is now appropriate 
to consider the development of HIV protease inhibitors (and ultimately drugs) to date 
in more depth.
Prerequisites of drug design.
A candidate protease inhibitor molecule should posses certain characteristics. It must 
inhibit HIV protease and be resistant to processing itself, whilst ideally possessing a 
high binding affinity, high specificity, and a broad spectrum of activity against viral 
genotypes. It must not pose any risk to the health of a patient, and it must also 
demonstrate compatibility with other therapies, both primary anti-HIV therapies and 
secondary anti-opportunistic infection therapies. Compatibility with other anti-HIV 
therapies has become especially important following the development of combination 
therapies. Therapies to combat secondary infections may include the use of 
antibiotics, antivirals, or antifungals against opportunistic infections; vaccinations 
against infectious agents; and prophylaxis of Pneumocystis pneumonitis. New 
inhibitor compounds must have circulatory and cellular drug levels that are 
consistently greater than their inhibitory constant ( K j ) .  They must exhibit good 
stability both in vivo (i.e. have long half-lives) and in terms of their formulation and 
storage. They must show good oral bioavailability, widespread tissue distribution, and 
be able to penetrate the blood brain barrier. Finally, where possible, they should be 
relatively cheap to manufacture and, in order to justify the high costs of drug 
development, it must be possible to protect the rights to any intellectual property 
involved - thus ensuring a return on investment for the developers. In reality a good 
inhibitor compound is likely to be a compromise solution that approaches each of 
these ideals most closely.
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Testing activity against mutant strains.
HIV-1 exhibits a very high degree of genetic diversity (Domingo, Escarmis et al. 
1996; Coffin 1992; Domingo and Holland 1997), which has been attributed to a high 
mutation rate (Mansky, Temin 1995), a rapid turnover (Perelson, Neumann et al. 
1996; Wei, Gosh et al. 1995; Ho, Neumann et al. 1995), and a large viral population 
(Piatak, Saag et al. 1993; Embretson, Zupancic et al 1993; Pantaleo, Graziosi et al. 
1993; Chun, Carruth et al. 1997). The combined effect of these characteristics causes 
the relatively high frequency of mutations observed in HIV proteins. This in turn has 
resulted in the accelerated development of drug resistant HIV strains (Ho, Neumann et 
al 1995; Wei, Ghosh et al 1995; Condra, Schleif et al 1995; Erickson and Burt 
1996). Many mutations have been observed to occur in the HIV protease (Erickson, 
Gulnik et al 1999), and in some cases these have conferred resistance to protease 
inhibitors. In addition, mutations may occur at the protease cleavage sites and in doing 
so compensate for any reduction in mutant protease efficiency (Cote, Brumme et al 
2001). Computer aided “co-evolution” studies have shown that compounds designed 
against the immutable properties (essential for the binding and cleavage of all native 
substrates) of the active site are better able to inhibit resistant strains, and also 
demonstrated that rational inhibitor design becomes more effective when designs are 
optimised against a large set of mutant enzymes (Rosin, Belew, et al 1999). New 
compounds are now typically designed to evade mutants, and tested in vitro against a 
variety of the most commonly occurring protease mutants in order to maximise their 
efficacy in vivo.
Testing non-specific binding.
In vivo an inhibitor is exposed to a plethora of cellular and blood-bome proteins en 
route to its protease target, thus any tendency to bind these proteins non-specifically 
will reduce it efficacy. Candidate protease inhibitor compounds are therefore tested 
for non-specific binding using cell based assays in the presence of 50% human serum.
Testing bioavailability.
Bioavailability is a function of aqueous solubility and hepatic metabolism. 
Consequently it may be influenced by molecular size, and hydrogen bonding 
capability. In order to determine the degree of oral bioavailability a series of animal 
experiments are required. Candidate inhibitors are initially administered orally to rats, 
then to dogs and finally to monkeys. In each instance the compound is delivered at
87
pre-determined concentrations (mg / kg body weight) and subsequent levels of the 
compounds in the animal’s blood are determined. The quantity detected in the blood 
may be influenced by the efficiency o f absorption, or by the rate of drug metabolism.
Strategies for drug candidate isolation.
There are a number of possible strategies for identifying potential inhibitor molecules, 
such as random screening, rational screening, or rational design.
Random screening.
Random screening involves monitoring HIV protease activity, by means of a high 
throughput assay, in the presence of each molecule from a very large library of 
candidates. The candidates are not pre-selected in any way, and every available 
library of compounds is used in the screening process. When a candidate exhibits an 
inhibitory effect it is selected for further analysis. The screening process may then be 
biased towards candidates of a similar type in order to identify further leads, or the 
compound may form the basis for development of rationally designed molecules. 
Random screening requires a very large number of candidate molecules for screening; 
large quantities of active protease; and an easily monitored, rapid and reliable assay 
system. There is no guarantee that suitable lead molecules will be discovered, 
however, this is a widely used technique for drug discovery in general.
Rational screening.
Semi-random, or rational screening entails high throughput screens of candidates 
having structural similarities to known inhibitor molecules, or to leads derived from 
random screens.
Rational design.
Rational inhibitor design is an iterative process comprising in silico structure based 
design, combined with in vitro testing and structural solution. It relies heavily on prior 
structural data, and on the ability to obtain further structural data as designs progress. 
This imposes an additional requirement on potential compounds -  their complexes 
with the target protease must crystallise to enable structural solutions to be obtained.
Each of these three general strategies has been employed in the search for HIV 
protease inhibitors, complementing and cross-fertilising each other in the process.
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A review of HIV protease inhibitors and their development.
In considering inhibitor development it is useful to be familiar with the fundamentals
of inhibitor-enzyme interaction and the basic strategies used to exploit these 
interactions. The enzyme’s affinity for its substrate relies on a network of non- 
covalent bonds and interactions. The nature of these has been elucidated through the 
solution of early aspartic protease-inhibitor complex structures, and they have 
influenced the design of subsequent generations of inhibitor.
The most obviously influential interactions occur between the enzyme’s substrate 
binding “pockets” and the inhibitor side chains. Inhibitor binding is mediated by 
numerous hydrogen bonds and Van der Waals contacts. In addition, inhibitors have 
frequently exploited hydrogen bonding between one or two inhibitor hydroxyl groups 
and the catalytic aspartates. These hydroxyls are intended to shift and replace the 
catalytic water molecule ordinarily coordinated by the catalytic aspartates, and 
responsible for nucleophilic attack on the substrate peptide bond. Hydrogen bonds 
also form between inhibitors and residues Gly27, Ala28, Ala29, Asp30, and Gly48, 
plus their alternate subunit counterparts (i.e. Gly27', Ala28', etc.) flanking the active 
site residues. A common feature revealed by structural studies of HIV PR-inhibitor 
complexes is a tetrahedrally coordinated water molecule linking the bound inhibitor 
molecule to the enzyme flaps (see fig. 25, page 97); noted in several structures it has 
been designated “water 301” (Swain, Miller, et al. 1990). This water accepts two 
hydrogen bonds from backbone amide hydrogen atoms of the of the flap residues 
Ile50 and Ile50' via its own oxygen atom, whilst donating two hydrogen bonds via it’s 
hydrogen atoms to the carbonyl oxygen atoms of the inhibitor -  thus inducing the fit 
of the flaps over the inhibitor. The distinction between the structural “water 301” - 
coordinated by the flaps and substrate - and the “nucleophilic” or “catalytic” water - 
coordinated by the active site aspartates (as proposed by the mechanism of Suguna, 
Padlan, et al. 1987; Pearl 1987) should be noted. Water 301 is located anterior to the 
scissile bond, while the nucleophilic water and the catalytic aspartyl side chain 
carboxyls are located on the posterior face of the scissile peptide bond (i.e. away from 
the flaps). In the following section the means by which these interactions have shaped 
inhibitor development will be considered, the problems associated with resistance will 
be considered and finally some alternative design strategies will also be explored.
Currently there are eight FDA approved HIV PR inhibitors compounds (table ). The 
structures of six of these are shown in figure 19 below.
Table 1 FDA Approved HIV Protease Inhibitors.
FDA Approved Pr<Dtease Inhibitors
Brand Name Generic Name Abbreviation Manufacturer
Aaenerase amprenavir APV GlaxoSmithKline
Crixivan indinavir IDV Merck
Fortovase saquinavir (soft gel cap) SQV (SGC) Roche
Invirase saquinavir (hard gel cap) SQV (HGC) Roche
Kaletra lopinavir/ritonavir LPV/r Abbott
Laboratories
Lexiva fosamprenavir FPV GlaxoSmithKline
Norvir ritonavir RTV Abbott
Laboratories
Revataz atazanavir ATV Bristol-Mvers
Sauibb
Viraceot nelfinavir NFV Pfizer
Figure 19 Chemical structures of six FDA approved PR inhibitors.
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Non-hydrolysable peptide inhibitors.
Pepstatin A (or isovaleryl-Val-Val-Sta-Ala-Sta) with a Kj of 360 nM for HIV-1 PR, 
represented a starting point for inhibitor development, and Richards et al. were able to 
demonstrate that acetyl pepstatin had a Kj of 20 nM (Richards, Roberts et al. 1989). 
However, the pepstatins lacked specificity for the HIV PR, and were thus of little 
therapeutic use. Despite this, pepstatin, and other known inhibitors of aspartyl 
proteases, did provide an insight into the HIV protease mechanism - as discussed 
earlier in the chapter -  and the statine moiety could also be incorporated into more 
specific inhibitor compounds, as will be seen.
The simplest strategy for the design of HIV protease specific inhibitors was to base 
them on a peptide substrate. This was facilitated by the characterisation of substrate- 
protease interactions that resulted in cleavage (considered on pages 59-64 this 
chapter). Studies by Griffiths et al. (Griffiths, Phylip et al. 1992) found a preference 
for proteolysis of substrates with scissile hydrophobic-hydrophobic (usually involving 
leucine, alanine, or valine) or aromatic-proline (i.e. phenylalanine-proline) peptide 
bonds. The substitution of a non-cleavable bond for the scissile site generates an 
inhibitor peptide.
Many of the earliest non-scissile substrate based inhibitors incorporated a reduced 
amide bond (Moore, Bryan et al. 1989), and the first protease-inhibitor complex 
structure solved by crystallography was that of HIV-1 protease in complex with the 
reduced amide inhibitor MVT-101 (fig. 20) (Miller, Schneider, et al. 1989). This 
compound did not have the central hydroxyl group that would become a feature of 
many subsequent inhibitors, consequently it did not interact with the catalytic 
aspartates and suffered low affinity.
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Figure 20 The reduced amide inhibitor MVT-101.
MVT-101
Structural analyses of peptide based compounds revealed a large degree of hydrogen 
bonding between the enzyme and peptide backbone suggesting relatively non­
specific, promiscuous, peptide binding characteristics. Consequently the variation of 
amino acid residues proved an unsuccessful strategy for the design of peptide based 
HIV PR specific inhibitors. In any case reduced amide compounds exhibited 
relatively low potency, and peptide based compounds displayed very poor 
pharmacokinetic properties (Plattner and Norbeck 1989).
Transition state analogue inhibitors.
Since the non-hydrolysable peptide isosteres - such as the reduced amides - had 
generally failed to provide effective therapeutic compounds, a mechanism based 
inhibitor design strategy was now pursued. Research into renin inhibitors (see 
Appendix, pages 332-333) had shown that transition state analogues were bound very 
tightly. The affinity of a substrate to an enzyme is generally very much lower than 
that of its transition state (Wolfenden 1999), thus the potency of protease inhibitors 
could be increased if they were based instead on the substrate transition state. Studies 
of renin had revealed the tetrahedral intermediate as approximating to the aspartic 
proteinase transition state, and identified statine, norstatine, hydroxyethylene and 
hydroxyethylamine based compounds as analogues of this state (fig. 21).
In 1989 Richards reported that compound H-261 (tBoc-His-Pro-Phe-His-Leu- 
v|/[CH(OH)]CH2]-Val-Ile-His5), known to be a potent inhibitor of human renin 
(Blundell, Cooper et al. 1987; Leckie, Szelke et al. 1985) and most typical aspartic 
proteinases (Valler, Kay et al. 1985), had a K, of 5 nM with respect to HIV-1 PR at 
pH 4.7 (Richards, Roberts et al. 1989). This hydroxyethylene compound was non- 
scissile and mimicked the sp3 carbon hybridisation of the supposed transition state 
geometry. However, it showed no specificity for HIV PR over other aspartic
5 (\|/[CH(OH)CH2] indicates the hydroxy-ethyl peptide bond replacement)
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proteases, such as human renin. Observations such as those by Richards et al. ensured 
that advances made during the development of transition state based renin inhibitors 
(Szelke, Leckie et al 1982; Rich 1990; Wiley and Rich 1993) would subsequently be 
applied to the design of HIV protease inhibitors. The development of renin inhibitors 
is considered further in the appendix (page 331-332).
Figure 21 The functional moieties of transition state analogue inhibitors.
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In pursuit of transition state analogue inhibitors of HIV protease, the statine and 
norstatine moieties were incorporated into substrate-analogue peptides (Raju and 
Deshpande 1991; Fehrentz, Chomier et al. 1992; Sakurai, Sugano et al. 1993; 
Mimoto, Imai, et al. 1991; Tam, Carriere et al. 1992; Slee, Laslo et al. 1995). Statine 
based compounds displayed low potency, probably because in lacking a PI' side- 
chain the number of hydrophobic contacts between compound and PR were reduced, 
lowering affinity for the enzyme (Sakurai, Sugano et al. 1993; Kempf 1994). In 
contrast the norstatine based compounds showed greater activity since they more 
closely resembled the native substrate. Norstatine has one (-CH2-) group less than 
statine and allows the reintroduction of a normal PT residue. Compound KNI-272 
(fig. 22 left) was based on norstatine and proved to be a potent HIV-1 PR inhibitor 
(Baldwin, Bhat, et al. 1995 (1); Baldwin, Bhat, et al. 1995 (2); Kiso 1996). However, 
despite low toxicity, it displayed poor bioavailability and was rapidly metabolised 
(Chokekijchai, Shirasaka, et al. 1995; Kiriyama, Nishiura et al. 1996; Mueller, 
Anderson, et al. 1998), whilst HIV-1 quickly developed resistant mutants when
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exposed to the compound in vivo. KNI-272 was subsequently used as the basis for JE- 
2147 (fig. 22 right), a potent norstatine based inhibitor incorporating a cyclic P2 
moiety that appeared to improve pharmacokinetic properties (Mimoto, Kato, et al. 
1999; Kiso, Yamaguchi, et al. 1998).
Figure 22 The Norstatine based inhibitors KN-272 and JE-2147.
KNI-272 Kj=5.5 pM JE-2147 Kj=0.33 nM
Ph
HO,
OH
OH
Difluoroketones (Sham, Betebenner et al. 1991; Sham, Betebenner et al. 1993) and 
difluorostatones have also been investigated as HIV PR inhibitors, employing a 
central fluorinated ketone moiety (fig. 21) to mimic the tetrahedral intermediate. 
Among examples of such inhibitors was compound MDL 74,695 (fig. 23) which had 
an IC50 of 5 nM, but unfortunately exhibited poor bioavailability, and rapidly 
selected for resistant mutants in vivo.
Figure 23 The Fluorinated ketone inhibitor MDL 74,695.
MDL 74 ,695  ICsos 5 nM
The crystal structure of acetyl-pepstatin complexed with HIV protease was solved at 
2.0-2.5 A resolution (Fitzgerald, McKeever et al. 1990) and demonstrated that the 
pattern of hydrogen bonding and subsite interactions for acetyl-pepstatin was similar 
to those observed for the hydroxyethylene inhibitor-HIV PR complexes. The main 
difference was the lack of a PI' residue occupying the ST subsite. The similarity 
between statine and hydroxyethylene based inhibitors is unsurprising when it is
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considered that statines are effectively truncated hydroxyethylene transition isosteres 
of Leu-Gly where the PI amide nitrogen is absent. However, their symmetrically 
hydrogen-bonded PI and P2' amide nitrogens are separated by only five bonds as 
opposed to the six present in peptide substrates, or hydroxyethylene and reduced 
amide isosteres.
Hydroxyethylene based compounds proved more potent than their statine or norstatine 
alternatives, and were the first compounds to exhibit activity in vivo, using cell-based 
assays (Dreyer, Metcalf et al. 1989; Meek, Lambert et al. 1990; Dreyer, Lambert et 
al. 1992; Roberts, Martin et al. 1990). Structures of HIV-1 protease complexed with 
hydroxyethylene-containing peptide mimics (Jaskolski, Tomasselli et al. 1991; 
Dreyer, Lambert et al. 1992; Graves, Hatada et al. 1992; Thompson, Fitzgerald et al.
1992) have shown that the hydroxyl group on the inhibitor adopts, at least 
approximately, the position usually occupied by the active site water molecule. 
Hydrogen bonding analysis of these hydroxyethylene inhibitor complexes lead to the 
conclusion that one of the two aspartates must be protonated in order to bind to the 
inhibitor hydroxyl group.
The majority of published hydroxyethylene based compounds have exhibited an S 
conformation at their hydroxyl group. The explanation for this becomes clear when it 
is considered that it is the stereochemical configuration of the hydroxyl group that 
determines the degree of interaction with the active site carboxylate side chains. In the 
S conformation (where the S hydroxyl group is in anti configuration with respect to 
the preceding R group of the PI substituent) the hydroxyl group is positioned such 
that it interacts with both carboxylates, whereas in the R conformation similar 
interactions would require major conformational rearrangements in the inhibitor 
backbone. Consequently a hydroxyethylene inhibitor compound having an R hydroxyl 
would adopt a higher energy inhibitor conformation, or exhibit weaker non-bonded 
interactions with the enzyme, or both it would therefore be less effective as an 
inhibitor compound.
Dihydroxyethylene groups have also been used to generate HIV PR inhibitors, such as 
U-75875 (fig. 24), which have a high affinity for the protease (Ashom, McQuade et 
al. 1990). Structural studies of the protease complexed with U-75875 indicated that
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the N-terminal hydroxyl group interacts equally well with either active site aspartate 
and in a manner similar to the isosteric S hydroxyl group of the monohydroxy 
inhibitors (Thanki, Rao, et al. 1992). Meanwhile the second hydroxyl group was only 
able to hydrogen bond with one of the aspartates (Asp 25), so that its contribution to 
inhibitor potency remains unclear, and the benefits derived from inclusion of an 
additional hydroxyl group appear negligible (Kempf and Sham 1996).
Figure 24 Structure of the dihvdroxvethvlene based inhibitor U-75875.
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Figure taken from Ashom, McQuade, et al. 1990
The hydroxyethylene compounds had tended to suffer from poor aqueous solubility 
and oral bioavailability, consequently the incorporation of a basic amine into their 
backbone was considered as a means to improve their characteristics. This resulted in 
development of the hydro xyethylamines.
Hydroxyethylamine based compounds introduce an additional bond between the PI 
and PT residues in comparison to the reduced amide and hydroxyethylene based 
compounds that had preceded them. Nevertheless, structural studies of HIV PR 
complexed with JG-365, a heptapeptide [CH(OH)-CH2-N] analogue (fig. 25), 
demonstrated that the inhibitor’s backbone adopted a similar conformation to that 
observed for both the reduced amide and hydroxyethylene based inhibitor structures 
(Swain, Miller et al. 1990), despite the additional bond and the constrained prolyl 
group. The JG-365 preparation was a racemic mixture of the R and S configurations at 
the hydroxyl carbon; however, the S isomer was exclusively present within the crystal 
structure. Furthermore the S hydroxyl group could be superimposed onto the S 
hydroxyl groups of hydroxyethylene based inhibitors, demonstrating that they adopted 
the same conformation.
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Figure 25 The dihvdroxvethvlamine inhibitor JG-365 binding HIV-1 PR.
p4 i* % v,
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Hydrogen bonding interactions between HIV-1 PR and JG-365 are represented by dashed lines.
Figure taken from Swain, Miller, et al. 1990.
In 1990 Roberts et al from Roche chose the Phe-Pro cleavage site sequence, located 
between the RT and PR of Pol, as their target (Roberts, Martin et al. 1990). By 
shortening the inhibitory peptide from six residues - initially believed to be the 
requisite minimum - to three, and by incorporating a hydroxyethylamino isosteric 
replacement, they generated a series of test compounds. Of these the compound Ro- 
31-8959 (Roberts, Martin et al. 1990), later known as Invirase or Saquinavir (see fig. 
19), was shown to be an effective inhibitor and became the first HIV protease 
inhibitor to be administered to humans. The compound consisted of a quinoline, 
asparagine, phenylalanine, decahydro-isoquinoline (DIQ) and NH-tertiary butyl. The 
Kj of this hydroxyethylamino isostere against HIV-1 PR was 0.4 nM, with antiviral 
activity in the nanomolar range. In comparison, the RT inhibitor (and first approved 
anti-HIV therapy) AZT was not active at 100 pM. Consequently this new anti-PR 
compound represented a breakthrough in AIDS therapy, and Saquinavir became the 
first clinically approved HIV protease inhibitor.
The shortened inhibitor peptides employed by Roberts et a l lacked a P3' residue, this 
revealed that the R, or syn, hydroxyl group configuration is preferred by 
hydroxyethylamine based inhibitors without a P3' residue. This contrasted with the 
preference for the anti hydroxyl group configuration observed in all previously
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described hydroxyethylene based protease inhibitors (both HIV PR and other aspartic 
protease peptidomimetic inhibitors). The R hydroxyl group compounds therefore 
differed from the S hydroxyl group compounds in their mode of enzyme binding. The 
binding mode for Ro-31-8959 with HIV protease was determined crystallographically 
(Krohn, Redshaw et al. 1991) and, as had been predicted, the DIQ and /-butyl groups 
bound the ST and S2' sub-sites, respectively. The DIQ carbonyl group was hydrogen 
bonded via the buried water to the flaps. However, the Nitrogen atom of the DIQ 
moiety had the opposite configuration to that of the corresponding pro line ring in the 
predecessor hydroxyethylamine compound JG-365, whilst the nitrogen of the t- 
butylamide was displaced by approximately 1.8 A preventing it from hydrogen 
bonding with the Gly27 carbonyl oxygen, as it might otherwise have done. The 
inhibitor backbone position prohibited any future chain extension into the S3' subsite, 
and steric hindrance by the large DIQ group in the PT position virtually precluded a 
hydroxyl group in the S configuration - unlike compounds having a proline at the PT 
site - and explaining the preference for an R configuration.
The development of hydroxyethylamines lead to reappraisal of some preceding 
hydroxyethylene compounds -  in particular LY289612 and L-685, 434 (fig. 26), both 
designed to imitate a Phe-Pro cleavage site.
Figure 26 The hvdroxvethylamine inhibitors LY289612 and L-685,434.
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The incorporation of a basic amine into their backbones resulted in significant
improvements and ultimately lead to their evolution into the FDA approved drugs 
Nelfinavir and Indinavir shown in figure 19 (Kaldor, Kalish et al. 1997; Reich, 
Melnick, et al. 1995; Jungheim, Shepherd, et al. 1996). Nelfinavir evolved from 
designs based on both Saquinavir and LY289612, each of these predecessors having 
exhibited poor oral bioavailability (Kaldor, Kalish et al. 1997; Reich, Melnick, et al.
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1996; Melnick, Reich, et al. 1996). Improvements were achieved by incorporation of 
an S-phenyl cysteine spanning P1-P3, and thereby improving hydrophobic interaction 
with the enzyme at these positions. The intervening P2 group was then optimised 
accordingly, and resulted in AG1343, also known as Nelfinavir. Similarly the 
introduction of an amine into L-685, 434, was intended to improve aqueous solubility 
and oral bioavailability (Thompson, Murthy, et al. 1994) and lead to the optimisation 
of several related hydroxyaminopentane amides (Vacca, Dorsey et al. 1994; Chen, Li 
et al. 1994; Dorsey, Levin, et al. 1994), culminating in L735,524 - a compound 
displaying good pharmacokinetic properties and oral bioavailability, later known as 
Indinavir.
Symmetrical and pseudo-symmetrical peptidomimetic inhibitors.
Structural solutions of HIV protease in complex with asymmetric (peptide based)
inhibitors revealed that both their N and C termini bound identical subsites as a result 
of the enzyme’s C2 symmetry. The design strategy of N or C terminal duplication (fig. 
27) resulted from this observation, and the development of symmetrical and pseudo- 
symmetrical inhibitor compounds followed. One of the advantages anticipated of this 
approach was high selectivity for the HIV PR; since the viral enzyme’s symmetrical 
nature was unique. This approach was initially adopted by Erickson et al. (Erickson, 
Neidhart, et al. 1990) who started with known inhibitors such as D-His-Pro-Phe-His- 
Phe-\j/[CH2NH]-Phe-Val-Tyr and made use of the complex structure of the Rous 
Sarcoma Virus protease. They exploited the C2 symmetry of this protease by 
replicating the left hand side ‘N-terminal’ of their peptide mimic on the right hand 
side, and incorporating an almost symmetrical tertiary hydroxyl moiety between them.
Figure 27 The N and C terminal duplication inhibitor design strategies.
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Effectively they produced a peptidomimetic with twin N-termini. The compound had 
a Kj of 4 nM, and was 10000 times more active against HIV PR than against other
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proteases. An equally feasible alternative involved replication of the C-terminus at 
each end. The N or C terminal duplication of inhibitors was intended to confer them 
with greater potency and specificity. The N-terminal duplication strategy was used by 
Abbot to generate the pseudo-symmetric di-amino-alcohol core of inhibitor A-74704 
(fig. 28, left), and X-ray crystallography confirmed highly symmetric binding of this 
inhibitor to the HIV PR active site. Abbott used the same strategy to develop the di- 
amino-diol core, as in compound A-77003 (fig. 28, right) -  which was clinically 
tested as an intravenous drug (Reedijk, Boucher et al. 1995).
Figure 28 The N terminally duplicated inhibitors A-74704 and A-77003.
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Rationally designed improvements were made to this class of compounds, including a
systematic investigation of P3 and P2' heterocyclic groups intended to decrease the 
rate of hepatic metabolism. The eventual replacement of the pyridyl groups with 
thiazoles provided increased chemical stability towards oxidation whilst maintaining 
sufficient aqueous solubility for oral absorption. These modifications generated the 
non-symmetric clinically approved compound Ritonavir (Erickson and Kempf 1994; 
Kempf, Marsh et al. 1995; Kempf, Sham et al. 1998).
The N-terminal duplication strategy has also been used by several other groups (Budt, 
Peyman et al. 1995; Mo, Markowitz et al. 1996, Ettmayer, Hubner et al. 1994). The 
C-terminal duplication strategy has also been employed to devise inhibitors (Kempf 
1994), but to a lesser extent. Bone et al. were the first to report a high affinity 
inhibitor, L-700,417 (fig. 29, left), exploiting the C-terminal duplication strategy, and 
crystallographic analysis revealed highly symmetric binding (Bone, Vacca et al. 
1991).
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Figure 29 Other terminally duplicated peptidomimetic inhibitors.
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Some incorporate one or two hydroxyl groups, maintaining a fully symmetric or 
quasi-symmetric character, while others are phosphinate based (Abdel-Meguid et al. 
1993). Their mode of binding does not necessarily reflect their structural symmetry, 
and some have been shown to bind asymmetrically (Dreyer, Boehm et al. 1993).
A more peptide-like inhibitor (fig. 29, right), which also exhibited a relatively high 
potency, was designed and synthesised independently by Babine et al. (Babine, Zhang 
et al. 1993). In designing these peptidomimetic compounds the hydrogen bonding and 
electrostatic interactions along the cylindrical groove, and optimal fitting of amino 
acid side chains into the binding groove were taken into account. Also, their central 
carbonyl groups were designed to interact, via hydrogen bonding, with water 
molecule 301 in order to stabilize the close formation of the flaps on the enzyme 
(West and Fairlie 1995). While inhibitors such as Ro31-8959, LY289612, and other 
similar peptidomimetic protease inhibitors proved to be potent antivirals in vitro, they 
suffered from poor absorption, poor oral bioavailability, short serum half-life values, 
high susceptibility to hydrolysis by degradative enzymes, and other pharmacological 
problems (Reich, Melnick et al. 1995). The limitations on peptidomimetic inhibitors 
have resulted in efforts to minimise the pharmacological problems by developing 
inhibitors that are structural mimics of peptides but with little or no peptidic character.
Reich, Melnick et al. (1995) approached this problem by beginning with the co­
crystal structure of HIV-1 protease with LY289612 (a peptidomimetic inhibitor). As 
their base design they retained only the non-peptidic hydroxyethyl-t-butylbenzamide 
portion of the original inhibitor. They then synthesized and attached a variety of 
substituents to fit the various active site pockets. An iterative, seven-cycle, process
101
involving solving the co-crystal structures of the protease with each new non-peptide 
inhibitor, and using the data to design the next, ultimately resulted in improved design 
and maximised binding affinities. Further characterization in vivo showed improved 
bioavailability of up to 30% and maintenance in plasma levels, at or above, the 
antiviral IC90 for five or more hours in rats, dogs, and monkeys. However, the 
majority of peptidomimetics exhibited poor bioavailability due to their inherent low 
solubility, and high clearance. Consequently the development of non-peptide inhibitor 
designs was preferred.
Non-peptide inhibitors.
Non-peptidic inhibitors included the compound UCSF-8 (Rutenber, Fauman et al.
1993), a modification of the drug haloperidol. Haloperidol was discovered to be an 
inhibitor of HIV-1 PR following a computational screen of the 10000 molecules 
comprising the Cambridge Structural Database. The screen sought those molecules 
that were complimentary to the HIV-1 PR active site in terms of their steric 
properties. However, haloperidol is toxic at high concentrations and thus unsuitable as 
a drug. Replacement of haloperidol’s functional ketone with a thioketal ring resulted 
in compound USCF8 shown in figure 30 (Rutenberg, Fauman et al. 1993).
Figure 30 The haloperidol based inhibitor UCSF-8.
UCSF-8
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In contrast to peptidomimetic inhibitors, USCF8 interacts mainly with the flaps of the 
enzyme in an open conformation. The interaction of USCF8 with the catalytic site of 
the protease is mediated by a water molecule located at equal distance (3 A) from two 
catalytic aspartates. This water molecule probably occupies a similar position to the 
catalytic water molecule responsible for substrate hydrolysis, but since the 
peptidomimetic inhibitors replace this water molecule with their hydroxyl groups, it 
had not previously been observed in their crystallographic structures. A
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pharmacophore6 was subsequently designed taking this water into account, and the 
resultant model - which addresses metal-organic compounds particularly - was used 
for screening new HIV PR inhibitors through the Cambridge Structural Database. 
Among the structures fitting into the active site of the enzyme, the compound 
SETCEZ, or Diaqua [bis (2-pyridylcarbonyl) amido] copper (II) Nitrate (Castro, Faus, 
et al. 1990), shown in figure 31, was found to behave as a competitive inhibitor of 
HIV-1 protease with a K* value of 480 uM (Lebon and Ledecq 2000). New copper 
coordination compounds, having an octahedral geometry favorable for the orientation 
of their interacting substituents within the protease subsites were designed and 
inhibited HIV-1 protease in the micromolar range (Lebon and Ledecq 2000).
Figure 31 The organo-metallic inhibitor SETCEZ.
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6 T he traditional m edicinal chem istry  defin ition  o f  a  pharm acophore is the m inim um  functionality  a m olecule has 
to  con tain  in order to  exh ib it activity. O n ly  m olecu les w hich interact at the sam e recep tor site in the  sam e way 
w ill share a pharm acophore.
The significance of “water 301
As structural data became more readily available, and the use of modelling and 
simulations became more common, structure based design prevailed. Molecular 
modelling eventually became an essential aid to crystallographers and medicinal 
chemists in the design of HIV protease inhibitors. Computer based designs enabled 
the development of non-peptide inhibitors able to displace both the catalytic water, 
and the structural water molecule 301, whilst exhibiting much improved 
pharmacokinetic properties.
Water 301 acts as a bridge between substrate and the enzyme flaps. It has been 
suggested that the hydrogen bonds contribute to distortion of the scissile bond away 
from planarity, increasing the electrophilic character of the bond carbonyl and 
facilitating catalysis of the bonds cleavage by the nucleophilic water. Baca and Kent 
showed that specific deletion of just these two hydrogen bonds leads to a drastic 
decrease in the catalytic efficiency of the enzyme (Baca and Kent 1993). This 
coordinated structural water (water 301) is found exclusively in the retroviral aspartic 
proteinases, and is not observed in the eukaryotic aspartic proteinases. Consequently 
the contrasting structural observations, and anticipated mechanistic differences 
between retroviral and eukaryotic aspartic proteinases relating to water 301, have 
provided a focus for structure-based drug design targeted at retroviral proteinases. The 
eukaryotic, pepsin-like, aspartic proteinases are two-domain, single polypeptide chain 
(i.e. monomeric) molecules having only one flap. Their single flap interacts with the 
substrate P2 and P10 carbonyls by direct, non-water-mediated, hydrogen bonding. 
Inhibitor designs have sought to exploit this difference in enzyme-inhibitor H-bonding 
between the aspartyl proteinases of human host and parasitic retrovirus respectively, 
based on the presumption that it is mechanistically relevant. The intention has been to 
generate inhibitors specific for HIV PR that have no deleterious effect on the function 
of host cell-encoded aspartyl proteinases.
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The cyclic urea inhibitors.
Lam et al from DuPont Merck were among the first to pursue this approach, 
publishing the rational design of their non-peptidic cyclic urea inhibitors (XM323 and 
XM412) in 1994 (Lam, Jadhav et al. 1994). Subsequent crystallographic analyses 
confirmed the computer generated predictions of successful water displacement by 
these compounds.
Figure 32 The design evolution of cyclic urea inhibitors.
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Figure taken from Hodge, Straatsma et al. 1998, and based on work by Lam, Jadhav et al. 1994.
Lam et al. began by designing a C2-symmetric dihydroxy-ethylene mimic, and then
using the Docking molecular modelling process to locate it within a protease 
structure. They then proposed a simple pharmacophore based on a hydrogen bonding 
group near the active site aspartates and two symmetric hydrophobic groups for PI 
and PI'. Three dimensional database searching presented the 1,6-para-dipheno 1-2,5- 
dimethoxy-6-hydroxybenzene molecule (fig. 32 I), where the phenol groups occupied 
the PI and PI' positions. The methoxy and hydroxyl substituents were designed to 
form hydrogen bonds within the active site, with the 2-methoxy group specifically 
intended to displace water molecule 301. For better positioning of these groups they 
selected a cyclohexanone ring (fig. 32 II), then expanded this to a seven-membered 
ring to accommodate a diol (fig. 32 III). Finally they introduced a cylic urea (fig. 32 
IV) to improve hydrogen bonding with the flap isoleucines. Additional modelling 
predicted the stereochemistry and conformation which was later confirmed by an X- 
ray structure. The resultant compound was a cyclic urea peptidomimetic of D- 
phenylalanines. Two further small hydrophobic groups for the P2 and P2' site 
(represented by P2 and P2' in fig. 32 IV) were produced by N-substitution, reducing 
the Kj from 4 pM to 4 nM. The hydrophobic groups, the hydrogen bonding pattern 
and the rigidity combined to make these compounds good inhibitors. After modelling 
in the S2 and S2' site, the hydrophobic side chains were enlarged to improve the
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inhibition to 0.3 nM. A hydrogen bonding group - OH, in XM323 (fig. 33), and later 
NH2 in XM412 - on the phenyl rings, improved the antiviral activity, and the 
bioavailability. Subsequent crystal structures have seemed to confirm the proposed 
binding mode (see fig. 34). While XM323 has 50% bioavailability and drug levels in 
plasma exceeds the IC90 for 4 to 16 hours, Phase I clinical trials were abandoned in 
1993 in favour of the derivative XM412 which was found to be more water soluble 
and bio-available (West and Fairlie 1995).
Figure 33 The cyclic urea inhibitor candidate XM323
XM 323
Figure taken from Otto, Reid et al. 1993, and based on work by Lam, Jadhav et al. 1994
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Figure 34 Stereo image of a cyclic urea (XK216) displacing water 301.
Key: H H
= hydrogen bonds
O = position of inhibitor oxygen (original position of water 301) and hydrogen bonds to flap
H = Hydrogen bonds between inhibitor and catalytic Aspartates.
Figure adapted from Ala, DeLoskey et al. 1998, showing HIV-1 PR (light blue) complexed with cyclic 
urea XK216 (dark blue). Water 301 has been displaced by the inhibitor oxygen, which also interacts 
with the flaps. The original position of water 301 prior to displacement is marked by superimposed 
electron density (pink).
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Given the differences between retroviral and host aspartyl proteases despite their 
presumed evolutionary, structural, and mechanistic similarities it was important to 
experimentally determine whether HIV PR required functional H-bonding from one 
or both flaps for normal catalytic activity. As already described the water mediated 
hydrogen bonding between substrate and flaps appeared to have important catalytic 
consequences; it was therefore a significant consideration in drug design.
Baca and Kent (Baca and Kent 1993, Baca and Kent 2000) determined to investigate 
the role of the flaps and water 301 in catalysis. As earlier described, HIV PR is a 
homodimer of two identical, non-covalently associated, 99-residue polypeptide 
chains, encoded by a single gene. Consequently, in order to carry out asymmetric 
modification of only one of the two monomers, Baca and Kent produced a “tethered 
dimer” construct, effectively making a single polypeptide of the two monomer chains. 
They used a total chemical synthesis technique, involving convergent chemical 
ligation, to generate a 202-residue synthetic HIV-1 protease whereby the two subunits 
were covalently joined by means of a short linker structure between the C-terminus of 
one and the N-terminus of the other.
Previously, covalent dimer analogues of HIV-1 PR had similarly been produced by 
recombinant DNA expression in bacterial systems and were shown to be identical to 
the native enzyme in terms of their kinetic properties (Dilanni, Davis et al. 1990; 
Cheng, Yin, et al. 1990; Tozser, Yin, et al. 1997). The engineered, synthetic, HIV-1 
PR analogue was generated such the Gly49-Ile50 amide bond N(H) was replaced in 
one flap only by an oxygen atom not capable of acting as a hydrogen bond donor. A 
control enzyme was also synthesised in which no such modification was introduced.
If, as predicted based on crystallographic observations, each flap contributed a 
catalytically relevant hydrogen bond then a PR analogue engineered to eliminate this 
H-bonding in one flap only would be expected to exhibit significantly reduced 
catalytic efficiency. Previously Baca and Kent had performed experiments in which 
they had used a similar technique to delete the relevant H-bonding in both flaps 
simultaneously by incorporation of sulphur to replace each of the Gly49-Ile50 
backbone amides (Baca and Kent 1993). This earlier experiment had resulted in 
considerable loss of activity, and based on their observations it was predicted that an 
asymmetrically engineered construct would display a rate (kcat) reduction of 100-fold
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compared with native HIV-1 PR. It was anticipated that the kcat reduction would 
result from a combination of two effects: an increase in the activation energy of 
enzyme-catalyzed substrate hydrolysis, and a two-fold rate reduction due to the 
asymmetry of the covalent dimer form of the enzyme - which would permit only one 
of the usual two orientations of substrate binding. However, if both the enzyme- 
substrate P2-P1' carbonyl H-bond(s) can be donated from a single flap (as in the 
pepsin-like proteinases), no change in intrinsic catalytic activity would result from 
deletion of the essential H-bonding element in only one of the two flaps. In this event, 
only a two-fold rate (kcat) reduction would be expected (because only one productive 
substrate binding mode would be possible in the now-asymmetric enzyme).
The catalytic activity and substrate specificity of both the Control and Modified HIV- 
1 PR constructs were evaluated by cleavage of synthetic peptide substrates. In both 
cases their enzymatic properties were consistent with those of the native homodimeric 
HIV-1 PR. The kcat values for the Control, native, and covalent recombinant dimer 
proteases were equivalent - demonstrating that the non-genetically encoded elements 
of covalent structure had no adverse effect on enzymatic function. Meanwhile the 
observed kcat for the modified HIV-1 PR was reduced only 2-fold relative to the 
control PR rather than the 100-fold effect expected if both of the Ile50 NH flap- 
substrate hydrogen bonds contributed equally to catalysis. Apparently deletion of the 
flap hydrogen bond donor in one flap only has virtually no effect on the catalytic 
efficiency of the enzyme. The 2-fold reduction observed is consistent with only one 
productive substrate orientation on binding to the engineered asymmetric enzyme 
molecule.
The observation that hydrogen bonding is required from only one flap for full 
enzymatic activity in HIV-1 PR has important implications. On the basis of 
crystallographic observations, it had been assumed that both flaps were intimately 
involved in enzyme action. It was further assumed that the unique tetrahedrally 
coordinated water 301, and the two hydrogen bonds it mediates, played a key role in 
the catalytic mechanism by stabilizing the distortion of the scissile amide bond from 
planarity and thus increasing its susceptibility to nucleophilic attack.
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Baca and Kent had themselves previously established that hydrogen bonds from the 
flaps to the substrate are important for the enzymatic activity of HIV-1 PR (Baca and 
Kent 1993). Deleting the H-bonding ability at the N(H) of Gly49-Ile50 peptide bonds 
of both flaps led to a 3000-fold decrease in catalytic activity. In addition to illustrating 
the importance of these bonds, this dramatic effect also demonstrated that other 
potential H-bond donors within the flaps were unable to replace the deleted 
interactions and restore enzymatic activity. The experiment also provided a control for 
their subsequent observation that H-bonding from only one flap was required for 
hydrolysis of a substrate Baca and Kent 2000).
However, prevailing structural data showed that the predominant binding mode for 
substrate derived inhibitors to HIV-1 PR involves both flaps and water 301 - even in 
solution. To explain this it was proposed that the coordinated binding of water 301 by 
both flaps forming an H-bond bridge with the substrate-enzyme complex is simply a 
favoured but unproductive binding mode. It was further suggested that the second flap 
(i.e. either flap in the native enzyme depending on the orientation of the bound 
substrate; or, the non-bonding flap in the modified enzyme construct) is not involved 
in the catalytic action of the enzyme molecule, and would remain in a highly mobile, 
raised, or open position - analogous to the open flaps of the RSV and SIV unliganded 
proteases. Structural data for the pepsin-like proteases shows inhibitor carbonyls 
interacting directly with a single backbone amide N(H) moiety of their single flap. 
Consequently, in theory, a single N(H) moiety ought to be sufficient for catalysis, 
even if two are available -  as in HIV PR. Thus it may be that HIV PR only uses a 
single flap at any one time during catalysis - in a manner analogous to the pepsin-like 
proteases. The activity of pepsin-like proteinases additionally demonstrates that a 
single flap is sufficient to provide the substrate desolvation, and other features, 
necessary for hydrolysis. If, in the engineered enzyme, the native flap closes over the 
ligand in a face-on orientation (rather than the edge-on orientation seen in native 
enzyme crystal structures) it could supply both hydrogen bonds to the P2 and PT 
carbonyls of the substrate. This would be analogous to the ligand binding mode 
observed in single flap pepsin-like aspartyl proteinases.
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Inhibition by MVT-101 was essentially unaffected by the loss of a single flap 
hydrogen bond (Baca and Kent 2000) or by the loss of both flap hydrogen bonds 
(Baca and Kent 1993) despite the clear presence of interactions with both flaps in the 
crystal structure of the MVT-101 complex with native enzyme (Miller, Schneider et 
al. 1989; Miller, Geller et al. 1997).
Cyclic ureas, such as DMP-323 were specifically designed to replace water 301. Their 
sub-nanomolar potency, and their high selectivity for HIV-1 PR over cell-encoded 
pepsin-like proteinases, has been attributed to their ability to form two flap-inhibitor 
hydrogen bonds - one with each flap - via a single carbonyl group that displaces water 
301 (Lam, Jadhav et al. 1994). It was therefore pertinent to ask whether the 
elimination of one of these flap hydrogen bonds would reduce their efficacy. 
Crystallographic analysis of an HIV-1 PR complex with a DMP323-related cyclic 
urea inhibitor appeared to confirm the existence of these hydrogen bonds, thus it was 
expected that deletion of one of them would result in a significant reduction in the 
binding affinity of this inhibitor. However, it transpired that binding of DMP-323 to 
the modified HIV-1 PR analogue is actually slightly stronger than to the Control HIV- 
1 PR or to the native HIV-1 PR (Baca and Kent 2000). This author conjectures that 
perhaps in the presence of both hydrogen bond donors the inhibitor carbonyl is 
centrally positioned between them by virtue of their equally attractive forces, and 
forms conventional hydrogen bonds with both. However, once one flap bond donor is 
deleted the carbonyl shifts towards the remaining hydrogen bond donor, and in 
achieving closer proximity a Short Strong Hydrogen Bond (SSHB) may form. SSHBs 
(discussed in the appendix, page 339) are much stronger than conventional hydrogen 
bonds, having similar characteristics to covalent bonds, and this could explain the 
increase in affinity that is observed. It may prove possible to determine the validity of 
this suggestion by means of neutron diffraction studies (also discussed on pages 81-85 
this chapter, and in the appendix, pages 334-338).
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Combating Resistant Viral Variants
In clinical trials HIV-1 protease inhibitors have been shown to cause a dramatic initial 
decline in viral plasma RNA in HIV infected individuals. However, in patients taking 
protease inhibitors alone, an increase in plasma viral RNA to near baseline levels 
occurs within one year (Kaplan 1996). Failure of HIV-1 protease inhibitor therapy is 
attributed to the development of resistant viral proteases.
Figure 35 Location of drug resistant mutations occurring in HIV-1 PR.
FIAPPTVOT POiNT
The spheres locate residues associated with drug resistant mutations of HIV-1 PR. 
Figure from Ala, Huston et al. 1998.
The combined effects of rapid viral replication (Wei, Ghosh et al. 1995) and the high 
error rate (Williams and Loeb 1992) of HIV RT - about 1 in every 10,000 bases - 
result in a high frequency of viral mutation, and where these confer drug resistance 
they are highly favourable (Erickson and Burt 1996). Computer simulations predict 
that if a mutant virus has a 5% selective advantage (i.e. a replication rate 1.05 times 
that of the wild-type virus) it will become the dominant genotype within 100 virus 
generations (Erickson and Burt 1996). Consequently the virus is able to evolve under 
selective pressure from a protease inhibitor, becoming drug-resistant - often within a 
single year of monotherapy - by encoding mutants with a reduced affinity for the 
inhibitor but retaining the ability to process viral precursor polypeptides (Condra, 
Schleif et al. 1995; Molla, Korneyeva et al. 1996; Patick, Mo et al. 1996).
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Approximately 34% of the protease residues (i.e. 34 of the 99) are associated with 
resistance to various inhibitors (Parikh, Larder et al. 2004), and a number of these are 
illustrated in figure 35. Mutations appear to accumulate in discrete steps initially in 
the active site and subsequently in peripheral or “compensatory” regions of the 
enzyme (Mo 11a, Korneyeva et al 1996). Mutations associated with resistance 
observed to date have tended to be clustered in and around the active site, reducing 
inhibitor binding potential (Ki values may be increased by between 100 to 1000 fold) 
either by limiting contacts between the inhibitor and the protease (reducing van der 
Waal interactions) or by competing sterically with the inhibitor (Chen, Li et al. 1994; 
Baldwin, Bhat et al. 1995 (3); West and Fairlie 1995; Hong, Trehame et al. 1996; 
Ala, Huston et al. 1997; Gulnik, Suvorov et al. 1995; Klabe, Bacheler, et al. 1998).
In addition to those associated with the active site, mutations are also seen in the flap 
pivot point, dimer interface, and double-stranded (3-sheet (Val56-Gly78) Mutations 
outside of the active site probably result in conformational changes to compensate for 
impaired activity resulting from synchronous mutations of the active-site. These 
peripheral mutants may preferentially increase the affinity for native substrates over 
the inhibitor or possibly increase the mutant enzyme's rate of catalysis (Pazhanisamy, 
Stuver et al. 1996; Schock, Garsky and Kuo 1996). However, little is known about 
such compensatory mutations since their effect on the protease structure is virtually 
imperceptible to structural analyses (Chen, Li et al. 1994).
Studies have also characterised cleavage site mutants. Since mutations at the active 
site can affect the rate at which the Gag and Gag-Pol polyprotein precursors are 
cleaved by the protease, mutations at the cleavage site of these respective protein 
precursors could potentially compensate for reduced mutant activity. Studies show 
that a mutation in the P1-P6 Gag poly-protein cleavage site, in which the wild type 
Phe-Leu cleavage site is replaced by a Phe-Phe, renders the 184V mutant protease 
capable of producing a virus with 102 to 103 fold decreased sensitivity to an inhibitor, 
BI-LA-2011 (Erickson and Burt et al. 1996). However, because most drug resistant 
mutations occur at the active site, in theory, only a limited number of mutations can 
be supported by the virus since random mutations can render the protease non­
functional. Thus by understanding the structural basis for resistance, new drugs can be
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designed to target major classes of mutants. For example, a “structured-directed 
oscillation therapy” might be developed to combat resistance. This would involve 
treatment with a fluctuating combination of protease inhibitors designed to alternately 
target the mutant and wild-type enzyme and thus manipulate selection pressure to 
mutate the protease back and forth between the wild-type and the treatable mutant 
variant (Erickson and Burt 1996). Studies have shown that resistance arises because 
viral replication is incompletely suppressed in the plasma or tissue during periods of 
time between doses when drug concentrations are lowest (Mo 11a, Korneyeva et al. 
1996; Kempf, Rode et al. 1998). Thus inhibitors that maximise bio-availability and 
sustain high plasma levels are required to combat resistance.
Currently the best means of ensuring that development of drug resistance is 
minimised involves the use of combined therapies. In order to achieve the best blend 
of anti-viral agents a thorough understanding of cross resistance is required. Ideally, 
the drugs used in concert with each other should not have overlapping toxicity profiles 
and should bind to different targets. The use of multiple PR inhibitors is therefore 
problematic since at present they share similar chemical structures and target similar 
PR attributes. The combined use of PR and RT therapies has been adopted to prevent 
onset of drug resistance, but although multi-drug therapy has maintained the viral load 
in some patients at undetectable levels for 2 years, studies have reported the isolation 
of a replication-competent virus from their resting CD4+ T cells (Wong, Hezareh, et 
a l  1997). The existence of latently infected HIV reservoirs with the ability to mutate 
is already cause for concern, but it is now becoming clear that in developing drug 
resistance the virus may also increase in vitality (Nijhuis, Schuurman, et al. 1999).
It has generally been thought that the wild type HIV population is ideally fit, and that 
sub-optimal anti-viral therapies can therefore only result in selection of drug resistant 
variants with reduced fitness. Studies supporting this view have shown that 
suboptimal therapies select for amino acid changes conferring a selective 
disadvantage during replication in a drug free environment in comparison with the 
original wild-type virus population (Back, Nijhuis, et al. 1996; Goudsmit, de Ronde, 
et al. 1996; Goudsmit, de Ronde, et al. 1997; Eastman, Mittler, et al. 1998; Zhang,
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Imamichi, et al. 1997; Zennou, Mammano, et al. . 1998; Mammano, Petit, et al. 
1998).
However, the study by Nijhuis et al. (Nijhuis, Schuurman, et al. 1999), investigating 
the effects of ritonavir on the evolution and fitness of HIV-1 viral populations, 
contradicts this view. They showed that whilst initial therapy lead to the selection of 
drug resistant viral variants having reduced protease catalytic efficiency and 
replicative capacity, the continuation of that therapy eventually resulted in generation 
of novel protease variants that displayed no further increase in drug resistance but did 
exhibit increased catalytic efficiency and conferred augmented replicative ability over 
viruses containing the wild type protease. In their studies a quadruple mutant of the 
HIV-1 PR displayed a three-fold increase in activity over the patient’s original wild- 
type PR, and this was manifested as an increase in vitality of the mutant virus over the 
wild-type. This study demonstrated that suboptimal antiretroviral therapy initially 
results in selection of drug resistant variants with impaired replication efficiencies but 
continued evolution in the presence of the drug allows the generation and selection of 
novel viral variants with increased fitness compared with the original wild-type 
population. This phenomenon is not limited to HIV, and increased fitness has been 
demonstrated in vitro for other RNA viruses and for bacteria (Novella, Clarke, et al. 
1995; Novella, Duarte, et al. 1995; Bouma, Lenski, et al. 1988; Schrag, Perrot et al.
1997).
Phylogenetic analysis demonstrated that the mutant variants were evolved during the 
treatment period. Given their increased fitness over the wild-type HIV-1 it was 
surprising that they had not been present in the population prior to treatment. In fact at 
least five nucleotide changes must be selected in order to generate protease variants 
with an increased fitness. The initial changes must confer drug resistance, but they do 
so at a cost in terms of proteolytic efficiency, consequently in the absence of the drug 
they would not be favourable and are counter selected. Since these initial changes are 
a prerequisite for the subsequent mutations resulting in increased enzyme efficiency, 
the enzyme cannot evolve into the variant form in the absence of selection pressure 
from the drug. On reflection, the observations of Nijhuis et al. (Nijhuis, Schuurman,
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et al. 1999) are in accord with Wright's concept of an adaptive fitness landscape 
(Wright 1932) which proposes that natural selection tends to drive a population to a 
local optimum, but that this is not necessarily a global optimum. Thus, a population 
may become trapped at a state with a suboptimal adaptation to its environment 
because natural selection does not allow it to pass through a trough of maladapted 
intermediate variants, even though a better solution may exist beyond them. It 
therefore appears that incomplete inhibition of viral replication creates an 
environment in which pre-existing drug resistant variants with an impaired replication 
potential are selected. Continued replication may then drive the population through a 
trough of maladapted variants towards a new fitness peak which may be higher than 
that of the original wild-type population. This may have serious implications for the 
design of AIDS therapies. If therapies are not sufficiently stringent they may simply 
result in the selection of more virulent strains than presently exist.
Alternatives to current PR inhibitors
Overcoming the problem of resistant mutants is likely to involve discovering 
alternatives to substrate and transition state analogue based inhibition -  especially 
since the combination of multiple PR therapies would more effective if diverse PR 
attributes could be simultaneously targeted.
Anti-dimerisation and defective monomer inhibitors.
Among the possible alternatives is the design of inhibitors intended to prevent 
dimerisation, and thereby eliminate enzyme activity (Weber 1990; Babe, Pichuantes 
and Craik 1991; Zhang, Poorman et al 1991; Babe, Rose et al. 1992; Schramm, 
Breipohl et al. 1992; Franciskovitch, Houseman et al. 1993; Arnold, Popinga et al. 
1994; Schramm, Boetzel et al. 1996; Zutshi, Franciskovich et al. 1997; Caflisch, 
Schramm et al. 2000), or the use of inactive monomers to titrate out active enzyme 
(McPhee, Good et al. 1996). The dimer interface is an attractive target for therapeutic 
interventions (Weber 1990; Babe, Pichuantes and Craik 1991) because dimerization is 
essential for activity, and because it may prove possible for inhibitors to bind the PR 
domain within the uncleaved gag/pol polyprotein prior to particle assembly. 
Furthermore, although subunit-subunit interactions occur in four regions (the 
'firemen's grip' at the active site; the flap region, the salt bridges, and the dimer- 
interface between the subunit termini) it is the four-stranded antiparallel (3-sheet 
interface created by the C- and N-termini that provides more than 50% of the subunit
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interactions (Todd, Semo and Freire 1998). The dimer interface residues are highly 
conserved, as is its fold, thus it may be less prone to mutation than the active site or 
substrate binding cleft. The strategy of using interfacing peptides to interfere with an 
enzyme’s subunit interactions has been successfully employed to inhibit the 
ribonucleotide reductase from Herpes Simplex Virus (Cohen, Gaudreau et al. 1986 
(1); Cohen, Gaudreau et al. 1986 (2); Dutia, Frame, et al. 1986), and was later 
developed into a potent peptidomimetic drug (Liuzzi, Deziel et al. 1994). The HIV-1 
RT has also been successfully inhibited by means of a peptide interfering at the dimer 
interface (Divita, Restle, et al. 1994).
The use of peptide inhibitors in this way to inhibit HIV-1 PR has also been attempted. 
Single peptides complementary to the N or C terminal regions have been utilised as 
have dual stranded peptides able to interdigitate with the monomer and reproduce the 
typical p-sheet structure. Two octapeptides derived from the sequence of the N- and 
C-termini of HIV-1 protease were tested for their ability to inhibit HIV-1 
reproduction, but weak inhibitory activity was found with each of the two peptides 
(Schramm, Nakashima, et al 1991). Several other structures derived from the 
terminal segments have shown comparable inhibition (Schramm, Breipohl, et al. 
1992; Babe, Rose and Craik, 1992). It has been demonstrated that the best inhibitory 
activity is obtained with sequences corresponding exactly to the full length p-strands 
in the four-stranded P-sheet region of the protease, while inhibitors derived from the 
C-terminus are usually better inhibitors than those from the N-terminus 
(Franciskovich, Houseman, et al. 1993).
C-terminal based peptides have been systematically modified on the basis of 
published PR structures, mutation studies, and sequence analysis of retroviral 
proteases. They were then modelled into their binding sites, and the best-fitting 
peptides were synthesized and tested in vitro (Schramm, Billich et al. 1993; Schramm, 
Boetzel et al. 1996). This rational design process resulted in an approximately 1000- 
fold improvement in terms of inhibition. These studies established a consensus 
sequence of potent peptidic inhibitors for positions 94-99 of the protease (Schramm, 
Boetzel et al. 1996), which can be considered as a pharmacophore for peptidomimetic 
or non-peptidic inhibitor design (Quere, Wenger, et al. 1996; Schramm, Quere, et al.
1998). Several triterpenes able to fit into the hydrophobic interface site of the relaxed 
monomer were identified by means of a virtual screen of the Cambridge Structural
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Database using one of the pharmacophore distances, and subsequent computer 
docking. The use of triterpene units to build non-peptide inhibitors has several 
advantages, including low cost, good bioavailability, rigidity, and the provision of 
opportunities for side chain modifications.
Since short peptides derived from both the N and C PR termini were found to be 
active and had been optimised to target distinct binding sites, attempts were made to 
combine them into dual-sequence peptides with N and C peptide joined using linkers 
(Babe, Rose and Craik, 1992; Arnold, Popinga, et al. 1994). Other dual peptides were 
similarly produced by linking two N-terminal sequence based peptides (Zutshi, 
Franciskovitch et al. 1997). The cross-linkers used to generate these interfacial 
peptides allowed a high degree of mobility, which in turn reduced their binding 
efficiency. Consequently a more rigid means of linking the peptides was sought, and 
rigid "molecular tongs" were devised containing either tripeptidic or tetrapetidic arms 
linked to pyridinediol- or naphthalenediol-based scaffolds which achieved 
submicro molecular range PR inhibition (Bouras, Boggetto et al. 1999).
The use of defective monomers or non-identical PR subunits to exchange with wild 
type PR homodimers and produce catalytically defective heterodimers has also been 
investigated as an inhibitory strategy (Babe, Pichuantes and Craik, 1991; Babe, Rose, 
and Craik, 1995). A structure-based approach was used to identify amino acid 
substitutions at the dimer interface of HIV-1 PR that would facilitate preferential 
association of the defective monomers. Expression of the designed PR monomers 
inhibited the wild-type HIV-1 PR and eliminated viral infectivity demonstrating that 
PR monomers can be used as macro molecular PR inhibitors. It has since been 
proposed that the use of defective PR monomers as trans-dominant PR inhibitors 
might be adopted in the clinical treatment of HIV-1 infection by gene therapy 
(McPhee, Good, et al. 1996).
The quest for active site binding, irreversible PR inhibitors resulted in the discovery 
that some haloperidol derivatives could also inactivate the enzyme via a sulfhydryl 
alkylation of the Cys95 belonging to the dimer interface (Salto, Babe, et al. 1994; De 
Voss, Sui, et al. 1994; Yu Caldera et al. 1996). Other sulfhydryl reagents such as 
Ellman’s reagent - 5,5'-dithio-bis-(2-nitrobenzoic acid) (DTNB), glutathione (Davis, 
Dorsey, et al. 1996), N-ethylmaleimide, and iodoacetamine (Meek, Dayton et al.
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1989) were also observed to interfere with PR dimerisation in the same way. These 
compounds provide an alternative avenue for the design of dimerisation inhibitors.
The identification o f a metal binding motif as a potential inhibitor target.
Studies involving the effects of metal binding on PR activity (Stadtman and Oliver
1991; Woon, Brinkworth and Fairlie 1992; Zhang, Reardon, et al. 1991) and in 
particular the effect of metal-cysteine interactions (Karlstrom and Levine 1991; 
Wlodawer, Miller, et al. 1989; Karlstrom, Shames and Levine 1993; Davis, Branca, et 
al, 1995; Lebon, De Rosny, et al. 1998; Lebon, Ledecq et al. 1999), and cysteine 
derivatisation (Davis, Dorsey, et al. 1996; Karlstrom, Shames and Levine 1993; 
D’Ettorre and Levine 1994; Davis, Yusa, et al. 1999) on PR activity have resulted in 
the discovery of an interesting site on the protease surface. This may provide an 
additional target for future drug development that is outside the realms of the active 
site or dimerisation region. It has been suggested that cupric ion binding to Cys67 
may interfere with the correct motion of the flaps. NMR studies of HIV-1 PR have 
demonstrated that flap movement is accompanied by cantilever-like compensatory 
changes in residues 59-75 (Harte, Swaminthan, et al. 1990). The Cys67-Gly68-His69- 
Lys70 residues of this “cantilever” region have subsequently been identified as part of 
a metal binding sequence. Interestingly Gly-His-Lys is also the metal-coordinating 
motif of a copper-binding growth factor isolated from human plasma and involved in 
copper transportation (Karlstrom, Shames and Levine 1993). The binding of copper to 
the region, or its derivatization with DTNB, causes enzyme inactivation, and it is 
therefore possible that any molecule binding this region could influence enzyme 
activity either via an oxidation mechanism or by means of allosteric deformations.
Cysteine residues 67 and 95 as targets for intervention.
The PR cysteines (Cys67 and Cys95) are also sensitive to glutathionation, providing a 
possible mechanism by which the protease may be regulated through cysteine 
modification. It has been shown that while glutathionation of cysteine 95 abolishes 
activity, modification of cysteine 67 with glutathione increases activity over the 
unmodified protein. In addition, glutathionation at cysteine 67 markedly stabilises 
enzyme activity presumably by reducing autoproteolysis. The greater stability of the 
Cys67 glutathiolated enzyme in conjunction with an increase in activity may function 
to regulate polyprotein processing in vivo (Davis, Dorsey, et al. 1996; Davis, Yusa, et 
al. 1999).
119
Irreversible PR inhibition (suicide inhibitors).
The development of irreversible inhibitors represents another strategy to suppress the 
development of resistant strains. For this purpose the carboxylic groups of Asp 25 and 
Asp 25' represent excellent targets since their inactivation leads to complete loss of 
catalytic activity, and because these residues are necessarily immutable.
HIV-1 PR is inactivated by l,2-epoxy-3-(p-nitrophenoxy)propane (EPNP) (Meek, 
Dayton, et al. 1989; Rose, Rose, et al. 1993) and by the epoxide antifungal antibiotic 
cerulenin (Blumenstein, Copeland et al. 1989). However, to date only a few epoxide- 
based inhibitors of HIV-1 PR have been reported (such as UCSF 84) capable of 
selectively inactivating HIV-1 PR (Salto, Babe, et al. 1994). It has been shown that 
the potency of irreversible epoxide based inhibitors can be increased by extending the 
peptide sequence (Lee, Choy, et al. 1996). NMR and topochemical studies of 
irreversible inhibitors containing a cis-epoxide as amide isostere have also revealed 
their preference for adopting extended conformations similar to the (3-strand in 
solution (Ro, Baek, et al. 1998). Epoxides are highly reactive species, and in vivo they 
are likely to undergo unintended reactions prior to reaching their target, something 
that has limited their potential as HIV-1 PR inhibitors so far. The first results chapter 
of this thesis (Chapter 3) investigates the preliminary development of two irreversible 
or “suicide” inhibitors, including an epoxide based inhibitor.
There now follows a review of the methods used during completion of the studies 
described in this thesis (Chapter 2: Materials and Methods). Subsequently Chapter 3
will describe the expression and purification of HIV-1 protease with the intention of 
using the pure enzyme to investigate the efficacy of the two in-house suicide inhibitor 
designs.
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Chapter Two: General Materials and Methods.
Bacterial strains used.
The strains listed in the table below were obtained from New England Bio labs, and a 
complete list o f strains available plus a key explaining their genotypes can be 
downloaded as a pdf file via the internet at
http://circuit.neb.com/neb/tech/tech resource/restriction/ecoli/genotvpes.html
Table 1_____ Bacterial strains used.
E.coli strain G enotype U se
JM109 
(Yanisch-Perron, Vieira et 
al. 1985)
F  traD36 laclq A(lacZ)M15 
proA+B+/el4'(McrA') A(lac- 
proAB) thi gyrA96 (Nalr) 
endAl hsdR17 (rf nik*) 
relAl supE44 recAl
Used for general DNA 
preparation, and for protein 
expression using non-T7 
based systems. Also used to 
screen T7 based DNA 
constructs prior to 
expression in BL21.
MC1061 
(Wertman, Wyman et al. 
1986; Raleigh, Trimarchi et 
al. 1989)
F' araD139 A(ara-leu)7696 
galE15 galK16 A(lac)X74 
rpsL (Strr) hsdR2 (rC nik+) 
mcrA mcrB 1
Cloning and expression of 
HIV-1 and HIV-2 proteases, 
except where stipulated 
otherwise.
BL21 (DE3) 
(Studier, Rosenberg et al. 
1990)
F  ompT (Ion) hsdSe (rB* 
me* an E.coli B strain) with 
DE3, a X prophage carrying 
the T7 RNA polymerase 
gene
Expression using T7 based 
plasmids (eg pRset)
BL21(DE3) pLys S As for BL21 (DE3) above, 
plus the pLysS plasmid 
(confering chloramphenicol 
resistance) which encodes 
T7 lysozyme
Expression using T7 based 
plasmids. The pLys S 
plasmid was intended to 
provide tighter control of 
expression, and made cell 
lysis easier.
XL1 Blue 
(Bullock 1987)
F' ::TnlO proA+B+ laclq 
A(lacZ)Ml 5/recAl endAl 
gyrA96 (Nalr) thi hsdR17 
(rf nik+) supE44 relAl lac
Used to make 
supercompetent cells for 
transformation of very low 
levels of DNA. Used during 
mutagenesis of HIV-2 PR.
BL21 -CodonPlus-RIL 
(DE3)-RIL 
(Stratagene)
E.coli B F  ompT hsdS (re- 
niB-) dcm + Tetr gal end A 
The [argU ileY leuW Camr]
General protein expression 
where codon usage is a 
limiting factor.
E.coli TGI SupE hsd A5 thiA (lac- 
pro AB)F' [traD3 6proAB+la 
cPlacZAMlS]
Used to test pKu2PR during 
development of pKulacIq 
PR vector (this thesis).
121
Cloning and expression vectors.
Table 2_____ Summary of vectors used.
V ector Source Prom oter A ntib iotic
resistance
D escription
pKulacIq Wellcome trc Ampicillin In-house expression vector
pMalcRI New England 
Bio labs
tac Ampicillin Maltose Binding Protein 
fusion system, for soluble 
expression and affinity 
purification.
pKK223.3
pTrc99A
Amersham
Pharmacia
Biotech
Amersham
Pharmacia
Biotech
tac
trc
Ampicillin
Ampicillin
General cloning and 
expression vector, used as 
the basis for pKulacIq. 
Expression vector, 
commercial equivalent of 
pKulacIq
pET23d
pTrcHIS
pRSetB
Novagen
Invitrogen
Invitrogen
T7 / lac
trc
T7 and 
M13
Ampicillin
Ampicillin
Ampicillin
Expression and shuttle 
vector
Histidine tagged expression 
vector
Histidine tagged expression 
vector
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Source of reagents and commercial enzymes.
All enzymes used for the modification, amplification or cloning of DNA during the 
course of this project were supplied by New England Bio labs (NEB), unless otherwise 
stated in the text, and were used in accordance with the suppliers instructions. All 
chemicals were supplied by Sigma, unless otherwise stated in the text, and Qiagen 
supplied all DNA miniprep and maxiprep kits. All PCR primers were obtained ‘Ready 
Pure’ from Perkin Elmer, chromogenic and other peptide substrates were obtained 
from Bachem.The SPA substrate was supplied by Amersham International 
(subsequently Amersham Pharmacia Biotech, now GE Healthcare) to the Wellcome 
Research Laboratories at Beckenham. T7 sequencing kits were obtained from 
Pharmacia Biotech (subsequently Amersham Pharmacia Biotech, now GE 
Healthcare). Details of any reagents not mentioned here are given in the text as they 
arise.
A list of suppliers’ details is provided in the appendix (page 325).
Buffers, solutions, broths and media.
The solutions and media referred to in the methods sections and in the text were all 
made according to the protocols described in Molecular Cloning volumes 1-3 
(Sambrook 1989), unless otherwise stated in the text.
Microcentrifugation and Ultracentrifugation.
Within this text microcentrifugation refers to the use of a benchtop microfiige 
equipped with a rotor to accept eppendorf tubes, and assumes that the maximum RCF 
is selected. Typically bench top microfuges generate between 13 -  16000 g at 
maximum rpm. Where the RCF is critical to the application it is stipulated within the 
text. Here the term Ultracentrifugation refers specifically to the use of a Beckman L8- 
M Ultracentrifuge in conjunction with an SW28 swing-out rotor and appropriate 
buckets. Disposable inner tubes were supplied by Beckman to fit the SW28 rotor 
buckets. The instrument was operated as recommended by Beckman, and specific run 
parameters are given in the text.
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Preparation of DNA.
Small scale or ‘minipreps’.
Miniprep DNA was prepared by an adaptation of the method of Feliciello and Chinali 
(Feliciello and Chinali 1993).
The solution of 88% isopropanol containing 200 mM Potassium Acetate was prepared 
in 50 ml batches by mixing 44 ml 100% isopropanol, 2 ml 5 M Potassium Acetate 
solution, and 4 ml ddw in a sterile 50 ml Falcon tube.
Miniprep solutions and their function.
Solution I  25 mM Tris-Cl, pH 8.0, 50 mM glucose, 10 mM EDTA
The glucose functions to maintain osmotic pressure while the Tris buffers the cells at 
pH 8.0. EDTA binds divalent cations in the lipid bilayer, thus weakening the cell 
envelope. Following cell lysis, EDTA also limits DNA degradation by binding Mg2+ 
ions that are a necessary cofactor for bacterial nucleases. Hen egg white lysozyme 
was added to a final concentration of 4 mgmf1 (immediately before use) to facilitate 
cell lysis.
Solution II 0.2 N NaOH, 1.0% SDS
The alkaline mixture lyses the bacterial cells, while the detergent SDS dissolves the 
lipid components of the cell envelope and the cellular proteins. The sodium hydroxide 
denatures both chromosomal and plasmid DNA into single strands leaving the 
intertwined circular plasmid DNA intact.
Solution III 3 M sodium acetate, 3 M acetic acid
The acetic acid restores the pH to neutral, allowing the DNA strands to renature. 
However, the large, disrupted chromosomal strands cannot rehybridize perfectly but 
instead collapse into a partially hybridized aggregate. Simultaneously potassium 
acetate precipitates the SDS from the cell suspension, along with the associated 
proteins and lipids -  trapping the renaturing chromosomal DNA in the 
SDS/lipid/protein precipitate. Only the smaller plasmid DNA, fragments of 
chromosomal DNA, and RNA molecules escape precipitation and remain in solution.
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A bacterial culture containing the desired plasmid DNA was grown in 5 ml LB 
overnight at 37°C with shaking in a 25 ml sterilin tube. The bacteria were harvested 
by centrifugation for 10 mins at 5500 g RCF. The supernatant was discarded, and the 
bacterial pellet resuspended in 250 pi of solution I before transfer to a 2 ml eppendorf 
tube. Cell lysis was achieved by mixing the suspension with 500 pi solution II. The 
precipitation of unwanted cellular proteins was achieved by mixing 750 pi of solution 
III with the lysate. The white pellet of precipitated protein was removed following 
microcentrifugation (ie. 15 minutes at 13000 rpm, and room temperature, in a 
benchtop microfuge - unless otherwise stated) using a sterile toothpick. The clarified 
solution was then mixed with 700 pi of 100% isopropanol, resulting in the 
precipitation of any nucleic acids present, which were then collected as a pellet by 
microcentrifugation. The supernatant was discarded and the pellet resuspended in 250 
pi of sterile ddw containing 1 pi of RNAse solution (10 pg/ml). Incubation at room 
temperature for 15 minutes ensured that any RNA present would be degraded. Finally 
the DNA was precipitated by addition of 300 pi of 88 % isopropanol containing 200 
mM potassium. The DNA was collected as a pellet by microcentrifugation, and the 
supernatant discarded. The DNA pellet was dried (either using a ‘speedivac’, or by 
incubation at 70°C for 5 mins), then resuspended in 10 pi sterile ddw and stored 
frozen (-20°C) pending use.
Large scale ‘midipreps’.
Here large scale is taken to mean a plasmid DNA preparation derived from 100 ml of 
bacterial culture - the amount of DNA produced being dependant on the copy number 
of the plasmid concerned (usually 5-15 ugml'1 of culture). Qiagen midi columns were 
used to prepare DNA on this scale, and the manufacturers directions were followed 
throughout the procedure with two exceptions. Following addition of solution III the 
prep was centrifuged at 5500 g for only 10 mins. Following this a white precipitate 
layer was removed from the surface of the solution using a sterile pipette tip, then the 
remaining solution was poured directly onto the pre-quilibrated column through a 
sterile 5 ml gilson tip which had a small wad of sterile siliconised glass wool 
compressed within it. The wool acted as a filter, removing any loose or floating debris 
that would otherwise block the column. This method had the advantage of reducing 
the required spin time and speed. Following elution of the DNA sample from the 
column, the 4 ml eluant was aliquoted into 2 ml eppendorf tubes, 1 ml per tube, and
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the precipitation steps were scaled down accordingly and carried out using the 
eppendorf tubes rather than larger centrifuge tubes. This had the advantage of using a 
bench top bench top microfiige, made the final resupension of the dried DNA pellet 
much easier, and produced ready made aliquots. Aliquots prepared in this way were 
ideal for sequencing or cloning use. The only disadvantage was the increased number 
of tubes involved, which became complicated if multiple samples were being 
prepared. In such cases the manufacturers protocol was adhered to.
DNA precipitation methods.
Ethanol precipitation.
The volume of DNA solution to be precipitated never exceeded 500 pi. Where a 
larger volume was involved it was split into 500 pi aliquots. The procedure was 
carried out using 1.5 ml eppendorf tubes. The DNA solution was mixed with one 
tenth its volume of 3 M Na acetate pH 5.2. An excess of prechilled 100% ethanol was 
then added, such that the eppendorf tube was filled to the 1.5ml mark. The contents 
of the tube were mixed by inversion, then incubated at -20°C for a minimum of 10 
minutes (or overnight if desired). The precipitated DNA was pelleted by 
microfugation, the supematent discarded and the eppendorf tube then spun briefly to 
drain any remaining supernatent to the bottom of the tube. The remaining supernatent 
was carefully removed using a longform glass pipette (previously extruded in a 
bunsen flame to provide a fine tip). The pellet was then allowed to air dry, or was 
dried either by ‘speedivac’ or in an oven at 70°C for 5 minutes.
Precipitation at -20°C gave a better yield than incubation on ice. Yield was also 
proportional to the microcentrifugation time, and 15 minutes was considered a 
minimum. Also note that for all such precipitation steps the eppendorf tube was 
located in the microfuge rotor such that the lid hinge was outer-most. This ensured 
that the position of the DNA pellet after microcentrifugation could always be 
predicted.
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Isopropanol precipitation.
This method was used both as an integral part of the miniprep method of Feliciello 
and Chinali (Feliciello and Chinali 1993) (See: Preparation of DNA; Small scale or 
‘minipreps’), and subsequently as a general replacement for the ethanol precipitation 
step above. It was used for the general reduction in volume of DNA solutions, 
removal of enzyme and buffers in between double restriction digests, and 
precipitation of DNA samples prior to loading onto agarose gels. It was carried out at 
room temperature (which was optimal), there was no need to incubate following 
addition of the isopropanol solution (thus it was quick), and it proved consistently 
effective. The 88% isopropanol / 200 mM Potassium Acetate solution was prepared as 
previously described (See: Preparation of DNA; Small scale or ‘minipreps’).
The volume of DNA solution to be precipitated was adjusted to precisely 250 pi, 
either by addition of ddw or by splitting it into appropriate aliquots. The DNA 
solution was then mixed by inversion with exactly 300 pi of the isopropanol / 
Potassium Acetate solution. The precipitated DNA was collected as a pellet by 
microcentrifugation, and the supernatent discarded. In order to remove all traces of 
the supernatent the eppendorf was briefly spun again (approximately 30 seconds) and 
any remaining supernatent was sucked out using a fine tipped glass pipette. The pellet 
was then allowed to air dry, or was dried either by ‘speedivac’ or in an oven at 70°C 
for 5 minutes. The DNA was then resuspended as required in either ddw or TE buffer, 
and stored or used as desired.
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Polymerase Chain Reactions
A variety of PCR based techniques were used for purposes including basic DNA 
amplification for cloning or as a diagnostic tool, site directed mutagenesis, whole 
gene synthesis, and ABI sequencing.
In principle the PCR method described by White et al., and Erlich respectively (Erlich 
1989; White, Amheim et al. 1989) was followed for all applications. However, for 
mutagenesis Stratagene's QuikChangeTm method was employed -  see Site directed 
mutagenesis, below.
For gene synthesis the Recusive PCR method of Prodromou and Pearl (Prodromou 
and Pearl 1992; Wheeler, Prodromou et al. 1996) would have been used (see Chapter 
6 Results and Discussion). ABI sequencing reactions were carried out using an ABI 
Prism™ kit (Applied Biosystems), and following the manufacturers instructions.
Choice of polymerase
Taq polymerase was used for general PCR reactions since it was reliable and cheap. 
Vent and Pfu were used when higher fidelity was required (eg during gene synthesis 
or site directed mutagenesis).
Additional components
Reactions occasionally required the presence of additional components in the reaction 
mixture to achieve successful amplification. The component required depended on the 
polymerase used - MgCb (at 0, 2 and 4 mM) was used for Taq, MgSCT* (0, 2 and 4 
mM) for Vent, and DMSO (0 and 5 %) for Pfu.
Primer design
General PCR primers were designed manually, according to the Wallace rule (Itakura, 
Rossi et al. 1984), with a view to obtaining an optimum annealing temperature (or 
melting temperature Tm) and incorporating the necessary restriction sites for the task 
in hand. Typically each primer had a 5' GC rich non-coding clamp region, followed 
by the desired restriction site sequences, and subsequently a stretch of coding 
sequence, designed to anneal to the template DNA, ending in a GC rich coding region 
intended to act as a 3' GC clamp. The 5', GC rich, non-coding region, besides acting 
as a clamp, also served to flank the restriction enzyme sites. This enables some 
restriction enzymes to cut their respective site more efficiently.
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Primers used for site directed mutagenesis were designed as complementary pairs, 
with the mutant bases located centrally, flanked each side by a stretch of coding 
sequence. This is described in more detail below (Site directed mutagenesis).
Primers for gene synthesis by recursive PCR were designed with the aid of computer 
programs written especially for that purpose, since the design parameters were too 
complex for this task to be successfully achieved manually. This process is described 
in Chapter 6.
Site Directed Mutagenesis.
The QuickChange site directed mutagenesis kit (supplied by Stratagene) was used 
according to the manufacturers instructions. Information can be found at 
http://stratagene.com/homepage/. and a pdf file of the QuickChange manual can be 
downloaded from http://stratagene.com/lit/manuals.aspx. Briefly, a complementary 
pair of primers was designed for each mutation reaction, both containing the desired 
mutation in the centre of the primer. Such primers must be between 25 and 45 bps 
long, withlO-15 bases of correct sequence each side of the mutation site, and having a 
Tm > 78°C as determined by the formula:
Tm = 81.5 + 0.41 (%GC) -  675/N - % mismatch
Where N = primer length, and values for %GC and % mismatch are whole numbers.
Optimally the primers should have a GC content of 40% and should terminate in a 
clamp of one or more G / C bases. The primers need not be 5' phosphorylated, but 
must be HPLC or PAGE purified since impurities decrease mutation efficiency. In the 
final reaction mixture the primer concentration must be in excess over the template.
Reaction mixture typically consisted of 5 pi 10 x reaction buffer, 5 -  50 ng of dsDNA 
template, 125 ng of each primer, 1 pi of dNTP mix, and ddw up to a final volume of 
50 pi. The enzyme, 1 pi of Pfu Turbo DNA polymerase at 2.5 U/pl, was added last. 
The reaction cycles consisted of 30 seconds at 95°C, then 12-16 rounds of; 95°C 30 s, 
55°C 60 s, 68°C 120 s per kb of template plasmid length. 12 rounds were used for 
point mutations, 16 for single amino acid changes. Following this the reaction was 
cooled on ice for 2 minutes. The non-mutated supercoiled parent dsDNA was digested 
following the addition of 1 pi of Dpn\ restriction enzyme to the mix and incubating at 
37°C for 1 hour. Following this digestion step the remaining mutated DNA was
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annealed by cooling on ice, then used to transform XL 1-Blue supercompetent cells 
(see Chapter 2, Transformations, Preparation of supercompetent cells). 
Supercompetent cells were used to increase the probability of success, especially 
since the PCR reaction only incorporated up to 16 cycles (limiting the product yield). 
Transformants were picked, grown and their DNA miniprepped for diagnostic 
restriction enzyme digest (where incorporation of a site was possible simultaneously 
with the incorporation of a mutation), and sequencing.
Sequencing of DNA
Conventional double stranded DNA sequencing
Sequencing was carried out by the method of Sanger et a l, using a T7 kit from 
Pharmacia Biotech, and largely in accordance with the supplied instructions, but with 
the modifications described below.
Double stranded DNA to be sequenced was prepared using Qiagen midiprep kits 
(previously described). Pharmacia Biotech supplied the sequencing primers (T7 
forward and reverse), and where these were not appropriate PCR primers for the clone 
of interest were used instead.
Template DNA (250 jul or approximately 25 pg) was isopropanol precipitated, then 
resuspended in 10 pi ddw ready for denaturing and primer annealing. The denaturing 
and annealing procedure was carried out in one PCR style step, obviating any need for 
the alkaline denaturation, neutralisation and precipitation steps of standard protocols. 
The 10 pi of DNA template was mixed with 2 pi of primer and 2 pi of annealing 
buffer (as supplied in the T7 kit) in a small eppendorf. Primer concentrations were 
previously adjusted to between 2.5 and 5 pM (so that 2 pi contained 5-10 pmol). The 
mixture was then incubated on a PCR block programmed as shown in table 3.
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Table 3 PCR amplification program.
94°C 10 mins (heat denaturing step)
65°C 5 minutes (gradual annealing steps)
37°C 10 minutes
25°C 10 minutes
4°C oo (followed by storage on ice until ready to use)
The 35Sa dATP was supplied in 100 pCi aliquots from a centralised stock at the 
Biochemistry department UCL. This reagent was never more than 1 month old. 
Preparation of the sequenase enzyme, the labelling reactions and the other reagents 
was carried out in accordance with the manufacturers supplied protocol. However, the 
reaction, incubation, and heating steps were carried out using a 48 well microtitre 
plate rather than individual eppendorf tubes. The first four columns across the top of a 
plate were labelled A C G T, and the rows down the side were labelled with an 
appropriate sequence name. Reactions were then set up in the appropriate wells. This 
allowed easy manipulation, increased speed, ease of storage, and reduced the risk of 
confusion between reactions that could occur using multiple tubes. Each labelling 
reaction was first dispensed into the bottom of its respective well, then the appropriate 
sequencing mix was dispensed onto the side wall of the same well. Once the required 
time had elapsed (as stipulated by the protocol) the sequencing mixes were 
simultaneously added to the labelling reactions by simply tapping the plate sharply on 
the bench to dislodge the droplets on the sides of the wells. Mixing was achieved by 
rapid swirling of the plate, and the plate was incubated at 37°C by floating it in a 
water bath. As the incubation step neared completion the plate was removed from the 
bath. Stop mix was dispensed onto the side of each well, and at the desired moment a 
sharp tap was again administered so that the stop mix droplets were dislodged 
stopping all reactions simultaneously.
The complete plate of reactions was covered using Nesco film, and either floated on a 
hot water bath (80°C) for 2 minutes ready for loading onto a gel, or stored at -20°C 
pending analysis.
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Conventional sequencing gels
The stock solution for preparation of sequencing gels is shown below (table 4). 
‘Ultrapure ProtogeT acrylamide was used (30% acrylamide, 0.8% bis-acrylamide) and 
was purchased ready made from National Diagnostics. Both these solutions were 
stored in the dark at 4°C.
Table 4_____ 6% Stock solution for sequencing gels.
250 g urea dissolved in 125 ml ddw
plus 50 ml TBE (lOx stock)
plus 100 ml 30% acrylamide / bis stock.
Solution microwaved on medium setting for 10 seconds to dissolve urea, then made 
up to 500 ml with ddw and 0.45 pm filtered.
The gel mix was prepared immediately before pouring, using 75 ml of the above stock 
plus 750 pi of fresh 10% APS solution, and 32.5 pi TEMED. The constituents were 
added, mixed using a vortex, and used immediately.
A vertical slab apparatus (Raven) was used to run the gels. The gel was poured 
between two glass plates (50 cm x 20 cm) separated by a spacer down each edge (0.4 
mm). The casting method as described by Sambrook et al (1989) was modified as 
follows. Unconventionally, the plates were not taped up at the sides and bottom, but 
were instead held together by bulldog clips (from Niceday) - two on each side near the 
bottom and middle of the plates. The plates were then positioned horizontally on the 
bench, raised slightly at the top end by resting them on a Duran bottle lid. The gel mix 
(described above) was prepared, and quickly drawn into a 50 ml sterile syringe. The 
mix was gently applied by syringe between the plates from the top end, using a 
sweeping side-to-side motion to ensure even distribution across the width of the 
plates. Simultaneously the plates were gently tapped at the leading edge of the gel 
solution with a pipette handle to help maintain an even flow and prevent bubble 
formation. With this method capillary action drew the gel mix down the plates until 
they were completely filled. Then the Duran lid was removed and the plates layed flat, 
stopping further movement of the gel solution. The combs were then positioned flat 
side first (ie upside down) into the top of the gel, between the plates, and held tightly 
in place with two further bulldog clips. The gel was then left to set.
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This method was faster and simpler than conventional methods of the time, rarely 
incorporated bubbles, never leaked, and did not require messy tape. Leaking was 
common with the conventional method and (ironically) was in fact a product of 
pouring vertically while using tape.
In all other respects gels were set up and run according to the method of Sambrook et 
al (1989), and as recommended by the manufacturers of the sequencing apparatus 
used. Gels were pre-run at 55 W for 30 minutes to warm them to running temperature, 
and wells were flushed clear of urea prior to loading using a plastic Pasteur pipette. 
Sequencing reactions were incubated at 80°C for 2 minutes prior to loading, and 2 pi 
of reaction mix was loaded per well using a Gilson P10 pipette. Electrophoresis was 
carried out at a constant voltage of 37 W until the lower dye front reached the bottom 
of the gel. Occasionally a duplicate batch of reactions was loaded at this point, and 
electrophoresis recommenced until the lower dye-front from the second loading 
reached the bottom. In this way the range of readable sequence was increased.
On completion of electrophoresis the gel plates were carefully prized apart, ensuring 
that the gel stuck to one plate only. The gel was then removed from the plate by 
lowering an appropriately sized square of dry Whatmann 3 MM paper evenly onto the 
gel, and pressing firmly. The paper was then gently lifted from one end, and the gel 
was removed from the plate having stuck to the paper. The conventional fixing step 
was omitted since it was found to be unnecessary, and made the transfer of the gel 
from plate to paper more problematic. This modification also shortened the drying 
time required (30 minutes at 80°C under vacuum, using a BioRad slab gel dryer).
Fuji medical X-ray film was exposed to the dry gel overnight (or longer if required), 
and subsequently processed using an autoradiograph developer (from AGFA).
Fluorescent Automated DNA Sequencing
Automated DNA sequencing was carried out using the ABI Prism system from 
Applied Biosystems, and the protocol supplied by the manufacturer (details available 
at www.appliedbiosvstems.com). Completed samples were sent for analysis to 
Cambridge Biosciences.
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DNA manipulations
Agarose gel electrophoresis
A 0.5-1% w/v agarose solution was prepared in either TBE or TAE (buffers prepared 
as described by Sambrook 1989) and the melted agarose dissolved into the buffer by 
microwave heating. Ethidium bromide was added to a final concentration of 0.5 
mgmf1, and the solution allowed to cool until approximately 55°C before pouring. 
The gel tray to be used was prepared according to the relevant manufacturer’s 
instructions (i.e. with damns in place, and combs positioned with the teeth 1-2 mm 
above the tray surface). The gel melt was poured to a depth of approximately 5 mm 
and allowed to solidify. The gel was placed in the running chamber, immersed in the 
appropriate running buffer (1 X TBE or TAE), also containing ethidium bromide at 
0.5 mgml'1, and the comb was removed to form sample wells. Samples (including 
size standards) were prepared as described below, loaded into the wells 
(approximately 10 pi per well), and the chamber lid fitted. Electrophoresis was carried 
out using 50-100 volts until the dye markers had migrated sufficiently (dependant on 
size of DNA analysed). After electrophoresis the gel was observed over a UV light 
box (set at short wave for visualization, or long wave for band extraction -  since long 
wave UV causes less DNA damage). UV absorbant goggles and face shield were used 
throughout the visualization process. Photographs were taken as required.
Samples were prepared by adding 1 pi of 10 X DNA loading buffer per 10 pi final 
volume of sample solution. Size standards were either of bacteriophage X DNA cut to 
completion with PstI restriction endonuclease, or commercially produced DNA 
ladders supplied by NEB. DNA loading buffer consisted of 0.21% bromophenol blue, 
0.21% xylene cyanol FF, 0.2 M EDTA, pH 8.0 and 50% glycerol in sterile ddw.
Restriction enzyme digests
Restriction enzyme digests were typically completed in a final volume of 100 pi, 
comprising 10 pi of the appropriate lOx reaction buffer (supplied with the enzyme 
used), usually 1-2 pi of enzyme (but never more than 10 % of the final reaction
- t
volume) , and the remainder DNA solution in water. Digests were carried out in 
sterile 500 pi eppendorf tubes, at 37°C (unless otherwise stipulated by the supplier of 
the enzyme used) overnight. Double digests, where DNA was incubated with two
7 because enzymes are stored in glycerol, and greater than 10% glycerol in the reaction can be inhibitory.
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enzymes simultaneously, were carried out using a buffer / temperature suitable for 
both enzymes (as advised by the supplier). Where enzymes were incompatible, 
separate digests were carried out interspersed by a clean up step or an ethanol (or 
isopropanol) precipitation. Analysis of a small aliquot (usually 10 pi) by agarose gel 
electrophoresis was used to assess the success of a digest.
Band purification of DNA
Extraction of DNA bands from agarose gel was used to isolate a desired fragment 
from other contaminating fragments (eg. during the excission of a gene from an 
unwanted plasmid). Separation of the DNA fragments was achieved using the 
standard agarose gel electrophoresis procedure (though it is essential to use freshly 
prepared agarose), the gel was then viewed under long wave ultraviolet light (which is 
less deleterious to the DNA than shortwave UV) and the desired band excised using a 
clean scalpel. A number of methods could be used to extract the DNA from the 
excised gel, the most reliable involved using the QIAquick gel extraction kit from 
Qiagen (used according to the manufacturers instructions).
Dephosphorylation.
This was carried out using Calf Intestinal Alkaline Phosphatase (Cl AP or CIP), which 
catalyses the removal of 5' phosphate groups from DNA, RNA and ribo and 
deoxyribonuclease triphosphates. Since CIP treated fragments lack the 5' phosphoryl 
termini required by ligases, they cannot self ligate (Sambrook 1989). This property 
has been used here to decrease the religated vector background seen during some 
cloning strategies. Following the digestion by restriction enzyme of the DNA in 
question, any remaining enzyme was removed using ‘Strataclean Resin’ as 
recomended by the manufacturer (Stratagene). Following this the DNA was 
precipitated using either isopropanol or ethanol (as previously described) and the 
pellet resuspended in 100 pi ddw and 10 pi CIP x 10 buffer (as supplied). To this 
solution was added lp l of CIP enzyme, and the resultant reaction mixture was 
incubated at 37°C for 30 mins. Next 5 pi of 500 mM EDTA pFI 8.0 was added and 
the mix incubated for 10 mins at 75°C. The combined effect of heat and the chelation 
of Mg from the buffer served to inactivate the CIP enzyme. Subsequently a further 
three Strataclean extractions were carried out (20 pi of slurry per extraction). Finally 
the DNA was precipitated by addition of 1/10th volume of Na acetate pH 7.0 (Not pH 
5.2, otherwise EDTA would not remain in solution), and ethanol followed by
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incubation at 20°C for 5 mins and centrifugation at 13000 rpm for 15 mins (a chilled 
70% ethanol wash step is optional). The DNA pellet was dried using a speedivac, then 
resuspended in ddw as required.
Generating blunt ended DNA using Klenow and T4 DNA polymerase enzymes.
Where the DNA insert and the vector MCS contained incompatible sites blunt ended
ligation was utilised. The insert DNA was first cut with an appropriate restriction 
enzyme to yield an overhanging end, then the overhang was converted to a blunt-end 
for ligation to the vector. Both Klenow (DNA Polymrase I Large Fragment) and T4 
DNA Polymerase were use (as appropriate) to fill 5' protruding ends with dNTPs 
since both enzymes have 5' to 3' polymerase activity. T4 DNA Polymerase was also 
used to polish 3' protruding ends in the presence of dNTPs by exploiting its robust 3' 
to 5' exonuclese activity The enzymes used were supplied by Promega, and the 
protocols used are described in the Promega Corporation “Protocols and Applications 
Guide” (Third Edition - 1996), and the Promega Corporation “Enzyme Resource 
Guide: Cloning Enzymes” (#BR075B).
Strataclean resin
‘Strataclean’ resin was used to extract unwanted restriction enzymes, and CIP, from 
DNA solutions where they may interfere with subsequent reactions, such as ligations. 
The resin was used as supplied by Stratagene according to the following method. The 
volume of resin used per extraction was equal to the square root of the volume of 
DNA solution to be cleaned. Certain enzymes require multiple extractions in order to 
ensure that they are completely removed from the solution (this information is 
available from Stratagene, and is supplied with the resin). The appropriate volume of 
resin was added to the DNA solution and the mixture vortexed for 15 seconds, and 
incubated at room temperature for 1 minute. The resin was pelleted by centrifugation 
(1 minute at 13000 rpm, benchtop microfuge), and the supernatent removed to a fresh 
tube. Care was taken to avoid carry-over of any resin to the fresh tube, and only a 
volume corresponding to the original volume of the DNA solution was taken. Any 
remainder was discarded along with the unwanted pellet. A second spin further 
ensures that there is no carry-over. As an alternative 0.2 pm microfuge spin filters 
(available from Sartorius) were used to filter out any remaining resin.
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The slurry bound unwanted protein, removing it from solution. Subsequently the resin 
pellet and bound protein were discarded while the DNA remained in solution and was 
retained with the supernatent. The resin represented a useful alternative to phenol 
chloroform, especially where small (pi) volumes were involved, and sample losses 
would otherwise have been high. However, this process also involved a small but 
inevitable loss of some DNA.
Ligations
DNA ligations were carried out typically in a final volume of 20 pi. Vector and insert 
DNA were mixed in a ratio of 9 pi : 9 pi (given that their concentrations were 
approximately the same), melted by incubation at 50°C for 2 - 5 minutes, then left to 
cool slowly to room temperature (allowing annealing to occur). Alternatively a 
process identical to that used for the annealing of sequencing primers to double 
stranded template using a PCR block (see Conventional double stranded DNA 
sequencing) was used. Following the annealing process, the ligation mix was stored 
on ice, and an appropriate volume (here 2 pi) of xlO ligation buffer was added to the 
cooled DNA mixture, followed by 1 pi of T4 DNA ligase (as supplied by NEB). The 
mixture was then incubated over night either at room temperature or in a cold room 
water bath set at 16°C -  reputed to be the optimum temperature for ligation reactions 
(Sambrook 1989).
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Transformations
Here the term ‘transformation’ (first used by Fred Griffith in 1928) indicates the 
uptake of plasmid DNA by bacterial cells (though transfection would perhaps be more 
accurate and avoid possible confusion with the use of ‘transformation’ in relation to 
the process of tumorigenesis). The state of a bacterial cell in which it is able to take up 
plasmid DNA (ie. be ‘transformed’) is termed ‘competence’. It has been observed that 
bacterial cells treated with ice cold CaCh become competent, and when exposed to a 
brief heat shock can be transformed with any plasmid DNA present in their 
suspension (Mandel and Higa 1970; Cohen, Chang et al. 1972; Higa and Mandel 
1972; Mandel and Higa 1992). This is the basis of all transformation methods (with 
the exception of electroporation).
The preparation of competent cells.
Transformation efficiency for a given plasmid is defined as the number of 
transformants per pg of DNA (Hanahan 1983), and the method described here 
typically yielded cells with an efficiency not less than 107 transformants per pg, and 
up to 109 transformants per pg (results not shown) using the plasmid pRsetB. These 
cells were sufficient for most transformation purposes. On occassions where the 
concentration of DNA was very low, for example during procedures such as 
mutagenesis, supercompetent cells (efficiency of up to 1011 transformants per pg) 
were used. The production of supercompetent cells is described later in this section.
A 5 ml volume of LB was inoculated with the desired E. coli strain, either from 
freshly grown colonies on an agar plate or from a glycerol stock. Appropriate 
antibiotic was added if required (eg. in the case of BL21 (DE3) plys S, 
chloramphenicol would be used), and the culture incubated with shaking at 37°C 
overnight.
The overnight culture was used to inoculate 200 ml of prewarmed LB, which was 
incubated with shaking at 37°C, the OD6oo (Optical Density measurement at a 
wavelength of 600 nm, made using a spectrophotometer and plastic 1 ml cuvette) of 
the culture being recorded at regular intervals after the first 1 {/i hours in order to 
assess the correct stage for harvesting. Studies of cell competency vs OD600 (Tang,
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Nakata et al. 1994) have shown that there are two peaks of optimal competency 
during the growth of an E. coli cell culture, the first occurs at approximately OD600 = 
0.3 - 0.4 and the second at OD6oo= 0.94 - 0.95. The latter of these two peaks provides 
cells of the greatest competency, however, the peak tails off sharply and can easily be 
missed. The earlier peak provides slightly less competent cells, but has the advantage 
that the peak is broad and in any case if it is missed the culture can be grown to reach 
the second peak. Between these peaks there is a trough in the levels of competency 
with a minima at OD600 = 0.7. Typically cells were harvested on reaching an OD600 = 
0.94 consistent with the second peak of competency.
Harvesting was carried out by transferring the culture to four 50 ml Falcon tubes, 
followed by centrifugation at an RCF of approximately 5500 g for 5 minutes at 4°C. 
The supernatent broth was poured off, and each pellet resupended in 5 ml of ice cold 
100 mM MgCC prior to being made up to 12 ml with the same solution. The 
centrifugation step (above) was repeated and the supernatent MgCL solution 
discarded. The pellets were then resuspended in 5ml of ice cold 100 mM CaCL prior 
to being made up to 25 mis with the same CaCL solution and incubated on ice for 
between 30 and 90 minutes. Following this the centrifugation step was repeated, the 
CaCh supernatent was discarded, and the pellets very gently resuspended in 2 ml of 
85 mM CaCC solution containing 15% glycerol. The total 8 ml of competent cell 
suspension was finally dispensed into prechilled sterile eppendorfs in 200 pi aliquots, 
then frozen at -70°C for storage. Aliquots were thawed on ice immediately prior to 
use, but it should be noted that thawed and refrozen cells ceased to be competent.
Preparation of supercompetent cells
Supercompetent cells (ie. competent cells yielding 1011 transformants per microgram 
of DNA) were used for transformations where DNA concentrations were low (eg. 
after a mutagenesis reaction), and the chances of obtaining colonies with ordinary 
competent cells would therefore have been remote. Typically XL 1-Blue cells were 
used for this purpose, although JM109 cell could also be used if required.
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Table 5 Media and Buffers required to prepare supercompetent cells.
SOB
20 g Tryptone, 5 g Yeast Extract and 0.5 g NaCl were dissolved in 1 litre of 
ddw and the solution was autoclaved.
The following solutions were made separately, sterilised by 0.2 pm filtration 
and added in the amounts stipulated after the media had cooled:
10 ml 250 mM KC1, 5 ml 2M MgS04 and 100 pi 5M NaOH.
TB
100 ml of 10 mM PIPES buffer containing 15 mM CaCE and 250 mM KC1 
was made, and adjusted to pH 6.7 with KOH. MnCE was added to a final 
concentration of 55 mM, and the solution sterilised by 0.2 pm filtration.
A 100 ml volume of SOB medium (table 5) contained within a sterile 500 ml flask 
was innoculated with the desired bacterial strain and incubated with vigorous shaking 
at 18°C until an OD600 of 0.6 was reached. This typically took in excess of 30 hours. 
At this point the culture was chilled on ice for 10 minutes, then harvested by 
centrifugation at a low RCF (less than 2000 g) using a chilled rotor. The supernatent 
was carefully removed, and the cells were gently resuspended in 30 ml of TB (table 
5). The resuspension was left to stand on ice for 10 minutes, then centrifuged as 
before. The supernatent was again removed, and the cells resuspended in 8 ml of TB 
containing 7% DMSO then left to stand on ice a further 10 minutes. The cell 
suspension was aliquoted into pre-chilled eppendorf tubes (typically in 200 pi 
portions), and each aliquot was flash frozen using liquid Nitrogen. Aliquots were 
stored at -70°C, and thawed on ice immediately prior to use. As with normal 
competent cells, thawed and refrozen cells ceased to be competent.
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The transformation procedure.
An aliquot of frozen competent cells was thawed on ice, then gently resuspended by 
lightly flicking the eppendorf tube. The DNA to be used for the transformation was 
added to the cell suspension and the mixture incubated on ice for between 3 0 - 9 0  
minutes. The eppendorf was then transferred to a heat block or water bath preset at 
42°C and incubated for 3 minutes (or 37°C for 5 minutes). Immediately following this 
incubation the tube was returned to ice and left a further 5 minutes. The cells were 
then spread onto dried warm LB agar plates containing the appropriate antibiotic(s) 
(50 - 75 pi cell suspension per plate), and the plates incubated at 37°C overnight. It 
was found that the addition of warm LB to a cell suspension followed by incubation 
for 1 hour at 37°C prior to plating out (traditionally recomended as a means of 
overcoming ‘phenotypic lag’, allowing expression and build up of the phenotypic 
properties conferred by the plasmid before exposure to antibiotic selection) was 
counter productive. Experiments (results not shown) confirmed that more 
transformants survived when cells were immediately spread onto plates. This was true 
for all transformations carried out during the work described in this thesis, regardless 
of strain or resistance marker used. It also had the added advantage of saving time, 
and was adopted as a standard procedure. It can be explained at least in terms of 
ampicillin resistance, since there is no phenotypic lag with this marker. Resistance 
develops rapidly, and ampicillin effects cell wall biosynthesis only in cells that have 
progressed into active growth (Old and Primrose).
Testing of competent cells.
Transformations are often the final stage of cloning procedures involving many 
complex and time-consuming stages. Indeed, the DNA used in a transformation 
sometimes represents a unique sample - making it very important to ensure that each 
new batch of cells is actually competent. Tests were carried out on each new batch of 
competent cells prior to their use. All cells were tested after freezing to ensure that the 
freezing process itself had not caused any deleterious effect. A single 200 pi aliquot, 
thawed on ice, was normally sufficient to carry out all three tests.
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Table 6 Competent cell tests.
• Vitality Cells were still alive.
• Resistance Cells were not antibiotic resistant (unless intended to be).
• Competence Cells were competent
Vitality.
50 pi of thawed cell suspension was spread aseptically onto a fresh LB agar plates 
devoid of any antibiotic. The plate was then incubated overnight at 37°C. Confluent 
cell growth was expected. No cell growth indicated that the cells had not survived the 
process, and the batch was discarded.
Resistance.
50 pi of thawed cell suspension was spread onto each of several LB agar plates 
containing different antibiotics. The plates were incubated at 37°C overnight. No cell 
growth on agar plates containing antibiotic was expected, unless those cells were 
already known to contain a resistance gene. Where cell growth did occur it indicated 
the presence of unwanted resistance and the whole batch was discarded to avoid a 
high background during transformations. Cells were routinely tested for resistance to 
ampicillin and chloramphenicol. If the use of other antibiotics was anticipated then 
cells were tested for resistance to these also.
Competence.
50 pi of thawed cells, transformed with approximately 1 ng of a control plasmid 
(usually a cloning or expression vector), was spread onto an LB agar plate containing 
the appropriate antibiotic. The plate was incubated overnight at 37°C, and the extent 
of cell growth indicated the level of competency. This test required that the cells were 
also shown to have no prior resistance to the antibiotic used (see ‘Resistance’ above).
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Screening clones for the presence o f an inserted gene or DNA 
fragment
Quick screen
When a new gene or PCR product is ligated into a cloning or expression vector it is 
necessary to select the correct construct from a background of incorrect constructs and 
empty vectors. Potential clones can be selected after a ligation by comparing the 
relative sizes of native plasmid DNA and transformant DNA. If the plasmid DNA 
isolated from a transformant is the same size as the native plasmid then it is unlikely 
to contain the insert of interest. However, if it is larger by an amount corresponding to 
the size of insert, then it is likely to contain that insert. A ‘Quick Screen’ allows this 
selection process to be carried out very quickly, and on a large number of samples 
simultaneously.
Materials required include the Quick Screen Buffer (QSB), shown in table 7, and 
sterilised toothpicks.
Table 7 Quick Screen Buffer.
1 X TBE buffer containing 6% glycerol, 1% SDS, 10 pgml'1 RNAse,
and 0.002% Bromophenol blue._______________________________________
A small amount of cells from the colony to be screened are scraped up with a sterile 
toothpick, and then transferred to an eppendorf containing the Quick Screen buffer. 
The toothpick is swiftly twisted in the buffer to release the cells into the buffer, and 
mix them. The buffer causes cell lysis to occur (this happens in a few minutes, usually 
while other samples are being prepared for the same screen), releasing plasmid DNA 
into the solution. The tubes are then spun in a bench top microfuge for 10 minutes. 
The solutions can then be directly loaded onto an agarose gel for electrophoresis. A 
gelatinous pellet forms during centrifugation, and this can be removed from the tubes 
by pipette. Only the clarified supernatent should be loaded onto the gel. Cells 
containing the control plasmid (with no insert) should be prepared in the same way, 
and loaded at either end of the gel to provide a size standard. Once the gel has been 
electrophoresed, the ethidium bromide stained plasmid DNA can be viewed using a 
UV transilluminator. Lanes containing plasmid that is larger than the control (ie. the
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bands are higher up the gel) correspond to transformants that are worth further 
investigation.
Restriction digest screen
Potential clones are selected from unwanted background, or mis-incorporated 
insertions, by preparing their DNA by miniprep and incubating it with restriction 
enzymes. The enzymes are selected such that they will release the inserted fragment 
or gene from the vector, if it is present. Usually the same enzymes used to create the 
construct are also used to digest it. The presence or absence of an insert is revealed 
following digestion by agarose gel electrophoresis. This screen has the advantage of 
also demonstrating that the restriction sites used to make the construct are still 
recognisable by the enzymes - in other words the junctions between vector and insert 
are likely to be correct. It is a lengthy process, however, involving growth of cells, 
minipreps of their DNA, and incubation with (possibly expensive) enzymes. 
Frequently this was used as an additional screen used on clones, which had proved 
positive with the Quick Screen (above). Transformants were picked from the original 
plate and streaked onto a fresh one using a toothpick. The same toothpick was then 
dropped into a sterilin tube containing 5 ml of LB (supplemented with the appropriate 
antibiotic). Both the fresh plate and the 5 ml culture were grown overnight at 37°C. 
The streaked cells were then used for the Quick Screen, and pellets from cultures 
corresponding to Quick Screen positives were then used to provide miniprep DNA for 
restriction screens and further transformations.
PCR screen
The presence of a gene of interest in a new construct can be demonstrated using a 
PCR screen. This is a conventional PCR using the construct under investigation as the 
template, and primers, which will amplify the target gene if it is present. The 
completed reaction is analysed using an agarose gel for the presence of amplified 
product (indicating that the desired gene is present). A construct, which does not 
contain the target gene, is used as the template for a control reaction to ensure that 
there is no non-specific amplification. Usually miniprep DNA was used as the 
templates, but it is also possible to use lysed bacterial cells directly.
144
Protein expression screens
The presence of a gene of interest was also demonstrated by detection of the desired 
protein following induction of protein expression. This had the advantage of allowing 
selection of clones able to express the required protein. However, it had the 
disadvantage of not allowing detection of genes which are present but which for some 
reason (eg toxicity or poor codon usage) are not overexpressed. It also could not 
necessarily distinguish between a construct which was correct and a construct, which 
was incorrect but produced a protein of the expected size. Protein expression was 
therefore used to select clones in conjunction with DNA based screens, rather than in 
isolation.
Small scale (5 ml) cultures were prepared as described in the next section (see: 
Bacterial cell culture for protein expression - Small scale protein expression) and the 
uninduced cells compared with induced cells by means of SDS PAGE analysis, 
Western blots and Dot blots (as described in the section: ‘Protein preparation and 
analysis’, page 153). Activity assays were used where the expressed protein was 
expected to exhibit an activity, which could be assayed in some way (assays used are 
described in: ‘Protein preparation and analysis’ page 163).
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Bacterial cell culture for protein expression.
Small scale protein expression
In order to maximise protein expression, small-scale trials using 5 ml culture volumes 
were undertaken. Generally a colony was used to innoculate 5 ml of LB, containing 
sufficient antibiotics to maintain selection of the plasmid. This was grown at 37°C 
overnight and 50 pi then used to inoculate a fresh 5 ml broth. Once the fresh culture 
reached mid-log phase, as determined by an OD6oo = 0.5, 500 pi of the broth was 
removed for analysis (uninduced sample), and the remaining 4.5 ml was induced by 
addition of IPTG to a final concentration of 1 mM. The culture was grown for a 
further 4 - 6  hours, during which time the OD600 was measured at hourly intervals and 
500 pi aliquots of cell culture removed at each interval for analysis. The cell aliquots 
were harvested by microcentrifugation in eppendorf tubes, and the cell pellets were 
resuspended in distilled water.
The volume of water used to resuspend the cell pellet harvested from 1 ml of culture 
was equal to OD600 value for that culture divided by 4. Thus the cell pellet from a 
500 pi culture of OD600 = 0.6 would be resuspended in a volume of 100 pi (see 
working below, and table 8).
(0.6 -7- 4) x 0.5 ml = 0.1 ml 
Table 8 Standardised resuspension of cells for SDS-PAGE analysis.
(OD60o- 4)  x culture volume (ml) = resuspension volume (ml)
By preparing each cell pellet in this way their cell densities were standardised, 
allowing a direct comparison of protein expression levels to be made between 
aliquots. This method also ensured that provided 15 pi of cell suspension was loaded 
per lane the gel would not be overloaded.
For whole cell protein analysis 15 pi of cell resuspension was added to 5 pi of SDS 
PAGE sample buffer, and the mixture heated at 90°C for 2 minutes prior to loading 
onto an SDS-polyacrylamide gel. The remaining cell suspension was lysed by 
sonication, microcentrifuged to separate the soluble and insoluble fractions and then 
the soluble fraction was carefully removed and filtered through a 0.2 pm
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microcentrifiige spin filter (Sartorius) to ensure that there were no residual insoluble 
particulates present. The insoluble pellet was then resuspended in 250 pi of water, 
mixed in order to wash away residual soluble fraction, and harvested by 
microcentrifugation. The supernatent wash was removed and discarded, and the pellet 
resuspended in its original volume (as calculated above) of water. This process 
provided a suspension of insoluble protein and a solution of soluble protein (each of 
equivalent volume and from an equivalent density of cells). A 15 pi aliquot of each 
was taken, heated at 90°C for 2 minutes in 5 pi of SDS-PAGE sample buffer then 
analysed by SDS-PAGE.
This process allowed an assesment of protein expression with time post induction, and 
an indication of protein solubility at each stage following induction. Thus the 
optimum point for cell harvest could be determined. Where expression was poor 
Western blots were used to detect the desired protein (see ‘Western blots and dot 
blots’, on page 153 within the ‘Protein preparation and analysis’ section).
Large scale cultures
E.coli, from a glycerol stock, carrying the appropriate plasmid were spread onto an 
agar plate supplemented with the antibiotics required to maintain selection of the 
plasmid. The plate was incubated at 37°C overnight allowing a lawn of confluent cells 
to develop. Cells were scraped from one half of the plate (using a sterile disposable 
cell scraper from Costar) and used to innoculate a starter culture of 25 ml LB, also 
containing the necessary antibiotics. The cells remaining on the other half of the plate 
were used to innoculate an additional 25 ml broth, which would be used as the starter 
for another, concurrently prepared, main culture (this text describes the steps used in 
preparation of just one of these cultures). The 25 ml starter culture was incubated with 
shaking at 37°Cg for 3 hours whereupon the cells were harvested by centrifugation 
and resuspended in 5 ml of fresh LB. The resuspended cells were used to innoculate a 
prewarmed (to 37°C8) 1 litre main culture of LB, supplemented with appropriate 
antibiotics.
8 Unless otherw ise stipulated
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Main cultures were incubated with shaking at 37°C8, and induced by addition of 
IPTG, to a final concentration of 1 mM, on reaching an OD6oo ~ 0.5 - 0.7. Each 
culture was allowed to continue growing for the optimum period post induction, as 
determined by the small-scale trials (described in the previous section).
The cells were harvested by centrifugation, and resuspended in buffer A9 (table 9) at 
a density of approximately 12.5 ml buffer per litre of cells cultured. The cell 
suspension was stored frozen at -70°C pending protein purification. Where IMAC was 
to be used as a purification procedure the EDTA and DTT were omited from the 
buffer. When required larger culture volumes were grown and induced accordingly.
Table 9 Buffer A.
50 mM Tris pH 8.0, 1 mM EDTA, 1 mM DTT, ImM PMSF
Fermentation
Fermentation was often used as an alternative to shake flask cultures when large-scale 
(8 L) preparations were required. It offered the advantage of increased biomass, 
resulting largely from more efficient aeration and the use of a richer media. A 
disadvantage was the increased possibility of plasmid loss without continual selective 
pressure in favour of the plasmid maintenance.
An LH series 210 fermenter (from Inceltech) was used. This featured a direct drive 
motor, 10 L maximum capacity, temperature control, pH control, and provision for 
use of Oxygen (which was not utilised). The media used was ‘Terrific Broth’ (table 
10) and a pH of 7.2 was maintained by the buffering effect of Potassium diHydrogen 
orthoPhosphate within the media.
Table 10 Terrific Broth.
Bactotryptone 20 gL*1, Yeast extract 10 gL'1, Sodium Chloride 5 gL'1, 
Potassium diHydrogen orthoPhosphate 6.8 gL'1, Glucose 1 gL'1, and Glycerol 
2 mlL'1 - adjust pH to 7.2 using 40% Sodium Hydroxide.
9Except where specific alternative buffers are stipulated
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A typical run used 8 L of terrific broth. The ingredients were dissolved in 1 L, 
adjusted to pH 7.2, transferred to the fermentation vessel, then made up to the final 
volume required with water. The fermenter vessel was assembled according to the 
manufacturers instructions with the media in situ, and autoclaved at 121°C for 40 
minutes at 115 psi. Autoclaving was usually carried out the night before a run, and the 
fermentation vessel remained in the autoclave until morning. In this way the vessel 
cooled slowly, and had generally reached about 37°C by the time it was required. 
Media and glassware for preparation of the starter culture were autoclaved at the same 
time.
In order to produce sufficient starter culture for the fermenter 75 pi of E.coli glycerol 
stock containing the desired plasmid was spread onto each of four agar plates 
supplemented with appropriate antibiotics to maintain plasmid selection. The plates 
were incubated at 37°C overnight, producing a confluent lawn of cells. The cells were 
scraped from each plate using a sterile disposable scraper and used to inoculate 100 
ml of Terrific Broth also supplemented with the appropriate antibiotics. This starter 
culture was incubated with shaking at 37°C for three hours. The cells were then 
harvested by centrifugation, resuspended and washed in 100 ml LB, re-harvested and 
finally resuspended in 100 ml of fresh Terrific Broth containing the antibiotics. This 
cell suspension was then used to inoculate the main fermentation vessel, also 
supplemented with the appropriate antibiotics. The purpose of this lengthy inoculum 
preparation procedure was to obtain an actively growing culture, which had been 
subject to stringent selection pressure aimed at maintaining the desired plasmid, with 
a view to ensuring that high levels of the plasmid were present in the main culture.
The culture was grown at 37°C, with a stir speed of 800 rpm, and an air-flow rate of 
greater than 3000 mlmin'1 (usually 5000 mlmin1). Airflow into the vessel was passed 
through Whatman Hepa-Cap 0.2 pm filters (previously autoclaved and oven dried) to 
ensure sterility of the air intake. The Hepa-Caps were chosen because they maintained 
a high air-flow rate, without blockage, throughout a run. The cell density (OD600) was 
monitored throughout the run via a sample collection port, and induction was 
achieved by addition of IPTG to a final concentration of 2 mM (via an inlet port) once 
mid-log phase was reached at an OD600 of 0.5. The culture was then grown for a 
further 2 hours, and typically reached a final OD600 approaching 2.0. Total run times
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were usually less than 6 hours. At the end of a run the heating element was unplugged 
and the bulk of the culture was expelled via the sample collection port, by exploiting 
the positive air pressure within the vessel, and collected for harvest. When no further 
culture could be removed in this way the vessel was disassembled and the remaining 
culture poured out manually and harvested. The fermenter and vessel were then 
cleaned and disinfected as per the manufacturers recomendations. The cell paste was 
weighed, typically an 8 L fermentation yielded 40 g of cell paste, and resuspended in 
200 ml buffer A prior to storage at -70°C pending purification.
Lysis of bacterial cells
In order to release over expressed protein from bacterial cells prior to purification the 
cells must be disrupted. The French Press and Sonication techniques were routinely 
used, and the instruments were operated in accordance with manufacturers 
recomendations. Freeze thawing of cells in the presence of lysozyme was often used 
to augment mechanical lysis techniques.
Using a French Press
The French press comprises a stainless steel cylinder closed at one end, except for an 
adjustable narrow bore aperture, and fitted with a stainless steel piston from the other 
end. The whole assembly sits in a large motorised press which allows the operator to 
lower or raise the piston. The cell slurry to be disrupted is poured (or drawn via an 
inlet port) into the cylinder, and then forced out through the narrow aperture as 
pressure is applied via the piston. A combination of increased pressure, followed by 
rapid decompression, and shearing forces results in cell lysis. It was often necessary to 
perform repeated passes to ensure complete lysis. The cylinder assembly was chilled 
at 4°C prior to use, and sample slurries were kept on ice throughout the process. The 
main advantage of the French Press method was that no heat was generated during the 
process, reducing the likelihood of unwanted proteolysis or denaturation of protein.
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Using a Probe Sonicator
Ultrasonication involves the exposure of cell slurry to high frequency vibrations (20 
kHz or more) generated by a sonication probe immersed in the slurry. The high 
frequency vibrations cause areas of rapidly interchanging compression and rarefaction 
(gaseous cavitation), which in turn generate shock waves able to disrupt bacterial cell 
walls. Typically the cells for disruption were resuspended in lysis buffer at 20% w/v 
or less (to reduce viscosity and ensure adequate mixing). The buffer used varied 
according to the protein to be isolated, but usually incorporated 1 mM EDTA and 0.1 
mM PMSF to reduce proteolysis. Disruption is dependent on exposure time, however, 
a great deal of heat can be generated during the process which will cause proteins to 
denature. For this reason the sonicator probe was pre-chilled by storing on ice for 20 
minutes prior to use, and cell slurries were kept on ice throughout the procedure. Also 
sonication was controlled using a programmable timer and carried out in short bursts 
(30 secs each), interspersed by periods of cooling (1 or 2 minutes). Sonication was 
especially used for disrupting small volumes, such as 1 ml slurries in (an eppendorf) 
for small scale protein expression analysis.
By freeze thawing in the presence of lysozyme
This method of cell disruption was often used in conjunction with sonication in order 
to reduce the sonication time required for complete disruption. Lyophilised hen egg 
white lysozyme was dissolved in the buffers used for cell resuspension following 
harvest. The cell pellets were stored frozen until required, then thawed on ice. During 
the thawing process the lysozyme begins to break down the peptidoglycan in the 
bacteria cell walls. A 50 ml cell paste typically took 30 minutes to thaw, and in this 
time the majority of cells would have lysed. The thawed paste was usually very 
viscous due to the release of DNA from the cells, this was reduced by the addition of 
DNAse and RNAse to the resuspension buffer following harvest, or by a subsequent 
sonication step. Cells that expressed lysozyme (eg cells containing the pLys S 
plasmid) obviated the need for inclusion of hen egg white lysozyme in the harvest 
buffer.
151
Protein preparation and analysis
SDS-PAGE Analysis of Proteins
Sodium Dodecyl Sulphate - Poly Aery lamide Gel Electrophoresis (SDS-PAGE) of 
proteins was carried out using methods based on those described by J. V. Maizel and 
co-workers, and Laemmli (Shapiro, Vinuela et cil. 1967; Maizel and Summers 1968; 
Shapiro and Maizel 1969; Laemmli 1970). The apparatus used in all cases was the 
Bio Rad Miniprotean system, and this was assembled and used as per manufacturer’s 
instruction. Resolving gels were typically either 12% or 15% with respect to 
acrylamide content, as required. The constituents of gel mixes (stacking and 
resolving), loading (sample) buffer, and running buffer are given in the table below. 
Gels were electrophoresed by application of 30 mA current per gel for a period of 
approximately one hour (depending on the specific requirements of the experiment), 
using a Bio Rad ‘Power Pac 300’ (sic) power supply. Samples containing high salt, 
urea or guanidine were first acetone precipitated, then resuspended in 1 x loading 
buffer. This technique avoided poor resolution and other problems commonly 
associated with high salt samples, and also obviated the need for gels containing 
chaotropic reagents.
Size Standards for PAGE
Standard size markers were used with each gel to provide an estimate of protein size, 
and also to indicate successful electrophoresis. The markers used in each case are 
stipulated in the text. Prestained markers were often used since they allowed a real 
time indication of the extent of electrophoresis during a run, and were also useful 
indicators for Western blots.
Acetone precipitation
An aliquot of up to 250 pi of the protein solution to be precipitated was taken in a 
2 ml eppendorf, which was then filled to the maximum fill line with acetone. The 
contents of the tube were mixed by inversion or vortexing, and then subjected to 
microcentrifugation at maximum rpm for at least 10 minutes, usually 30 minutes. The 
supematent was discarded, and the precipitate allowed to air dry prior to resuspension 
as desired.
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Western blots and Dot blots
Blotting was first described as a technique for the transfer of DNA from agarose gels 
to nitrocellulose membrane (Southern 1975) and was later applied to the transfer of 
proteins (Renart, Reiser et al 1979; Bowen, Steinberg et a l 1980). Electrophoretic 
transfer as a means of eluting protein from a gel onto a membrane was first described 
by Towbin et al (Towbin, Staehelin et al. 1979), and is known as ‘Western blotting’.
Proteins are first separated according to their molecular weight via conventional 
PAGE (as described above), then transferred horizontally onto a nitrocellulose 
membrane by electrophoresis. The membrane is then ‘blocked’ by incubation with a 
solution of BSA or skimmed milk powder to prevent non-specific binding of antibody 
to the nitrocellulose. The membrane is then exposed to a primary antibody specific for 
the protein of interest. A secondary antibody is then applied which specifically 
recognises the primary antibody, and is labelled (either chemically, photochemically, 
or radioactively) to allow its detection. Finally binding of the secondary antibody is 
detected (method dependant on the label used) and indicates the presence (or absence) 
of the protein of interest.
The Western blots described here were carried out using the BioRad ‘Mini Trans- 
Blot’ electrophoretic transfer cell, which is compatible with the ‘Mini-PROTEAN’ 
system used here for PAGE, and also supplied by BioRad. Details of the assembly 
and operation of the blotting apparatus are available from the Mini Trans-Blot 
Instruction Manual, supplied by BioRad. Details of the assembly of blot components 
within the cassette are given below. Two transfers could be carried out simultaneous, 
running them at 400 mA for 90 minutes.
Table 11 Western blot transfer buffer.
25 mM Tris pH 8.3, 192 mM Glycine, 20% v/v methanol
It should be noted that this buffer was used with nitrocellulose membranes. Other m edia may require different buffer.
Dot blots were developed in the same way as Westerns, but differed in that protein 
was placed directly onto the membrane rather than transferred from a preceding 
PAGE step. Dot blots provided a quick visual assay for the presence of a specific 
protein in a solution, but did not give any indication of the relative size of the protein 
in question.
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Assembly of the blotting components within the BioRad cassette.
A PAGE gel was run, as previously described, using prestained markers. The gel was
carefully removed from between the glass plates and placed into a dish of Western 
blot transfer buffer (table 11). For each gel to be transferred a square of nitrocellulose 
membrane was cut to size (approximately 7.5 cm x 10 cm) and soaked in transfer 
buffer, as were two 7.5 cm x 10 cm squares of Whatman no.l filter paper, and two 
fibre pads (supplied with the blotter).
The blotting cassette was placed open in a shallow dish filled with tranfer buffer, with 
the grey panel (to be orientated towards the cathode during the run) in the base of the 
dish. Gloves were worn throughout component assembly and disassembly, to avoid 
contaminating the blot, or contact with polyacrylamide. A pre-soaked fibre pad was 
placed on the grey panel, followed by a saturated square of filter paper, and then the 
gel, with its surface flooded with transfer buffer. The nitrocellulose membrane was 
next laid on top of the gel and a glass pipette was rolled over the membrane to exclude 
any trapped air bubbles from between the gel and the membrane. The surface of the 
membrane was then flooded with buffer, and a square of filter paper placed over it, 
followed by a second fibre pad. When assembling the blot components great care was 
taken to ensure that no air bubbles were incorporated within the layers, and that they 
were centred within the cassette. This ensured a complete and undistorted transfer. 
The closed and secured cassette was then placed within the electrode assembly, 
orientated such that the grey panel (i.e. the gel side) faced cathode electrode.
Blot development
Following transfer (or dot blotting) the nitrocellulose membrane was incubated with 
shaking in blocking solution (table 12), at 4°C for at least 30 minutes, then washed 
twice - first with PBS + 0.1% Tween 20, then with PBS alone.
Table 12 Western blot blocking solution
Phosphate buffered saline (PBS), 5% w/v dried milk powder *, 0.1% TWEEN 20
PBS tablets are available from Sigma, use one tablet per 200 ml of solution.
(* marvel or five pints etc.)_________________________________________________________________________ _
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The membrane was then incubated in PBS containing 5% milk powder and primary 
antibody, for at least one hour - or even over night. The antibody was used at the final 
concentration recommended by suppliers. Incubation times required vary with the 
efficacy of the antibody, and with levels of the target protein present. Here the 
membranes were exposed to primary antibody overnight, since protein expression 
levels were usually poor. The primary antibody solution can be re-used several times, 
and was stored at -20°C between blots.
After exposure to the primary antibody, the membrane was washed again in two 
changes of PBS / TWEEN, then two changes of PBS. Next the membrane was 
exposed to the secondary antibody in PBS for one hour (the secondary antibody 
solution was not re-used). The PBS / TWEEN and PBS wash steps were repeated, and 
the membrane finally washed in two changes of distilled water.
The secondary antibodies used were conjugated to alkaline phosphatase, consequently 
blots were developed by incubation in a 10% solution of 1,4-dichloronapthol, until 
bands appeared and were fully developed. The reaction was stopped by removing the 
blot from the developer and immersing in distilled water, then changing the distilled 
water several times to ensure thorough washing. The membranes are extremely fragile 
- especially when dried - and also fade or discolour with age. They can be dried 
between transparent sheets (using the BioRad gelair system) in the same way as 
protein gels, and this helps prevent deterioration.
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Refolding insoluble proteins.
Where protein is expressed in the insoluble fraction of the cell lysate (as inclusion 
bodies) it can be isolated by centrifugation (retaining the pellet) and in many cases 
refolded. Frequently insolubility is caused by mis-folding of the protein during 
expression, resulting in deposition as inclusion bodies. It is usually better to optimise 
soluble expression rather than resort to refolding, however, occasionally this is either 
unsuccessful or undesirable (eg. when deposition of a protein in inclusion bodies is 
intentional). In these cases refolding will be necessary. Following complete cell lysis 
the insoluble fraction is isolated as a pellet by centrifugation, and washed with a low 
chaotropic buffer such as 0.5 M guanidine or Urea. The pellet is then dissolved in 
high concentration chaotropic buffer (eg. 6 M guanidine or 8 M Urea), gentle 
sonication and stirring may be required to ensure total dispersion of the pellet. Any 
remaining insoluble particles are then removed by ultracentrifugation, and the 
clarified supernatant retained. This contains the unfolded protein. Refolding is 
achieved by gradually reducing the levels of chaotrope until they are negligeable. The 
refolded protein should remain in solution, but inevitably some components of the 
solution will precipitate from solution and these are removed by ultracentrifugation. A 
concentration step will then reduce the volume of the refolded protein solution and 
concentrate the target protein.
Gradual removal of the chaotrope can be achieved in several ways, which is chosen 
depends on the ease with which a protein refolds. The quickest and simplest method 
involves conventional dialysis into a non-chaotropic buffer; this is the method of 
choice. WTtere straight forward dialysis is unsuccessful step dialysis against a series of 
progressively lower chaotropic refolding buffers may be employed. Finally, for 
proteins that do not refold well by dialysis, a slow drop-wise dilution of the solution 
with a non-chaotropic refolding buffer can be used. For all methods, the components 
of the refolding buffer should be optimised for solubility of the target protein by 
careful choice of characteristics such as pH, salt concentration, and presence of 
additives (such as glycerol, DTT or cofactors). All steps in the refolding process 
should be carried out at 4°C.
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The retroviral proteases are relatively small proteins, and refold very easily - usually 
by means of a single dialysis step. Refolding was thus used during several stages of 
protein purification for each of the proteases described in this thesis. Specific methods 
and buffers used for each protease are described in the methods sections of the 
relevant chapters. Figure 1 summarises the basic methodology for protein refolding in 
general, and the characteristics of refolding buffers that must be considered.
Figure 1 The refolding of insoluble proteins.
Refolding insoluble proteins
Step 1. Unfold protein.
Dissolve inclusions / pellet in buffer + 6 M Guanidine 
Step 2. Controlled reduction of denaturant.
• Dialysis into refolding buffer.
• Multi-step dialysis into refolding buffer.
• Drop-wise addition of refolding buffer.
Keep Cold, Keep Stirring, Proceed Slowly!
Step 3. Remove insoluble debris
• Centrifugation
Step 4. Remove unwanted denaturants
• Dialysis
Refolding buffer components.
pH > 1 unit from pi
Buffer ~ 50 mM
Salts at least 100 mM NaCl
Additives 2 -2 0  mM DTT or BME
2% Sarkosyl or Triton X-100 
Cofactors?
ATP (ATP binding proteins)
Phosphate (Kinases)
1M o f either urea, Arginine, or 
Glycine
Disulphide shuffling
Consider a redox gradient eg. using 
reduced & oxidised glutathione, or 
cysteine and cysteamine.
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Microdialysis.
Microdialysis was used where small ( jlxI) volumes were to be dialysed -  for example 
during testing of inhibitors in Chapter 3, or the refolding steps described in Chapter 6 
for preparation of S I V a g m  PR. Microdialysis buttons were generated from the tops of 
eppendorf tubes, as shown in figure 2.
Figure 2 Production of microdialvsis buttons.
ta
i
1. Heat scalpel
2. Cut below rim of eppendorf
3. Remove lid and rim for use
4. Fill lid with sample for dialysis
5. Place membrane over sample
6. Hold membrane in place with rim
7. Dialysis button ready for use
The sample to be dialysed was pipetted into the lid of the tube, which acted as the 
button well. A square of dialysis membrane was placed over the sample and then held 
in place by fitting the rim of the tube over the lid. The completed button was then 
placed into the dialysis buffer, membrane downwards, for dialysis. Once dialysis was 
complete, the sample was removed by slitting the membrane with a scalpel, pushing a 
pipette tip through the slit, and drawing the sample out. This system was inexpensive, 
used readily available materials, and was highly effective.
Chromatography
All chromatographic procedures were carried out using a Fine Performance Liquid 
Chromatography (FPLC) system from Pharmacia (subsequently Amersham 
Pharmacia Biotech, now GE Healthcare), and all columns and packing materials were 
supplied by Pharmacia unless otherwise stipulated. Chromatography was carried out 
at room temperature, unless stated otherwise, and all buffers were drawn through a 0.2 
pm filter by vacuum prior to use. Eluted protein was detected by UV absorbance at 
280 nm, and fractions were collected automatically using a Pharmacia fraction 
collector. Individual chromatographic protocols are described in the relevant text. The 
modes of chromatographic separation used were Size Exclusion Chromatography 
(SEC), Hydrophobic Interaction Chromatography (HIC), Ion Exchange 
Chromatography (IEC), Immobilised Metal Affinity Chromatography (IMAC), and 
Affinity Chromatography - particularly the use of Pepstatin Agarose. The principles 
involved in each of these techniques are explained well in the texts below (table 13), 
and are also explained in a number of general biochemical textbooks.
Table 13 Texts describing chromatographic analysis of proteins.
• Protein Purification, Principles and Practice (Robert K Scopes)
• Protein Purification, A Practical Approach (T.E. Creighton)
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Pepstatin-agarose affinity chromatography
Pepstatin-agarose resin (obtained from Sigma) binds aspartic proteases generally, with 
a binding capacity of approximately 1 mg porcine kidney renin per ml of resin. Since 
pepstatin is a potent inhibitor of both HIV and SIV proteases this resin allowed 
affinity purification of the retroviral proteases studied here. The principle of using a 
peptide substrate analogue immobilised on agarose resin for the purification of HIV 
proteases has previously been described by Heimbach et al. 1989 (Heimbach, Garsky, 
et al. 1989) and protocols for the use of pepstatin-agarose have been described by 
Rittenhouse et al. 1990 (Rittenhouse, Turon, et al. 1990) and Wondrak et al. 1991 
(Wondrak, Louis, et al. 1991). In general pepstatin inhibition of HIV-1 PR is greater 
at high ionic strength, and optimal below pH 5.5 becoming weaker above pH 6 
(Billich et al. 1990). Elution can therefore be achieved by means of a reduction in 
ionic strength and an increase in the pH.
The purification procedure adopted was essentially as described by Rittenhouse et al. 
1990. Pepstatin-agarose was packed into a 5 ml column (Pharmacia), and washed 
thoroughly with equilibration buffer (table 14). Samples were prepared in 
equilibration buffer and applied to the column, the flow through was collected for 
later analysis. The column was then washed with five volumes of equilibration buffer.
Table 14 Pepstatin-Agarose equilibration buffer.
50 mM HEPES pH 7.5, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF
The elution buffer (table 15) was applied to the column, and 10 ml fractions were 
collected into tubes containing 0.5 ml 2M HEPES, immediately neutralising the 
samples. Fractions collected in this way were stored at -20°C pending further use.
Table 15 Pepstatin-Agarose elution buffer.
250 mM Sodium 8-aminocaproate pH 10.5, 5% glycerol, 5% ethylene glycol, 
1 mM EDTA, 1 mM DTT, 0.1 mM PMSF
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The column was cleaned immediately after use with five volumes of 6 M guanidine- 
HC1 followed by five volumes of equilibration buffer containing 20% ethanol. All 
purification steps were carried out using a Pharmacia FPLC, at a flow rate of 0.5 
ml/min.
Concentration of proteins by ultrafiltration
Ultrafiltration (UF) uses semi-permeable membranes to separate solvents from solutes 
of various sizes. UF membranes have a thin dense skin with pores in it (whose size 
are precisely controlled during manufacture), supported by an open-celled spongy 
substructure. Any molecular species able to pass through the pores of the skin will be 
able to freely pass through the substructure. Thus retention of a molecule is a function 
of its size and shape, compared with the pore size of the membrane. Membranes are 
available with various pore sizes, and thus varying degrees of solute retention. They 
are assigned a molecular weight cut-off (MWCO) in Daltons to indicate the molecular 
weight of solute which will be 90% retained by the membrane. Any molecule smaller 
than the MWCO for a given membrane may pass through that membrane. The 
membranes are inert, non-cytotoxic, do not bind or denature proteins, and withstand 
repeated use (provided the outer skin is not damaged). UF was predominantly used as 
a means of concentrating protein samples, but could also be used to desalt or buffer 
exchange samples.
Pressure cells and centrifugal concentrators were used as described below. In both 
cases membranes were chosen according to the size of protein to be concentrated, and 
were prepared and used in accordance with the manufacturers instructions - with 
particular attention to pressures or RCF applied.
Amicon pressure cell concentrators
Large volume protein samples (ie. > 100 ml) were reduced in volume using UF in a 
stirred pressure cell supplied by Amicon. The protein solution to be concentrated was 
held within the body of the pressure cell, and gently stirred throughout the 
concentration process by a magnetic stirrer suspended from the cap assembly of the 
cell. The membrane was supported by a holder which sat in the base of the cell, and 
leaks were prevented by O-rings in the cap and base assemblies. The entire cell was 
positioned inside a retaining stand, which prevented the cap from blowing off once 
gas pressure was applied. Nitrogen gas was then applied through a nozzle in the cap 
assembly, and the pressure exerted by the gas forced solvent through the membrane at
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the base. Solute molecules larger than the MWCO for the membrane used were 
retained within the cell body. The stirrer prevented concentration polarisation (which 
would have reduced the flow rate). Amicon pressure cells of various volumes were 
used, depending on initial sample size, and concentration was carried out at 4°C. Care 
was taken to ensure that the cells did not run dry, and that precipitation of the sample 
protein was avoided. Cells were assembled and operated as recomended by the 
manufacturer.
Centricon and Centriprep spin concentrators
These UF protein concentration devices were also supplied by Amicon, and were used 
to concentrate small sample volumes (10 ml - 100 pi). Protein solution was held in a 
reservoir above the membrane, which was itself supported above a flow through 
collection tube. The entire assembly was spun in a fixed angle centrifuge rotor and 
solvent was pushed through the membrane by centrifugal force. The maximum RCF 
that could be applied during a spin was determined by the membrane type, and was 
specified in literature accompanying the concentrators. During the concentration 
process the centrifuge was periodically stopped so that the speed of progress could be 
monitored. Sample could be topped up if necessary, and the flow through tube 
emptied if required. The sample in the reservoir was regularly mixed using a pipette to 
avoid concentration polarisation. Periodic inspection of the sample also reduced the 
risk of sample precipitation or of the concentrator running dry. Following 
concentration the flow through collection tube was removed, and a retentate collection 
tube was fixed over the opening of the sample reservoir. The concentrator was then 
inverted and spun at a low RCF to collect the concentrated sample solution.
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Protease assays
Monitoring protease activity.
Protease activity was monitored where possible using an assay developed 
commercially by Amersham International pic (subsequently Amersham Pharmacia 
Biotech, now GE Healthcare). This is a system based on the scintillation proximity 
assay (SPA) principle (Udenfriend, Gerber et al. 1987; Cook, Jessop et al. 1991) 
whereby beads containing a scintillant are attached to radioactive 123I via a peptide, 
which acts as the proteolytic substrate. The proximity of 12H to the scintillant causes 
the beads to emit light which can be detected by a scintillation counter. If proteolytic 
activity severs the peptide, causing the I and the bead to separate, scintillation will 
cease. Protease activity is therefore detected as a drop in scintillations counted. This 
assay was used as a rapid means of following the protease activity during the 
purification procedures. Assays were routinely carried out at 37°C for 1 hour. Typical 
reaction conditions consisted of 100 pi SPA reagent, 10 pi enzyme, and 90 pi SPA 
reaction buffer (table 16).
Table 16 SPA reaction buffer
100 mM 2-(N-Morpholino)ethanesulphonic acid (MES) pH 6.5, 1 mM DTT,
1 mM EDTA
Plus 200 mM NaCl for HIV-2 PR assays (not required for HIV-1 PR assays).
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Kinetic analysis of proteases
The SPA assay was unsuitable for kinetic studies, therefore Km determinations were 
carried out using chromogenic substrates (supplied by Bachem) under the conditions 
described in Pennington et al (1990) (Pennington, Dick et al. 1990). This type of 
assay exploits the difference in molar absorptivity between the substrate and the 
products, where the change in absorption is proportional to the extent of cleavage. It is 
preferable to use a system where this difference is greatest in the visible range, since 
measurements in the UV range will be subject to interference from other components 
of the sample extract (especially if crude lysates are analysed). Details of substrates, 
precise conditions, and instrument settings used are given in the relevent text.
Data was recorded using a Shimadzu Graphicord UV-240 dual beam 
spectrophotometer (able to monitor absorbance over a range from 190 - 1100 nm) 
with PR-1 printer attached. Samples were analysed using a pair of matched 1 ml 
quartz cuvettes plus lids (supplied by Hellma). Reaction buffers varied dependent on 
the protease under study, and are described in the relevant text. All buffers were 
prewarmed to 37°C, while enzyme and substrate were stored on ice prior to use. The 
spectrophotometer's chamber was maintained at 37°C by water pumped from a 37°C 
bath through heating ducts within the chamber. Final reaction volumes were 1 ml and 
measured against a blank containing buffer alone. Addition of substrate and enzyme 
to the reaction mix was compenstated for by prior removal of an equivalent volume of 
reaction buffer, so that the 1 ml final volume was always maintained. Substrates were 
supplied as a lyophilised powder, and were dissolved in water to give a concentrated 
stock solution which was aliquoted and stored at -20°C. An aliquot of this stock was 
thawed on ice immediately prior to use, and diluted with water to provide sufficient 
substrate of the required concentration for that day’s experiments.
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Table 17 Procedure for protease assays using chromogenic substrate.
1. The spectrophotometer housing was allowed to warm to temperature (37°C), 
and the appropriate wavelength (300 nm), chart speed (20 nm/cm), scan speed 
(slow), mode (time), and deflection settings (a maximum deflection of 0.05) 
were set.
2. Sample and reference cuvettes were filled with buffer alone, and the 
spectrophotometer was adjusted to zero.
3. Substrate stock (volume calculated to achieve the desired final concentration) 
was added to the sample cuvette and mixed by inversion. A base line 
measurement was then made.
4. The enzyme (usually 10-20 pi) was added to the sample cuvette, mixed, and 
the initial velocity of any proteolytic activity measured.
Each reaction was measured for a sufficient length of time to allow a reasonable linear 
trace to be obtained. If the slope of the trace was too great (ie greater than about 60°) 
adjustments were made to rectify this. Typically either the spectrophotometer’s 
deflection was adjusted, a faster chart speed was selected, or the enzyme stock was 
diluted. Readings were taken in triplicate for a given substrate concentration, their 
initial velocities were calculated and a mean value determined. Results were obtained 
over a range of substrate concentrations (stipulated in the relevant text) and values for 
Km, Kcat and Vmax were derived using a computer fit of the data calculated by the 
Enzfitter program (from Biosoft).
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Small scale affinity purification experiments.
General principle
These experiments exploited the ability to isolate a protein on a bead by means of a 
fusion tag or by affinity purification. They were carried out on a small scale (~ 100 pi 
volume) in eppendorf tubes. In principle the procedure was the same for all pull-down 
experiments. First the protein solution (usually 100 pi) was mixed and incubated with 
the chosen beads in an appropriate binding buffer. Next the beads were isolated, either 
by microcentrigugation or micro filtration, and the supematent / filtrate was discarded. 
The beads were then washed with several volumes of fresh binding buffer to remove 
any unbound, or non-specifically bound protein. Finally the beads were collected in 
microcentrifuge spin filters (available from Sartorius) and bound protein eluted from 
them into an eppendorf tube either by using an appropriate elution buffer, or by direct 
application of SDS-PAGE sample loading buffer. The eluted protein was then 
analysed by SDS-PAGE. The controls required for the gel included the input protein 
solution, the beads alone, and the beads plus a similar protein solution which does not 
include the target protein. If the target protein is present in the initial solution and has 
interacted with the beads it should be present in the eluted sample, whilst other 
proteins present should not bind to the beads.
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His-tag pull-downs
A target protein having an N-terminal 6 x histidine tag was used, and pull-down was 
achieved using Talon resin (from Clonetech).
Table 18 His-tag binding / wash and elution buffers.
Tris pH 8, 100 mM NaCl, 1 mM immidazol 
Supplemented with 100 mM immidazol for elution.
MBP pull-downs
The target protein was fused to Maltose Binding Protein (MBP), by cloning into the 
pMalcRI vector from NEB. The resin used was Amylose (available from NEB).
Table 19 MBP binding / wash and elution buffer.
20 mM Tris pH 7.4, 200 mM NaCl, ImM EDTA, ImM DTT 
Supplemented with 10 mM Maltose for elutions.
Pepstatin-agarose pull-downs
Pepstatin immobilised on the resin binds aspartic proteases, allowing them to be 
pulled-down. Binding and elution are pH and salt dependent (see ‘Protein preparation 
and analysis’ - ‘Pepstatin-agarose affinity chromatography’ page 160).
Table 20 Pepstatin-Agarose equilibration, binding and wash buffer.
50 mM HEPES pH 7.5, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF
Table 21 Pepstatin-Agarose elution buffer.
250 mM Sodium s-aminocaproate pH 10.5, 5% glycerol, 5% ethylene glycol, 
1 mM EDTA, 1 mM DTT, 0.1 mM PMSF
167
Chemical characterisation
Amino terminal analysis (N-terminal analysis)
N-terminal analysis by means of automated Edman degradation reactions was carried 
out by the Wellcome Research labs, Beckenham.
Mass spectrometry (MS)
Electrospray Mass spectroscopy of HIV proteases was carried out by the Wellcome 
Research labs, Beckenham, MS analyses of inhibitor compounds were carried out by 
Dr. J. Hill of the Chemistry Department, UCL.
Circular Dichroism (CD)
CD analyses were carried out by Dr. Ronan O’Brian at the Biochemistry and 
Molecular Biology Dept. UCL, Gower St. London. For details of CD methodology, 
and of the interpretation of spectra see ‘Protein secondary structure and Circular 
Dichroism: a practical guide’ (Johnson 1990).
(For further reading see the following references:- (Rosenkranz 1974; Rosenkranz 
1974; Johnson 1988; Johnson 1990; Bloemendal and Johnson 1995; Kuwajima 1995; 
Woody 1995; Greenfield 1996; Woody, Sugeta et al. 1996).
Nuclear Magnetic Resonance (NMR)
NMR spectroscopic analysis of the inhibitor compounds was carried out by Dr. Abil 
Aliev at the Chemistry department of UCL.
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Crystallographic methods
Preparation of proteins for crystallography
When preparing a protein for crystallography the aim was to obtain a stable solution 
of pure protein at high concentration (10-20 mgml'1). Purification of the protein to be 
crystallised (preferably to homogeneity) was followed by dialysis into the desired 
buffer for crystallisation. Dialysis included at least two changes of buffer, 
approximately twelve hours apart. A buffer was chosen which maximised the 
protein’s stability in solution. If a prefered buffer had not yet been established then a 
50 mM Tris-HCl buffer at pH 7.5 was used as an initial choice. Low levels (0.02%) of 
sodium azide were included to prevent fungal or bacterial growth during storage or 
crystallisation trials. In general the ionic strength of the solution was kept as low as 
possible without jeopardising protein stability (some proteins require the presence of 
salt if they are to remain in solution). Following dialysis the protein was concentrated 
using either an Amicon stirred pressure cell, or a Centricon (depending on the initial 
volume of solution). Where possible the solution was taken to a slightly higher 
concentration than intended, so that the concentrator membrane could be washed with 
buffer and the wash then incorporated into the sample (bringing it back to the 
intended concentration). Concentration was determined by measuring absorbance at 
280 nm since it was a quick and easily reproducible method found to give a 
reasonable approximation to the actual protein concentration.
Once concentrated the protein was aliquoted into appropriate sized fractions (typically 
100-200 pi) and stored at -70°C. Aliquoting fractions reduced the number of freeze 
thaw cycles the protein was exposed to, and a 100 pi aliquot was just enough to allow 
both Hampton sparse matrix screens to be set up.
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Methods of crystal growth 
The Microbatch method
This technique involves the use of microtitre plates filled with mineral oil, and drops 
are set up in the wells beneath the oil layer (Lloyd, Brick et al 1991; Pav, Lubbe et al 
1994; Zhao, Smith et al. 1996; Chayen 1997; Chayen 1998; Dong, Boggon et al 
1999). The technique uses only small volumes of buffer solutions (typical drop sizes 
are 1 or 2 pi), can easily be automated (Chayen, Shaw et al 1994), and the final 
concentration of drop components can be precisely determined. Once set up the 
screens are quite robust and trays can be transported without great risk, however, 
manipulation of crystals may be slightly impeded by the oil layer. The technique was 
predominantly used for initial screening (Sparse Matrix screening) as described in the 
next section.
The ‘Hanging Drop’ or ‘Vapour Diffusion * method
This method involves the suspension of the crystallisation drop above a reservoir full 
of the crystallisation buffer. It exploits the dynamic equilibrium between the drop, the 
well buffer and the vapour in the intervening space. The drop was formed in the 
centre of a siliconised glass coverslip (usually 50/50 protein solution to crystallisation 
buffer), and was typically 2 - 4 pi in volume. A limbro plate with large wells was 
used to provide the reservoir which was filled with 1 ml of the crystallisation buffer. 
The rim of the reservoir was smeared with silicon grease, and the coverslip was 
inverted and carefully lowered over the reservoir so that the drop was suspended 
above the well. The coverslip was gently pressed into the grease to ensure a good seal. 
The entire plate was then incubated at the required temperature (usually 14°C for 
retroviral proteases), and the drop inspected by microscope at daily intervals for signs 
of crystal growth. Hanging drops allow a gradual drift in buffer / protein 
concentration within the drop as the system approaches equilibrium. Ideally a drop 
should pass through conditions that allow both nucleation and crystal growth as it 
equilibrates. Vapour diffusion is considered in greater detail in the texts recomended 
for further reading in the appendix (Appendix: Further Reading; Table 9, page 352).
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Determination of crystallization conditions 
‘ Wild Screens * or ‘Sparse Matrix9 screens
The initial conditions for crystallization were determined by means of a ‘Wild Screen’ 
or ‘Sparse Matrix’ approach (Jancarik and Kim 1991). This employs a total of 50 
buffered, precipitant solutions selected from known or published successful 
crystallisation conditions. This principle has subsequently been used to create various 
commercially available screens. The solutions used here were initially prepared in the 
laboratory at UCL in accordance with Jancarik and Kim 1991, though the ‘Crystal 
Screen I’ by Hampton Research was subsequently used. The screen was carried out 
using droplets under oil, in microtitre plates, as described in the previous section (ie. 
by microbatch). Further details of the screen are available at 
www.hamptonresearch.com/2110.html.
Optimisation
Once an initial condition had been established, crystals were grown by the hanging 
drop vapour diffusion using that same condition. The first few drops were observed 
carefully and further drops were set up using subtle variations of the initial conditions 
to achieve optimum crystal growth. In particular variations in protein and precipitant 
concentrations were explored by titration over a series of drops. The ultimate aim was 
to produce good crystals of a reasonable size (preferably greater than 100 pm in 
diameter) which would be suitable for data collection. Establishing a crystallisation 
condition can be a complex, lengthy procedure, for more detailed information and 
methodology see ‘Protein Crystallization: Techniques, Strategies, and Tips -  A 
Laboratory Manual (Bergfors 1999).
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Macro seeding
In circumstances where large individual crystals are difficult to obtain, a potential 
strategy is to seed fresh drops with a single crystal harvested from a previous drop. 
The seeded crystal acts as a nucleation site, and with luck it will grow at the expense 
of any other nucleation sites in the drop. The composition of the drop should set such 
that in the absence of a seed nucleation would not occur, but in the presence of a seed 
crystal growth will occur. This strategy is termed macroseeding because the 
nucleation site (seed crystal) is already fairly large (ie visible under the microscope 
and identifiable as a crystal). Other seeding techniques involve the use of seeds that 
cannot necessarily be seen, and tend to be used where nucleation events are otherwise 
rare. Further information on seeding techniques can be found in ‘Protein 
Crystallization: Techniques, Strategies, and Tips -  A Laboratory Manual’ (Bergfors 
1999). Seed crystals were grown under hanging drop, as described. Then a ‘pre- 
quilibrated’ buffer was prepared by pooling the well buffer from previously used 
hanging drop wells and 0.2 pm filtering it. It was reasoned that the constituents of this 
buffer would be equivalent to those of the droplet in which the seed crystals had 
grown. Consequently this solution could be used for the manipulation, relocation and 
seeding of crystals without risk of their dissolution. Hanging drops were set up using 
part fresh protein solution, part pre-equilibrated buffer, and were seeded with a single 
crystal. Crystals to be seeded were transferred direct from their original drop, which 
was first swelled using pre-equilibrated buffer or the drop’s own well buffer, to the 
new drop using a Gilson P10 pipette. It was found, contrary to textbook 
recomendations, that the washing of crystals prior to transfer was counter productive, 
and caused the ‘showering’ it had been intended to prevent. This was due to the 
extreme delicacy of the crystals, any excess manipulation caused minute fragments of 
crystal to break away and act as nucleation points for crystalisation. This was 
undesirable because it deprived the main crystal of the additional protein intended to 
increase its size. Since the laboratory temperature fluctuated greatly, and occasionally 
caused unwanted evaporation of droplets during manipulation, a procedure was 
adopted to minimise such loss to the atmosphere. A petri dish containing a ring of 
Whatman no.l filter paper soaked in distilled water was used such that a coverslip 
supporting a drop to be manipulated could be positioned in the centre of the ring. This 
provided a humid microatmosphere for the drop during manipulation, and if required 
the petri dish lid could be replaced allowing the drop to be left temporarily without
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risk of evaporation. This was also useful when studying or manipulating a drop under 
the microscope, when the light source may be developing significant heat.
Three well buffer types were used with macroseeded droplets:
A. Fresh buffer as for a normal drop
B. Pre-equilibrated buffer (ie well buffer already used to grow crystals)
C. Fresh buffer with a slightly increased concentration of the various constituents 
intended to concentrate the drop further thereby inducing additional deposition 
of protein onto the seed crystal.
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Mounting crystals for X-ray analysis
Crystals were mounted in thin walled glass capillaries (supplied by Hampton) suitable 
for X-ray data collection. The thin glass minimised both absorption of scattered X- 
rays and background due to the glass. These capillaries were supplied sealed at both 
ends, so that the ends had first to be snapped off using forceps (whilst trying to avoid 
the inclusion of minor glass fragments into the capillary) - this also served to shorten 
the capillary, since most are too long to fit on an X-ray camera unmodified. To avoid 
shattering the capillary during this step the outside was coated in bees wax at the point 
where it was to be snapped. The capillary could then be attached via fine rubber 
tubing to a Hamilton syringe, enabling a suitable buffer (any buffer in which the 
crystal remained stable - for the purposes of this work the crystallisation buffer itself 
was used) to be sucked part way into the tube. In this way a reservoir of buffer was 
created inside the capillary once the tube was sealed, providing a stable atmosphere to 
maintain the integrity of the mounted crystal. The syringe was then removed from the 
capillary. The capillary was then attached to a microscope slide, using plasticine, with 
the opposite end to the reservoir upmost. This enabled the crystal to be deposited into 
the end of the capillary. The hanging drop containing the crystal to be mounted was 
swelled in volume using its own well buffer. The crystal was then picked up in a 
small drop of buffer using a Gilson P10 pipette, and transferred directly into the 
capillary. This was found to be easier than alternative methods which involved using a 
Hamilton syringe to suck the crystal up from its drop into the capillary. A syringe was 
occasionally used to draw a crystal further into its tube once deposited there, since the 
aim was to mount the crystal roughly midway into the tube. The liquid surrounding 
the crystal would then be reduced or removed using a fine length of twisted lens tissue 
to wick it away. Excess liquid surrounding a crystal would otherwise result in a large 
solvent ring during data collection, and may also have allowed the crystal to slip 
during the collection process. With the crystal in position and a reservoir of buffer at 
one end (to provide a saturated atmosphere within the sealed capillary), the tube was 
sealed at each end using melted bees wax. The approximate position of the crystal was 
marked on the outside of the tube using a fine tipped indelible marker. This enabled 
the crystal to be found more easily when aligning it for data collection. A crystal 
mounted in this way can be seen in chapter 4 figure 15 (page 226).
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Data collection
The basic instrumental components involved in data collection.
• The source. A source of X-ray radiation (electromagnetic waves of lengths 
between 0.1 and 100 A).
• The optics (monochromator plus collimator). A means of creating a tight X-ray 
beam of the desired wavelength from the source.
• The goniometer and goniometer head. Apparatus to hold and manouvre the crystal 
in the beam.
• The beam stop. A shield to prevent the main beam passing straight through from 
the back of the crystal to the detector.
• The detector. A means of detecting the diffracted X-rays scattered by atoms within 
the crystal.
Crystal alignment
During data collection X-rays are passed through the crystal, and at the same time the 
crystal may be rotated in the beam. Maintaining the crystal in the centre of the beam is 
achieved by first attaching the capillary in which the crystal is mounted to a 
goniometer head. This accessory to the camera allows both rotation and translation of 
the crystal with respect to the beam by means of a goniometer (a system of stepping 
motors). The capillary is held in place on the goniometer head using plasticene, and 
the gonoimeter head is attached to a stand, called an optical analyser, that emulates 
the rotation of the camera whilst allowing the position of the crystal to be observed by 
microscope. Adjustments can then be made to the goniometer head settings such that 
the crystal is always central during rotation on the optical analyser. The goniometer 
head can then be transferred directly to the gonoimeter on the camera, and the crystal 
should now be maintained in the centre of the beam throughout data collection. 
Modem cameras have goniometer heads that allow adjustment of the crystal in situ 
using optic fibre technology to visualise the crystal.
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Radiation sources
There are two methods by which X-rays are produced for crystallography. The first 
involves accelerating electrons at high voltage into a metal target (eg. a Rotating 
Anode X-ray source), and the second uses synchrotron radiation emitted by a 
Synchrotron Radiation Source - SRS. The former method is a laboratory-based 
technique, while the latter is limited to a few large international facilities (such as at 
Daresbury in Cheshire, or Grenoble in France). During the course of this project both 
types of source were used, but only the SRS produced useful data. Consequently only 
the synchrotron source will be described here, though details of the laboratory sources 
can be found elsewhere (Garman 1996).
An SRS uses electrons and positrons held in orbit within an enormous storage ring 
consisting of magnets. The electrons are accelerated around the curve of the ring and 
in the process they emit synchrotron radiation (a form of X-ray radiation so called 
because it was first observed using a synchrotron). The radiation is concentrated into a 
beam by specialised magnets known as ‘wigglers’ and directed into a shielded area 
called a ‘hutch’ where experimentation can be carried out. Personnel remain outside 
the hutch and so are protected from the intense beam. An SRS can provide an X-ray 
beam up to two orders of magnitude brighter than the best laboratory source. As 
crystals are exposed to X-rays they are subject to irreversible radiation damage that 
ultimately limits the useful data that may be collected from a crystal. The extent to 
which the beam initiates damage is not directly proportional to the intensity of the 
beam, but is a combination of factors, including X-ray intensity, exposure time, X-ray 
wavelength, crystal water content and the degree of scattering. The use of a high 
power X-ray source, such as that generated by a synchrotron, allows more useful data 
to be collected before a crystal is damaged. Rapidity of data collection limits exposure 
of the crystal, while also allowing more efficient use of the X-ray equipment. The 
brightness of a synchrotron beam also allows data to be collected from very small 
crystals (even as small as 50 pm, although at least 100 pm is desirable). The intensity 
and high quality optics of a synchrotron source is also ideal for collecting data from 
crystals with large unit cells. In recent years cryocrystallography -  the freezing of 
crystals prior to collection, and the use of nitrogen streams to maintain crystals in the 
frozen state during collection - has become widespread.
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The advantages of cryocrystallography are summed up in the “Notes on 
cryocrystallography”, from the X-Ray Crystallography Group of Bernhard Rupp, in 
the paragraph below.
“Intrinsic limitations due to diffraction quality, can be dramatically improved by cryo- 
techniques, in which crystals are flash-cooled to near liquid nitrogen temperatures. 
Many factors contribute to improvements in data quality: Obvious benefits are 
reduced thermal vibrations, enhanced signal-to-noise ratio, reduced conformational 
disorder, and in many cases, a higher limiting resolution. An important secondary 
effect is the suppression of radiation damage, permitting a complete data set to be 
collected from one single crystal. This in turn eliminates errors from merging and 
scaling of data sub-sets from multiple crystals. In addition, crystal mounting is vastly 
simplified over conventional capillary techniques. These improvements combined 
lead to enhanced contrast and sharper detail in electron density maps, facilitating 
model building and reducing the total time required for structure determination.”
Unfortunately this technique was unavailable at UCL during the period 1992 -  1994 
when HIV-2 PR crystals were being subjected to data collection, and 
cryocrystallography systems had not yet been installed at the Daresbury SRS.
Detectors
A variety of methods are available for the detection of diffraction patterns, including 
the use of film. Today the image plate represents the most common form of detector, 
and the data obtained during this study was collected by MAR image plate.
Briefly a plate consisting of a barium halide phosphor (BaFBr) and europium (Eu+2) is 
exposed to incident X-rays, and in the process the europium is excited into a 
metastable state (Eu+3) at areas of the plate which were bathed in the rays. The excited 
portions of the plate are then stimulated to produce violet light (390 nm) by scanning 
the plate with a red He-Ne laser (633 nm). A photomultiplier is then able to detect the 
emitted light, the intensity of which is proportional to the number of absorbed X-rays. 
Following integration the eventual result (an output file) resembles a scanned film. 
The plate can be regenerated for another round of collection by exposure to bright 
yellow light, which erases any record of the previous image and returns the europium 
to its unexcited state (Eu+2). Further details of image plate operation are provided by
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‘Modern methods for rapid X-ray diffraction data collection from crystals of 
macro molecules’ (Garman 1996).
Data analysis
All data analysis steps were carried out using unix based CCP4 programs run on a 
Silicon Graphics 320. Data files for analysis were transferred to the hard disc of the 
Silicon graphics computer, and compressed in order to reduce the disc space they 
occupied. The packimages command was used to compress image files whilst still 
allowing them to be read by other CCP4 programs. Files containing oscillations or 
stills were then visually inspected (using the ipdisp command) in order to assess 
whether they were suitable for further processing. If a diffraction pattern was visible 
then the program Tmstills’ was used, this created a file containing a list of the 
coordinates and intensities of the spots present on the images collected. The output 
files from Imstills were then fed into the autoindexing program ‘Refix’, which 
determined the crystal orientation and possible cell parameters (ie. the unit cell and 
space group). Initially the Refix commands were edited such that the program 
assumed the data related to a crystal of unknown parameters. The output was in the 
form of a list of potential cell parameters. These were studied to identify a space 
group with the highest order of symmetry, a good quality of fit (ie. < 20) and unit cell 
constraints that were as close as possible to the required coordinates for that particular 
Bravais lattice / Space group. The Refix program was then re-run having been 
modified to assume that the crystal has cell parameters corresponding to those just 
selected from the previous run’s output.
Further information concerning the CCP4 programs used can be obtained from the 
MOSFLM users guide mosflm_user_guide.doc (available from Andrew Leslie, 
andrew@uk.ac.cam.mrc lm b).
Further reading
If a more detailed account of any technique involved in the production of protein 
crystals or collection and refinement of data is required there are a numerous text 
books (See Appendix: Further Reading; Table 9, page 352) dealing with these topics 
in depth.
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Chapter Three: HIV-1 Protease.
Cloning, expression, purification and crystallisation of HIV-1 
protease isolated as an insolubly expressed enzyme from E. coli: 
and preliminary analysis of rationally designed HIV-1 PR inhibitors.
INTRODUCTION.
Expression and purification of crystallisation quality HIV-1 PR.
The aspartate proteinase of HIV-1, as discussed in chapter 1, has long been an
attractive target for anti-viral drug therapy (Kramer, Schaber et al. 1986; Johnston, 
Allaudeen et al. 1989; Roberts, Martin et al. 1990). Identification, testing and 
refinement of active compounds necessarily requires a consistent source of the pure 
protease and the expression, purification and crystallisation of this enzyme has 
previously been described by a number of groups (Lapatto, Blundell et al. 1989; 
McKeever, Navia et al. 1989; Wlodawer, Miller et al. 1989). However, the majority 
of published procedures require large culture volumes, complex expression systems or 
numerous chromatographic procedures in order to obtain sufficient purified enzyme 
suitable for structural analysis and rational drug design. The development of a rapid 
and efficient system to overproduce and purify this viral enzyme would therefore 
facilitate further biochemical and biophysical studies. Our intention was to develop a 
tightly controlled expression system, in conjunction with an easily executed 
purification protocol, which together would provide HIV-1 PR of sufficient yield and 
quality for structural and kinetic studies.
HIV, in common with several other lentiviruses, exhibits cytotoxic effects on infected 
cells in culture. There is evidence implicating the viral protease as a possible cause of 
this cytotoxicity (Hostomsky, Appelt et al. 1989; Baum, Bebernitz et al. 1990; Korant 
and Rizzo 1990; Kaplan and Swanstrom 1991; Korant and Rizzo 1991). It is supposed 
that this is the result of proteolytic activity, since it is known that many eukaryotic 
proteins (especially cytoskeletal proteins) are substrates for HIV protease (Honer, 
Shoeman et al. 1991; Shoeman, Honer et al. 1991; Shoeman, Kesselmier et al. 1991; 
Shoeman, Mothes et al. 1991; Tomasselli, Howe et al. 1991; Tomasselli, Hui et al. 
1991). Where HIV protease has been expressed in bacterial cells a similar effect has 
been noted and yields of the protease are generally low, approximately 0.3 mg
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protease per litre of cell culture (0.75 -  2.5% of total cell protein) (Danley, 
Geoghegan et al 1989). In terms of practicality protein yields in excess of 1 mg per 
litre of cell culture are preferred prior to engaging in crystallographic analyses. Some 
studies have therefore focused on synthetically produced enzyme (Wlodawer, Miller 
et al. 1989), but this is an expensive option. The expression system described here 
produced the HIV-1 protease in an insoluble form, and with a slight improvement in 
yield over previous protease expression protocols. The system provided sufficient 
protease for use as a control in assays of retroviral protease activity, for the testing of 
protease inhibitors, and for use in crystallisation trials.
A two-step chromatographic purification procedure was developed, producing HIV-1 
PR that was > 95% pure as determined by SDS-PAGE, which was enzymically active, 
and crystallised readily under conditions described for the solubly expressed protein 
(Lapatto, Blundell et al. 1989; McKeever, Navia et al. 1989). Crystallisation of HIV-1 
protease refolded from insoluble bacterial inclusion bodies had not been previously 
reported.
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Preliminary analysis of novel, rationally designed, HIV-1 PR inhibitors.
The development of compounds able to inhibit HIV proteases in vivo, preventing viral
maturation and consequently limiting the progression of AIDS in man is the ultimate 
aim of work in this field. This chapter also describes the initial stages in development 
of two potential inhibitor compounds.
Early inhibitors were almost exclusively based on pepstatin and peptide substrate 
analogues. However, these are reversible, competitive inhibitor compounds and thus 
do not permanently disable the target enzyme since binding is non-covalent. 
Consequently viral strains with mutant proteases resistant to such inhibitors have 
arisen. Inhibitors able to bind covalently with the enzyme active site would produce 
permanent protease inhibition. Such compounds would also be less susceptible to the 
development of resistant strains since they target the conserved active site residues. 
Irreversible ‘suicide’ compounds therefore have a clear advantage over conventional 
inhibitors. The two compounds described here were based on this strategy, and were 
synthesised at UCL by Dr. George Nicolau. The principle of irreversible HIV PR 
inhibition has been demonstrated using l,2-epoxy-3-(p-nitrophenoxy)propane (EPNP) 
(Meek, Dayton et al. 1989), which is a weak and non-specific irreversible inhibitor of 
aspartyl proteases (fig. 1), reacting with the catalytic aspartate residues of pepsin 
(Tang 1971) and penicillopepsin (James et al. 1977). It was subsequently shown to 
inhibit HIV-1 PR in a pH dependant manner, suggesting modification of a single 
active site aspartate (Meek, Dayton et al. 1989).
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Figure 1 Structure of EPNP (1, 2-Epoxv-3-(p-nitrophenoxv) propane).
EPNP 1,2-Epoxy-3-(p-nitrophenoxy)propane
O"
C8H7N 0 4
Exact Mass: 181.04 
Mol. Wt.: 181.15
C, 53.04; H, 3.89; N, 7.73; O, 35.33
An epoxide moiety was incorporated into the first of the inhibitor compounds 
described here, and an aziridine moiety into the other, each with the intention of 
provoking a covalent interaction between the compound and a catalytic residue of 
HIV-1 PR.
The aziridine moiety, like epoxide, is a highly reactive group consisting of a strained 
ring -  with the exception that the aziridine ring contains Nitrogen rather than Oxygen. 
Both epoxides and aziridines are susceptible to nucleophilic ring opening, thus it was 
anticipated that they might both be able to inactivate HIV PR by alkylation of an 
active site aspartate. Both inhibitors were based on the following structure:
BOC-Phe -  active moiety -  O-methyl where BOC = tert-Butoxycarbony 1
(see fig. 2).
The Phenylalanine was intended to engage with the substrate-binding cleft at SI and 
thus locate the reactive group in close proximity to the catalytic residues.
HIV-1 PR produced by means of the expression and purification method described in 
this chapter was used in conjunction with a chromophoric assay (Richards, Phylip et 
al 1990) to test the efficacy of these inhibitors. Preliminary results are presented here 
demonstrating that the aziridine based compound was able to inhibit HIV-1 PR 
activity. Further experiments to confirm the mode of action and allow kinetic
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characterisation would have been desirable and are therefore briefly discussed. 
However, a limited and finite supply of the compounds precluded them.
Figure 2 Compounds intended to irreversibly inhibit HIV-1 PR.
Suicide Inhibitors
O CH,■N— CH------1 •N C
Boc (/«rr»-Butoxycarbonyl)
Aziridinyl based inhibitor.
C ,8HJ4Nj0 5 
Exact Mass: 348.17 
Mol. Wt 348 39
C, 62 05; H, 6 94; N, 8 04; O. 22.96
Phenylalanine
Aziridinyl group
CH3 0 ° 
J X J - ,CH-
CH,
  Boc (tert-Butoxycarbonyl)Epoxide based inhibitor.
Phenylalanine
Epoxy group
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MATERIALS AND METHODS.
Construction of the HIV-1 PR expression vector pKUlacIq (HIV-1PR).
A Reverse Transcriptase expression vector, mpRTl, (Larder, Purifoy et al. 1987)
containing the pol operon derived from the HIV-1 strain HXB-2 (Shaw, Hahn et al. 
1984), was made available to us by G. Darby of Wellcome. The 309 bp gene encoding 
HIV-1 PR was obtained from mpRTl by PCR. In the process the 5' and 3' ends of the 
HIV-1 PR gene were modified (fig.3 i) to facilitate cloning into the pKU2 vector. The 
pKU2 plasmid (Pharmacia) (fig.3 ii) and the HIV-1 PR gene were each digested with 
(restriction enzymes), then ligated to insert the HIV-1 PR gene downstream of the trc 
promoter giving pKU2 (HIV-1 PR) (fig.3 iii). The trc promoter is IPTG inducible and 
in order to maintain tight transcription regulation of the HIV-1 PR gene the laclq gene 
(taken from a vector - pMC9 - provided by Richard Skinner, Wellcome) was inserted 
into the unique EcoRI restriction site of pKU2 (HIV-1 PR) to yield p K U 2 iaciq (HIV- 
1PR) (fig.3 iv).
Monitoring HIV-1 PR activity by SPA
HIV-1 PR activity was monitored throughout the purification procedure by means of 
the SPA assay, described in Chapter 2. It should be noted that when an aliquot of the 
protease in 5 M guanidine (or 8 M urea) is pipetted into a larger volume of SPA assay 
buffer it refolds instantly thus allowing detection of active fractions whilst utilising a 
chaotropic buffer.
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Figure 3 Cloning strategy for the expression of HIV-1 PR.
mpRTl PR RT
Ptac
Hind HI
Ncol
TTA A AT TTT TAAGCTT
L N F STOPTCC ATG GAC TTC CCT
Hind IIINcol PR
309bp
amp
Pvul
l5SEcoRI
Li Hind 111 
f- PslI  
— Ncol 
pTRC
pKU2 {2 8kb)
pKU2PR
EcoRIORl
CUT WITH 
H;nd 111 Ncol ORl
amp
Hind
EcoRI
Lac lq
pTRC
pKU2 PR Lac iq
(iv)
ORl
amp
Key to cloning strategy.
(i) Site directed mutagenesis o f mpRTl to introduce an in frame ATG and Ncol site at the 5' end 
and a TAA translational stop and Hindlll site at the 3' end o f the protease gene.
(ii) Construction o f the expression vector pKU2 using the 1.2 Kb PvuI/EcoRI fragment from a 
vector PKK233-2 which contains the pTrc promoter and the rrmDTlDT2 termination signals 
and the 1.6Kb PvuI/EcoRI fragment from the vector pUC18, which contain the pUC origin of 
replication.
(iii) Insertion o f the 309bp Ncol/Hindlll protease fragment into pKU2 down stream o f the ptrc 
promoter.
(iv) Insertion o f the lac lq repressor gene into the unique EcoRI restriction site o f pKU2PR to form 
pKU2PR lac lq.
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Large scale cell growth and protein expression
The pKUlacIq (HIV-1 PR) plasmid was used to transform E.coli strain MCI061, and 
grown as described in Chapter 2 (for transformation see page 138, and for cell growth 
see page 145). Optimum yields were obtained when the culture was grown to late log 
phase (OD600 0.7), induced with 2 mM IPTG, and grown for a further two hours prior 
to harvesting. A litre culture typically yielded 2.5 g of cell paste. Protease expression 
was monitored both by Western blotting and SPA. Both techniques are described in 
Chapter 2 (see page 153).
Extraction of insoluble HIV-1PR
Frozen cell pellets (~20 g) were thawed and the E.coli lysed using a probe sonicator 
(Soniprep 100). The cell suspension was chilled on ice throughout the lysis procedure, 
which consisted of 10 X 30 s bursts of the sonicator with a 60 s pause between bursts. 
The lysate was clarified using a Beckman L8-M ultracentrifuge in conjunction with an 
SW-28 rotor at 28000 rpm for 30 min at 4°C. The supernatant was discarded, but the 
pellet was resuspended in 30 ml of buffer A, resonicated and re-centrifuged, as above.
Table 1 Buffers A and B.
Buffer A:
50 mM Tris pH 8.0, 1 mM EDTA, 1 mM DTT 
Buffer B:
5 M Guanidine HC1, 100 mM MES pH 6.5, 1 mM EDTA, 5 mM DTT
The supematent was again discarded, and the pellet was solubilised at room 
temperature by resuspension in 30 ml of Buffer B, followed by agitation overnight.
Insoluble particulates were removed by ultracentrifugation (as above), this time for 90 
minutes at 28000 rpm and 4°C. The pellet was discarded and the clear, golden 
coloured supematent was retained. The volume of the protein solution by this stage 
was -50 ml. The solution could be stored at 4°C for several weeks without any 
apparent effect on subsequent HIV-1 PR activity, though usually chromatography 
immediately followed extraction.
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Size Exclusion Chromatography of insoluble HIV-1 PR
Following extraction and dissolution, the insolubly expressed proteins were subjected 
to size exclusion chromatography, using a 5 x 90 cm Sephacryl S-200 HR column 
equilibrated with Buffer B. The sample was introduced to the column via a 50 ml 
superloop then a single column volume of Buffer B was pumped through the column 
at 1 ml min'1. Once the void volume of 120 mis had eluted, 20 ml fractions were 
collected for analysis. Those fractions identified as having HIV-1 protease activity, 
using the SPA, were pooled; giving approximately 160 ml of proteolytically active 
sample (see figs. 4 and 5 pages 192-193, and Appendix tables 1 and 2, pages 343- 
344).
Refolding the semi-purified HIV-1 PR
The 160 ml active fraction was adjusted to 10% (v/v) glycerol and the protease 
refolded by a two step dialysis procedure at 4°C. The first dialysis step was against 
buffer C over an 8 hour period with four changes of buffer, the second was against 
Buffer D and carried out for 16 hours at 4°C.
Table 2 Buffers C and D.
c
100 mM MES pH 6.5, 2 M Guanidine HC1, 1 mM EDTA, 5 mM DTT,
10% glycerol 
Buffer D:
50 mM MES pH 6.5, 1 mM EDTA, 5 mM DTT, 10% glycerol______________
A white precipitate was formed during dialysis, which was removed by 
ultracentrifugation (as described, at 25000 rpm and 4°C for 90 mins). The supernatant 
was retained for further chromatography.
Ion Exchange Chromatography of refolded HIV-1 PR
The clarified solution of refolded HIV-1 PR was loaded on to an S-Sepharose high 
load 16/10 ion exchange column (at 1 ml min'1), previously equilibrated with Buffer
D. The column was washed with 5 column volumes of Buffer D, or until a steady 
baseline was reached. Protein was eluted in Buffer D by means of a salt gradient, 
initially rising from 0 M to 200 mM NaCl at a rate of 100 mM per column volume. 
Then, after a period of 2 column volumes at 200 mM NaCl, the gradient was 
continued up to 1 M NaCl. Protein solution eluted during the 200 mM NaCl wash
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was collected, subjected to SPA analysis and shown to contain HIV-1 PR activity (see 
results fig. 6). Purity was assessed by means of coomassie stained SDS-PAGE.
Concentration and storage of purified HIV-1 PR
Active fractions from the S-Sepharose column were pooled (15 ml total volume) and 
dialysed against Buffer E.
Table 3 Buffer E.
10 mM MES pH 6.5, 1 mM DTT, 1 mM EDTA
This removed unwanted NaCl and glycerol (which may have interfered with 
crystallography), while also reducing the concentration of MES. The volume of 
solution was reduced using a Centricon 10 (as described in Chapter 2, pages 161-162) 
until a protein concentration of approximately 5-6 mgml'1 was reached (as determined 
by UV spectroscopy at X = 280 nm and given an extinction coefficient for HIV-1 PR 
native dimer of 25800 cm^M-1). The concentrated solution was stored in aliquots of 
50 pi at -70°C pending further use.
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Determination of kinetic parameters for the purified HIV-1 PR
The procedure for determination of KM, Kcat and Vmax is described in Chapter 2 (pages
164-165). The reaction buffer used for kinetic analysis of HIV-1 PR was 100 mM 
Sodium Acetate pH 5. A 10 mM stock of chromogenic substrate III from BACHEM 
(Fig. 7 b.) was freshly prepared in water, and reactions were carried out over a range 
of final substrate concentrations from 0 -  200 pM. Reactions were repeated in 
triplicate and the mean initial velocity calculated at each substrate concentration. 
HIV-1 PR concentration was constant throughout at 0.6 pgml'1 final. Values for Km 
Kcat, and Vmax were determined using the Enzfitter program.
Crystallographic analysis of HIV-1 PR
Crystals were grown by the hanging drop method (Chapter 2, page 170) under 
conditions described by McKeever et.al. (McKeever, Navia et al. 1989). Briefly, a 2 
pi drop consisting of 50% protein solution and 50% crystallisation solution was 
incubated at 4°C over a well containing 1 ml of the crystallisation solution. The 
crystallisation solution consisted of 100 mM imidazole / HC1 pH 7.0, 250 mM NaCl, 
10 mM DTT and 1 mM NaN3. Typically crystals were seen after 3-4 days. Data 
collection was carried out at the Synchrotron Radiation Source, Daresbury, and 
processed as described in Chapter 2 (pages 174-178).
Computer aided design of HIV-1 PR inhibitors
The inhibitors were designed with the aid of three dimensional (3D) computer 
models, based on the available HIV-1 protease structural data in early 1992 (Protein 
Databank files 4HVP, 5HVP, 7HVP, 8HVP, 9HVP, 3PHV). Laurence Pearl and 
George Nicolau carried out the modelling and inhibitor at UCL, using the modelling 
programs Quanta and CHARMm (available from Accelrys Ltd.).
Chemical synthesis of the HIV-1 PR inhibitors
The inhibitors were synthesised by George Nicolau at UCL and characterised by the 
UCL Chemistry department using Mass Spectrometry (MS), and Nuclear Magnetic 
Resonance (NMR) to ensure that they had been synthesised correctly (George 
Nicolau, personal communication).
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Assays to detect inhibition of HIV-1 PR activity
Assays using the chromogenic substrate III, from BACHEM, (Richards, Phylip et al. 
1990) were carried out essentially as described in Chapter 2 (pages 164-165) to 
determine the extent of HIV-1 PR activity in the presence and absence of the various 
potential inhibitors, using Acetyl-Pepstatin (from BACHEM) as the control inhibitor. 
The reaction buffer was identical to that used for the KM determination described 
above, and total reaction volume was lml. Substrate III and HIV-1 PR were used at 
final concentrations of 50 pM and 0.6 pgml'1 (27.9 nM) respectively. The inhibitor 
compounds and the acety 1-pep statin control were dissolved in DMSO and tested at a 
final concentration of 1 pM. The dual beam spectrophotometer used (see Chapter 2, 
page 164) allowed the use of a blank containing the inhibitor compound under test, 
thus controlling for the absorbance due to these compounds.
Dialysis of suicide inhibitor -  protease complex
Microdialysis (as described in Chapter 2, page 158) of reaction mixtures containing 
HIV-1 PR alone (control mix) or HIV-1 PR plus inhibitor compound (inhibitor mix) 
was carried out to determine whether the suicide compounds were able to irreversibly 
inhibit the protease. A non-covalently bound inhibitor would be able to dissociate 
from the active site, and diffuse out of the reaction mixture into the surrounding 
dialysis buffer. A compound diffusing into the dialysis buffer would be massively 
diluted, thus its return to the reaction mixture is highly improbable. Therefore if a 
compound were not a true suicide inhibitor, dialysis should allow restoration of 
protease activity. The control reaction mixture was 3 ml final volume and consisted of 
HIV-1 PR reaction buffer supplemented with final concentrations of 40% v/v 
glycerol, 1 mM DTT and 10 % v/v DMSO, plus HIV-1 PR at 0.6 pgmf1 (27.9 nM) 
final concentration. The presence of glycerol and DTT was intended to stabilise the 
enzyme and preserve activity during the dialysis procedure, whilst the DMSO was 
required to maintain solubility of the inhibitors. The inhibitor mixtures were made up 
in the same way (taking into account the additional DMSO added with the inhibitor 
solutions) and contained their respective inhibitor compound at a final concentration 
of 100 pM. Dialysis was carried out overnight, with gentle stirring, at 4°C in 250 ml 
of HIV-1 PR reaction buffer also supplemented with 40% v/v glycerol, ImM DTT, 
and 10% v/v DMSO.
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RESULTS AND DISCUSSION
Protein expression
The majority of expression systems reported for over production of the HIV-1 PR 
were developed as compromise solutions, in order to overcome the toxicity of the 
protease gene product in the E. coli host and the need to obtain sufficient enzyme for 
crystallisation (Danley, Geoghegan et al. 1989; McKeever, Navia et al. 1989; Goobar, 
Danielson et al. 1991). Some of these expression systems utilise very careful control 
of growth conditions (Danley, Geoghegan et al. 1989) in order to keep the protease 
gene repressed, or complex dual vector systems for expression (Cheng, McGowan et 
al. 1990), and often require large volumes of bacterial culture, to obtain sufficient 
enzyme for purification (McKeever, Navia et al. 1989).
The pKU2 vector, which formed the basis of our construct, was originally designed to 
be a high copy number vector (having a pUC origin of replication) with a strong 
inducible promoter (trc promoter) in order to produce large amounts of expressed 
protein. However, expression of the HIV-1 PR gene from pKU2 PR in E.coli resulted 
in poor bacterial growth. This could be explained by previous observations that the 
protease may be toxic to the bacterial host (Baum, Bebernitz et al. 1990). It was 
therefore desirable to ensure tight control of expression by introduction of the Lac lq 
repressor gene. No improvement was seen even when the plasmid was used to 
transform the E.coli host TGI, which carries a single copy of the Lac lq gene. Cloning 
of the Lac lq gene into pKU2 PR (fig 3) to yield pKU2|aciq (HIV-1 PR) greatly 
improved the stability of the clone, and allowed it to be maintained adequately in the 
host E.coli strain MCI061. Indeed the growth characteristics exhibited by the E.coli 
transformed with pKU2 PR (Ladq) (HIV-1 PR) were similar to that of E.coli harbouring 
the parent vector pKU2 (HIV-1 PR) alone. The rationale for placing the Lac lq gene 
on the same expression vector as the protease gene was to maintain equal copy 
numbers of the repressor protein and its target promoter. Consequently the repressor 
protein is not titrated out by the high copy number of the promoter sequence due to 
the multicopy nature of the pKU2 plasmid. A commercial vector, pTrc99A 
(Amersham Pharmacia Biotech), has since become available which shares these 
characteristics.
The strength of the trc promoter from pKU2 resulted in the accumulation of 
significantly more enzyme in the insoluble fraction than we had previously observed
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using other systems. Since better yields of the protease could be produced as insoluble 
material it was decided to exploit this by extracting, purifying and refolding protease 
from the insoluble fraction of the cell lysate.
Purification of HIV-1 PR
The protease was purified by molecular sieving through Sephacryl S-200, following 
solubilisation of the pellet fraction with guanidine. Protease activity was detected by 
SPA in fractions 8 to 15 (fig 4) of the low molecular weight peak eluting from the 
column (fig 5). The SPA data is presented in tables 1 and 2 of the appendix. Refolding 
by dialysis and subsequent analysis by PAGE of the proteins contained within this 
peak fraction showed that it contained a number of proteins of a MW range from ~ 6 - 
20 kD (fig. 7). The HIV-1 protease contained within this fraction was estimated to be 
> 60% pure.
Figure 4 SPA data plot.
Fractions exhibiting > 70% relative activity (8 -1 5  inclusive) were pooled.
Analysis of S200 fractions for HIV-1 PR activity using SPA.
90
40
Series 1
-10
-20
Fraction number
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Figure 5 Size Exclusion Chromatography of insoluble HIV-PR.
100
Fractions 8 - 1 5 .
100
% of MAX 
ACTIVITY
The pellet following cell lysis was dissolved in 5M Guanidine HC1, and loaded onto a Sephacryl S200 
size exclusion column. This figure shows the resulting chromatogram, the solid line represents 
absorbance (mAu) at X = 280 nm, the broken line represents HIV-1 PR activity. Most protease activity 
was contained within the low molecular weight peak. The bar represents fractions 8 to 15, which were 
pooled and retained._____________________________________________________________________________
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The refolded protease was further purified by S-sepharose chromatography. This 
resulted in the elution of two protein peaks (fig. 17), the protease being isolated from 
the second peak. A simple salt gradient failed to separate these two conjoined peaks of 
protein adequately. However, by holding the NaCl gradient at 200 mM for 2 column 
volumes an improved separation was achieved and highly purified active HIV-1 
protease obtained.
Figure 6 Cation Exchange Chromatography of refolded HIV-1 PR.
100
% of W ax 
Absorb anie
H >x x
200 mM
Refolded HIV-1 PR was loaded onto a S-Sepharose Hi-load column, and eluted by an NaCl stepped 
gradient. Protease activity (detected by SPA) was found exclusively in the second peak eluting from the 
column during the 200 mM NaCl step.
absorbance at X = 280 nmComplete line:
% protease activityDashed and dotted line:
[NaCl] M.Dashed line:
The final HIV-1 PR yield was typically between 0.5 -  1.0 mg of pure enzyme from
each litre of bacterial culture harvested, and was essentially 90% pure as assessed by 
SDS-PAGE analysis (fig. 7).
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Figure 7 SDS PAGE analysis of the purified HIV-1 PR.
kD Std HIV-1 PR
200
116
HIV-1 PR
Characterisation of the purified HIV-I PR
The SPA assays used to track activity throughout purification had already indicated 
the presence o f HIV-1 PR. N-terminal analysis and Mass Spectrometry (both carried 
out a Wellcome Laboratories, Beckenham) established that the purified protein was 
indeed HIV-1 PR (data not shown).
Kcat and KM determination of HIV-1 PR
The SPA substrate was unsuitable for a Km determination since the SPA substrate 
cleavage site does not correspond to a natural cleavage sequence, and because it is not 
possible to estimate the concentration o f  peptide attached to each microsphere. In 
addition to this our scintillation counters were unsuitable for the measurement o f 
initial velocity.
A Km for the purified protease enzyme o f 27 pM and a KCat o f  0.0657 sec _1 was 
obtained using the chromogenic substrate (fig. 8 a and b), which compared well with 
the value obtained by Pennington et al. (Pennington, Dick et al. 1990).
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Figure 8 The hydrolysis of chromogenic substrate by purified HIV-1 PR.
a. Lineweaver-Burke transformation.
Variable Value
Kcat 0 .0 6 5 7  s e c -
Km 2 7 .8  uM
b. Amino acid sequence o f  chromogenic substrate. 
H-His-Lys-Ala-Arg-Val-Leu-p-nitro-Phe-Glu-Ala-Nle-Ser-NH2
____________ HIV Protease substrate III, suplied by Bachem, product no. H-9035
V a lu e s  o f  K m a n d  K cat w e re  e s ta b l i s h e d  fo r  H IV -1  P R  a c t iv ity  b y  m e a n s  o f  c h ro m o g e n ic  a ssa y .
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Crystallisation
Tetragonal bi-pyramidal crystals appeared after four days. These crystals were 
approximately 100 pm  in length and produced measurable diffraction intensities to a 
resolution o f 2.9 A, having the same unit cell dimensions as previously described 
(McKeever, Navia et al. 1989; Wlodawer, Miller et a l  1989) (fig. 9).
The ability to grow these crystals confirmed that the enzyme obtained by the 
procedures described was o f suitable quality for structural studies. Since the unit cell 
was the same as that reported by groups using the solubly expressed enzyme it can be 
inferred that our protein was correctly refolded and in its native configuration.
Figure 9 Tetragonal binvramidal crystal of HIV-1 protease.
C ry s ta ls  w e re  g ro w n  to  a p p ro x im a te ly  100 p m  in len g th , w e re  te tra g o n a l  a n d  th e  u n it c e ll d im e n s io n s  
w e re  a = b = 5 0 .3  A a n d  c = 1 0 6 .8  A, a  =  p  =  y =  9 0 ° , w ith  a  sp ace  g ro u p  o f  e ith e r  P 4 |2 ,2  o r P 4 32 !2 .
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Inhibitor testing.
The SI compounds were intended to covalently bind the active site (via an epoxide or 
aziridine moiety respectively), permanently inactivating the protease (figs. 10 and 11).
Figure 10 The anticipated mode of action for the epoxide compound.
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Figure 11 T he anticipated  m ode o f  action for the aziridine com pound.
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The initial activity rate for HIV-1 PR was measured by chromogenic substrate in the 
absence of inhibitor and taken as 100% relative activity, or 0% inhibition. No activity 
was measured in the presence of the control inhibitor, Acetyl-Pepstatin (supplied by 
BACHEM), and this was said to exhibit 100% relative inhibition (fig. 12).
Figure 12 Investigation of potential HIV-1 PR inhibitor compounds.
Effect o f inhibitor com pounds on HIV-1 PR activ ity .
Sample N um ber
1 HIV-1 PR control
2 HIV-1 PR + Acetyl-pepstatin
3 HIV-1 PR + Epoxy Compound
4 HIV-1 PR + Epoxy Compound (2 hrs)
5 HIV-1 PR + AziridineCompound
6 HIV-1 PR + AziridineCompound (2 hrs)
Absorbance was measured at 600 nm for 200 
seconds and the rate o f change calculated for 
each sample. Reaction rate (Au/s) for the 
HIV-1 PR control was taken to be 100%, and 
the rates for all other samples were expressed 
as percentages relative to the HIV-1 PR 
control.
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The epoxide compound did not appear to inhibit the protease at all, and even after two 
hours incubation with this compound the protease retained virtually 100% relative 
activity (fig. 12). Whilst the reason for this is unclear, it may indicate that the epoxide 
moiety could not adopt a suitable position relative to the catalytic residues while the 
compound occupied the protease active site. In contrast, the aziridine compound 
reduced relative protease activity by 40% (fig. 12). Incubation of inhibitor and 
enzyme for two hours prior to assay also resulted in a 40% reduction in relative 
activity.
Activity of an enzyme in complex with a reversible inhibitor can be restored by 
dialysis into fresh buffer because the inhibitor compound will eventually diffuse out 
of the active site. The activity of an enzyme in complex with an irreversible inhibitor 
cannot be restored in this way since the association between inhibitor and enzyme is 
permanent. Thus the inability to restore activity by buffer exchange is diagnostic of 
irreversible inhibition. Attempts to determine whether HIV-1 PR activity could be 
restored following buffer exchange by dialysis to remove the inhibitor were 
ambiguous because activity was reduced in the uninhibited control by the overnight 
dialysis process. Consequently, although no restoration of activity was seen, this 
could not be directly attributed to the continuing presence of inhibitor. An alternative 
means of demonstrating suicide inhibition by buffer exchange might have been to use 
a small desalting column (eg PD10 column). This would have enabled buffer 
exchange (and thus removal of all unbound inhibitor) to be achieved much more 
quickly, and thus eliminated the problem of natural deterioration in protease activity 
with time seen in the dialysis control. However, it might not provide sufficient time 
for dissociation to occur. Mass spectroscopy could have provided a more conclusive 
method for demonstrating that the compound was irreversibly inhibiting the protease. 
Where the compound was covalently bound to the protease an increase in the mass of 
the protease consistent with the mass of the inhibitor compound would have been 
detectable. A similar non-covalent interaction would not have generated this effect 
since a non-covalent interaction would be extremely unlikely to survive the ionisation 
process involved in conventional mass spectrometry. Furthermore, enzymatic digest 
of the inhibitor-protease complex (using Trypsin) and subsequent analysis of the 
resultant peptides by tandem MS methods could have demonstrated the exact site of 
covalent interaction. Ultimately a crystal structure of the protease in complex with the
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compound would have provided a confirmation of covalent interaction, and the 
opportunity to improve the compound design.
Although preliminary, these results suggest that the aziridine compound is a weak 
inhibitor of HIV-1 PR and may therefore be a useful lead in the further development 
of a suicide inhibitor. A more detailed analysis of this compound is required to ensure 
that it is inhibiting the protease by the intended mechanism, and kinetic experiments 
would be desirable to characterise the inhibition further. It would also be interesting to 
investigate the effect these compounds, on HIV-2 and S I V agm  pro tease activity. 
However, further experiments on these compounds were precluded by their finite 
supply.
Subsequent to the work described in this Chapter, crystallographic analysis has 
demonstrated that EPNP is able to bind covalently to a single catalytic aspartate 
residue of SIV protease, thus confirming its mode of action (Rose, Rose et al. 1993), 
and other studies have demonstrated that epoxide based compounds can be effective 
as irreversible HIV-1 PR inhibitors (Salto, Babe et al. 1994).
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SUMMARY,:
An E.coli expression system producing insoluble HIV-1 PR was developed which was 
able to produce more mg of active pure protease per litre of culture than had 
previously been possible. The expression and purification procedures described in this 
chapter were simpler than contemporaneously published HIV-1 PR purification 
procedures (Danley, Geoghegan et al. 1989) and represented an improvement in terms 
of yield and ease of protein production over other published methods (Danley, 
Geoghegan et al 1989; Darke, Leu, et al 1989).
The system gave protease yields that exceeded those of soluble expression systems, 
presumably due to an absence, or reduction of cytotoxicity exerted by the insoluble 
protease. Furthermore the insoluble protease simplified purification, allowing a two 
stage chromatographic procedure to suffice; and utilised widely applicable 
chromatographic materials, rather than expensive and highly specific affinity resins. 
This represented an improvement on many of the existing methods. The procedure 
might also be adopted for other proteins exhibiting toxicity in their soluble forms, 
providing they can be successfully refolded.
A yield in terms of HIV-1 PR per volume of cell culture of 0.5-1.0 mg/L was typically 
obtained, which compares favourably with many other reports of retroviral protease 
expression (Danley et al. 1989, Strickler et al 1989, Wan and Loh 1995). However, it 
is noted that expression was not as high as is achieved with certain other proteins 
using similar expression systems. This suggests either that there was still significant 
cytotoxicity, or that other factors may have been limiting protease expression. Similar 
observations have been made where the protein of interest exhibited poor codon usage 
(Graham, Atkinson et al 1993; Martin, Vrhovski et al 1995), and this may also be a 
factor here. Codon usage for HIV-1 PR was compared with that of genes encoding
E.coli proteins in general and the result showed that the HIV-1 PR gene contains a 
high number of codons which are used only rarely, if at all, by E.coli. The view that 
codon usage may be a limiting factor when expressing HIV-1 PR in E.coli is 
supported by the work of Rangwala et al. (Rangwala, Finn et al. 1992), where 
expression levels improved following synthesis of an HIV-1 PR coding sequence 
optimised in terms of codon usage for expression in E.coli. In light of this our system
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could have been similarly optimised, perhaps by utilising the Recursive PCR method 
later developed in our laboratory (Prodromou and Pearl 1992)10.
The protease was found to have a Km = 27.8 pM and a Kcat = 0.0657 sec'1 - values 
consistent with those reported by others using the same substrate (Pennington, Dick et 
al. 1990).
Crystals of the apoenzyme diffracted x-rays to below 2.9 A resolution and had the 
same unit cell as those produced by other groups (McKeever, Navia et al. 1989) using 
either solubly expressed or synthetically produced protein (Wlodawer, Miller et al. 
1989).
A preliminary evaluation was carried out on two rationally designed compounds 
intended to inhibit the HIV-1 PR by means of covalent binding to the active site. One 
of these, an aziridine compound designed to bind the active site irreversibly, was 
shown to inhibit HIV-1 PR activity, and further studies were discussed.
HIV-2 poses as serious a threat human health as HIV-1, consequently compounds 
able to inhibit HIV-2 PR are also required. The expression of HIV-2 PR was known to 
be as problematic as that of HIV-1 PR, meanwhile much less work had been carried 
out on HIV-2 PR and no structural information was yet available. It was therefore 
decided to apply some of the information gained from working on HIV-1 PR to the 
study of HIV-2 PR with a view to carrying out structural studies on the enzyme. The 
following chapter (Chapter 4) describes these efforts.
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10 This option is further considered with respect to SIVAGm PR in Chapter 7.
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Chapter Four: HIV-2 Protease.
The purification and crystallisation of recombinant HIV type 2 
protease.
INTRODUCTION.
Whilst both Serotypes of HIV cause disease in man (Essex and Kanki 1988; Marlink, 
Ricard et al. 1988), the majority of studies, at the time of this work, had concentrated 
on HIV-1 PR (Lapatto, Blundell et al. 1989; McKeever, Navia et al. 1989; Navia, 
Fitzgerald et al. 1989; Wlodawer, Miller et al. 1989). However, the differences in 
substrate specificity (Le Grice, Ette et al. 1989; Wu, Carr et al. 1990), inhibitor 
binding (Richards, Broadhurst et al. 1989) and amino acid sequence (Guyader, 
Emerman et al. 1987) between the HIV-1 and HIV-2 proteases were sufficient to 
warrant studies of HIV-2 PR. Consequently it was desirable to obtain a 
crystallographic structure of HIV-2 PR, in the pursuit of a more complete 
understanding of the HIV proteases generally. At the inception of this project a 
structure for HIV-2 PR was not available, and the preliminary crystallisation of native 
HIV-2 PR as presented here was completed before any such structure or 
crystallographic data had been published.
MATERIALS AND METHODS.
Cloning and Expression.
The HIV-2ROd strain (Cheng, Patterson et al. 1992) was used as the source material 
for this study. An infectious DNA clone of HIV-2ROd (designated pROD35B) had 
previously been prepared (by Larder, B. A. and Darby, G. at Wellcome laboratories 
Beckenham), from which we excised a Hindlll / EcoRI region comprising the PR 
gene and flanking sequence (fig. la). Using this as a template, and with specifically 
engineered primers, we generated the PR gene as a 300 bp PCR product incorporating 
an Ncol site with an integral ATG codon in frame with, and immediately preceding 
the PR coding sequence, plus a Hindlll site with an integral TAA stop codon 
immediately following the gene sequence (fig. lb). The PCR product was digested 
with both Ncol and Hindlll enabling ligation (fig. lc) into a pKU2 Laclq plasmid 
vector (described in Chapter 3), to produce pKU2Laciq(HIV-2PR). The new construct 
was subsequently used to transform E.coli MCI061 cells for protein expression.
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Clones containing the correct plasmid were identified by restriction digests (fig. 2), 
induced to express the protease by addition of IPTG, and analysed for protease 
expression by Western blots with human HIV-2 polyclonal antisera as the primary 
antibody (fig. 3). The plasmid DNA sequence from those clones reacting positively 
with the HIV-2 antisera was determined by the Sanger di-deoxy method (Sanger, 
Nicklen et al 1977; Sanger and Coulson 1978), as described in Chapter 2 (pages 130- 
133).
Cell growth and expression of recombinant HIV-2 Protease.
Cell growth and HIV-2 PR expression were first optimised on a small scale, and it 
was established that a regime essentially identical to that used to express HIV-1 PR 
(Chapter 3) provided the optimum yield of active enzyme. Typically a cell pellet of 
2.5 gL'1 was obtained, and routinely the cell paste was stored in 20 g batches, at - 
70°C, in 50 ml of Buffer A (Chapter 3, table 1, page 186) containing 2 mM PMSF.
Purification of recombinant HIV-2 Protease
A 20 g pellet of cells was first thawed, then lysed by passing three times through a 
French Press at 4°C. The cell debris was removed from the lysate by centrifugation at 
an RCF of 30000 g for 1 hour at 4°C. The supematent was further clarified by 
ultracentrifugation at an RCF of 141000 g for 1 hour at 4°C, then dialysed for 12 
hours at 4°C against Buffer B (Chapter 3, table 1, page 186). A slight precipitate 
formed during dialysis and the solution was clarified by ultracentrifugation, as 
described above. The solution (50 ml) then underwent SEC, exactly as described for 
HIV-1 PR in Chapter 3, and 20 ml fractions were collected for analysis using the 
Scintillation Proximity Assay (SPA) (fig. 4) which was carried out as described in 
Chapter 2 (page 163).
Active fractions were pooled and dialysed for 8 hours at 4°C, against 5 L of 1 M 
guanidine in Buffer F (table 1), followed by dialysis against 5 L of 1 M Ammonium 
Sulphate in Buffer F for 12 hours at 4°C. A slight precipitate formed during these 
dialysis procedures, which was removed by ultracentrifugation as described above. 
The clarified supernatent (120 ml) was then loaded at a flow rate of 0.5 mlmin'1 onto a 
Pharmacia HiLoad 26/10 phenyl-sepharose HIC column previously equilibrated with 
a 1 M solution of ammonium sulphate in Buffer F. Protein was eluted using a gradient 
of ammonium sulphate (from 1 to 0 M) in Buffer F over a total of 50 ml (fig. 5).
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Protein fractions were collected as peaks, analysed by SDS-PAGE (fig. 6) and 
assayed for activity using the SPA (fig. 7).
Active fractions were pooled (~ 10 ml), dialysed against Buffer G (table 1) for 12 
hours at 4°C, and then loaded at a rate of 1 mlmin'1 onto a 16/10 fast flow S- 
Sepharose IEC column, previously equilibrated with Buffer G.
Table 1 Buffers F. G and H
Buffer F:
100 mM Phosphate buffer pH 7.4, 1 mM EDTA, 1 mM DTT 
Buffer G:
50 mM Na-acetate pH 4.4, 1 mM EDTA, 1 mM DTT, 10% v/v glycerol 
Buffer H:
10 mM acetate pH 4.4, 1 mM EDTA, 1 mM DTT
The protease was eluted using a gradient of 0-1 M NaCl in Buffer G, with a stepped 
interval in the salt gradient at 400 mM NaCl (fig. 8). Peak fractions were collected 
and checked for activity by SPA (fig. 9); the active fractions were pooled and 
analysed by SDS-PAGE (fig. 10). Protease eluted during the 400 mM NaCl step and 
was essentially pure.
For crystallisation purposes, the pooled active fraction was dialysed against Buffer H 
(table 1) for 12 hours at 4°C. The volume of the protease solution was then reduced 
using a Centricon 10, until a concentration of approximately 15 mgmf1 was reached 
(as determined by absorbance measurement at X = 280 nm, given an extinction 
coefficient calculated to be 19060 cm‘lM '1 using the combined methods of Edelhoch 
1967 and Gill, and von Hippel 1989). Protein was analysed by SDS-PAGE at this 
final stage of the procedure to assess its purity (fig. 10).
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Isoelectric focusing
The pi of HIV-2 PR was determined using an Immobiline DryStrip Kit, as directed by 
the manufacturer (supplied by Pharmacia). A pH range 3.0 - 10.5 was used in 
conjunction with a High pi calibration Kit (pH 5- 10.5). The running time was 16 
hours, giving a total 22 kVh. Detection was achieved using Coomassie staining.
Crystallisation and data collection.
Crystallographic methods have been described in Chapter 2 (pages 170-171). The 
initial conditions for crystallisation were determined using a ‘wild screen’ in droplets 
under oil, and optimised by means of the hanging drop vapour diffusion method. 
Optimally crystals were grown over 3 to 5 days at a constant temperature of 15°C 
from hanging drops prepared using 3 pi of HIV-2 PR stock at 6 mgml'1, mixed with 
an equal volume of a precipitating solution Buffer I (table 2), 1 ml of which was also 
used to fill the reservoir. Crystals grew to a diameter of 100 pm at best, and smaller 
crystals were macroseeded into fresh drops to augment their size.
Table 2 Buffer I.
0.1 M NaHEPES pH 7.5, 0.2 M CaCl2, 10% v/v polyethylene glycol (PEG) 400
Crystals were mounted into glass capillaries as described in Chapter 2 
(Crystallographic Methods, page 174). Crystals were analysed by X-rays at the 
Daresbury SRS, the data collection and processing procedures are also described in 
Chapter 2 (pages 175-178).
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RESULTS AND DISCUSSION.
Cloning and sequencing of the HIV-2 PR gene.
The HIV-2 PR gene was isolated by PCR from an EcoRI / Hindlll DNA fragment 
derived from the construct pROD35B (fig. 1). Nhel and Hindlll restriction enzyme 
sites were engineered into the 5' and 3' termini of the gene during the PCR step 
allowing insertion into the expression vector pKU2Laciq (as used previously with HIV- 
1 PR - see Chapter 3).
Figure 1 Construction of pKU2i .ACin HIV-2PR.
Hi E H
H IPRI H
E/H FRAGMENT
PURIFIED
- pROD35B
PCR REACTIONS
pROD35B cut 
EcoRI / Hindlll
HIV-2 PR gene amplified by PCR using 
primers to engineer ATG /  T A A  codons 
plus N co l /  H indlll sites.
H EI------ 1
ATG TAA 
N H P C R  P R IM E R S
PCR product cut N col /  H indlll and 
purified by band extraction.
CUT WITH N/H 
PURIFY 3 0 0 bp FRAG
HIV-2 PR gene ligated into vector 
prepared using N col /  H indlll.
LIGATE INTO N/H CUT 
pKU2 Laclq
H
 )
pKU2 Laclq
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The new construct was used to transform E.coli MCI061 and miniprep DNA was 
isolated from these transformants for analysis. Two clones, numbered 11 and 12, were 
identified by restriction analyses using the enzymes Ncol, Hindlll and SspI (fig. 2). 
The vector alone contained two SspI sites and thus digestion of the control released an 
SspI-SspI fragment in addition to the linearised vector (indicated by the blue arrow in 
fig. 2, SSP 1, lane C). Since the PR gene also contained an SspI site any construct 
containing the PR gene should release two SspI-SspI fragments in addition to the 
linearised vector on digestion with this enzyme -  as clones 11 and 12 were observed 
to do (indicated by green arrows, fig. 2, SSP 1, lanes 11 and 12). Digestion of the 
control vector with Ncol and Hindlll was expected to cut the vector within its 
multiple cloning site, releasing a fragment too small to be resolved by agarose gel 
electrophoresis - thus only linearised vector was visible in the control lane (indicated 
by the purple arrow, fig. 2, Ncol / Hindlll, lane C). However, since the PR gene was 
inserted into the construct via Ncol and Hindlll sites, digestion with both these 
enzymes was expected to release the PR fragment, as was observed with clones 11 
and 12 (indicated by the red arrow, fig. 2, Ncol / Hindlll, lanes 11 and 12). Taken 
together these digests verified the presence of the PR gene fragment in clones 11 and 
12.
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Figure 2 Restriction enzym e analysis o f d K U 2 i  (HIV-2 PR) construct.
Restriction analysis of +ve HIV-2 clones
Linearised vector
SspI-SspI fragment 
from vector
SspI-SspI fragments 
from clones
SSP 1
Ncol / Hindlll
C
11 and 12
S S P  1 Nco I/Hind
C 11 12 11 12 C
—
■
Linearised
vector
.HIV-2 PR gene
SspI restriction digest 
Combined Ncol and Hindlll digest 
Control (ie. vector without insert) 
Clones investigated
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Figure 3 Expressed protein cross reacts with HIV-2 PR anti-sera.
Western blot of expressing clones probed with HIV-2 
human polyclonal sera
12 11 c
i s i s i s MW
r&VVjt
C Control {E.coli lysate in the absence o f HIV-2 PR construct)
MW Molecular weight markers (indicated in kD)
I Insoluble fractions 11 = lanes relating to clone 11
S Soluble fractions 12 =  lanes relating to clone 12
The arrow indicates the position o f the HIV-2 PR bands. These are most clearly seen in lanes relating 
to clone 11, and particularly in the insoluble fraction derived from clone 11. No equivalent band is seen 
in the control lanes.
Western blot analysis of proteins expressed after IPTG induction of the positive 
clones showed that both clones expressed a soluble protein of molecular weight ~ 10 
kD, which cross reacted with HIV-2 human polyclonal anti-sera (fig. 3).
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DNA sequencing of both clones 11 and 12 showed 4 base substitutions, when 
compared with the pROD35B sequence, although none of these substitutions would 
have resulted in a change to the amino acid sequence. In addition, clone 12 had further 
base changes which resulted in the alteration of one amino acid, consequently clone 
11 was selected for all subsequent work.
Purification of HIV-2 PR.
Although HIV-2 PR was produced solubly in E.coli, it was necessary to employ 
denaturing conditions for the initial SEC, since it was found that under native 
conditions the protein did not resolve on this column. It had previously been 
established with HIV-1 PR that under denaturing conditions it was possible to resolve 
the protein from the Sephacryl S-200 column, resulting in a 60% purification of the 
protease. Furthermore it had then been possible to refold it into an active, 
crystallisable form (Chapter 3). It was anticipated that HIV-2 PR could be prepared in 
the same way. Following dialysis of the soluble extract of HIV-2 PR into Buffer B 
(containing 5 M guanidine) and chromatography using a Sephacryl S-200 column, the 
protease eluted along with the low molecular weight peak, and active fractions were 
detected by means of SPA (fig. 4). The SPA data is presented in table 3 of the 
appendix (page 345).
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Figure 4 HIV-2 PR activity detected in Sephacryl S200 elution fractions.
SPA analysis of HIV-2 PR activity in fractions 
eluted from Sephacryl S200 column.
60.0
500
40.0
30.0
10.0
0.0
- 10.0
Fraction num ber
Fractions eluted from S-200
Fraction volumes = 20 ml
Fractions 10-15 contained FIIV-2 PR activity and were pooled. 
Column = XK50, column volume = 2000 ml.
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Dialysis of the eluent against 1 M guanidine in Buffer F (table 1) resulted in the 
refolding and further purification of the protease. It also served to replace an MES 
buffer (Buffer B -  Chapter 3, table 1) with a phosphate buffer (Buffer F), raising the 
pH in the process. The refolded protease was then prepared for the phenyl-sepharose 
column by dialysis against 1 M ammonium sulphate in Buffer F. By replacing 
guanidine with ammonium sulphate this step caused the protease to adopt its 
dehydrated state - enabling it to bind to the phenyl-sepharose column HIC column11. 
Protein was eluted from the Phenyl-Sepharose column by means of a decreasing 
ammonium sulphate gradient, from 1 to 0 M ammonium sulphate, (fig. 5) and 
fractions were analysed by PAGE (fig. 6). Protease activity was detected by SPA in 
the fourth peak, having eluted at 0 M ammonium sulphate (fig. 7 and appendix table 
4, page 346).
11 T he tw o-state  p rotein  m odel (C hen and Sun 2003) assum es that a  protein  can ex ist in  tw o sta tes - hydrated  and 
dehydrated. N orm ally  a  p ro tein  is coated  w ith structured  w ater m olecules, form ing a  hydration  shell over the 
protein surface (the hydrated  state). T he addition o f  salt (usually  am m onium  sulphate) to a protein  solu tion  strips 
the hydrophobic surfaces o f  a  protein o f  its hydration shell, causing the protein  to  adopt the dehydrated  state  in 
w hich the  hydrophobic zones o f  its surface are exposed to  the bulk  solvent. T hese hydrophobic patches then 
ten d  to  associate w ith  o ther hydrophobic ligands. T his association  is term ed  "hydrophobic  in teraction", and 
form s the  basis for th is separation  technique.
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Figure 5 Phenvl-Sepharose Chrom atograph.
Peak V
P 0 M  A m m o n iu m  
S u lp h a te
HIV-2 PR Purification,
Phenyl Sepharose H igh Perform ance R esin  
Pharm acia X K I 6  Hi load 2 6 /1 0  colum n (2 0  m l) 
Gradient 1 to 0  M  A m m onium  Sulphate 
Butter 100 m M  Phosphate pH 7  4, I m M  EDTA, 1 m M  DTT
H IV -2  P R  e lu tio n  b y  A m m o n iu m  S u lp h a te  g ra d ie n t from  a 
P h en y l S e p h a ro se  c o lu m n . H IV -2  P R  a c tiv ity  w a s  d e te c te d  
in p eak  4.
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Figure 6 Analysis o f Phenyl-Sepharose fractions by PAGE.
Phenyl-Sepharose elution of HIV-2 PR
Ammonium Sulnhate 
1 M * ► OM
MW L XL 1 2 3 4
a rro w  in d ic a te s  H IV -2  P R  
M W  =  M o le cu la r  w e ig h t k D
L =  L o ad
X L  = F lo w  th ro u g h
1-4 =  P eak  n u m b e rs
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Figure 7 Detection o f active fractions eluted from Phenyl Sepharose
HIV-2 PR (Phenyl-Sepharose).
45 - 
40 - 
35 
30 
25 
20 
15 - 
10
feak 4 -  active fractio
-10 J
Fractions
F ra c tio n s  e lu te d  from  th e  P heny l S e p h a ro se  c o lu m n  w e re  su b je c ted  to  S P A  a n d  H IV -2  PR  a c tiv ity  w as 
d e te c te d  in p e ak  4 ( fra c tio n s  10 -  16) - see  a p p e n d ix  tab le  4 , p a g e  3 4 6 ; a n d  figs. 5 &  6, p ag es  2 1 6  &  
2 1 7 .
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Figure 8 C hrom atograph o f HIV-2 PR elution from S-Sepharose.
10CU%
UV Absorbance (280 nm)
% NaCl gradient (100 % = 1 M NaCl) with step at 400 mM NaCl
HIV-2 PR was detected in peak 3
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Peak four was then dialysed against Buffer G, lowering the pH from 7.4 to 4.4 by 
changing a phosphate buffer for an acetate buffer. This ensured that the pH was below 
the anticipated pi (~ pH 5) of HIV-2 PR in preparation for the S-Sepharose IEC 
column. The protease was not observed to precipitate out at this stage, despite 
crossing its isoelectric point - suggesting that once refolded it is readily soluble. The 
sample was then loaded onto the S-Sepharose column and elution achieved by means 
of a stepped gradient (fig. 8) in order to obtain a better separation. The eluted fractions 
were analysed by SPA assay, and activity was detected in the third peak (fig. 9), 
which eluted during the 400 mM NaCl step. The purified protease appeared as a 
single band in peak number 3 when pooled fractions were analysed by SDS-PAGE 
(fig. 10). The final dialysis step served to remove glycerol and NaCl, whilst reducing 
the sodium acetate content. The pure protease was concentrated to a typical final 
concentration of approximately 15 mg/ml and stored pending use at -70°C.
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Figure 9 SPA analysis o f  S-Sepharose peak fractions.
SPA analysis of S-Sepharose peak fractions.
80
60
40
20
0
-20
-40
Fraction number
Peak number 3 (see fig. 8, page 219) incorporated fractions 6 - 1 5  inclusive. 
Fractions 6 - 1 1  contained the bulk of PR activity and were pooled 
Data shown in appendix table 5, page 347.
Figure 10 SDS PAGE analysis of S-Sepharose peak fractions.
Peak numbers refer to peaks from S-Sepharose chromatograph shown in figure 8, page 219.
Peak numbers
Mwt- 
kD Std
1 4 -----
HIV-2
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Characterisation of purified HIV-2 PR.
The purified protease was subjected to amino-terminal analysis o f the first 19 
residues, confirming it to be the HIV-2 PR desired. This also revealed that the N- 
terminal initiator methionine (resulting from translation o f the ATG start codon, 
engineered into the HIV-2 PR expresssion vector) had been lost during expression and 
purification. This was probably the result o f cleavage by E.coli methionine 
aminopeptidase (Lowther, Zhang et a l 1999), an enzyme essential for E.coli cell 
growth (Chang, McGary et al. 1989), or conceivably as a result o f cleavage by the 
HIV-2 PR itself. This loss o f the methionine ensured that the amino-terminal o f the 
purified protease was identical to that o f naturally occuring HIV-2 PR (ie. PQFSL etc 
rather than MPQFSL).
Isoelectric focusing revealed that the pure active HIV-2 PR has a pi of 5.2. 
Crystallisation, data collection and analysis.
The crystal screen resulted in the growth of small tetragonal bipyramids under two 
separate, though similar, conditions. The first o f these consisted of 0.1 M NaHEPES 
buffer (pH7.5) containing 0.2 M CaCl2, and 20% v/v PEG 400. This solution resulted 
in greater than 20 tetragonal bipyramids from a 2 pi drop under oil - at least ten of 
which were single, the others being twinned. The first o f the bipyramids appeared 
after a period of 5 days, the remainder developed over a period of one month.
Figure 11 Small tetragonal bipyramid crystals were observed under oil.
Small (approximately 10 pm diameter) HIV-2 
PR crystal, grown under oil, prior to 
optimisation of conditions.
Conditions:
0.1 M NaHEPES (pH7.5)
0.2 M CaCl2  
20% v/v PEG 400 
1 mg/ml [HIV-2 PR]
The second solution consisted o f 0.1 M NaHEPES (pH 7.5) containing 0.2 M MgCl2 
and 30% v/v PEG 400. This solution produced clusters o f very small tetragonal 
bipyramids (identical in morphology to those grown from the first condition) after a 
period o f one month.
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Other solutions screened which incorporated either a NaHEPES buffer (pH 7.5), PEG 
400, a group two metal salt, or a chloride were reviewed, though no further crystals 
were observed. A series of hanging drop experiments were carried out to investigate 
optimum conditions for crystal growth using both solutions. Initial investigation 
centred on protein concentration. A final protein concentration o f > 3 mgrnl'1 tended 
to produce very rapid crystal growth, and crystals formed were o f poor morphology - 
often feathered or twinned (fig. 12) - therefore 3 mgml'1 was adopted as the maximum 
final concentration for further study.
Figure 12 Poor crystal morphology was observed at IHIV-2 PR1 > 3 mg/ml.
Example of poor crystal morphology.
Conditions:
0.1 M NaHEPES (pH 7.5)
0.2 M MgCl2
30% v/v PEG 400
5 mg/ml HIV-2 PR
Vapour diffusion at 20°C for 14 hours.
The effect of a lowered PEG 400 concentration was investigated, as was the effect of 
the extra ionic components. A series o f hanging drops containing either CaCl2, 
MgCl2, NaCl, or no ionic component, and using varying concentrations of PEG 400 
over the range 5% v/v to 10% v/v was set up. Following 52 hours at 20°C 12 single 
tetragonal bipyramids o f between 50 - 80 pm in length (figs. 13 and 14) were 
observed in the drop containing a final PEG 400 concentration o f 10% v/v, and CaCl2 
at 0.2 M. No crystals were observed under the other conditions. Repetition of these 
conditions yielded further tetragonal bipyramids o f 100 pM in length (fig. 15).
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Figure 13 Tetragonal crystals o f HIV-2 PR grown by vapour diffusion.
Crystals shown above are approximately 50 pm in diameter and were grown by vapour 
diffusion from 0.1 M NaHEPES (pH 7.5), 10% v/v PEG 400, and 0.2 M CaCl2 at 20°C 
over a period o f 52 hours.
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Figure 14 O ptim isation o f HIV-2 PR crystals grown by vapour diffusion.
Crystals of approximately 80 pm diameter were grown by vapour diffusion from:
0.1 M NaHEPES (pH 7.5), 10% v/v PEG 400, and 0.2 M CaCl2 at 20°C over 52 hours.
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Figure 15 HIV-2 PR crystal mounted for X-rav ananlvsis.
Tetragohal 
bipyramid crystal of 
HIV-2 PR. 
approximately 100 
pm in length and 
mounted hr an X-ray 
eapi ij ary r e a d j^ ip ^  
analysis.
The pH of crystallisation buffer established here reflects the results o f McKeever et 
al., who found that well formed tetragonal bipyramids o f HIV-1 PR were obtained at 
pH 7 only. The morphology of the HIV-2 PR crystals described here was essentially 
indistinguishable from that of HIV-1 PR crystals (see Chapter 3, fig.9, page 197). The 
crystals were analysed by SDS-PAGE and Western blot, and the enzymatic activity o f 
re-dissolved crystal protein was investigated using the SPA method. In both cases 
results were identical to those obtained with the stock protein (data not shown).
The crystals were found to diffract to between 3 and 4 A using the SRS at Daresbury 
(December 1992), although they were not stable long enough for significant data 
collection. This was probably a function o f their small size and possibly indicative of 
high water content. Attempts were made to increase crystal size by macro seeding 
techniques (described Chapter 2, page 172) which eventually yielded crystals with 
diameters > 100 pm. However, no significant improvement in stability was seen, 
despite the increased crystal size. Stability might have been improved by co­
crystallisation with an inhibitor. This was attempted using pepstatin, but without 
success - no crystals were observed in the presence of pepstatin.
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A number of macroseeded crystals were mounted for x-ray analysis (fig. 11), and 
exposed to x-rays both at Birkbeck’s in house source, and at the Daresbury SRS. The 
best results were obtained at the SRS (in April of 1994) and consisted of only three 
stills (at 0°, 90° and 45°), and a further 9 oscillations (fig. 12) of 1° per oscillation 
(starting at 0°) before data collection was abandonned due to deterioration of the 
crystal. The crystal diffracted to 4.5 angstroms resolution, and was found to be in a 
tetragonal space group 14, with unit-cell parameters of a=b=130, c=185 A, 
a=p=Y=90°. There were calculated to be eight molecules per asymmetric unit (each 
containing approximately eight monomeric units of the enzyme, or four dimers) and 
the crystal had a solvent content of 73%. Typically the solvent content of a crystal 
may range from between 25% to 70 %, meaning that the water content of these 
crystals was very high. This coupled with the complexity of the asymmetric unit, and 
the extreme difficulty involved in collecting sufficient data (at nine oscillations per 
crystal, forty crystals would be required to complete an entire data set) it was 
considered that to pursue a structural solution was unfeasible without the use of 
specialised techniques (such as Cryo-crystallography and solvent flattening). Cryo- 
crystallography in particular may have improved chances of obtaining sufficient data 
since this technique minimises damage to the crystal during data collection by 
freezing it throughout the process in a stream of Nitrogen. Consequently individual 
crystals diffract for longer periods, and fewer are therefore required to complete a data 
set (often one is sufficient). However, this technique was in its infancy at that time, 
and was not available to us. The only viable alternative was to obtain crystals of HIV- 
2 in complex with an inhibitor, in the hope that the presence of the inhibitor would 
stabilise the crystal and allow it to diffract more efficiently and for longer periods. 
However, in light of the two contemporary structural solutions for HIV-2 -  inhibitor 
complexes that had recently been published (Mulichak, Hui, et al. 1993; Tong, Pav, et 
al. 1993) it did not seem worthwhile to pursue this approach.
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Figure 16 HIV-2 PR diffraction pattern.
HIV-2 PR apoenzyme image no. 004
This image was collected during a 1° oscillation and is typical of the images collected,
a. is the whole image b. is an enlargement of the central area.
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SUMMARY
The HIV-2 PR was cloned, expressed and purified from a recombinant expression 
system in E.coli. The expressed protease was found to be soluble, and was purified 
using a three column chromatographic procedure. The amino terminal sequence, 
molecular weight, and pi were shown to agree with those previously determined for 
HIV-2 PR. Tetragonal bipyramid crystals of the apoenzyme approximately 100 pm in 
length were grown by means of the hanging drop vapour diffusion method. They were 
found to diffract x-rays to 3 A at best. The crystal morphology was indistinguishable 
from that described for HIV-1 PR, whilst the space group was found to be tetragonal 
14, with unit-cell parameters of a=b=130, c=185 A, a=p=y=90°. There were 
calculated to be eight molecules per asymmetric unit (each containing approximately 
eight monomeric units of the enzyme, or four dimers) and the crystal had a solvent 
content of 73%. The crystallisation described here preceded the publication of any 
similar work by any other groups. However, two rival groups published structures of 
HIV-2 PR in complex with inhibitors (Mulichak, Hui, et al 1993; Tong, Pav, et al
1993) before we were able to obtain data of publishable quality. Given the technical 
difficulties involved in obtaining sufficient data for a full structural solution of the 
native protease, and in light of the rival published structures, it was not considered 
worthwhile to pursue a structural solution further. Since that time a number of 
structural solutions for HIV-2 PR -  inhibitor complexes have been published (Chen, 
Li, et al 1994, Tong, Pav, et al 1995, Priestle, Fassler, et al 1995) as has a native 
SIVMac structure which is within the sequence identity envelope of HIV-2 PR 
sequences (Wilderspin and Sugrue 1993; Wilderspin and Sugrue 1994). However, to 
date no structure for the native HIV-2 PR has been published or deposited. The 
similarity of SIVMac and HIV-2 proteases, and the availability of the native SIVMac 
sequence for modelling purposes have arguably made a native HIV-2 PR structure 
less interesting, and therefore less likely to be pursued in the future. The native 
S IV ag m  PR structure by contrast has possibly become more interesting, given the 
relative dissimilarity of S IV ag m  PR to either HIV-1 or HIV-2 proteases (see 
Introduction, fig. 2, page 27) demonstrating it to be a truly Simian in origin.
While considering the PR structure and mechanism a general comparison of cysteine 
and aspartic protease active sites was made, leading to the proposal that their catalytic 
residues might be interchangeable. This hypothesis was investigated next (Chapter 5).
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Chapter Five: The mutagenesis of HIV-2 
Protease.
Three dimensional modelling, construction, expression, and 
purification of HIV-2 PR active site mutants, and the subsequent 
creation and characterisation of an HIV-2 PR heterodimer with the 
catalytic residues of a cysteine proteinase.
INTRODUCTION
A comparison of HIV-2 PR and the cysteine proteinase papain in terms of substrate 
specificity, mechanism of action, amino acid sequences and overall structures would 
reveal that they are very different. However, it was proposed that if the two catalytic 
aspartate residues of HIV-2 PR were replaced by the catalytic residues of papain (i.e. 
His and Cys) their relative spatial orientations in the resultant mutant HIV-2 PR 
protein would be sufficiently close to their native arrangement in the papain active site 
that the mutant HIV-2 PR might retain proteolytic activity (fig. 1). Catalytic activity 
would thus persist in the mutant enzyme despite replacement of the aspartates 
ordinarily essential for catalysis, because the replacement residues would enable 
proteolysis by means of a different mechanism - that of a cysteine proteinase rather 
than an aspartic proteinase. This chapter describes the modeling and creation of a 
heterodimeric HIV-2 PR His-Cys mutant in order to test this hypothesis12.
12 In this Chapter the catalytic residues of the HIV-2 PR dimer are given as single letter / residue no. code and are 
separated by an oblique / ,  ie. the native homodimeric HIV-2 PR is D25/D25, the homodimeric HIV-2 PR 
mutants are C25/C25 and H25/H25 respectively, and the heterodimeric mutant is C25/H25. Numbering is as for 
HIV-PR.
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Figure 1______Com parison of Papain and proposed mutant o f HIV-2 PR
1. Native Papain.
2. Native HIV-2 PR.
Key,
Comparison of enzyme active sites.
Catalytic residues = blue.
Papain monomer = yellow
HI V-2 homodimer and mutant heterodimer Subunits = yellow and pink.
231
HIV-2 PR
HIV-2 PR is a dimeric, retroviral, aspartic protease. The characteristics of the aspartic 
proteases, and the retroviral proteases in particular, have been discussed in Chapter 1. 
The cloning, expression, purification and crystallisation of HIV-2 PR were the subject 
of chapter 4. The reader is therefore refered to these chapters as sources of 
introduction to this enyme.
Papain
Papain is a monomeric, cysteine protease present in the tropical papaya fruit (Carica 
papaya). Proteolytic activity was first associated with extracts from the papaya by 
Wurtz and Bouchut in 1879 (Wurtz and Bouchat 1879), and was later attributed to a 
mixture of four or more cysteine proteases and other enzymes (Brocklehurst, Baines 
et al. 1981) including papain. Papain has been isolated and purified (Kimmel and 
Smith 1954; Brocklehurst, Baines et al 1981) and extensively studied. Early work on 
papain is discussed in reviews by Smith and Kimmel (Smith and Kimmel 1960), 
Brocklehurst et al (Brocklehurst, Baines et al 1981; Brocklehurst, Willenbrock et al 
1987), and Baker and Drenth (Baker and Drenth 1987). Papain’s three dimensional 
structure was the first solved for a cysteine protease (Drenth, Jansonius et al 1968).
The biochemical characteristics of papain
Papain is a fairly basic protein with a pi of 8.75. Structurally it is a monomeric 212 
residue polypeptide of 23429 Da. It is globular, has three disulphide bonds and two 
interacting domains that create the substrate-binding cleft. An active site cysteine 
residue (Cys25, Papain numbering) has been shown to be essential for activity (Finkle 
and Smith 1958). Furthermore Cys25 is required to be in a free state, and the active 
site must also incorporate a nearby histidine residue (His 159, papain numbering) 
(Drenth, Jansonius et al 1971; Glazer and Smith 1971; Drenth, Kalk et al 1976). In 
its active state the enzyme is thought to consist of a thiolate-imidazolium ion pair (fig. 
2) formed between the active site residues Cys 25 and His 159 (Storer and Menard 
1994).
232
Figure 2 The active site catalytic residues of Papain.
Thiolate - imidazolium ion pair between residues Cys25 & His 159.
— Hisl59
Cys25 s — H
Cys25 S'
N — H
-His 159
H-
The catalytic Cys25 is involved in a tautomeric equilibrium between the neutral and zwitterionic
forms.
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Papain has seven subsites in its active site cleft (fig. 3), 4 (S1-S4) accomodate 
residues P1-P4 on the N-terminal side of the scissile site and 3 (ST-S3') accept 
residues that are C terminal of it (PT-P3'). Arg and Lys are prefered at position PI 
(Kimmel and Smith 1957) while Val is not accepted (Baker and Drenth 1987). Bulky 
non-polar side chains are prefered at P2 - eg Phe (Berger and Schechter 1970). Little 
is known about the preferences of the S’ subsites, but the choice of residues at Pl'-P3' 
appears to be broad (Menard, Carmona et al. 1993). The lack of any clear preferences 
in terms of substrate binding means that papain can generate numerous cleavage 
patterns, and papain sites within a protein are hard to predict.
Figure 3 The papain substrate binding cleft.
Diagramatic representation of Papain substrate binding cleft. 
Substrate peptide chain, residues P4 - P3’
Active site cleft
Preferred residues at P4 - P3’
PI = Lys or Arg - Not Val
P2 = bulky non-polar r esidues eg. Phe
Preferences not known for ot her positions.
Key.
N • • • • • • » (
Substrate peptide chai n 
* = Scissile sit e in peptide chain
Substrate binding subsites or pockets
MAMMA.
N P4) P3} P2 15^  & - C
Papain substrate binding subsites S4 - S3’
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The enzyme is stable and active between pH 4 and pH 10, and at temperatures up to 
80°C (Glazer and Smith 1971), and still retains activity in the presence of 8 M urea. It 
can be stored at 4°C, but will lose up to 50% of its activity within one week due to 
oxidation of the thiol group. This loss of activity can only partially be restored by the 
addition of thiol reagents. Long-term storage can be achieved either by addition of an 
equimolar amount of mercuric chloride (to yield mercuripapain) or by using 2,2'- 
dipyridyl disulphide to produce 2-pyridyl papain disulphide. Both of these derivatives 
are inactive and stable for several months at 4°C. They can be reactivated using thiol 
reagents such as 2-mercaptoethanol (2ME) or Dithiothreitol (DTT).
Papain is produced in vivo as an inactive precursor or proenzyme -  propapain 
(Brocklehurst and Kierstan 1973, Cohen et al.. 1986, Vemet, Tessier et al. 1990) 
which is converted to Papain on activation (Brocklehurst and Kierstan 1973; Vernet, 
Khouri et al. 1991). Recombinant proenzyme has been expressed as soluble fully 
folded protein in baculovirus cells (Vernet, Tessier et al. 1990, Vernet, Khouri et al.
1991), and as inclusion bodies (which required refolding) in E.coli (Taylor, Pratt et al.
1992). In both instances however, the final yields of pure active protein were low (1-2 
mg per litre of cell culture). For further information on Papain there are reviews by 
Baker and Drenth (1987) (Baker and Drenth 1987), Brocklehurst et al. (1987) 
(Brocklehurst, Willenbrock et al. 1987), and Storer and Menard (1994 and 1996) 
(Storer and Menard 1994).
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Comparison of HIV-2 PR and Papain mechanisms.
The mechanism of action for HIV-2 PR is dealt with in Chapter 1, whilst that of 
papain is described briefly below, and in the following references (Klein and Kirsch 
1969; Lowe 1970; Brocklehurst and Kierstan 1973; Brocklehurst and Malthouse 
1978; Smolarsky 1978; Smolarsky 1980; Brocklehurst, Willenbrock et al. 1983; 
Willenbrock and Brocklehurst 1985; Vernet, Khouri et al. 1991; Storer and Menard
1994).
Papain is the best studied of the cysteine family of proteinases, and the cysteine 
proteinase mechanism, as exemplified by papain, is similar in many respects to that of 
the serine proteinases. Each mechanism involves an acylation and deacylation step, 
however, in the cysteine proteinases the attacking nucleophile is the sulphur atom of 
Cys25 rather than the hydroxyl group of a serine. The proximity of His 159 to Cys25 
stablises the existence of a thiolate ion (fig. 2) by allowing formation of an ion pair 
between the Cys25 sulphur and the imidazolium group of His 159. Catalysis is 
possibly also facilitated by the effect of hydrogen bonding between the Asp 158 side 
chain carboxylate and the imidazolium of His 159. On binding of substrate to the 
active site cleft the thiolate ion engages in a nuclephilic attack on the carbonyl carbon 
of the substrate’s scissile peptide bond. A negatively charged tetrahedral transition 
state results, covalently bound to the enzyme via a thioester bond with Cys25. The 
transition state is also stabilised by hydrogen bonding between the substrate carbonyl 
oxygen and the two backbone -NH- groups of enzyme residues Gin 19 and Cys25, 
which together form an ‘oxyanion hole’ as described by Robertus et al. (Robertus, 
Kraut et al. 1972). Collapse of the transition state results in cleavage of the peptide 
bond; this releases the amino portion of the substrate as the first product (Pi). The acyl 
portion of the substrate remains bound to the enzyme via Cys25 as a covalent acyl- 
enzyme intermediate. This completes the acylation step of the mechanism. 
Deacylation then procedes via enzyme-catalysed attack by water; this generates the 
acyl product (P2), and restores the enzyme active site to its free state. A diagramatic 
representation of the cysteine proteinase mechanism is provided (fig. 4) for 
comparison with a recent mechanism proposed for the retroviral aspartic proteases 
(fig. 5).
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Figure 4 The m echanism  o f Papain.
I r t t  n u w  arthc Mlc
C«2» S— H ------ \ ^ , N — H
Hhl?»
 H—\ ^ , N  — H
1.
^  r T0 0 5  > — i f  V  s'*— H
Hhlft
-NH— I'H— II I
PI O
Prudncl 1 released
7 ~  ....\
0 0 5  N ..............H— V ^ N —H
-NH— I'll— I  — NH—<H—< -I k  I I
P ! 0 *  PI O
Mirharltt 
Cnaplrt
2 .
C ns\»- f t
-NH-U^ * \
O - H *
H
HM5»
^  r f
(NOS N  —  H
Tetrahedral
inlcrnwtfutt
-NH—CH—C -*-NH—CH—C-I I I
P2 P! 0
/ \ h »  '  \  >05 
hachhniw backbone
Oxyanion
hole
3.
lnojN r CV N- H
His 151
-Ml—CH—CI
PI (I 
Act i r a i l  me iMrrinrduUr
Prudact I rclrjvd
H—NH—CH—C-I I
PI (I
6 . 5. 4.
1. Ion pair formation between Cys25 and His 159.
2. Thiolate ion nucleophilically attacks substrate carbonyl carbon.
3. Negatively charged tetrahedral transition state forms, with covalent thioester bond between
Cys25 sulphur and substrate carbonyl carbon. Hydrogen bonds between substrate carbonyl 
oxygen and Gin 19 / Cys25 backbones form ‘Oxyanion hole’.
4. Collapse of transition state, cleavage of peptide bond, release of first product.
5. Covalent acyl intermediate attacked by water. Acyl product 2 released, enzyme active site
restored to free state.
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Figure 5 G eneral acid-base m echanism  for HIV-1 PR (Piana et al. 2002).
Substrate '
.N—Ho=< N -H
O *
o
T SI O
Asp25 Asp25’
ES
INT
Products
EP T S 2
O O
L Substrate binds, water is displaced, rotations about Asp CP-Ca bonds occur, proton transfers 
occur.
2. Michaelis complex formation, nucleophilic attack by water on substrate carbonyl carbon.
3. Gem-diol tetrahedral intermediate formed.
4. Substrate peptide nitrogen protonated.
5. Substrate peptide bond breaks, products are released, active site regenerated.
6. Free enzyme, catalytic Asps adopt symmetrical monoprotonated state, coordinating a water 
molecule.
Unlike the papain mechanism there is no formation of a covalent intermediate.
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Mutant heterodimer formation.
Visual comparison of the respective crystal structures of HIV PR and Papain lead to 
the proposal that if the two catalytic aspartate residues of HIV-2 PR (D25 on each 
monomer) were replaced by those of papain (i.e. D25H on one monomer and D25C 
on the other) the relative spatial orientations of the His and Cys residues in the 
resultant C25/H25 mutant HIV-2 PR protein would be close to the arrangement of 
these residues in the native papain active site (fig. 1). Thus it was conceivable that an 
C25/H25 mutant HIV-2 PR may retain proteolytic activity, despite replacement of the 
aspartates ordinarily essential for catalysis, because the replacement residues would 
enable proteolysis by means of a different mechanism - that of Papain. Computer 
modelling suggested that the replacement catalytic residues could orientate so as to 
engage a peptide substrate and initiate proteolytic cleavage (figs. 6 and 7).
Figure 6 Catalytic residues of proposed mutant and possible substrate
interaction.
2.8A.. .  H—
, 2.8A
Cys25 'S
„ a \  ,
8+  /
NH— CH— C — NH— CH
I
P2 .0 8- P1
C
IIo
✓
/  2 .8 A \
H ^
His25
H
His 25 and Cys 25 residues o f proposed heterodimeric mutant HIV-2 PR and their predicted 
interaction with a substrate peptide.
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Figure 7 Model of the HIV-2 PR heterodimeric mutant active site with
bound substrate.
HIV-2 heterodimer subunits:
D25H = yellow and 
D25C = green 
Substrate = red
Dotted lines indicate distances (angstroms).
The above figure shows one view of a model of the heterodimeric HIV-2 mutant 
binding an HIV-2 PR substrate. The distances between the catalytic residues and the 
substrate approximate to those required for catalysis (ie. those seen in the native 
papain active site, and illustrated in fig. 6).
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The C25/H25 protease thus envisaged would be a heterodimeric active site mutant of 
HIV-2 PR. The mechanism of action for such a mutant HIV-2 PR would be that of a 
cysteine protease (papain) rather than that of an aspartic protease (HIV-2 PR), whilst 
the enzyme’s substrate specificity should remain unchanged.
This Chapter describes the production of two homodimeric mutants of HIV-2 PR, 
D25C (ie C25/C25) and D25H (ie H25/H25) and the attempts to form and detect the 
activity of a heterodimeric mutant derived from them. It was envisaged that the 
heterodimeric mutant could be formed by means of monomer exchange between the 
two homodimeric mutants as a result of dynamic equilibrium between monomeric and 
dimeric states of the protein. A similar equilibrium has been observed in the native 
enzyme (Grant, Deckman et al. 1992). It was proposed that mixing the two inactive 
homodimeric mutant forms of HIV-2 PR should produce a heterodimeric mutant 
detectable by virtue of its activity.
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MATERIALS AND METHODS
Three dimensional modelling
Modelling was carried out using Swiss model and Swiss PDBviewer, both available 
on the internet at http://www.expasv.ch/swissmod/SWISS-MODEL.html.
Mutagenesis reactions
The ‘QuickChange’ Site Directed Mutagenesis method from Stratagene was used to 
generate the desired mutants. Primers were designed exactly following the 
recommendations from Stratagene (see Chapter 2, page 129, Site directed 
mutagenesis; and the Stratagene QuickChange Manual, p4) and were purchased 
‘ReadyPure’ from PE-Applied Biosystems UK, arriving ready to use. Two primers 
were required for each mutation (one foward, one reverse) - each the exact 
complement of the other. The primers (fig. 8) were designated His+ve, His-ve and 
Cys+ve, Cys-ve. The primers were designed such that they would also introduce a 
unique Agel restriction enzyme site, thus enabling clones to be screened for 
successful mutation by restriction digest.
The plasmid pHIVSET5 was used as the mutagenesis template. This was constructed 
(fig. 9 i-iii) by insertion of the HIV-2 PR gene as an NcoI/EcoRI PCR product into 
pRsetB (Invitrogen). The polylinker between the His tag encoding region and the start 
of the gene was then excised using the flanking Nhel and Ncol sites which were cut, 
filled and religated, maintaining the orginal frame in the process (fig. 9 iv-v). This 
truncated the construct to remove the enterokinase cleavage site such that the 
expressed protease would have an N-terminal histidine tag for affinity purification 
directly before the protein.
The reaction mixtures and PCR cycles were as recommended by Stratagene, and 
described in Chapter 2, page 129, Site directed mutagenesis.
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Figure 8 HIV-2 active site m utagenesis primers.
Asp to His mutagenesis primers.
+ve 51-ccagtagaagttttgttacacaccggtgctgacgactcaatag-3' 
-ve 5 ' -ctattgagtcgtcagcaccggtgtgtaacaaaacttctactgg-3'
Asp to Cys mutagenesis primers.
+ve 5 ' -gccagtagaagttttgttatgcaccggtgctgacgactcaatag-31 
-ve 5 ' -ctattgagtcgtcagcaccggtgcataacaaaacttctactggc-31 
Blue = DAH or DAC Red = Agel site.
Transformations
Super competent XL1 Blue E.coli cells were generated as described in Chapter 2 (See 
General Materials and Methods, Transformations, The preparation of super competent 
cells, page 139) and transformed with the completed PCR reaction mixtures described 
above. The Stratagene ‘QuickChange’ protocol was followed to effect the 
transformation, and cells were then spread onto LB agar plates, supplemented with 
Ampicillin (concentration = 100 pgml'1), and incubated overnight at 37°C.
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Figure 9 The construction o f pHIVsetS.
11
m
IV
Ndel Nhel BamHI Ncol Hindlll
6x His Xpress
Ndel Nhel
Epitope EK MCS o
pRsetB
(Invitrogen).
BamHI Ncol Hindlll
P j7 ) RBSQB] 6x His Epitope EK
Ndel Nhel BamHI Ncol Hindlll
PT7 R B SE5E 6x His Epitope EK MC HIV-2 PR
pRsetB cut 
Ncol / Hindlll
HIV-2 PR PCR fragment 
cut Ncol / Hindlll and 
inserted into vector to 
produce pRsetB_HIV2PR
Ndel Nhel Ncol Hindlll
Ndel
HIV-2 PR
 Nhel Hindlll
PT7
pRsetB_HIV2PR cut Nhel / Ncol 
to remove Xpress Epitope and 
Enterokinase (EK) polylinker. 
Overhangs filled and ends ligated, 
maintaining the reading frame.
RBS^^6x^HisJ HIV-2 PR PT7 = T7 promoter
RBS = Ribosome Binding Site
ATG = Start codon
6 x His= Histidine tag encoding region
term = Stop codon
244
Selection and sequencing of mutants
Colonies resulting from the above transformation were used to generate plasmid 
minipreps (as described in Chapter 2, page 124, Preparation of DNA, Small scale or 
‘Minipreps’). The minprep DNA was then digested with both Agel and Hindlll as a 
diagnostic test to identify positive plasmids. Only clones containing the desired 
mutations cut with both enzymes to yield a linearised DNA fragment of 
approximately 350 bp. Midiprep DNA (Chapter 2, page 125, General Materials and 
Methods, Preparation of DNA, Large scale ‘Midipreps’) was prepared from the 
positive clones (ie. those containing both sites), and was used for sequencing of the 
mutant genes. ABI sequencing was carried out by Cambridge biosciences Ltd (see 
page 133, and the List of suppliers, Appendix, page 325).
Expression and purification of the mutant homodimers
Each of the two mutants was expressed and purified individually in the form of 
mutant homodimers (i.e. H25/H25 and C25/C25), using BL21 (DE3) pLysS as the 
host strain. Cultures were innoculated with freshly transformed cells and grown to an 
OD280 of 0.5 at 37°C, then allowed to cool to 16°C and induced by addition of IPTG 
to a final concentration of 0.1 mM. The cultures remained incubating with shaking at 
16°C overnight, and were then harvested by centrifugation. Cell pellets were 
resuspended in Buffer J (table 1) and stored at -70°C pending to use.
Table 1 Buffer J.
50 mM Tris pH 8.0, 100 mM NaCl, 1 mM PMSF, 0.01% Sodium azide
Frozen cells were thawed and lysed by sonication as required. Cell lysates were 
clarified by ultra centrifugation at an RCF of 141000 g for 1 hour at 4°C. The mutant 
protease was isolated from the supernatant fraction by Talon IMAC chromatography 
(see Materials & Methods, page 159) following the manufacturers (Clonetech) 
recommended protocol. The eluted protease solution was then supplemented by 
addition of EDTA and DTT, each to a concentration of 1 mM, and reduced in volume 
using an Amicon pressure cell prior to further purification by SE chromatography 
using an XK26/60 Superdex S200 column (Pharmacia). The final protease solution 
was dialysed into Buffer G (see Chapter 4, table 1, page 207), and its volume reduced 
by means of Amicon pressure cell, then Centricon 3, until a concentration of 
approximately 10 mgml'1 was achieved.
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Characterisation of the mutant homodimers.
PAGE and Western blot analysis.
Each of the two purified mutant proteases were analysed by SDS-PAGE and Western 
blots using anti-HIV-2 PR, and anti-histidine tag primary antibodies to ensure that 
they were the histidine tagged mutants of HIV-2 PR.
Solubility screen.
The mutant proteins were observed to form light precipitate during storage. A 
solubility screen was therefore carried out in order to establish solubility 
characteristics of the mutants compared with the native enzyme. The screen was 
carried out manually, but in principle used the method later described in Hinks et al. 
2003 (Hinks, Roe et al 2003). A buffer grid of 1 pi drops varying in pH (50 mM 
Phosphate pH 4 - 8) and NaCl concentration (0 - 1000 mM in 200 mM increments) 
was set up under paraffin oil in a 48 well microtitre plate. An equivalent volume of 
the protein to be analysed was then dispensed into each well and mixed with the 
contents. The droplets formed were then observed using a light microscope (set to 
dark field illumination) to determine the extent of precipitation, if any, in each well. In 
this way the optimal and pessimal conditions for protein solubility could be 
established in terms of the pH and salt content of its buffer. An initial observation was 
made immediately after dispensing the protein, and a subsequent observation was 
made after 24 hours at 14°C.
Activity assay.
Chromogenic substrate VII (Bachem) was used to assay each mutant for possible 
proteolytic activity (method as described in Chapter 2, General Materials and 
Methods, Protease assays, Kinetic analysis of proteases, page 164).
Formation and detection of the mutant heterodimer
The methods by which formation of this heterodimeric mutant was attempted are 
described below. In each case, activity was assayed by means of chromogenic 
substrate (See Chapter 2, General Materials and Methods, Protease Assays, Kinetic 
analysis of proteases, page 164). The SPA assay would have been more suitable for 
the detection of heterodimer formation. However, this option was no longer available 
in our laboratory at the time of experimentation.
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Simple mix method
The pure mutant homodimers (in solution at 2 mg/ml) were mixed in approximately 
equimolar amounts, and 10 pi of the mixture was added to 1 ml of the activity buffer, 
at 37°C in the presence of chromogenic substrate (a baseline absorbance for buffer 
and substrate at 300 nm having previously been established). A reduction in 
absorbance at 300 nm was indicative of substrate cleavage. The presence of 
heterodimer with the desired papain active site would thus be detected as proteolytic 
activity.
Initial measurements were carried out over a period of 180 seconds, and subsequent 
readings were taken after 20 hours. Since it was anticipated that heterodimer 
formation might be a slow process, the long incubation was intended to detect the 
cumulative effect of any substrate cleavage that may occur.
Refolding method
Each of the homodimers was separately dialysed into buffer G supplemented with 8 
M urea to produce two solutions containing the denatured mutant monomers.
Approximately equivalent molar amounts of the two denatured monomer solutions 
(each 2 mg/ml) were mixed, and the mixture was then dialysed back into non­
denaturing buffer G (i.e. not supplemented with urea) to refold the mixed proteins. 
The refolded proteins were then assayed for proteolytic activity as described above.
Assay conditions
Activity assays were carried out at conditions optimal for both HIV-2 PR, and papain. 
A pH range between 4 and 8 was investigated, in conjunction with salt concentrations 
of 0 and 1 M NaCl. Sodium acetate (100 mM) buffer was used for solutions at pH 4 
and 5, whilst 100 mM phosphate was used to buffer solutions between pH 6 and 8 
inclusive. DTT was incorporated into all buffers at a final concentration of 1 mM, and 
freshly prepared protein was used for all the assays. The effect of temperature was not 
investigated, and 37°C was used in all cases.
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RESULTS AND DISCUSSION
Mutagenesis
A number of mutagenesis systems were considered and attempted without success 
during the preliminary stages of this work, among them the Recombinant Circle 
method (Jones and Howard 1990) and the ‘Altered Sites’ mutagenesis system, by 
Promega. Finally the ‘QuickChange Site Directed Mutagenesis’ method was 
employed following several personal recommendations, supporting the assertion by 
Stratagene that it was indeed a “reliable means to conduct site-directed mutagenesis” 
(QuickChange manual, Stratagene). Generally the Stratagene protocol was observed 
throughout (as described in Chapter 2, Site Directed Mutagenesis, page 129) however, 
there was no necessity to purchase the kit itself. All the enzymes required, such as Pfu 
DNA polymerase (selected for its fidelity and proof reading ability) and Dpnl 
restriction endonuclease (used to remove the original template DNA), could be bought 
more cheaply elsewhere (see Chapter 2, page 123, Suppliers of reagents and 
commercial enzymes; and the List of suppliers, Appendix, page 325). The Stratagene 
mutagenesis protocol utilises only 16 amplification cycles in order to minimise non­
specific mutations, consequently the PCR product yield is low. This necessitates the 
use of super competent E.coli cells (XL 1-Blue), and these were produced following 
the method previously described (see Chapter 2, page 139, Transformations, 
Preparation of super competent cells). Potential mutants were screened by Agel 
digestion followed by ABI sequencing of clones positive for the restriction site (fig. 
10).
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Figure 10 Sequencing confirm ed the successful m utagenesis o f  HIV-2 PR.
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ABI sequencing confirmed the successful mutagenesis o f HIV-2 PR.
The native active site Asp 25 residue was changed to Cys in the D25AC25 mutant (top), 
and to His in the D25AH25 mutant (bottom).
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Expression and purification
Here 0.1 mM IPTG was used at an induction temperature of 16°C, ensuring a slow 
expression rate. This was observed to improve yields of the soluble protein, 
presumably reducing the rate of expression allowed the protein time to fold correctly. 
Figure 11 shows expression of the mutant proteases as visualised by SDS PAGE.
Figure 11 SDS-PAGE analysis of HIV-2 mutant expression in E.coli.
1 2  3 4  5 6  7 8
1 2 3 4 5 6 7 8
Marker -  Insoluble -  Soluble - Whole Lysate -  Empty - Insoluble -  Soluble - Whole Lysate 
M  Cys mutant ---- ► M----  His mutant ---- ►
-► = Mutant HIV-2
In both cases it was observed that there was a significant improvement in yield over 
native HIV-2 PR preparations, however it was also noted that the expression levels 
were higher for the C25/C25 mutant than for the H25/H25 mutant. This was 
particularly apparent when the results from the IMAC purification step for the two 
mutants were compared (fig. 12). The purification process for each mutant was the 
same (IMAC followed by Size Exclusion), and consequently the SDS-PAGE analyses 
of each step are shown for the Cys mutant only (figs. 14 and 16).
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Figure 12 Comparison of IMAC data for the HIV-2 PR mutants.
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The above figure shows chromatographs obtained from IMAC purification of both 
H25/FI25 and C25/C25 mutants (top and bottom respectively). Cell cultures were 
prepared in the same way in both cases, equivalent volumes of cell lysate were loaded 
and the identical column and instrumentation was used for both runs. A comparison of 
the chromatographs shows that twice as much protein from the C25/C25 lysate bound 
to the Talon resin compared with the H25/H25 lysate. This reflects the PAGE results, 
and suggests that in this system expression of the C25/C25 mutant is favoured over 
expression of the H25/H25 mutant.
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It has for some time been accepted that retroviral proteases are - by virtue of their 
proteolytic activity - toxic to cells in which they are expressed, and that this toxicity is 
responsible for the poor yields observed (Rangwala, Finn et al. 1992; Stebbins and 
Debouck 1994; Gustafson, Junger et al. 1995; Wan and Loh 1995). The improved 
expression observed here might therefore be attributable to the disruption of 
proteolytic activity by mutagenesis.
However, the difference in expression levels between the constructs is harder to 
explain, and suggests an additional factor or factors effecting protease expression in 
E.coli. It may be that toxicity is a major cause of poor protease yields, but the results 
presented here, and in Chapter 6 suggest that this is probably not the only influence. 
The presence of codons which are rare in E.coli would also explain poor expression 
levels (this is discussed at length in Chapter 6). The comparison of codon usage 
between the native and mutant proteases (fig. 13) illustrates that the HIV-2 PR active 
site Glycine is encoded by a rare codon (GGA) in the native enzyme that has been 
optimised in the mutants. Similarly the less frequent Threonine codon (ACG) also 
found in the native enzyme has also been optimised, raising its frequency from 
approximately 10% to about 40%. The native protein contains five rare Glycine 
encoding codons (see Chapter 6 fig. 20) and they are the least frequent of the protein’s 
codons. The elimination of one such rare codon, plus the optimisation of the 
Threonine codon may be expected to have a beneficial effect on expression levels of 
the HIV-2 PR mutants. This combined with the elimination of proteolytic activity 
would explain the improved expression of the mutants. However, since the mutants 
differ by only a single amino acid, and since the codon selected to encode for the new 
amino acid was optimised for E.coli expression, this is not a likely explaination for 
the difference in expression between the two mutants.
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Figure 13 C om parison o f codon usage for HIV-2 native and m utant PR.
Codon usage analysis of the mutagenesis primers.
Produced using “E. coli C odon U sage  A n a lysis  2.0" by M orris Maduro.
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Figure 14 SDS-PAGE of IMAC fractions for HIV-2 PR Cvs mutant.
21 kDa
14 kDa
HIV-2 PR Cys mutant
1. Novex Mk 12 size standards
2. Whole soluble lysate.
3. Flowthrough.
4. 10 mM imidazole wash.
5. 6 and 7. Eluted mutant protease.
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Figure 15 C hrom atographs follow ing size exclusion chrom atography.
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Chromatographs obtained using a Superdex S200 Column, and superimposed.
Black Size standards (values in kDa)
Blue HIV-2 PR Cys mutant
Red HIV-2 PR His mutant
Each mutant eluted with a retention volume equivalent to a protein of approximately 22 kD, suggesting 
that they were both dimers in solution.
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Figure 16 SD S-P A G E  o f fractions follow ing size exclusion chrom atography.
Stds (kD ) Lane num bers.
Possib le HIV-2 PR Cys HIV-2 PR Cys m utant
m utant aggregate.
HIV-2 PR mutants eluted from the Superdex S200 column with a retention volume consistent with a 
protein of approximately 22 kD, and ran at approximately 11 kD on a denaturing gel (lanes 9-12), 
suggesting that they were dimeric. There was also some evidence o f possible aggregation, since trace 
amounts o f protease were visible in earlier fractions (lanes 4-8). This was especially true of the His 
mutant.
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Figure 17 SDS-PAGE of purified and concentrated mutant HIV-2 PRs.
PR
HIV-2 PR Cys mutant HIV-2 PR His mutant
Lanes 1 and 2 Cys mutant
Lanes 3 and 4 His mutant
Lanes 1 and 3 pooled fractions following final purification step
Lanes 2 and 4 pooled fractions after concentration
The His mutant appears less pure once concentrated than the Cys mutant. This is 
primarily because the degree of concentration for the His mutant was two-fold greater 
than that of the Cys mutant in order to achieve an approximately equivalent final 
concentration. As a result the contaminants present in both appear more prevalent in 
the His mutant preparation.
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Characterisation of the mutant homodimers.
Each of the two mutants ran on a coomassie stained SDS-PAGE gel (figs. 14, 16, 17) 
at a size of approximately 11 kD. When analysed by Western blot both mutants cross­
reacted with anti-HIV-2 PR antibody (fig. 19), and with anti-Histidine tag antibody 
(fig. 18).
Figure 18 Western blot of Histidine tagged mutant HIV-2 proteases.
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Cys mutants 
8 9 10
Primary antibody = anti His tag
1. Seeblue plus 2 prestained markers
2. Positive control His tagged protein
3. Negative control E.coli lysate
4. DAH HIV-2 PR (whole lysate)
5. DAH HIV-2 PR (soluble fraction)
6. DAH HIV-2 PR (insoluble fraction)
7. Unused lane
8. DAC HIV-2 PR (whole lysate)
9. DAC HIV-2 PR (soluble fraction)
10. DAC HIV-2 PR (insoluble fraction)
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Figure 19 M utants cross react with HIV-2 PR specific antibody.
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The presence of a histidine tag, as demonstrated by the purification procedure and 
western blotting, confirmed that there had been none of the autocatalytic cleavage 
characteristic of active retroviral proteases at the N-terminal. Neither mutant exhibited 
any proteolytic activity when assayed in isolation, even when present in high 
concentration, confirming that all HIV-2 PR activity had been knocked out (illustrated 
in fig. 20).
Figure 20 Chromogenic assay of homodimeric mutants illustrating inactivity.
m v-2 Mutants Assay
. ■-, .WI
Tim e (s e c )
Blue (top) = Cys mutant A constant absorbance with time in all
Black (middle) = His mutant cases indicated inactivity.
Light blue (bottom) = substrate alone
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HIV-2 PR mutant homodimers are less soluble than the native PR.
The mutants were overexpressed in both the soluble and insoluble fractions, though
only protein from the soluble fraction was purified for analysis. However, during 
storage (or sometimes as a result of dialysis) the mutant proteins had a tendancy to 
precipitate out of solution. This had not been observed with the native HIV-2 PR. 
Oxidation of the active site cysteine may be implicated in precipitation of the 
C25/C25 mutant homodimer, but could not explain precipitation of the H25/H25 
homodimer. A solubility screen was carried out (figs. 21 and 22), and this 
demonstrated that the mutants were significantly less soluble at low pH conditions (ie. 
between pH 4 and 6) than the native protease. This range incorporated the pH 
conditions under which native enzyme activity would normally be seen, and 
precipitation was even observed in the HIV-2 PR activity buffer routinely used for 
native assays.
It was also noted that neither of the mutant homodimers could be crystallised using 
the optimal conditions for the native HIV-2 PR. The single amino acid change buried 
within the PR active site was not expected to have very much effect on solubility or 
crystallisation, and yet it did. The results may indicate a change in the protease 
conformation following mutation, or perhaps that the mutants failed to fold correctly 
thus exposing hydrophobic residues and resulting in reduced solubility.
HIV-1 PR has been investigated for the presence of cooperative folding units 
(Wallqvist, Smythers et al. 1998), defined as “structural units that exhibit a relatively 
stronger protection against unfolding than do other parts of a given molecule” 
(Wallqvist, Smythers et al. 1998). Wallqvist et al. have identified a folding core 
within HIV-1 PR consisting of the following spatially close sets of residues 22-32, 74- 
78, and 84-91. Mutations seen in HIV-1 PR, occuring either naturally or as a result of 
induction by drug therapy, are predominantly (if not exclusively) within regions not 
essential to the structural stability of the protein (ie. not within the folding core 
regions). The consequence of mutations within the folding core regions would be 
structural instability and a resultant loss of activity, thus they could not persist in vivo. 
It is reasonable to expect that similar folding core regions are present in other 
retroviral proteases, such as HIV-2 PR.
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Figure 21 Solubility screen results at tim e zero.
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Figure 22 Solubility screen results after 24 hours.
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The active site residues are numbers 25, 26 and 27 (DTG in the native HIV-1 and 2 
proteases, or in the HIV-2 PR mutants HTG and CTG respectively), which puts them 
within one of the folding core regions. It is possible therefore, that in creation of the 
active site mutants an HIV-2 PR cooperative folding unit has been disrupted, 
rendering the mutant proteases less likely to fold correctly. This may provide an 
explaination for the relatively high levels of mutant protease observed in the insoluble 
fraction of the cell lysates. It might also explain their reduced solubility and tendancy 
to precipitate from solution. The analysis by SDS-PAGE of fractions eluted following 
size exclusion chromatography suggested the presence of some aggregated protein; 
however, the bulk of soluble protein appeared to be dimeric. It therefore appears that a 
large proportion of the mutant protein was able to fold and dimerise, but that it was 
less stable than the native protein and with time the disrupton to the folding core 
caused further aggregate to form resulting in the precipitation observed.
Localised disruption within the folding core could very likely explain the lack of 
activity seen on attempted formation of the heterodimeric C25/H25 mutant protease. 
Minor local misfolding might prevent the anticipated positioning of Histidine and 
Cysteine relative to each other within the heterodimer, without necessarily having a 
gross effect on the protein’s folding as a whole. Consequently mutant monomer 
subunits would still be able to dimerise, but the intended formation of a papain active 
site would not occur. Indeed the formation of the active site cleft may also be 
disrupted with the result that substrates cannot bind.
It is also possible that such disruption of the 22-32 folding core could prevent the 
mutants adopting the native HIV-2 PR conformation altogether. In this event 
dimerisation would not occur, and instead a non-functional, misfolded peptide or 
aggregate would result. The size exclusion chromatography results showed some 
evidence of aggregation, suggesting a gross effect on folding (and hence on 
dimerisation) did result from mutagenesis a proportion of the time. However, since 
the results also demonstrated the presence of dimer, it seems that predominantly any 
misfolding was sufficiently slight and localised that gross disruption did not occur and 
dimerisation remained possible.
However, further experiments would be required to determine whether the mutants 
are misfolded. Analysis by means of Circular Dichroism (CD) would be desirable,
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since this would allow investigation of the mutant protein secondary structure. CD 
spectra for each homodimer could be compared with spectra for the native enzyme to 
establish whether or not the mutants were folded protein or misfolded soluble 
aggregates. Alternatively ID NMR spectra could be used for the same purpose.
Formation and characterisation of the mutant heterodimer
The mutagenesis resulted in only a single amino acid change in a region not related to 
dimerisation. Consequently it was anticipated that the two mutant proteins would be 
expressed in homodimeric form, just as observed for the native protein. Thus for the 
D25AC25 mutant the expressed protein would be a homodimer of C25/C25, while the 
D25AH25 mutant would be expressed as an H25/H25 homodimer. Neither form of 
mutant homodimer was expected to possess activity. However, in solution the folded 
dimeric protein probably exists in a dynamic equilibrium with unfolded monomeric 
protein (Grant, Deckman et al. 1992) consequently in a mixed solution of the two 
mutant homodimers an exchange of monomers should occur with time. This would 
result in the formation of some C25/H25 heterodimer. This phenomenon of monomer 
exchange has been exploited to inhibit HIV PR activity via the addition of a defective 
monomer to a protease solution (Babe and Craik 1991; Babe, Pichuantes et al. 1991; 
McPhee, Good et al. 1996). Any C25/H25 heterodimer formed would have the 
catalytic residues of papain in its active site and may thus possess detectable 
proteolytic activity.
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Assay results for simple mix and refolding methods.
Assays were carried out (as described in Chapter 2, page 164) both in HIV-2 PR 
activity buffer, and in buffers over a pH range from 4 to 8 and with NaCI 
concentrations of 0, and 1000 mM. The simple mix and refolding methods were both 
investigated. No activity (as indicated by a reduction in absorbance with time at X = 
300 nm) was seen under any of these conditions during the first 60 - 180 seconds 
following mixing. Figure 23 shows the result obtained using HIV-2 PR activity 
buffer, and it can be seen that there was no reduction in absorbance throughout the 
period of the assay. This was typical of all the conditions tested, and indicates that 
there was little or no protease activity present. In order to detect any trace activity that 
may have been present, and also to allow time for heterodimerisation to occur, the 
samples were incubated at 37°C overnight and the absorbance at X = 300 nm was 
recorded for each assay mixture both before and after incubation. Protease activity 
would have resulted in a decrease in absorbance over this time, however, no such 
decrease was seen under any of the conditions tested (fig. 23 and Appendix, tables 6- 
8, pages 348-351). During the refolding process homo and hetero dimerisation was 
expected to occur. Given an equimolar mixture of the homodimers, and given that 
homo and heterodimerisation are equally likely, it was anticipated that about half the 
dimers formed would be C25/H25 heterodimers. Consequently if the heterodimer was 
truly active, that activity ought to be present in the resultant refolded solution. 
However, no activity was detected.
265
Figure 23 C25/H25 mutant heterodimcr assay results.
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The absence of detectable activity suggested either that any heterodimer formed was 
inactive, or possibly that the mutations prevented the intended heterodimer from 
forming (perhaps by disrupting the refolding process in some way). The formation of 
disulphide bonds between the Cys25 residues of the Cys mutant would have made 
homodimerisation of the Cys mutant more favourable than heterodimerisation. This 
undesirable situation was prevented by inclusion of 1 mM DTT in all buffers used.
Assay conditions
An optimum assay condition was not established since no activity was detected. If we 
assume that a heterodimer was formed, it was not active under the conditions 
favoured by native HIV-2 PR (fig. 23). It was anticipated that any heterodimer formed 
might be active in conditions preferred by papain -  which includes a broad range of 
pH. However, a range of pH and salt conditions failed to elicit any signs of activity 
from mutant mixtures (fig. 23). Had activity been detected it would have been 
interesting to try to inhibit it using pepstatin and E64 (specific inhibitors of aspartic 
and cystein proteases generally).
The results suggest either that heterodimer formation did not occur, or that the 
heterodimer formed but was inactive. Given that a heterodimer was formed, the lack 
of activity observed could be interpreted in a number of ways. For example it may 
indicate either that an additional co-factor is required (an unlikely scenario since 
neither papain nor HIV-2 PR require co-factors), or that the heterodimer is not active 
at 37°C (also unlikely given that both HIV-2 PR and papain are active at 37°C). More 
realistically it may be that the heterodimer does not share the same substrate 
specificity as native HIV-2 PR (perhaps mutation of the active site has disrupted 
substrate binding), or possibly the correct spatial configuration of Histidine with 
respect to Cysteine has not been achieved and thus a functional papain-like active site 
is not present. The exact nature of any heterodimer formed could be determined from 
a crystal structure — assuming a crystal and X-ray data could be obtained. However, 
this would require the ability to separate homodimers from the heterodimer prior to 
crystal growth, and would also rely on the stability of the heterodimer during 
crystallisation. If either homodimer crystallised more readily than the heterodimer
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then equilibrium in the crystal drop would shift in favour of homodimer crystal 
formation.
Another possibility is that the heterodimer was formed, and that it would have been 
active, but that activity was not seen due to oxidation of the thiol group during 
purification and subsequent analysis. However, DTT was used during preparation of 
the Cys mutant (except during the IMAC step) in order to minimise oxidation. Also 
oxidation is gradual so that any activity would have diminished with time, 
consequently some activity should have been detected even if oxidation was a 
problem since assays were carried out using freshly made protein.
The results can of course be explained if the intended His-Cys heterodimer was never 
formed. Two approaches to the formation problem were considered - first the mutants 
were simply mixed in equal quantity and assayed for activity; second they were 
denatured in urea, mixed in their denatured states then refolded together. The first 
approach relied on a natural dynamic equilibrium existing between the dimeric state 
and the monomeric state, the presence of such equilibrium has been exploited in the 
use of dominant negative mutations to form inactive HIV PR heterodimers (Babe, 
Pichuantes et al. 1991; McPhee, Good et al. 1996). Consequently a mixture of the 
mutant homodimers should eventually yield a mixed population of mutant homo and 
heterodimers due to monomer exchange. However, investigation of this equilibrium 
suggests that it conforms to a two-state model in which folded dimers are in 
equilibrium with unfolded monomers (Grant, Deckman et al. 1992). In such cases 
protein unfolding and dimer dissociation are concomitant processes, and the folded 
monomer cannot exist (Bowie and Sauer 1989). Given the inherent stability of the 
native dimer it seems probable that the homodimeric state would persist in preference 
to the unfolded monomer thus this exchange method would tend to be a particularly 
slow and inefficient means of generating the heterodimer. This concern, coupled with 
the experience o f refolding native proteases with relative ease, lead to investigation of 
the refolding method for generation of heterodimer. A similar method has since been 
adopted and described by Rozzelle et al. (Rozzelle, Dauber et al. 2000) for the 
characterisation o f HIV-1 PR based heterodimers.
An alternative solution to the problem of obtaining a heterodimer would have been to 
create a construct such that the two mutants were coexpressed from the same vector.
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The two genes could be positioned one immediately following the other in frame, 
with a short intervening region encoding a flexible linker of perhaps 5 or 10 residues. 
A heterodimeric form of retroviral protease consisting of monomers from HIV-1 and 
HIV-2 respectively has been created using a similar linked system (Bagossi, Cheng et 
al. 1996) (Bagossi, Cheng et al. 1998). In this way a monomeric enzyme could be 
created having the papain active site but otherwise resembling HIV-2 PR. It is 
conceivable that (if active) this monomeric form could cleave its own linker region 
and so revert to a dimeric form. Indeed this could be deliberately engineered by 
selecting an appropriate sequence for the linker region and might incidently provide a 
useful indicator of activity, since an SDS gel could be used to distinguish an inactive 
product (which would run at approx. 22 kD plus linker size) from active linker free 
dimer (which would migrate at approx. 11 kD). A linked heterodimer co-expression 
system would probably represent the best method of ascertaining whether or not such 
a heterodimer is active. One drawback of these co-expression methods might be that 
(if active) the mutant heterodimer could prove to be just as cytotoxic as the native 
protease, and would not therefore be over-expressed to any great extent by the host 
cells.
In order to maintain the advantage of separate expression in terms of cytotoxicity, and 
yet confirm heterodimer formation in the absence of detectable activity, it would be 
necessary to differentially label or tag the monomers in some way. An option might 
be to His tag the Cys mutant whilst fusing the His mutant to Glutathione S-transferase 
(GST) for example, it may then be possible to isolate a heterodimer from solution by 
sequential purification steps. Fluorescent or perhaps radiolabelling of the respective 
mutants could also be used to detect heterodimer formation. Biacore experiments 
using a Ni-NTA chip with a His-tagged mutant versus a non His-tagged mutant could 
be used to detect and measure the extent of any heterodimerisation, and conceivably 
even to isolate small quantities of heterodimer by elution from the chip.
An alternative to the mutagenesis of HIV-2 PR would have been to mutate Papain. 
Changing Papain's catalytic Cys and His residues to Asp could achieve a similar goal,
i.e. the conversion of the pro tease’s mechanism to that of another class of protease by 
mutagenesis o f the active site residues alone. Papain could be overexpressed in E.coli 
(or baculovirus) as ProPapain and subsequently activated, thus obviating problems of 
toxicity. Papain is monomeric, consequently there would be none of the problems
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associated with generating a heterodimer. Without Cys as a catalytic residue the 
mutant Papain should not be subject to rapid loss of activity due to oxidation. Whether 
or not such mutagenesis would disrupt the folding of Papain is not clear, and this 
might prove to be the major obstacle to success. It is nevertheless an intriguing 
possibility.
SUMMARY
The mutants were successfully constructed, expressed, purified and characterised. As 
expected neither homodimeric mutant showed any proteolytic activity. Unfortunately 
no activity was detected on combination of the two different mutants either. The 
possibility that there was little or no dynamic equilibrium between the dimeric, 
monomeric, and heterodimeric state was considered; and the mutants were mixed 
while unfolded, and then refolded in the presence of substrate. No proteolytic activity 
was detected during these refolding studies. The possibility that the heterodimer was 
active under different buffer conditions (pH and salt) from the native enzyme was also 
investigated. Assays carried out using a range of possible conditions failed to detect 
any activity, despite the fact that papain is active over a broad range of conditions.
It was concluded that either the heterodimer is not easily formed, or that it has been 
formed but is not active. A more precise explaination would require further work, and 
potential actions were discussed.
The belief that retroviral proteases are toxic to cells in which they are expressed, and 
that this explains the poor yields observed has been questioned by the results of this 
chapter, and in particular by the difference in expression levels between the mutants. 
Results presented in the next chapter (Chapter 6) also suggest that there may be other 
influencing factors to consider. Eliminating toxicity was the primary aim in 
constructing an S I V agm  PR expression system during attempts to express this 
protease for structural studies. The results were suprising, and lead to the investigation 
of codon useage as a primary cause of low S IV agm PR yields, and a possible cause of 
low retroviral PR yields generally.
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Chapter Six: UDG-SIVAgm Protease Fusion.
Development of an E.coli based protease expression system and 
preliminary crystaiiographic studies of the SIVAGM Protease.
INTRODUCTION
The relationship between HIV and SIV.
The Simian Immunodeficiency Virus (SIV) is a species of lentivirus, closely related 
to HIV (Fig. 2, Chapter 1, page 26), which naturally infects wild monkeys (Kanki, 
Alroy et al. 1985; Ohta, Masuda et al. 1988). SIV is the closest known relative of 
HIV in terms of genetic, biological and antigenic similarities, making it suitable for 
the study of the pathogenesis of HIV infection, and for the development of vaccines 
(Kurth, Kraus et al. 1988). Subspecies of SIV have been isolated from a variety of 
primates. These include the mandrill, the rhesus macaque and the African green 
monkey -  which each harbour distinct (i.e. primate species specific) forms of SIV, 
designated S I V m nd , S I V mac and S I V agm  respectively.
The S IV mac (Chakrabarti, Guyader et al. 1987) and S IV agm [TYO-1] strain 
(Fukasawa, Miura et al. 1988) genomes have been sequenced as have those of HIV-1 
[BRU] isolate (Wain-Hobson, Sonigo et al. 1985) and HIV-2 [ROD] isolate 
(Guyader, Emerman et al. 1987). They have also been compared with each other in 
terms of genomic organisation (Fukasawa, Miura et al. 1988). Comparison of these 
genomes has revealed that the S I V mac is more closely related to HIV-2 than to HIV-1 
(Chakrabarti, Guyader et al. 1987; Franchini, Gurgo et al. 1987). In contrast it has 
also been shown that S IV agm  is equidistantly related to both HIV-1 and HIV-2, and 
quite dissimilar to S IV mac (Fukasawa, Miura et al. 1988). It seems likely that these 
lentiviruses have diverged as their primate hosts evolved, and are now species specific 
(Fukasawa, Miura et al. 1988). In the case of HIV-1 and HIV-2 they have diverged 
from a common ancestor whilst maintained within separate isolated human 
populations.
SIV provides an animal model for HIV and AIDS.
Animal models are in use for the study of vaccines and drugs -  studies on cats 
infected with FIV provide a small animal model (Schnolzer, Rackwitz et al. 1996),
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whilst Macaque monkeys infected with SIV have been used for some time in vaccine 
trials (Almond, Jenkins et al. 1992) and are an ideal model for testing a variety of 
anti-retroviral drugs (Tomasselli, Bannow et al 1992). The African Green Monkey 
provides an interesting model because S I V agm is present in a large proportion of wild 
African green monkeys, its natural host, yet the virus does not induce disease in them 
(Kraus et al. 1989, Allan 1991, Hartung et al. 1992, Hirsch and Johnson 1994, Norley 
1996). Consequently studies of the African green monkey / S IV agm  system may 
reveal the processes by which these monkeys remain unaffected by their parasite.
Other lentiviral proteases may provide an insight into the HIV drug resistance 
problem.
HIV has demonstrated an aptitude for the rapid development of resistance to drugs, 
and in particular to PR inhibitors (Ho, Neumann et al. 1995) (Gulnik, Suvorov et al. 
1995) (Condra, Schleif et al. 1995). It has been demonstrated that greater than a third 
of the HIV-1 protease sequence is subject to drug-induced mutations (Schinazi, 
Larder et al. 1997). While the respective structures of retroviral PRs are very similar, 
there remain sufficient differences in terms of their interactions with substrates and 
inhibitors to provide possible insights into the nature of drug resistance in general 
(Wlodawer, Gustchina et al. 1995) (Gustchina, Kervinen et al. 1996) (Powell, Bur et 
al. 1996) (Slee, Laslo et al. 1995). This has provided a rationale for studies of the 
various retroviral PR structures. Of the SIV proteases, to date only the S IV mac PR has 
been solved (Wilderspin and Sugrue 1993; Wilderspin and Sugrue 1994), the work 
described in this chapter concerns the production of the S I V agm  PR, for the purpose 
of future structural analysis by crystallography.
Problems associated with high-level expression of S IV a g m  protease.
The SIVagmPR gene was first cloned into several conventional expression vectors
with a view to improving over expression and purification of the SIV agm protease for 
X-ray crystallographic analysis. S I V agmP R  expression levels using these vector 
systems were extremely poor however, and the need for a new system of expression 
for the protease was recognised.
Development of a new protease expression system.
In pursuit of this aim a novel, E.coli based, retroviral protease expression system was 
developed and is described here. It was intended to be an improvement on existing 
systems in terms o f yields, whilst allowing simplicity of detection and purification of
272
the protease. The system was developed primarily to allow the expression of S IV agm 
PR, although it is applicable in principle to other retroviral proteases. Ultimately it 
could be adapted to provide the basis for a low cost, high yield solution to the 
problem of producing retroviral proteases for industrial and research use. It comprises 
a fusion construct able to produce the protease in an insoluble, inactive, and thus non- 
cytotoxic, form. It allows purification by a single IMAC step, followed by refolding 
to yield active native S I V agm  PR.
Following development of this system, codon usage was identified as the severely 
limiting factor in bacterial overexpression of this protease, and means by which this 
problem could be overcome are discussed.
The precise PR cleavage site within the S IV agm  POL polyprotein at the N-terminal of 
the protease was identified and its significance is discussed.
MATERIALS AND METHODS
E.coli strains used
JM109 was used for all DNA preparation, BL21 (DE3) pLys S was used for all 
protein expression, except, as indicated in the text, where BL21-CodonPlus-RIL cells 
were used (supplied by Stratagene). The RIL strain cells carry extra copies of the 
argU, ileY, and ileW tRNA genes. The tRNAs encoded by these genes recognise 
AGA / AGG, AUA, and CUA codons respectively, which are the rarest codons in 
E. coli.
Source of the S IV a g m  PR gene
Professor Masanori Hayami kindly provided the S I V agm  PR DNA template as a 
Bluescript phagemid. The phagemid incorporated an Xbal-BamHI subclone of a 
circularised S I V agm  molecular clone, containing the entire gag open reading frame 
(ORF) and the first 1000 bases of pol. The coding sequence for a precursor form of 
the S IV agmP R  (with extensions of 38 amino acids at the N-terminus and 2 6  amino 
acids at the C-terminus) was amplified from the phagemid by PCR, and inserted into 
the expression vector pMAL-cRl to produce the construct designated pACS28 (A. 
Shearer, unpublished). All subsequent constructs incorporated PCR amplified gene 
products generated using pACS28 (fig. 1) as the template. The pACS28 fusion 
product is shown in figure 2.
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Figure 1 Vector pACS28, encoding a fusion of the Maltose Binding Protein
and an extended precursor of the SIVagm PR.
PACS28
Polyl inker
region Stop codon
SIVagm PR precursor
pMAL-cRI parent vector
Figure 2 MBP-SIV u -m PR-nrecursor fusion product encoded by nACS28.
N Maltose Binding protein C
s---S S SVPGRGSIEG *P 5FPIRPSKEAPAA
ICRERETTEGAKEESTGNESGLDRGIF 
FEL PLWRRPIKTVYIEGVPIKALLDTG 
ADDTIIKENDLQLSGPWRPKIIGGIGG 
GLNVKEYNDREVKIEDKILRGTILLGA 
TPINIIGRNLLAPAVPRLVM GQLSEKI 
PVTPVKLKEGARGPCVR STOP
NB. the factor Xa recognition sequence =  IEGR/X
Light blue = extended SIV AGM PR precursor sequence
Dark blue = SIVagmPR sequence
Black = Polylinker encoded region
Green box = Factor Xa cleavage site
STOP = Stop codon
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Source of the E.coli Uracil DNA Glycosylase (£cUDG) mutant.
The pRsetB (Invitrogen) based plasmid pBU 107.1 was constructed and provided by
R.Savva (fig. 3). The use of a pRsetB based construct provided a strong T7 promoter 
and allowed single step purification of the expression product using an IMAC 
protocol. Further details of the pRset vector system, including a vector map and 
description of the poly linker region, are provided in the appendix (pages 340-341).
The £cUDG gene was amplified by PCR using the primers to generate Ncol and 
Hindlll restriction enzyme sites at the 5 and 3 prime ends respectively. The PCR 
product and pRsetB vector were each digested using Ncol and Hindlll, and ligated to 
produce the construct pBU 107.1. Expression studies revealed the EcUDG gene 
product to be unexpectedly insoluble, leading to the assumption that the PCR product 
used to construct pBU 107.1 was a mutant form of the £cUDG gene (R.Savva 
personal communication).
Plasmid DNA was prepared by Qiagen midi-prep, as described in Chapter 2 (page 
125). Plasmid pBU 107.1 was used both for the expression of the mutant EcUDG for 
control purposes, and as the basis for construction of the novel S I V agm PR fusion 
plasmid pMIRA6, described in this chapter.
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Figure 3 C onstruction o f plasm id nBU107.1
Ndel Nhel BamHI Ncol Hindlll
1
I r bs Q 6x His j 9 Epitope ~e k | MCS 1
pR setB
Ndel Nhel
pRsetB cut 
with Ncol & 
Hindlll
BamHI Ncol
K 1 1
\
PT7 ,| r bs 6x His Epitope EK
Ncol Esp3I Hindlll
EcUDG PCR 
product cut with 
Ncol & Hindlll
Mutant EcUDG
H indlll
Mutant EcUDG 
insetted into 
pRsetB
Ndel Nhel BamHI Ncol Esp3I Hindlll
l
| r bs 6x His Epitope EK Mutant EcUDG
pBU107.1
PT7 = T7 promoter region
ATG = Start codon
MCS = Multiple Cloning Site
EK = Enterokinase cleavage site
RBS = Ribosome Binding Site 
6 x His = PolyHistidine tag 
term = Stop codon
The Xpress Epitope allows detection by antibody.
The above figure shows the construction o f plasmid pBU 107.1 by insertion of a mutant E.coli 
UDG gene into the multiple cloning site o f the expression vector pRsetB via Ncol and Hindlll 
restriction enzyme sites.
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C onstruction o f  the E cU D G -SIV AgmPR  fusion vector, pM IR A 6.
Preparation o f the SIVAGM PR gene by PCR
The SIVagmPR gene was amplified by PCR using the pACS28 construct as a 
template, and the primers illustrated in figure 4. The SIV gene contained an internal 
Ncol site, preventing the use of this enzyme for cloning purposes. AfUII generates 
overhanging ends that are compatible with those generated by Ncol, thus 
incorporation o f an AfUII site into the forward PCR primer allowed insertion of the 
PCR product into any vector prepared with Ncol. Ligation of DNA ends prepared 
with AfUII and Ncol eliminated both parent sites in the process, but retained the 
original frame. The reverse primer incorporated a Hindlll site and a stop codon. This 
strategy was used for insertion of the SIVagmPR gene into all o f the various 
conventional expression constructs investigated, and whilst it could not be employed 
in construction of pMIRA6, the same primers were nevertheless used for amplification 
of the initial SIV gene product.
Figure 4 SIVagm PR PCR primers, as used to construct pMIRAf,
Forward prim er
5'GC
Clam p M ET L E U PH E Coding 3' GC clamp
5  r^CGCGClACATGTTATTCTTTGAACTCCCTCTTTGG 3 ' 
AfllH  ~  . x o pT m  = 66  C
R everse prim er
5' GC 
Clam p S T O P
5  fG C G C CXAG C T Ti\TA A T TG TC C C A TT A C TA A
T m  =  5 8°C
Coding 3' GC clamp
£ c g V
H i n d l l l
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The cloning strategy
The EcUDG gene contained an Esp3I site at a position 70 bp from the 3' end. This 
was the site selected for insertion of the S I V agm PR PCR product into pBU107.1. The 
cloning strategy is illustrated in figure 5. The plasmid pBU107.1 was first digested 
with Esp3I (from Fermentas) and exposed to Klenow in order to generate blunt ends. 
Next the distal 70 bp of the 800 bp UDG gene was removed by digestion with 
Hindlll. Meanwhile the S I V agmP R  gene PCR product was digested at the 5' end with 
AfUII, then exposed to klenow generating a 5' blunt end. The SIV gene was 
subsequently digested with Hindlll to provide a 3' overhang. Following their 
preparation both plasmid and insert were purified by band extraction from an agarose 
gel. The 350 bp S I V agm PR gene was then inserted by ligation into the UDG 
construct, such that the blunt 5' end of the SIV gene ajoined the blunt 3' end of the 
shortened UDG gene. The S I V agm PR gene was thus positioned in frame with the 3' 
end of the truncated UDG gene so that uninterupted read-through would occur during 
translation. The procedures for digestion, use of klenow, and ligation are described in 
Chapter 2 of this thesis (see DNA manipulations, pages 134-137).
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Figure 5 The construction o f pM IR A 6.
The SIVAgm PR PCR product and pBU 107.1 were prepared as described in the text. The SIV 
gene was then inserted into the plasmid downstream and in frame with the recently truncated
EcUDG gene.
Ndel Nhel BamHI N col Esp3I Hindlll
1 1 1 1
^|r b s g  6 x  H is E pitop e EK M utant E cU D G
■
blunt with J 
Klenow, cut 
with Hindlll.
N col Blunt Hindlll
N'
| | r b s 6 x  His E pitope EK □ M utant E cU D G
Blunt
Cut PCR product
with AfUII, blunt
, , .  . , , ,  with Klenow, cut
H indlll ... .... . .  . . . .  with Hindlll.
I Blunt Hindm
I I AfUII Hindlll
AfUII Hindlll
SIV  . r, ,P R
"
SIV  „  ,.P R
Ligate.
Ndel Nhel BamHI N col
PT7 J R B S E H S 6 X E pitop e EK M utant E cU D G
Hindlll
SIV  ..-..P R  term
PMIRA6
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Isolation of clones containing the desired UDG-SIVfusion construct.
Transformation of E.coli JM109 cells with DNA of the final construct resulted in
numerous colonies which were screened for presence of the correct insert by the 
following methods: -
1. Restriction digest with Ncol, to yield two bands at 3.1 kb and 0.78 kb where 
the SIV-PR gene was present, or a single 3.6 kb band in the case of uncut or 
religated vector (illustrated in fig. 6 and results shown in fig. 12).
2. PCR amplification of the SIVagm PR gene, if present13 (results, fig. 13).
3. Direct sequencing of the DNA construct using a Pharmacia T7 sequencing kit 
and the SIV-PR 3' PCR primer (results, fig. 14).
Double restriction digest with both Ndel and Hindlll was not used as a screen since 
the correct construct would yield two bands of 2.8 kb and 1.0 kb, whilst uncut or 
religated pBU107.1 would yield two bands of 2.8 kb and 0.8 kb. These two results 
may have proved difficult to distinguish. Competent cell production, transformations, 
restriction digests, PCR reactions, agarose gel electrophoresis and DNA sequencing 
procedures were all carried out as described in Chapter 2 (see pages 138, 141, 134, 
128, 134, and 130 respectively).
l3Using primers described in figure 4 of this chapter.
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Figure 6 N col d igests indentified  the correet nM IR A  construct.
Ndel Nhel BamHI Ncol Esp3I Hindlll
PT7 J R B S H E  6 x  Hisl
1 1 1
Epitope EK □ Mutant EcUDG
PBU107.1
Digest pBU 107.1 with Ncol
Ndel Nhel BamHI Ncol Ncol Esp3I Hindlll
PT7
1 1
RBS 6x His Epitope EK
1
Mutant EcUDG
Digest results in linearised plasmid, seen as a 
single 3.6 kb band by electrophoresis.
Ndel Nhel BamHI Ncol Ncol Hindlll
PT7 J R B S i l E  6 x  Hisl
| 1 1 1
Epitope EK H Mutant EcUDG
PMIRA6
Ndel Nhel BamHI Ncol
PT7
1
| [ r b s 6 x  His Epitope EK □
Ncol
Digesting pMIRA6 with Ncol results in 
release of a 0.78 kb excerpt due to the 
presence of an internal Ncol site in
srvAGM pr.
Ncol
Ncol
Hindlll
E
Mutant EcUDG ]
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Small scale expression screens.
These were carried out as described in Chapter 2, using the BL21 (DE3) strain and 
BL21 (DE3) Codon-Plus-RIL strain.
Expression and purification of the mutant EcUDG control protein.
The mutant EcUDG was overexpressed in E.coli strain BL21 (DE3), containing the
pBU 107.1 plasmid. Cultures (1 litre) were prepared, grown (at 30°C), induced, and 
harvested as described in Chapter 2 (page 147). Cells were resuspended in 50 mM 
Tris pH 8.0, 100 mM NaCl and stored at -20°C pending use. Cells were thawed on ice 
to lyse (exploiting the activity of lysozyme encoded by the pLys S plasmid) and a 
brief sonication step reduced viscosity and ensured complete lysis (Chapter 2, page 
151). The lysate was clarified by ultracentrifugation at an RCF of 141000 g for 1 hour 
at 4°C. The clarified supernatent was discarded and the pellet fraction was briefly 
washed by resuspension in 50 mM Tris pH 8.0, 100 mM NaCl to remove any residual 
soluble protein, and re-pelleted by ultracentrifugation as before. Insoluble proteins in 
the pellet were dissolved by rotary incubation at 4°C overnight in 50 mM Tris pH 8, 
100 mM NaCl, containing 8 M deionised urea. Stubborn lumps of undissolved pellet 
were dispersed by brief sonication. Undissolved material was removed by 
ultracentrifugation at an RCF of 141000 g for 1 hour at 4°C, and the clarified 
supernatent was retained for loading onto a 50 ml histidine binding IMAC column 
pre-equilibrated in the same Tris / urea buffer. Purification by IMAC was carried out 
(see Chapter 2, page 159), with 8 M deionised urea present in all buffers. Urea was 
the chosen chaotrope in preference to guanidium HC1 on grounds of reduced cost. The 
flow through, wash and elution peaks were collected for analysis by PAGE.
Analysis of the mutant EcUDG’s susceptibility to cleavage by PR.
An aliquot (10 pi) of the pure mutant EcUDG was micro-dialysed (chapter 2, page
158) against each of the HIV-1 and HIV-2 PR activity buffers at 4°C overnight. 
Following dialysis they were transferred to eppendorfs, and 1 pi of the appropriate 
HIV PR was added to each aliquot. An additional aliquot was also dialysed against 
HIV-1 PR buffer, but no HIV enzyme was subsequently added to it. This tube acted as 
a control. The tubes were then incubated at 37°C overnight. The EcUDG was 
subsequently assessed for signs of degradation by Western blotting (Chapter 2, page 
153) using primary antibodies raised against the N-terminal 6x histidine tag present 
on the EcUDG (fig. 8).
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Expression and purification of the mutant £ cUDG-SIVAG\i PR fusion protein.
Large-scale (8 L) shake flask cultures were grown at 30°C, induced and harvested as
for the mutant EcUDG protein (above). Cell lysis, preparation of insoluble protein 
from the pellet fraction, and subsequent IMAC purification of the fusion protein were 
also carried out as described above for the mutant EcUDG protein (results fig. 19).
Concentration of the mutant EcUDG-SIVAG\ i PR fusion after IMAC.
The fusion protein was concentrated by removal of chaotrope through a “cold refold”
dialysis step. This concentration procedure exploited the fact that an aspartic protease 
would be inactive at pH 8 and 4°C, and thus unable to release itself from the fusion 
protein under these conditions even if it refolded. The precipitated fusion protein was 
then harvested and redissolved in a reduced volume of the original chaotropic buffer.
The eluent from the IMAC step (containing the mutant EcUDG-SIVagm PR fusion in 
50 mM Tris pH 8 containing 8 M urea, 100 mM NaCl, and 300 mM immidazole) was 
dialysed against 50 mM Tris pH 8 containing 100 mM NaCl, 1 mM EDTA, at 4°C 
overnight. The insoluble fusion protein dropped out of solution as the urea was 
removed and was then collected by ultracentrifugation at an RCF of 141000 g for 1 
hour at 4°C. The pellet was redissolved in a small volume (approx. 5 ml) of 50 mM 
Tris pH 8 containing 8 M urea.
Concentrating the fusion in this way prior to warm refolding maximised the efficiency 
of subsequent proteolytic cleavage. An additional benefit of having two refolding 
steps (cold and warm) was the removal (during the cold step) of any insoluble 
proteins that may otherwise have refolded in concert with the protease and 
contaminated the final preparation of soluble protease.
Autocatalytic cleavage and release of the SIVAG\i PR from within the fusion, by 
warm refolding.
The concentrated fusion protein solution in urea, resulting from the steps above, was 
dialysed against 50 mM Sodium acetate pH 4.5, 100 mM NaCl, 10% glycerol, 1 mM 
DTT, 1 mM EDTA at 37°C for 2 hours. As the urea concentration subsided a 
precipitate formed and was removed by centrifugation for analysis by SDS-PAGE. 
The supernatent solution following dialysis contained the refolded, active protease. 
The pure SIVAGm PR was concentrated by Centricon then stored at -20°C pending 
further characterisation. Release of the protease fragment from the fusion was 
visualised by SDS-PAGE (results fig. 19).
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Characterisation of the active, refolded, S IV a g m  protease 
PAGE analysis.
The concentrated S I V agm  PR was analysed by PAGE (results fig. 19), and visualised 
by coomassie staining.
Confirmation o f aspartic protease activity by inhibition of autocatalysis.
Inhibition o f protease release from the fusion product was investigated by inclusion of
10 pM pepstatin within the dialysis buffer during the warm refolding step (results fig. 
19).
Immunological characterisation of S IV a g m  PR-
Dot blots (Chapter 2, page 153) were carried out using primary antibodies raised 
against HIV-1 PR and HIV-2 PR.
N-terminal analysis and Mass Spectroscopy.
Aliquots of the pure protein were subjected to N-terminal analyses and Mass 
Spectrometry, by the Chemistry department, University College London.
Crystallographic analysis o f S I V a g m P R
Hanging drops (2 pi), using the conditions which had been successful in the 
crystallisations of HIV-1 PR (McKeever, Navia et al. 1989, and Chapter 3, pages 189 
and 197) and HIV-2 PR (see Chapter 4, pages 208, and 222-228) were set up as 
described in chapter 2  (page 170), using the pure active S I V agm  PR at a concentration 
of 6 mg/ml, in a ratio of 1:1 with the crystallisation buffer, and incubated at 14°C. The 
drops were observed regularly using a light microscope, over a period of 1 month.
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RESULTS AND DISCUSSION
The pMAL-cRl vector (from NEB) provides a strong tac promoter to drive the 
expression of a heterologous protein as a C-terminal fusion with the E.coli Maltose 
Binding Protein (MBP). The construct pACS28 (A.Shearer) was intended to provide 
an S I V agm  PR expression system, and utilised pMAL-cRl as the recipient vector. 
Following overexpression of the M B P - S I V Agm  PR fusion in E.coli, active site 
titrations using pepstatin-A had been carried out to determine the yield of S IV AGm PR 
obtained and it was estimated that the total protease yield was 0.75 mg per litre of cell 
culture, with 91% of protease activity recovered from the insoluble fraction and only 
9% recovered from the soluble fraction (A.Shearer, personal communication). 
Furthermore, only 10% of total protease activity could be isolated by means of 
binding to and elution from amylose resin via the MBP moiety (A.Shearer, personal 
communication) indicating that 90% of the protease had achieved release from the 
fusion protein in vivo. Since the use of an MBP fusion did not provide a significant 
advantage in terms of protease expression levels, solubility, or ease of purification it 
was decided to investigate alternative expression systems.
Expression of S IV a g m  PR from conventional bacterial systems.
Production of S I V agm  protease using a variety of commercially available protein
expression systems was investigated, but in all cases protease expression levels were 
exceptionally poor. None of the commercial systems were any improvement on the 
existing HIV expression system (described in Chapters 3 and 4) either in terms of 
yield, or in terms of purification procedures. These investigations are not reported in 
detail here, however, an SDS-PAGE analysis of whole cell expression screens 
representative of these investigations is shown to illustrate the point (fig. 7). Such 
poor expression makes purification extremely difficult and in the case of S I V agm this 
was exacerbated by its ability to cleave itself from conventional fusion or tagged 
systems. The absence of an S I V agm  PR specific antibody for Western blotting and the 
fact that the SPA system was no longer available to our laboratory, made detection of 
the protease during stages of expression and purification more difficult too.
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Figure 7 C onventional bacterial expression o f SIV \r;M  PR gives low yields.
SrVAGMPR SDS-PAGE Whole Cell Lysate Expression Screens
1 2 3 4 5 6 7 8 9
31 kD 
21 kD
Gel 1: pAC328 (SIVACMPR in pMalCRl)
2 3 4 5 6 7 8 9
Mttli
21 kD 
14 kD
All cultures were incubated at 30'C, induction 
t o  by addition of IPTG to 1 mM.
Each gel was loaded from left to right as follows
1. No vex Mk 12 si2e stds
2. Control cells (no pksmidXuiinduced
3. Control cells (no pl*smid)induced 3 hrs
4. 2 hows after induction (uninduced control)
5. 2 hows after induction (induced cells)
6. 3 hows after induction (uninduced control)
7. 3 hows after induction (induced cells)
8. Overnight incubation (uninduced control)
9. Overnight induction (induced cells)
21 kD
14 kD
Gel 2: pkulac^SIV (SIV^j^PR inpkulac^)
Gel 3: pTrcHis-SIV (SIVACMPR inpTncHisA)
Arrows indicate expected 
location of overexpressed 
protease.
1 2 3  4 5 6 7 8 9
21 kD
** **** mm
Gel 4: pSIVSET (SIVacwPR in pRsetB)
Overexpressed protein bands can be detected by SDS-PAGE analysis o f whole bacterial cells using 
Coomassie stain, and this is a good indication o f protein yield. In the examples above protein 
expression was induced in various conventional systems incorporating the SIVagm  PR- gene. 
Subsequent SDS-PAGE o f whole induced bacterial cells failed to reveal any overexpression of the 
protease visible by Coomassie staining, indicating that yields were extremely low.
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The toxicity problem
The expression of HIV-1 protease in living bacterial cells results in their loss of 
viability (Korant and Rizzo 1991). The degradation of cellular proteins in E. coli 
expressing large amounts of active HIV protease has also been observed (Korant and 
Rizzo 1991). The expression of the HIV-1 protease was found to be toxic to E. coli 
strain BL21(DE3) (Baum, Bebemitz et al. 1990). A strong correlation between the 
presence o f functional protease and toxicity has been both demonstrated and exploited 
as a selection procedure for the identification of protease mutations (Baum, Bebemitz 
et al. 1990).
The possibility that the S IV agm protease may be toxic to the bacterial cells in which it 
is expressed due to cleavage of host cell proteins by the protease was therefore 
considered as an explanation for the low yields of protease expressed using 
conventional vector systems. Innocuous proteins generally allow high cell densities to 
be achieved during host cell culture, and are overexpressed with yields of 20 -  60% of 
total cell protein (i.e. 8 -2 4  mg protein per litre of cell culture) (Huang, Newton et al. 
1987; Craig, Yuan et al. 1991). However, cytotoxic proteins often limit the cell 
density that can be achieved in culture, and are poorly expressed with yields of 0.75 -  
2.5% of total host cell protein (i.e. 0.3 -  1 mg protein per litre of cell culture) (Danley, 
Geoghegan et al. 1989; Menendez-Arias, Young et al. 1992).
Protein expression can be assessed in comparative terms by means of SDS-PAGE 
analysis. Commercial size standard markers (e.g. no vex mark 12) are intended to be 
clearly visible following coomassie staining and are typically formulated such that 
they approximate to 0.5 pg of protein per band, given that the recommended volume 
per lane is loaded. E.coli produce approximately 40 mg total cellular protein per litre 
of culture, when grown to an OD6oo of 1.0. If cells from 1 ml of culture (at an OD6oo 
of 1.0) are harvested, then resuspended in 250 pi, and 10 pi of the resultant 
suspension is loaded per lane onto a gel, the total cellular protein in each lane would 
be approximately 16 pg. This means that a band of 0.5 pg (i.e. one that is dearly 
visible, and roughly comparable to the size standard bands in quantity) represents just 
over 3.1 % of total cell protein -  or about 1.25 mg per litre of culture. It is generally 
considered that a yield of 1 mg per litre of culture is the practical minimum desirable 
for the commencement of structural studies. At yields lower than this very high 
volumes of cell culture would be required to produce sufficient protein for the
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screening, optimisation, and refinement processes involved in solving a 
crystallographic structure. Thus if a clear band of the desired protein is not visible by 
coomassie staining (given the gel loading parameters described here), then there is 
unlikely to be sufficient yield of that protein to commence structural studies. For the 
purposes of appraising the relative effectiveness of bacterial expression systems, 
analysis by means of SDS-PAGE and coomassie staining is a fast, simple, and 
convenient technique and has been used here to compare the expression of proteases 
using a variety of systems.
The effect of protease activity on yield was witnessed during expression of HIV-2 PR 
active site mutants described in the previous chapter. The mutation of a single amino 
acid (Asp 25) to knock out protease activity resulted in an immediate improvement in 
protease yield (Chapter 5). Similar results had been reported elsewhere (Baum, 
Bebemitz et al. 1990). The problem remained, how to achieve a high yield whilst also 
producing an active native protease as the final product?
HIV-1 PR was expressed in an insoluble form as inclusion bodies, whereas HIV-2 PR 
was expressed in solution from the same system (work presented in previous 
Chapters). Yields of HIV-1 PR were generally observed to be moderately better than 
HIV-2 PR, and this was attributed to the inactivity of HIV-1 PR in inclusion bodies. A 
protease expressed as an insoluble, misfolded aggregate is prevented from dimerising 
and thus from becoming active. It had been established that these proteases could be 
easily refolded from chaotropic solutions. Insolubly expressed HIV-1 PR can be 
released with 8 M urea from washed cellular inclusion bodies, and after refolding 
such preparations cleave HIV-1 PR substrate with a specific activity comparable to 
column-purified HIV-PR (Cheng, McGowan et al. 1990). This was a procedure 
exploited in the production of both HIV-1 PR and HIV-2 PR (Chapters 3 and 4), and 
during the attempts to create an HIV-2 PR heterodimeric mutant (Chapter 5). Protease 
activity was detectable immediately upon refolding. A solution of unfolded protease 
in guanidine or urea can be dispensed into a larger volume of an activity buffer and 
protease activity is detected at once (this thesis). It was therefore considered that if the 
protease could be forced into an insoluble state by fusing it to a naturally insoluble 
protein it may still be possible to achieve release of the protease from the fusion by 
autocatalysis after refolding it from a chaotropic solution under favourable conditions 
for activity. The protease would be rendered inactive, and consequently non-toxic,
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until deliberately refolded following purification. Selection of a fusion partner protein 
that was highly expressed in E.coli was also calculated to improve the yield of fusion 
and thus protease expressed.
The selection of a mutant E.coli Uracil DNA Glycosylase as the fusion protein
The characteristics required of the fusion protein were that it should not be a substrate
for the retroviral protease, it should be highly insoluble, not likely to refold, and it 
must be expressed at high levels in E.coli. To achieve high level insoluble 
overexpression in E.coli the natural choice is a highly abundant insoluble E.coli 
protein.
Uracil DNA glycosylases are ubiquitous enzymes able to recognise and remove 
misincorporated uracils from single and double stranded DNA, thus initiating a base 
excision repair pathway. These enzymes were the subject of other projects being 
pursued within our laboratory concurrent with this thesis, and have been extensively 
reviewed elsewhere (Parikh, Putnam et al. 2000; Pearl 2000; Scharer and Jiricny 
2001).
Plasmids encoding the E.coli Uracil DNA Glycosylase (£cUDG) for overexpression 
in E.coli were available in our laboratory. The £cUDG derived from these systems 
was highly expressed, however, it was also highly soluble. By chance a mutant 
£cUDG gene was isolated during the construction of other plasmids, and expressed an 
insoluble form of the protein (Savva, R. personal communication). The mutant 
£cUDG was expressed at exceptionally high levels in E.coli but remained completely 
insoluble and resisted all attempts to refold it (Savva, R. personal communication). It 
was subsequently demonstrated to be totally resistant to cleavage by the proteases 
from HIV-1 and HIV-2 (fig. 8). This is perhaps not suprising since it has recently 
been shown that HIV-1 is able to package human UDG into viral particles by means 
of interactions between the UDG and the HIV-1 IN protein (Willetts, Rey et al. 1999).
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Figure 8 Incubation of m utant EcUDG with HIV nroteases.
1
Lane Content
1. HIV-1 PR
2. HIV-2 PR
3. EcUDG
4. Empty lane
5. EcUDG + H IV -1 PR
Since Lentiviruses from primate species do not contain UDG encoding sequences in 
their genomes it is possible that incorporation of the host enzyme may be a ploy to 
regulate uracil misincorporation into the viral genome. Since the virus packages an 
RNA genome presumably activity by captured human UDG would be utilised in the 
cytoplasm of a subsequent host following reverse transcription of the RNA genome 
into DNA prior to integration. Indeed, this may explain why the interaction is 
specifically with IN -  the enzyme responsible for integrating viral DNA into the host 
cell’s genome. The virus would need to package UDG in this scenario, since the 
enzyme would be absent from the host cell cytoplasm (it is present only in the 
nucleus). Furthermore it is likely that since none of the primate lentiviruses encode 
their own UDG that this system of enzyme capture pervades them all -  including SIV. 
Given that human UDG is packaged within HIV-1 viral particles and is required to 
ensure the integrity of the viral genome, a selection pressure exerted on the virus in 
favour of a protease that does not cleave human UDG is likely. It may be that the 
similarities between human UDG and E.coli UDG are sufficient to ensure that the 
bacterial enzyme is also resistant to the retroviral proteases. Whatever the reason 
behind £cUDG resistance to PR, this characteristic, coupled with the others discussed, 
made it an ideal candidate for the role of a fusion protein in the development of a new 
S IV agm PR expression system.
2 3 4 5 6
_  ,  _____  _____a —  EcUDG
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Design of the fusion junction to allow protease release
Attempts to express S IV agm  PR in our laboratory from a Maltose Binding Protein 
(MBP) fusion had already revealed its ability to cleave itself from within a soluble 
fusion protein (Shearer, A. personal communication). This demonstrated either that 
the extended S I V agm  PR gene sequence used in pACS28 incorporated the 
uncharacterised sequence encoding the S IV agm  PR N-terminal cleavage site, or that a 
similarly recognised sequence was present within the MBP fusion protein. N-terminal 
analysis of autocatalytically cleaved S IV agm  PR from pACS28 would have provided 
the first experimental evidence for the precise location of this cleavage site, however 
insufficient protein had been available for the analysis.
In order to maximise the probability of autocatalysis on refolding, the fusion needed 
to incorporate the region most likely to contain protease cleavage site 5 (see fig. 10 
Chapter 1). The precise locations of S I V agm  PR cleavage sites within the S IV agm 
polyproteins were not known, nor was any information concerning S IV agm PR 
substrate specificity available from the literature. However, this information was 
available for HIV-1 protease, and had been predicted for HIV-2 PR and SIVMac PR 
(fig 11, Chapter 1). Consequently inferences could be made concerning the likely sites 
cleaved by S I V agm  PR- Initially a basic sequence alignment between the HIV and SIV 
proteases was carried out, and the cleavage sites already known were used as an 
indication of the possible positions of those that were not. For the purposes of fusion 
protein construction the most important site was number 5 (fig 11, Chapter 1, page 
60), releasing the N-terminal end of the protease from within the S I V agm POL 
polyprotein. Using the alignment in combination with the information available with 
respect to substrate specificity for HIV-1 PR (fig 12, Chapter 1, page 60) the likely 
position of cleavage site 5 in S I V agm  was predicted to be between two phenylalanines 
(fig. 9). A structure-based alignment of three retroviral proteases (HIV-1, HIV-2, and 
S IV mac) with the amino acid sequence of the S I V agm  PR ( a s  expressed by the fusion 
construct) has subsequently been generated (fig. 10) using the bioinformatics 
programs Comparer, Clustal W and JOY (colours as per (Taylor 1997)) and concurs 
with the prediction originally made.
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Figure 9 Preliminary sequence alignment and prediction of SIVacm PR
cleavage site numbers 5 and 6.
Multiple sequence alignment of the proteases from HIV-1 fBru). HIV-2 (ROD). SIV-MAC. and SIY-AGM
H IV -2  PR (ROD) 
SIV-MAC PR 
H IV -1  PR (BRU) 
SIV-AGM PR
H IV -2  PR (ROD) 
SIV-MAC PR 
H IV -1  PR (BRU) 
SIV-AGM PR
SAGADTNSTPSGSSSGSTGEIYAAREKTERAERETIQGSD] L< 
ASGADANCSPRRTSCGSAKEIiHALGQAAERKQREALQGGD; L- 
QTRANS PTISSEQTRANS PTRRELQVWGRDNN SLSEAGAD1 L (  
------------PIRPSKEAPAAICRERETTRGAKEESTGHRSGL D H
GLTAPRAGGDTIQGATNRGLAAPQFSLWf
---------------------------- GFAAPQFSL1
QGTV----------------------------- SFNFPQITLW )
G---------------------------------------- IFFELPL'
•5
(RPW TAYIE
PW TA H IE
RPLVTIKIG
PIKTVYIEW tR
GQPVEVGLDTGADDSIVAG— IELGNNYSPKIVGGIGGFIKTKEYKNVEIEVGNKKVRATIMTGDTPINIFGRNILTAL 
GQPVBVGLDTGADDSIVTG--IELGPHYTPKIVGGIGGFINTKEYKNVEIEVLGKRIKGTIMTGDTPINIFGRNLLTAL 
GQLKKALLDTGADDTVLEE— MSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQI 
GVPIK AU j DTGADDTI IKENDLQLSGPWRPKIIGGIGGGLNVKEYNDREVXIEDKILRGTILLGATPINI ig r n l l a p a
H IV -2  PR (ROD) 
SIV-MAC PR 
H IV -1  PR (BRU) 
SIV-AGM PR
G—
g —
G
VPfl
MSLNLPVAI 
MSLNLPIAI 
- C TL N FPISI 
LVMGQLSEl
6
VEPIKIMLKPGKDGPKLRQWPLT--KEKTEALKEICEKMEKEGQLEEAPPTNPYNTPTFAIKKKDKN
VEPVKSPLKPGKDGPKLKQWPLS--KEKIVALREICEKMEKDGQLEEAPPTNPYNTPTFAIKKKDKN
IETVPVKLKPGMDGPKVKQWPLT --EEKIKALVEICTEM EKEGKI SKI GPENPYNT PVFAIKKKDST 
IPVTPVKLKEGARGPCVRQWPLS--KEKIEALQ-----------------------------------------------------------------------
H IV -2  PR (ROD) 
SIV-MAC PR 
H IV -1  PR (BRU) 
SIV-AGM PR
KWRMLIDFRELNKVTQDFTEIQLGIPHPAGLAKKRRITVLDVGDAYFSIPEHEDFRPYTAFTL 
KWRMLIDFRELNRVTQDFTEVQLGIPHPAGLAKRKRITVLDIGDAYFSIPLDEEFRQYTAFTL 
KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTI
SF N F P Q IT  = H IV -1 PR c lea v a g e  site  5 
T L N F P IS P  =  H IV -1 PR c leavage  site  6
R G IFFE L P =  P o ssib le  S IV -A G M  PR  c lea v a g e  site 5  
VMGQLSEK =  P ossib le  S IV -A G M  PR  c lea v a g e  site 6
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Figure 10 Structure based alignment supports initial SIVacm P R  cleavage 
site predictions.
1 0  2 0  3 0  4 0  5 0
Hiv-i PR p q v tlw q r p  l v t l k l  g g q lk e A lld tg a d d T v L e e — rtisLp— grwk 
HIV-2 PR p q fs  Iw k r p w tA y l e q q p v e V lld tqadd S iV aq — Ie L g — nnys  
SIVmac PR p q it lw k r p  l v t l r l  g g q lk e A lld tg a d d T V L ee— mnLp — gkwk 
SIVagmPR MLFFELPLWRRPIKTVYIEG' K LDTGADDTIIKENDLQLS— GPWR 
b b b b b b  b b b b b b b  b b  b
6 0  7 0  8 0  9 0  1 0 0
HIV-1 PR pkm ig g ig g fik V rq Y d  g i l l e l  c ----------qhkAiqtVLVq----p tp v n v l
HIV-2 PR p k iv g  g ig g f in T le Y k  nVeleV 1 ------------n k k v ra tlM tg -----d t p in iF
SIVmac pRkmigg igg fik V rq Y d  g ip V e l c ------------qhkAiqtVLVq -----p t p v n i l
SIVagm PR PKIIGGIGGGLNVKEYNDREVKIE----------DKILRGTILLG----ATP INI I
b b b b b  b b b b b b b b b b b b b b  b b b b b b b b b  b b
110
Hiv-1 PR G r n L L tq ig c t ln f  
HIV-2 PR G r n ll ta L g m s ln l  
SIVmac Pr G r n L L tq ig c t ln f  
SIVagm PR GRNLLAPAVPRLVMGQL 
aaaa
The program “Comparer” was used to align the structures of the proteases from 
HIV-1, HIV-2, and SIVmac using their respective PDB files. The result was 
then used to produce a structure based alignment o f these proteases with the 
sequence from SIVagm PR using “ClustalW”. The results were formatted for 
presentation using “JOY”. The SIVAGm PR residues are presented in the Taylor 
colours (Taylor 1997).
Key:
alpha helix 
beta sheet 
solvent accessible 
solvent inaccessible 
hydrogen bond to main-chain 
hydrogen bond to main-chain carbonyl 
positive phi torsion angle 
Consensus secondary structure
red
blue
lower case 
UPPER CASE 
bold
underline
italic
a =  alpha helix b= beta sheet
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Figure 11 C lu s t a i  W  s t r u c t u r e - b a s e d  a l i g n m e n t  o f  r e t r o v ir a l  p r o te a se s  w ith  
th e  S I V agm P R  p r e c u r s o r  a n d  th e  £ cU D G - S I V acmP R  fu s io n  
ju n c t io n .
Ibv9a = HIV1 PR 
SIVagmext = 
SIVUDGjun
5upja = HIV-2 PR lytha = SIVMAC PR
SIVagm PR precursor as cloned into pACS28
SIVagm PR and junction with the C-terminal region of UDG
l y t h a  -----------
S lV a g m a x t P 
SIV U D G jun
r u l a r  1
**;;*****
l b v 9 a  
5 u p j a  
l y t h a  
S lV a g m a x t 
S IV U D G jun
r u l a r  .....................9 0 .................... 1 0 0
l b v 9 a -----------------------------------  99
5 u p j a ----------------------------------- 9 9
l y t h a -------------_ _ _ _ _ ----------  9 9
S lV a g m a x t CVRQWPLSKEKIEALQ 1 7 6
S IV U D G jun  -----------------------------------  1 1 4
r u l a r  ..................1 7 0 ................
Summary of N-terminal P P '
protease cleavage sites. 4 3 2 1 : 1 2 3 4
H IV -1  PR S F N F : PQ IT
H IV -2  PR GLAA:PQFS
SIV-M AC PR GFAA: PQFS
SIV-AGM  PR R G IF : FELP
EcU D G /SIV -A G M  PR GMLF: FELP
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If the alignments based on the known sites for HIV-1 had correctly identified cleavage 
sites 5 and 6 for HIV-2, SIVmac and SIVagm, then the result could be used to assess 
the new sequence at the junction created between EcUDG and SIVAGm PR in the 
fusion protein. The probable SIVagm PR site 5 recognition sequence was 
RGIF: FELP, and this was compared with the UDG: SIV fusion sequence of 
GMLF:FELP.
Position PI
At PI in both cases there was a phenylalanine, consequently no effect on cleavage 
efficiency was envisaged. Furthermore HIV-1 PR also had a phenylalanine at this 
position.
Position P2
At P2 there was a change from isoleucine to leucine. These residues are isomeric and 
they are similarly sized, non-polar, uncharged aliphatic residues. This change would 
probably not prove problematic. In terms of HIV-1 PR consensus for this position the 
most important parameter was that P2 residues were never charged, and both the 
isoleucine and leucine fulfilled this criteria.
Position P3
P3 represented the most disparate change, from glycine to methionine. There was an 
obvious size difference, with glycine being much smaller than methionine. Otherwise, 
both were non-polar, uncharged, non-aromatic residues. The HIV-1 PR consensus for 
P3 was for a small non-polar residue, which fit glycine but perhaps excluded 
methionine by virtue o f size. However, HIV-1 PR actually had a phenylalanine at P3 
of site 5, and one was also predicted by alignment for SIV m a c  PR, while HIV-2 PR 
was predicted a leucine. Leucine is o f roughly comparable size to methionine, whilst 
Phenylalanine is slightly larger. Consequently it was considered that the methionine 
might be tolerated in this position.
Position P4
The final change was at P4, where arginine was exchanged for glycine. There was no 
conflict in terms of exclusion by size, since glycine is smaller than arginine. The 
general consensus for HIV-1 at the P4 position was for a very small residue, usually 
serine or threonine, consequently glycine should be tolerated here. In addition a 
glycine was predicted at residue P4, site 5, for HIV-2 PR and SIVmac PR sequences, 
suggesting that this may be an acceptable change. Finally a charged residue was never
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seen at P4 in any o f  the HIV-1 sites, and since arginine is a charged residue the 
exchange at this position may ironically have made the SIVagm PR cleavage more 
efficient.
These analyses suggested that insertion of the protease gene at the Esp3I site of 
EcUDG would, on translation, create a UDG-SIV junction compatible with the 
characteristics of the anticipated natural N-terminal cleavage site of the S I V agm PR 
and similar to the known sequences for retroviral proteases (Chapter 1, fig. 12 and 13, 
pages 61-62). Furthermore it could be constructed without requiring new SIV PCR 
primers, or necessitating PCR amplification of the UDG gene to engineer a suitable 
site at its 3' end, or the need to use cassettes or complex rounds of mutagenesis.
The strategy with respect to construction of the UDG-PR junction was intended to 
maximise the possibility o f autocatalysis whilst simplifying plasmid construction. It 
achieved both goals.
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Isolation o f the desired UDG-SIV fusion construct from miniprep DNA.
Transformants were screened (as earlier described) by digestion with Ncol (fig. 12), 
amplification of the SIVAGM PR gene by PCR (fig. 13), and by direct sequencing (fig. 
14). Only clone 6. was positive in all respects, and this was designated pMIRA6.
Figure 12 Ncol screens.
Positive clones released a 0.78 kb fragment 
(indicated by arrow) on digestion with Ncol.
Figure 13 PCR screens.
+ —  SIV agm  PR PCR product 
<—  Primer dimer product
Positive clones were used as templates in a PCR reaction with SIV agm  PR primers, 
and those producing an amplified product were selected for sequencing.
14 6 8 + control
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Figure 14 Sequence across E cU D G -SIV .ir.i. PR junction in pM IRA6.
T G C A
■
M il  -
■ < _
JLton4-
1
tfit J  . . .
CAGTGGCT
junction
CCCTCTTT
The data below shows the DNA and amino acid sequence of the junction between the 3 
prime end o f jCcTJDG and the 5 prime end of S1VAGM PR within the clone pMIRA6.
fcG A A C A A C G T G G dA T G T T A T T C T T T G A A C 'I® M H H 0ftA G A A G A C C A A T A  
GTCACCGACCTTGTTGCACCGTACAATAAGAAACTTGAGGGAGAAACCTCTTCTGGTTAT
G ln T r p L e u G lu G ln A r g G l^ M e tL e u P h e P h e G lu L e u P r o L e u T r p A r g A r g P r o I le  
^  _____
3 prime end of 
EcUDG gene
5 prime end of 
S I V a g m  P R  «ene
junction
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Small-scale bacterial expression of the UDG-SIV fusion protein from pMIRA*.
The small-scale expression screen showed that pMIRA6 did not overexpress the
desired fusion product at high levels (fig. 15, gel 1, lanes 12 and 13). The full-length, 
uncleaved fusion was detected by western blot (fig. 16) within the insoluble fraction 
of the pMIRA6 cell lysate using antibodies raised against the 6 x Histidine tag 
(supplied by Clonetech), and small scale IMAC experiments (not shown) on the 
insoluble fraction confirmed that the fusion was expressed and could be isolated at 
low levels. No evidence of a truncated or cleaved fusion product was detected during 
either experiment. These results suggested that the protease was not cleaving itself 
from the fusion within the bacterial cells, yet expression levels of the fusion product 
remained low despite this.
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Figure 15 Sm all scale expression  screens o f  the UDG -SIV (pM IRA) clones.
Gel 1.
1 2  3 4
p -y
5 6 7 8 9 10 11
EcUDG 
30.2 kD
t.Truncated 
EcUDG 
(28.4 kD)
Gel 2
Clone 6 
produced no 
visible
expression of the 
fusion, the native 
UDG, the 
truncated UDG, 
or the cleaved 
protease (using 
coomassie 
staining).
1 2 3 4 5 6 7 8 9 10 11 12 13 14
EcUDG 
30.2 kD
EcUDG 
30.2 kD
Truncated 
EcUDG 
28.4 kD
Gel 1 Gel 2
1 Low range prestained BioRad standards 1 Low range prestained BioRad standards
2 /3 pBU 107.1 uninduced / induced 2 empty lane
4 /5 pRsetB uninduced / induced 3 / 4 pBU 107.1 uninduced / induced
6 / 7 BL21 (DE3) uninduced/ induced 5 / 6 pRsetB uninduced / induced
8 /9 Clone 1 uninduced / induced 7 / 8 BL21 (DE3) uninduced / induced
10/11 Clone 4 uninduced / induced 9 / 1 0 V + L 1 un induced / induced
12/ 13 Clone 6 uninduced / induced 11 / 12 V + L 5 un induced / induced
1 3 / 1 4 -ve clone 2 un induced / induced
V + L (vector+ligase) = cut and religated vector (pBU107.1). 
pBU107.1 encoded £cUDG. pRsetB = parent vector.
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Figure 16 W estern  blot o f  sm all scale pM IR A 6 expression screen.
1 2 3 4 5 6
< ---------- His-EcUDG-SIVAGM PR
36 kD —— ►
1. BioRad prestained marker.
2. Whole pMIRA6 lysate
3. Soluble fraction
4. Insoluble fraction
5. Empty lane
/ 6. BL21 cell lysate
— ■----- —-------------- -
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The possibility that the fusion itself was toxic was investigated by comparison of cell 
growth rates (as assessed by measuring optical densities at X = 600 nm for 1 ml 
aliquots of cultures at regular time intervals), by transformation efficiencies (using 
standardised DNA and competent cell preparations), and using viable cell counts 
(plating out aliquots from cultures prior to and following IPTG induction) but no 
differences were discerned between control strains (either without plasmid, or 
containing empty pRsetB plasmid, or pBU 107.1) and cells containing the fusion 
construct (data not shown).
Overexpression using codon plus strains
The S I V agm  PR gene sequence was analysed for the presence of rare codons (fig. 17) 
and was found to contain several. To investigate the influence of rare codons within 
the SIV gene, small-scale expression screens were carried out using the BL21- 
CodonPlus-RIL strain as the host. These cells express additional tRNAs 
complementary to rare codons encoding Arg, Isoleucine and Lysine 
(http://www.stratagene.eom/pdf/brochure/B R38.pdfande=7317). Suprisingly, no 
improvement in expression levels was detectable by PAGE (data not shown).
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Figure 17 C odon usage analysis o f  S IV akm PR gene sequence.
E. coti Codon Usage Analysis 2.0 by Moms Maduro Sequence: SIVAGM PR (324 bases)
5 ' -A T G T T A T T C T  TTGAACTCCC TCTTTGGAGA AGACCAATAA AGACAGTGTA TATAGAAGGG GTCCCCATTA AGGCACTGCT
AGACACAGGG GCAGATGACA CCATAATTAA AGAAAATGAT TTACAATTAT CAGGTCCATG GAGACCCAAA ATTATAGGGG
GCATAGGAGG AGGCCTTAAT GTAAAAGAAT ATAACGACAG GGAAGTAAAA ATAGAAGATA AAATTTTGAG AGGAACAATA
TTGTTAGGAG CAACTCCCAT TAATATAATA GGTAGAAATT TGCTGGCCCC GGCAGTGCCC CGGTTAGTAA TGGGACAATT
A TA A -3 1
Codon
ATTTGC C C TAAC AA AGT AGGGC AAGC C GAGGGG AAAAG AGTC TTGC T AC A 
Codon TTTTATCTGGGCTACTATAGTCTACTTACGCAACTTAAAATATCGCGGCA 
G ACT AC TTG  AAAAG AGT AAGCCTG AG AC AGATC C AT AATT AAAAT AG AC A
Amino Acid h l f f e l p l w r r p i k t v y i e g v p i k a l l d t g a d d t i i k e n d l q l s g p w r p k  
Position 10 30 30 *o so
100
Codon
Freq. 50
0lLI.ii 1.......11J1..1.1. ■in
A AGG AGGGC AG AGT AG AGG A AGG A AT AG AATTGG AC A AA AG AATC GC GGC 
Codon TTGGTGGGTATAAAAAGATATAAATTGGCTTTGCCCTATTGGATTCCCTC 
TAGC AAAC TTAAATC CGAAAAAT ATG AAAAG AAATCTTAAT ATGGCGAGC 
Amino Acid i i g g i g g g l n v k e y n d r e v k i e d k i l r g t i l l g a t p i n i i g r n l l a p a v p  
Position 60 70 so 90 ioo
100
Codon
Freq.
50
o ..l  A..
CTGAGCTT 
Codon GTTTGATA 
GAAGAAAA 
Ammo Acid RLVHGQLZ 
Position
Colors: ■= less than 10% of codons for same ammo acid; ■= at least 10% 
Fraction of sense codons below threshold (=10.00): 45/107 (42%)
The above figure (1 7 )  plots the frequency with which codons of the S IV agm P R  gene 
are found in E.coli. Those codons used by E.coli on less than 10% of possible 
occasions are plotted in red.
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Large scale expression and purification of the EcUDG-SIVAGM PR fusion.
Since it had been established that a fusion product was expressed, albeit at low levels,
it was decided to pursue a strategy of large-scale cell culture in order to obtain 
working quantities o f the fusion protein. Protein was prepared from multiple large- 
scale (8 litre) cultures, as described in the methods section of this chapter. Aliquots 
from different stages of the preparation were concentrated by acetone precipitation to 
allow analysis by coomassie stained SDS-PAGE (fig. 18). The acetone precipitation 
not only increased fusion protein concentration to detectable levels for the gel, it also 
served to remove urea from the sample prior to electrophoresis.
The purpose of the cold dialysis step was primarily to concentrate the fusion protein 
by removing the chaotrope. The dialysis was carried out at low temperature and at a 
pH that would not be expected to support aspartic (and hence S I V Ag m ) protease 
activity, so that the protease would remain fused to the insoluble UDG throughout. 
The precipitated fusion protein was harvested by centrifugation and redissolved in a 
much smaller volume o f chaotropic buffer, thus concentration was achieved (fig. 18 
lane 5). This step also ensured that other insoluble contaminant proteins able to refold 
were eliminated in the discarded supernatent following the cold dialysis step (fig. 18 
lane 4). The fusion product appeared to be essentially pure following IMAC (fig. 18 
lane 3), however the cold dialysis step greatly concentrated the sample and following 
this numerous contaminants could be seen (fig. 18 lane 5). However, since these 
contaminants were insoluble, and had failed to refold during the cold dialysis step, 
they posed no problems in terms of contamination of the final S I V agm PR solution. 
The concentration of the sample by cold dialysis also ensured a greater density and 
proximity of refolded protease molecules during the warm dialysis, increasing the 
likelihood of dimerisation, activity and autocatalysis. The S I V agm PR released during 
the warm dialysis step remained in solution, and was consequently diluted, but it was 
still clearly visible on a coomassie stained gel after concentration by acetone 
precipitation. No contaminant bands were visible in the final preparation (fig. 18 lane 
6).
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Figure 18 L arge sca le preparation  o f  the E cU D G -SIV acm PR fusion product.
Purification of SIVAGM PR from a His-
tagged insoluble fusion protein.
N-H l-C
Junction mimics SlVMiM 
protease cleavage site.
21.5
I4J5
63
Key:
1. Mwt markers. kDa
2. Ec His* UDG Mutant (whole lysate)
3. SIV.UDG Fusion (IMAC elution)
4. Cone, supematent after cold dialysis
5. Pellet after cold dialysis
6. Cleaved soluble SIV PR after refold
Soluble, active SIV AGMPR
The His tagged £cUDG mutant is visible in lane 2 at approx. 31 kD, whereas the His 
tagged £cUDG-SIVAGm PR fusion can be seen in lanes 3 and 5 at approx. 39 kD. The 
band at approx. 28 kD in lane 4 is a contaminant that has refolded during the cold 
dialysis step.
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Characterisation of the active, refolded, SIVagm protease 
PAGE analysis.
Concentrated S IV agm  PR appeared as a pure single band of 11 kD when analysed by 
PAGE and visualised by coomassie staining (results fig. 18).
Confirmation o f aspartic protease activity by inhibition o f autocatalysis.
Addition of pepstatin to the refolding buffer inhibited cleavage during the warm
refold (fig. 19), confirming that an aspartic protease was responsible for fusion 
cleavage and release o f  the soluble 11 kD product (S IV ag m  PR).
Figure 19 The inhibition of cleavage by pepstatin.
-/+ Pepstatin -/+ Pepstatin
Western blot. SDS-PAGE.
Primary antibody mouse anti-His tag. Coomassie stained 15% gel.
His tag
Mutant EcUDG 
S IV agm P R
The warm refold o f  EcUDG-SIV fusion in the 
presence and absence o f pepstatin was analysis by 
means o f  SDS-PAGE and Western blotting. This 
revealed release o f the S IV AGm PR in the absence o f  
pepstatin (-), but not in the presence o f 10 pM 
pepstatin (+)•
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Immunological characterisation o f SIVAGM PR.
Dot blots were carried out to investigate the possibility that S IV agm PR might be 
immunologically similar to HIV-1 or HIV-2 PR. Primary antibodies raised against the 
HIV proteases cross-reacted only very weakly with the S I V agm PR. These antibodies 
could not therefore reasonably be used for future detection of the S IV agm PR.
Crystallographic analysis o f SIVAGMPR
No crystallisation was observed under the conditions tested, however, these were not 
comprehensive, and further screens would have been desirable. Future preparations of 
the enzyme could be used to carry out sparse matrix screens in order to ascertain the 
preferred conditions for S I V agm  PR crystallisation, and optimisation of these 
conditions could then be carried out.
N-terminal analysis and Mass Spectroscopy.
The pure S I V agm PR was subjected to both N-terminal analysis and Mass 
Spectroscopy in order to provide both a positive identity of the protein, and to identify 
the exact N and C terminal cleavage sites. N-terminal analysis confirmed that the first 
nine residues were FELPLWRRP, suggesting that the fusion’s cleavage site was 
indeed GMLF:FELP as predicted. MS analysis gave a monomeric mass of 11142.0 
kD. Given an N-terminus beginning at FELP, the mass suggests that the monomer 
ends with a C-terminal sequence of RLVM. Thus we can conclude that the N and C 
termini of the pure S I V agm  PR after release from the fusion are N-FELP and RLVM- 
C as predicted. Whilst this does not absolutely confirm the nature of the native 
cleavage sites for S I V agm  PR, it does strongly support the predictions made in this 
thesis concerning their location. A similar construct utilising extended regions of the 
sequence on either side o f the protease gene could be produced in order to provide an 
absolute answer.
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Why was expression of the EcUDG-SIVAgmPR fusion so poor?
Taken in context with subsequent sequencing data, the poor expression levels of the 
UDG-SIV PR fusion protein from clone 6 suggested several possibilities.
First, perhaps the SIV-PR was able to cleave itself from the UDG fusion (possibly 
because the truncation o f the UDG followed by addition of the SIV had rendered the 
UDG soluble once more), and was thus able to exert a toxic effect on the cells. 
However, the truncated UDG was already known to be insoluble. It was predicted that 
the fusion would be generally hydrophobic in nature so that it should also be 
insoluble. Furthermore, the fusion protein expressed was always detected exclusively 
in the insoluble fraction following cell lysis, and no protease activity was ever 
detected in the soluble fraction.
If the protease had been able to cleave itself from the fusion in vivo we would expect 
to see the formation of at least two bands on induction, one corresponding to the 
protease, the other to the truncated UDG. However, no such bands were observed. 
This could be explained if the protease, having released itself from the fusion, was 
able to cleave the UDG into numerous fragments too small to resolve. If release of the 
protease occurred shortly after induction, it may also have exerted a cytotoxic effect 
further limiting production o f the fusion. As a result no overexpressed bands (fusion, 
truncated UDG, or released PR) would be visible on the gel, whilst relatively small 
amounts of the protease activity would be present. However, the incubation of mutant 
UDG with the HIV proteases suggested that the insoluble form of UDG was resistant 
to proteolysis by these enzymes, and therefore probably also resistant to cleavage by 
SIV proteases. Furthermore, the limited expression that is observed occurs in the form 
of an uncleaved fusion suggesting that the EcUDG is not cleaved in the host cell. 
Finally the UDG portion of the fusion product remains in tact even after autocatalytic 
release of the S I V agm  PR in optimised buffer at 37°C (as is illustrated by fig. 19), this 
strongly supports the idea that the mutant EcUDG is resistant to cleavage by SIVagm 
PR. Therefore degradation of the EcUDG by the PR is unlikely, and thus cannot 
explain the absence of bands corresponding to overexpressed £cUDG or fusion from 
analyses o f lysates by SDS-PAGE.
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Potentially the fusion itself may be toxic - despite being insoluble, inactive, and 
composed primarily of a non-toxic E.coli protein that is ordinarily highly 
overexpressed. There is a possibility that the fusion was somehow interupting the 
function of the host cell’s own UDG or related proteins. If this were the case, 
however, we would not expect to see the mutant UDG overexpressed -  whereas in 
fact it is normally highly expressed apparently without deleterious effect. Also given 
that the protease is toxic by virtue of its proteolytic activity, and given that if active it 
would release itself from the fusion, we can assume that the fusion itself is non-toxic 
with respect to protease activity. This is the premise for the fusion design. The 
possibility that the fusion itself was toxic was nevertheless investigated by 
comparison of cell growth rates, transformation efficiencies and viable cell counts, yet 
no difference in the relative vitalities of bacteria with or without pMIRA6 (the UDG- 
SIV PR fusion vector) prior to or following induction, was observed (data not shown).
It is interesting to compare the expression of UDG-SIV PR fusion with the HIV-2 PR 
active site mutants described in Chapter 6. The expression levels of HIV-2 PR 
increased hugely once the active site was mutated. This cannot be explained in terms 
of codon usage, since it represents only a minimal change to the DNA sequence. It is 
instead presumably the result of knocking out proteolytic activity and thus reducing 
the deleterious effect of the protease on the host cells. It is strange then that, given the 
fusion similarly renders SIV inactive, we do not see a significant increase in SIV 
yield. A  comparison of codon usage in the HIV-2 PR and S IV agm  PR genes reveals 
that the HIV-2 PR gene sequence contains fewer rare codons than the S I V agm PR 
sequence, and HIV-2 PR does not suffer the long runs of consecutive rare codons 
found in the SIV gene (see fig. 20 for analysis of HIV-2 PR codon usage).
Abundance o f tRNA and codon usage
Finally, rare codons could be the source of low protease yields, and consequently of 
low fusion yields.
The genetic code contains 61 codons encoding 20 amino acids (Crick et al. 1961). 
This means that a given amino acid may be encoded by several distinct (yet 
synonymous) codons, each read by one or more transfer RNAs (tRNAs). Where 
several codons encode the same amino acid they do not necessarily arise with the 
same frequency within a given organism’s genome (Nakamura 1996), or within its’ 
population of messenger RNAs (mRNAs) (Dong 1996). In fact certain codons are
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apparently favoured over others encoding the same amino acid - a phenomenon 
known as codon bias - and the precise nature of this bias varies between species. The 
frequency of a codon’s use generally correlates with the availability of the tRNA that 
recognises it (or vice versa) (Dong 1996, Ikemura 1981), and in highly expressed 
genes the most frequently used codons tend to be those recognised by the most 
abundant tRNA (Post et al. 1979). It has been demonstrated that this arrangement 
favours more rapid protein synthesis and lower rates of amino acid substitution errors 
than would otherwise be observed (Ehrenberg and Kurland 1984).
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Figure 20 C odon usage analysis o f the H IV-2 PR gene sequences.
E . c o t i  Codon Usage Analysis 2.U by Moms Maduro 
Sequence: HTV-2 PR (300 bases)
5 ' -GCACCTCAAT TCTCTCTTTG GAAAAGACCA 
GTAGAAGTTT TGTTAGACAC GGGAGCTGAC 
AACAATTATA GCCCAAAAAT AGTAGGGGGA 
AAAAATGTAG AGATAGAAGT TCTAAATAAA 
ACCCCAATCA ACATTTTTGG CAGAAATATT
GTAGTCACAG CATACATTGA GGGTCAGCCA 
GACTCAATAG TAGCAGGAAT AGAGTTAGGA 
ATAGGGGGAT TCATAAATAC CAAGGAATAT 
AAGGTACGGG CCACCATAAT GACAGGCGAC 
CTGACAGCCT TAGGCATGTC ATTAAATCTA - 3 '
100
Codon
Freq.
5 0«
0 lil I. .ill.I .1 .
GC C TTC T AAC GGAGTAGGC C GGGTTGAGGGGTAGGGAGTGAATAC AAGGG 
Codon CCATCTGAGCTTCCATAGACTATTTACGCAACTTCGTATGAAAGCATTGG 
ATAC TTGAAAAC AAC TGTGAAATGACGATC C AAAAAAGAAC TTC AAAAGA
Amino Acid a p q f s lw k r p v v ta y ie g q p v e v l ld tg a d d s iv a g ie lg n n y s p k iv g g  
Position 10 20 30 40 50
100
Codon
Freq.
50
0 .III III. .1 . l l .
AGGT AAAAGTAAGGAGGC AAAGC GAAAAGGAC AAATGAAAC AGTGATTAC 
Codon TGGTTACAAAAATATATTAAATGCCTTCGACCTATTGGATTCCTGTCTAT 
AG AC ATC GAT AT AG A AT AT AG AGC C AG AC C C AC C TTC ATTG AC AC G A AT A 
Amino Acid i g g f i n t k e y h w e i e v l n k k v r a t i m t g d t p i n i f g r n i l t a l g m s l n l  
Position <50 70 so 90 100
Colors: * =  less than 10% of codons for same amino acid; ■= at least 10% 
Fraction of sense codons below threshold (=10.00): 30/100 (30%)
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Given the correlation between frequency of codon usage and tRNA abundance, plus 
the observation that rapid and high level protein expression occur where the encoding 
mRNA contains frequently used codons, it is reasonable to expect that the opposite 
would also be true. Where infrequently used codons (rare codons) predominate in an 
mRNA its’ translation would be predicted to be problematic. A low rate and level of 
protein expression and an increased rate of substitution errors might be expected, and 
has been observed (Robinson et al. 1984, Kane 1995). A comparison of protein 
synthesis involving different codons in mutants of the E.coli lacz gene showed that 
rare codons were translated at a rate of only 2 peptide bonds/sec, equivalent to about 
20% of the rate of common codons (Sorensen, et al. 1989). Other work supports this 
observation of non-uniform translation rates at different codons in E.coli (Bonekamp 
and Jensen 1988, Sorensen and Pedersen 1991).
It had been anticipated that the position of the SIV gene following such a large fusion 
sequence may overcome any potential codon usage problems, since it has been 
reported that positioning of rare codons can influence their effect on expression levels 
(Bulmer 1988; Chen and Inouye 1994; Goldman, Rosenberg et al. 1995). If rare 
codons are the explanation for the persistently low levels of S IV agm PR expression, 
then positioning the SIV gene downstream of the UDG did not have the desired effect 
in this respect. However, the use of codon plus strains, and in particular the RIL 
strain, did not produce any significant improvement in yield (as assessed by SDS- 
PAGE and Western blot analyses -  data not shown) either. This seemed to indicate 
that the S IV agm PR gene codon usage is so incompatible with E.coli that codon plus 
strains are insufficient to overcome the problem.
Investigation of the S IV agm  PR sequence using the Codon Usage Analysis 2.0 
program (By Morris Maduro) revealed that 42% of the SIV codons occur at a 
frequency of less that 10% in E.coli (fig. 17), while 36% occur at a frequency of less 
than 5%. Using the term “rare codon” as arbitrarily defined by Wada et al. (Wada, 
Wada et al. 1992) (and susbequently used by Kane 1995 (Kane 1995)), to mean 
codons used at a frequency of less than 1%, then 15% of the S IV agm PR gene codons 
are rare in E.coli. In particular there are seven rare Arginine codons (six are AG A - 
which occur at a frequency of 2.1 per 1000 codons in E.coli - and 1 is CGG which 
occurs at a frequency of 4.6 per 1000 E.coli codons) including an adjacent pair 
located near the start of the gene.
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The analysis also confirmed the presence of rare codons for Threonine, Glycine, 
Proline and Serine in addition to the rare Arginines, Iso leucines and Leucines that 
were compensated for by the three rare tRNAs expressed by the RIL strains. The 
presence of these non-RIL rare codons explains the ineffectiveness of the RIL strains. 
Of the 45 most rare codons 16 were non-RIL. Codons occurring at a frequency of less 
than 10% were distributed throughout the gene such that there were seven instances 
where two were adjacent, one instance of three being adjacent, and one instance of 
eight being adjacent. The row of eight suboptimal codons occurred in the middle of 
the gene and included 2 that are classified as rare according to the Wada definition.
The occurence in a gene of two or more adjacent rare codons is known to have a 
deleterious effect on protein expression (Rosenberg, Goldman et al. 1993; Kane 1995; 
Phoenix, Pewsey et al. 1995), consequently the presence of a run of eight rare codons 
would presumably prove extremely difficult for a host cell to express.
Given that the large number of rare codons is the likely cause of poor S IV agm PR 
expression in E.coli there are perhaps two possible solutions, change the host 
organism or synthesis an optimised gene. Possible alternative hosts may include 
Bacillus subtilis, which has no codon preference (Ogasawara 1985; Loshon, Tovar- 
Rojo et al. 1989) and has also been used for protein expression (Conrad, Savchenko et 
al. 1996; Chan, Chan et al. 2002). Possibly eukaryotic host cell based systems (eg. 
yeast, insect, or mammalian) would provide viable alternatives, but are typically more 
expensive and technically more difficult than their bacterial counterparts. Total 
synthesis of the protease gene using codons optimised for expression by E.coli is 
preferable since it would allow the use of established expression methods and E.coli 
as the host. The optimisation of codon usage by gene synthesis has successfully 
augmented the expression of other proteins (Graham, Atkinson et al. 1993; Martin, 
Vrhovski et al. 1995) including the korB protein from Pseudomonas in our laboratory 
(S.Singh personal communication). One possible caveat is that there is probably a 
limit to the size of gene that can be successfully synthesised by current methods, and 
in such a situation an alternative host organism may prove the better alternative unless 
mutagenesis of key rare codons was sufficient to restore expression levels.
Given the results of this study it was considered that poor expression of the fusion 
very probably resulted from the widespread presence of rare codons within the
313
S IV agm  PR gene sequence. To establish the validity of this suggestion would require 
the application of one of the solutions discussed above. The S I V agm  PR gene is 
sufficiently short that synthesis of the optimised gene is quite feasible, whilst 
conventional mutagenesis would require multiple reactions to be carried out in order 
to eliminate the runs of adjacent rare codons. Consequently gene synthesis would be 
the preferred approach.
The ‘Recursive PCR’ method of Prodromou and Pearl (Prodromou and Pearl 1992) 
would have been the method of choice, though financial and practical constraints (ie. 
the cost of the large oligos required, and the need for a computer program specifically 
to design them) precluded this experiment.
For the purposes of discussion the procedure for design of recursive PCR primers 
would have been as follows:-
1. Carry out codon usage analysis of S IV agm  PR with respect to frequency of codon 
occurrence in E.coli genes (fig. 17), and locate any rare codons.
2 . Generate a modified S I V agm  PR gene sequence (eg. using GCG, Genetics 
Computer Group, now Accelrys) such that all codons are now optimised and found 
with high frequency in E.coli. Ensure that the amino acid sequence has not been 
inadvertently altered in the process.
3. Map the restriction sites present in the optimal gene, and choose useful, unique 
sites (preferably at regular intervals - eg 30 bp intervals) - or if necessary alter 
codons to create such sites - which may be used to clone parts of the synthetic gene 
if it proves impossible to make the whole gene in one piece.
4. Select restriction sites to be incorporated at the 5' and 3' ends of the gene for 
cloning purposes, and design suitable sequences for use in the exterior primers 
(ensuring that the gene will be inserted in frame once cloned). This requires 
knowledge of the vectors you may wish to use in future.
5. From the sequence thus far created, design a set of overlapping primers, which 
alternate between the positive (5! to 3') strand, and the negative (3* to 5') strand. 
These should preferably be about 60 bps in length and should overlap with their 
adjacent primers by 10-15 bps.
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6. The primer design must now be adjusted to ensure that the Tm of each overlap is 
approximately the same as the Tm for all the others, preferably they should all 
have a value of about 60°C. Varying the respective lengths of the primers may be 
required at this point to obtain the desired Tm values. The position of unique 
restriction sites should also be checked to ensure that they are usefully located with 
respect to the primers.
7. This first generation of primer designs now have to be checked relative to each 
other to ensure that they would not mis-prime, and will only anneal to the intended 
complementary primer. Where mis-priming is detected the primers involved must 
be redesigned by modifying the sequence as required to prevent mis-priming, but 
while maintaining optimal codons as far as possible. In this way a second 
generation of primer designs is produced, and these are once more checked against 
each other to ensure there is no mis-priming. This cyclic checking and modifying 
process is repeated until an optimal design is achieved. The primers can then be 
synthesised.
This last cyclical step is critical since mis-priming is highly likely if the design is 
poor, and it will result in a total failure of the reaction. In reality this step is usually 
too complex to be carried out manually and all successful use o f recursive PCR has 
relied on computer aided primer design, with programs written specifically for the 
task of checking recursive PCR primers against each other. Until recently this meant 
that experimentalists had to write their own program, however, software (Juniper) has 
now been developed for the purpose (C. Richardson, unpublished). Juniper accepts 
the amino acid sequence in FASTA format and produces an optimised nucleotide 
sequence, from which it designs appropriate primers. This was used to design primers 
(figs. 21 and 2 2 )  for synthesis of an optimised S IV agm  PR gene (fig. 2 3 )  in the future.
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Figure 21 Results from Juniper.
The SIVagm PR gene was optimised for expression in E.coli, and designed to 
incorporate a 5' Afllll site, a 3' Hindlll, and a Stop codon. The SIV amino acid 
sequence encoded begins with the complete N-terminal PR recognition sequence. The 
resultant nucleotide sequence was then used to generate overlapping oligos, as shown 
below.
Top strand: 5* to 3*
GCCGCGCACATGCGTGGCATCTTCTTCGAACTGCCGCTGTGGCGTCGTCCGATCAAG
ACCGTTTACATCGAAGGTGTTCCGATTAAAGCTCTGCTGGACACCGGTGCTGACGAC
ACCATCATCAAAGAAAACGACCTGCAGCTGTCCGGTCCGTGGCGTCCGAAAATCATC
GGCGGTATCGGTGGTGGTCTGAACGTTAAAGAATACAACGACCGTGAAGTTAAAATC
GAAGACAAAATCCTGCGTGGTACCATCCTGCTGGGTGCTACCCCGATCAACATCATC
GGTCGTAACCTGCTGGCTCCGGCTGTTCCGCGTCTGGTTATGGGTCAGCTGTAAGCT
TGGCGC
Bottom strand: 5' to 3'
GCGCCAAGCTTACAGCTGACCCATAACCAGACGCGGAACAGCCGGAGCCAGCAGGTT
ACGACCGATGATGTTGATCGGGGTAGCACCCAGCAGGATGGTACCACGCAGGATTTT
GTCTTCGATTTTAACTTCACGGTCGTTGTATTCTTTAACGTTCAGACCACCACCGAT
ACCGCCGATGATTTTCGGACGCCACGGACCGGACAGCTGCAGGTCGTTTTCTTTGAT
GATGGTGTCGTCAGCACCGGTGTCCAGCAGAGCTTTAATCGGAACACCTTCGATGTA
AACGGTCTTGATCGGACGACGCCACAGCGGCAGTTCGAAGAAGATGCCACGCATGTG
CGCGGC
Oligo overlaps:
1 GCCGCGCACATGCGTGGCATCTTCTTCGAACTGCCGCTGTGGCGTCGTCC
5 1  GATCAAGACCGTTTACATCGAAGGT............................................................................
..................CTGGCAAATGTAGCTTCCACAAGGCTAATTTCGAGACGACCTGT
1 0 1  ....................   . . CGACACCATCATCAAAGAAAACGACCTGCAGCTGTCCGGT
GGCCACGACTGCTGTGGTAGTAGTTTCTTT............................................................
1 5 1  CCGTGGCGTCCGAAAATCATCGGCGGTATCGGTGG.............................................
 .............................................. TAGCCGCCATAGCCACCACCAGACTTGCAATT
2 0 1  ..............................................................TTAAAATCGAAGACAAAATCCTGCGTGGTA
TCTTATGTTGCTGGCACTTCAATTTTAGCTTCTGTTTTAGGA......................
2 5 1  CCATCCTGCTGGGTGCTACCCCGATCAACATCATCGGTCGTAACC.............
.................................................................................TTGTAGTAGCCAGCATTGGACGAC
3 0 1  .....................................................................................................................................................
CGAGGCCGACAAGGCGCAGACCAATACCCAGTCGACATTCGAACCGCG
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Figure 22 Results from Juniper.
The o lig o n u cleo tid e  d esig n s thus generated w ere as sh ow n  b elow .
Forward oligos: 5' to 31
1 . GCCGCGCACATGCGTGGCATCTTCTTCGAACTGCCGCTGTGGCGTCGTCCGATCA  
AGACCGTTTACATCGAAGGT
2 . CGACACCATCATCAAAGAAAACGACCTGCAGCTGTCCGGTCCGTGGCGTCCGAAA  
ATCATCGGCGGTATCGGTGG
3 . TTAAAATCGAAGACAAAATCCTGCGTGGTACCATCCTGCTGGGTGCTACCCCGAT  
CAACATCATCGGTCGTAACC
Reverse oligos: 5 ’ to 3 1
1 . TTTCTTTGATGATGGTGTCGTCAGCACCGGTGTCCAGCAGAGCTTTAATCGGAAC  
ACCTTCGATGTAAACGGTC
2 . AGGATTTTG TCTTCG ATTTTAACTTCACG G TCG TTG TATTCTTTAACG TTCAG AC  
CACCACCGATACCGCCGAT
3 . GCGCCAAGCTTACAGCTGACCCATAACCAGACGCGGAACAGCCGGAGCCAGCAGG  
TTACGACCGATGATGTT
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Figure 23 Codon analysis o f the proposed synthetic SIV ahm PR gene.
K  coti C odon U sage Analysis 2 .0  by M om s Maduro
Sequence entered (348  bases):
S'-GCCGCGCACA TGCGTGGCAT CTTCTTCGAA CTGCCGCTGT GGCGTCGTCC GATCAAGACC GTTTACATCG
GATTAAAGCT CTGCTGGACA CCGGTGCTGA CGACACCATC ATCAAAGAAA ACGACCTGCA GCTGTCCGGT
CGAAAATCAT CGGCGGTATC GGTGGTGGTC TGAACGTTAA AGAATACAAC GACCGTGAAG TTAAAATCGA
CTGCGTGGTA CCATCCTGCT GGGTGCTACC CCGATCAACA TCATCGGTCG TAACCTGCTG GCTCCGGCTG
GGTTATGGGT CAGCTGTAAG CTTGGCGC-31
100
C o d o n
F re q .
GGC AC G ATI &C C CT C C C AA AGT AGGGC A ACC C G AGGGG AAAA G AGC C C1GCT C C A A AGG A 
CodOncCArGGTTTMCTWGCTACTAXAGTCTACTTACGCAACTTAAAAXAICGCGCCAXTGGT 
CGCGTCCCCAGG&GTTGCGCTCCAXTGTATGGCCTTCCCCCAACCGGGCTGGTGACCCTC 
A m ino  A c id  IKTVYIEGVP IKALLDTGADDT I liZSDLQLSGPtlRPKX IGGI
P o s itio n  10 20 30 40 30 60
100
C o d o n
F re q .
GGGC AG AGT AGC GGAA&GAACC GAAC C GG AC AAA AGC AC C GC GGC C C & AGC CT GT C 
C o d o n  GGGT ATAAAAAGATATAAATTGGCTTTGCCCT ATTGGATTCCCTCGTTTGATACGG 
TTTGCTAACCCTATACACACGTTCC&GTTCGCCCCTTCGGTGTTGTGTGTG&ATGC 
A m ino  A c id  &G&LMVKETODBEVK IEDK ILR&T ILL&ATP IS I IGRBLLAPAVPRI.UKGQLZAI3R
P o s itio n  70 80 90 100 110
Colors: ■ = less than 10% of codons for same amino acid; ■ = at least 10%
Fraction o f  sense codons below  threshold (=10.00): 0 /115 (0% )
AAGGTGTTCC
CCGTGGCGTC
AGACAAAATC
TTCCGCGTCT
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SUMMARY
A novel expression system was developed (based on a pRsetB based construct 
containing a mutant of the E.coli UDG) allowing the expression of an insoluble UDG- 
S IV agm PR fusion protein as inclusion bodies. The system was designed to eliminate 
the cytotoxic effects of the protease by rendering it insoluble. It was also intended to 
provide a simple two step purification of the protease by means of IMAC, and 
autocatalytic release of the protease under specific refolding conditions. The presence 
of the construct had no apparent toxic effect on host cells, even during induction. The 
fusion was expressed insolubly, purified in a single IMAC step, and the protease was 
successfully released following the refolding procedure and separated from the 
insoluble UDG by centrifugation. The construct design was thus considered a success.
However, the fusion was poorly expressed despite lack of toxicity, and protease yields 
remained low. The S IV agm PR gene sequence contains a large number of codons 
which are rarely used by E.coli, and this probably explains the persistently low 
expression of this gene. Neither the position of the gene downstream of UDG, nor the 
use of Codon Plus strains (such as RIL) in conjunction with the fusion system 
produced any improvement in expression. Presumably the SIV sequence contains a 
sufficiently large number, wide variety, and clustered distribution of rare codons that 
even these measures were insufficient to overcome the problem. It was concluded that 
the best solution would be total synthesis of the protease gene using codons optimised 
for expression by E. coli, and a method was proposed.
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Chapter Seven: General Discussion.
This thesis has described the cloning, expression, and purification, of three native 
retroviral proteases from HIV-1, HIV-2 and S IV agm - Also reported were the 
crystallisation and preliminary crystallographic analysis of the HIV-2 protease, the 
analysis of two novel protease inhibitors, the creation and analysis of a mutant 
heterodimeric HIV-2 PR, and the development of a novel expression and purification 
system for S IV agm  protease which is applicable in principle to all retroviral proteases.
The retroviral proteases are now among the best-characterised enzymes known, and 
HIV-1 protease in particular has been the target of comprehensive study by a great 
many groups, both academic and industrial, worldwide. Drugs have been developed to 
target the HIV proteases and these have proved successful, however, the problem of 
drug resistant strains has meant that these compounds might ultimately have a limited 
useful life span. Consequently workers in this field cannot become complacent, and 
the development of new compounds continues apace. The HIV-1 protease expressed 
during the course of this project was used to perform preliminary tests on two new 
inhibitor designs.
Inevitably the urgent requirement for new drugs means that there is a high demand for 
pure, crystallography grade, retroviral proteases for use in high throughput screens 
and drug development programs. The yield of these enzymes is typically very poor, as 
has been discussed, so that production on the scale required for drug discovery is an 
expensive and difficult process. A means by which these enzymes can be expressed at 
high levels and purified with ease would consequently have a huge beneficial impact 
on the drug development process. There would be savings in terms of scale, 
manpower, time and ultimately costs per unit of enzyme. Academia, the 
pharmaceutical industry, and their suppliers alike would therefore eagerly embrace a 
new, high yield expression and purification system for these enzymes. During the 
course of this work problems of toxicity and poor codon usage have been faced and 
strategies for overcoming them have been developed. The U D G - S I V agm protease 
fusion system, with optimised protease codons, represents possibly the ultimate 
system for high yield expression and simplified purification of this enzyme. 
Furthermore the same system could easily be applied to any of the other retroviral
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proteases. Consequently this system could be of significant use to workers in the field. 
The construction of similar vectors for expression of HIV-1 and HIV-2 proteases, 
each with optimised codons, would be an immediate future aim.
The HIV-2 protease was successfully crystallised at a time when no structural data for 
this enzyme existed. Unfortunately it was not possible to obtain a structure for the 
technical reasons already described, and only preliminary data is presented. However, 
this was certainly one of the earliest (if not the earliest) crystallisations of this 
enzyme. There are still far fewer structures of HIV-2 protease complexes than there 
are of HIV-1 protease complexes, and there are no structures of the native HIV-2 
protease publically available to date. Paradoxically HIV-2 remains the largest killer 
between the two HIV serotypes, so that studies specific to HIV-2 protease would 
potentially provide the greatest benefit to mankind.
The production of mutant HIV-2 PR illustrated the effect of toxicity on expression 
levels of this enzyme in bacteria. It also demonstrated the effect of a single mutation 
within the active site on correct folding. It may be possible to design inhibitors able to 
interact with the enzyme via residues located in the protein’s folding core. In this way 
resistant mutants cannot arise since they would necessarily cause misfolding. A series 
of site directed mutagenesis experiments could be carried out to determine residues 
crucial to enzyme folding, and establish whether other residues can be tolerated at 
these positions. Any positions that cannot tolerate mutation could then be made 
targets for drug design. The principle of this strategy is the anticipation of resistant 
mutants prior to drug design in order to eliminate the possibility that resistance can 
arise later.
As discussed, early protease inhibitors allowed breakthroughs to be made in the 
understanding and treatment of the disease (General Introduction, AIDS is a global 
health problem, page 20 onwards). In the period since 1997 (when work on this 
project ceased) the use of protease inhibitors has continued to have an impact on our 
understanding of the disease, and has revolutionised treatment of it. The combined use 
of RT and PR inhibitors simultaneously has had a dramatic effect. AIDS deaths have 
been dropping steadily (from their peak in 1995) since combination therapy was 
introduced (1995 -  1996) with a drop in death rate of 47% in 1997 alone.
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Combinatorial therapy eliminated 99% of plasma-borne virus within two weeks 
(Perelson, Essunger et a l 1997), however, this was followed by a much slower phase 
of decline which suggested that perhaps 3 years of treatment would be required to 
destroy surviving reservoirs of virus, and many more would be required to eliminate 
the virus entirely. This was thought to be due to reservoirs of infected cells within the 
lymphoid tissues, which considerably exceeded the numbers of free and cell- 
associated virus circulating in the bloodstream. These were shown to be relatively 
unscathed by existing monotherapies targeting Reverse Transcriptase only (Haase, 
Henry et al. 1996; Cohen, Pantaleo et al. 1996). However, a three drug treatment 
simultaneously targeting both Reverse transcriptase and the viral Protease cleared 
99.9% of virus from the lymphoid tissue reservoir within 6 months, eliminating this as 
the source of the slow second-phase decay of plasma viraemia described by Perelson, 
Essunger et al. It was not clear from this study whether such therapy could completely 
eliminate the virus, or whether lifelong treatment would have to be maintained, since 
an alternative reservoir existed. Replication competent, integrated, yet latent, provirus 
in “resting” (ie. non-dividing) CD4+ cells provides a steady source of new infectious 
particles as they became activated by host cell division. A coincident study by Chun et 
al (Chun, Carruth et al 1997) measured this reservoir of latent virus and found that 
the most prevalent HIV DNA in CD4+ cells was a full length, linear, unintegrated 
form that was not replication competent. They found a very low load of replication 
competent, fully integrated, latent provirus among infected CD4+ cells, yet this small 
reservoir was sufficient to ensure disease progression (Chun, Carruth et al 1997). 
These results suggested that cessation of combinatorial therapy at any point would 
result in reinfection, since viral DNA could linger in host cells long after viral load (as 
measured in terms of RNA) has been eliminated. Less than 0.05% of the resting 
CD4+ cell population harboured pro viral DNA, yet when stimulated to divide many 
of these were capable of producing infectious virus (Chun, Carruth et al 1997). 
Furthermore it was not clear how long these cells would persist, it was conceivable 
that they could survive for months or even years, allowing the virus to evade detection 
by the immune system and destruction by therapeutic agents.
The combined use of compounds (usually three at once) targeting both RT and PR has 
since been termed Highly Active Antiretroviral Therapy (HAART), and is currently 
the best available treatment regime. This regime was shown to largely restore immune
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function by allowing the regeneration of CD4+ and CD8 cell levels, although a 
complete recovery to normal levels was not observed (Autran, Carcelain et al. 1997). 
It has been shown that there is no emergence of drug resistant strains in patients 
treated with the HAART regime, even after two years (Wong, Hezareh et al. 1997; 
Finzi, Hermankova et al. 1997). However, in these same patients there is still a 
reservoir of infected memory T-cells (<16 cells per million) that when stimulated 
(using immobilised antibody to CD3 and CD28 -  see Spina, Prince et al. 1997) 
produce replicating virus (Wong, Hezareh et al. 1997). The observations of Wong et 
al. and Finzi et al. support the notion that the slow-phase decay described by Perelson 
et al. is due to the long term survival of latently infected memory T-cells, rather than 
to a failure of the drug treatment.
To determine whether the reservoir of infected cells would be sufficient to reinitiate 
infection studies were carried out on patients having already been treated with 
HAART for over 30 months, and whose plasma viral RNA were observed to be 
negligible (Chun, Davey et al. 1999). On cessation of HAART treatment their plasma 
viral RNA was seen to increase, demonstrating a re-emergence of infection, within 
two weeks. Once HAART treatment was resumed the viral RNA levels dropped once 
more, and had significantly reduced within 2-4 weeks -  although they did not reach 
their former low levels within the duration of the study. Administration of interleukin 
2 (11-2) at intervals during HAART treatment was also studied (Chun, Engel et al., 
Chun and Fauci 1999). This was intended to stimulate infected memory T-cells, thus 
forcing integrated provirus out of latency making it vulnerable to the HAART. 
Measurements showed a decline in the degree of latent infection within the memory 
T-cell population following the IL-2 treatment, providing a means to reduce the viral 
reservoir at an increased rate (Chun, Engel et al. 1999, Chun, Davey et al. Nature 
brief 1999).
A comprehensive review of this area of AIDS / HIV research up to and including 
1999 is provided by Hasse (Haase 1999). Overall it seems that HAART is now an 
extremely effective strategy for the control of viral infection, and that patients 
receiving treatment even in the latest stages of AIDS can benefit greatly from 
treatment and will recover partial immune function (although slowly). However, until 
means can be developed to eliminate all vestiges of the viral reservoir current 
therapies simply contain the disease rather than curing it. The development of
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Integrase inhibitors may have the desired effect, however, in the meantime something 
like 5 million people per year are newly infected with HIV worldwide making 
prevention of infection imperative. Education and welfare efforts are being conducted 
to this end, but ultimately success may depend on the development of a vaccine -  
progress towards this goal is reviewed in Ho and Huang 2002.
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Appendix
List of suppliers.
Accelrys Ltd.
Amersham Biosciences 
(GE Healthcare)
Amicon
Bachem (UK) Ltd.
BioRad (UK)
Biosoft
334 Cambridge Science Park,
Cambridge, CB40WN UK. Phone 01223 228500
(formerly Amersham Pharmacia Biotech UK Ltd) 
Amersham Place, Little Chalfont, Bucks. HP7 9NA 
England. Phone 0870 606 1921 
http://www.apbiotech.com
Amicon is affiliated to Millipore -  see Millipore.
69 High Street, Saffron Walden, Essex, CB10 1AA, 
England. Phone +44 / (0) 1799 526465 
http://wAvw.bachem.com
Bio-Rad United Kingdom Customer Service
Life Science Research
Freephone 0800 181134
Clinical Diagnostics
Freephone 0800 181134
Informatics | Sadtler
Freephone 0800 78945000
http://www.bio-rad.com
2D Dolphin Way, Stapleford, Cambridge, CB2 5DW 
http://wAvw.biosoft.com
Cambridge Biosciences Ltd. 5 Signet Court, Swann Rd. Stourbridge Common
Business Centre, Cambridge.
Phone: 01223 316855 
Fax: 01223 360732
Clontech Labs, Inc.
Costar
Unit 2, Intec 2, Wade Road, Basingstoke,
Hants. RG24 8NE, UK. Phone 01256 476500 
http://www.clontech.com
Distributors in the UK are:
Cole-Parmer Instrument Company Ltd.
Unit 3, River Brent Business Park, Trumpers Way 
Hanwell, London W7 2QA 
Phone: 0208 574 7556 
Fax: 0208 574 7543
Fermentas http://www.fermentas.com
Local distributer is Helena Biosciences Ltd.
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Helena Biosciences Ltd.
Hellma
Inceltech
Colina Ave., Sunderland Enterprise Park, Tyne and 
Wear, SR5 3XB, UK. Phone 0191 549 6054 
http://www.helenabiosciences.com
Hellma GmbH and Co KG
Klosterrunsstrasse 5
D-79371 Mullheim
Phone+49-7631-182-0
Fax +49-7631-13546
Email info@helhna-worldwide.de
http://www.hellma-worldwide.com
New Brunswick Scientific Co. (below) has acquired the 
assets and business of Inceltech.
Perkin Elmer Chalfont Road, Seer Green, Beaconsfield, 
Bucks. HP9 2FX, UK. Phone 01494 874515 
http://uk.instruments.perkinelmer.com
PE-Applied Biosystems UK See Perkin Elmer.
Promega UK
Millipore
New Brunswick
New England Biolabs 
(UK) Ltd
Sartorius
Delta House, Chilworth Science Park,
Southampton, SO 16 7NS.
Tel: (44) 23 8076 0225
Fax: (44)23 8076 7014
FREEPHONE: 0800 378994
E-mail Address: ukcustserve@promega.com
Web Address: www.promega.com/uk/
Millipore (U.K.) Limited,
(Sales and Customer Support Facilities),
Units 3 and 5 The Courtyards, Hatters Lane 
Watford, WD18 8YH, UK.
Phone: (44) (19) 238-16375 
http://www.millipore.com
17 Alban Park, Hatfield Road,
St Albans, Herts. AL4 OJJ 
Phone: 01727 853855 
Fax: 01727 835666 
http://www.nbsc.com/
67 Knowl Piece, Wilbury Way, Hitchin, Herts.
SG4 OTY, UK. Phone 01462 420616 
info@uk.neb.com
Sartorius Ltd., Longmead Business Centre, Blenheim 
Rd., Epsom, Surrey, KT19 9QQ. Phone 01372 737100 
http://www.sartorius.com/
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Shimadzu
Sigma -  Aldrich Co. Ltd.
Stratagene
QIAGEN UK Ltd.
European Headquarters
Shimadzu Deutschland GmbH
Albert-Hahn-Str. 6-10, 47269 Duisburg
Tel: +49-203-7687-0
Fax: +49-203-766625
UK Office in Milton Keynes.
http://eu.shimadzu.de/home/
Fancy Rd., Poole, Dorset, BH12 4QH, England. 
Phone 01202 733114 
http://www.sigma-aldrich.com
Stratagene Europe
PO Box 12085, 1100 AB Amsterdam, Netherlands.
UK customer services 0800 917 3282 
http://www.stratagene.com/
Boundary Court, Gatwick Rd., Crawley, West Sussex, 
RH10 9AX. Phone 01293 422 911 (orders) 999 (tech) 
http://www.qiagen.com/
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General Introduction - supplementary information.
The interaction of HIV envelope glycoproteins with CD4 and Chemokine 
receptors facilitates the viral entry process.
HIV and related retroviruses belong to a class of enveloped fusogenic viruses that 
include corona-, paramyxo- and orthomyxoviruses (e.g. influenza virus). It is known 
that the gp41 equivalent (envelope transmembrane) proteins o f  these viruses are 
similar in sequence, especially at their N-terminal fusion peptides, and that they are 
directly involved in membrane lusion. The gp41 ectodomain has the ability to form a 
coiled coil resembling that o f influenza haemagglutinin HA2 (Kowalski, Potz et al. 
1987, Lu, Blackow et a l  1995, Bullough, Hughson et al. 1994), supporting the idea 
that this class o f  viruses may share some common features o f virus entry. However, it 
is also known that the various enveloped viruses use differing modes o f entry; for 
example direct membrane penetration for HIV, and endocytosis for influenza virus. 
Even closely related viruses may use unique receptors, consequently the gpl20 
equivalent (exterior envelope) proteins are also specialised. For this reason there is no 
similarity in sequence, or structure, between the receptor binding portion o f HIV and 
that o f murine leukaemia retrovirus (Fass, Davey et al. 1997) for example. 
Mechanisms for receptor-mediated triggering o f fusion may also be virus-specific.
The sequential interaction o f the HIV gpl20, with CD4 and a chemokine receptor on 
the host cell surface initiates fusion o f the viral and cellular membranes. Entry o f  a 
primate immunodeficiency virus into the host cell involves binding o f  the gpl20 
envelope glycoprotein to the CD4 glycoprotein, which serves as the primary receptor. 
The role o f  gpl20 in the process o f fusion and entry is crucial. It locates the host cell, 
anchors the virus to the surface, and orientates the viral spike next to the target 
membrane. In addition gpl20 retains the trimeric gp41 in a metastable conformation 
and triggers the coordinated release o f the three gp41 N-terminal fusion peptides. 
Elucidation o f the gpl20 structure is therefore important for an understanding o f HIV 
infection and for the design o f therapeutic and prophylactic strategies.
The CD4 receptor has four immunoglobulin-like domains, and structures o f the two 
N-terminal domains (Ryu, Kwong et al. 1990, Wang, Yan et al. 1990) and the entire
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extracellular portion o f  CD4 (Wu, Kwong and Hendirckson 1997) have been 
determined. It is the most N-terminal o f the four Ig domains that is bound by gpl20. 
Mutagenesis o f  the CD4 structure analogous to the second Complementarity- 
Determining Region (CDR2) o f immunoglobulins has shown that it is critical for 
gpl20 binding (Moebius, Clayton et al. 1992; Sweet, Truneh et al. 1991). Conserved 
gpl20 residues important for CD4 binding have also been identified by mutagenesis 
(Kowalski, Potz et al. 1987; Olshevsky, Helseth et al. 1990; Cordonnier, Montagnier 
and Emerman 1989). CD4 binding induces conformational changes in gpl20, some 
either exposing or forming a binding site for specific chemokine receptors. These 
chemokine receptors, mainly CCR5 and CXCR4 for HIV-1, serve as obligate second 
receptors for virus entry (Moore 1997; Feng, Broder et al. 1996). The gpl20 third 
variable (V3) loop is the principal determinant o f chemokine receptor specificity 
(Speck, Wehrly et al. 1997). However, other more conserved gpl20 structures 
exposed on interaction with CD4 are apparently also involved in chemokine-receptor 
binding. This CD4-induced exposure is indicated by the enhanced binding o f  several 
gpl20 antibodies (Thali, Moore, et al. 1993; Sattentau, Moore et al. 1993) which, like 
V3-loop antibodies, efficiently block the binding o f gpl20-C D 4 complexes to the 
chemokine receptor (Wu, Gerard, et al. 1996). These are called CD4-induced (CD4i) 
antibodies. CD4 binding may trigger additional conformational changes in the 
envelope glycoproteins. For example, in some HIV-1 isolates the release o f gpl20 
from the complex is induced (Moore, McKeating et al. 1990) - although it is not clear 
why.
The structure o f an intermediate state in the fusion process, during which gpl20 is 
bound to CD4, and that o f a final ‘fusion-active’ state o f the gp41 ectodomain have 
been solved (Kwong, Wyatt et al. 1998; Chan, Fass et al. 1997; Weissenhom, Dessen 
et al. 1997). Kwong et al. reported the crystal structure at 2.5 A resolution o f a 
partially deglycosylated HIV-1 gpl20 core bound to a two-domain fragment o f the 
CD4 cellular receptor and to the antigen-binding fragment (Fab) o f an antibody, 17b, 
that was directed against a CD4i epitope. The neutralizing antibody, 17b, blocked 
chemokine-receptor binding. Their accompanying letter related this structure to the 
antigenic properties o f  gpl20 envelope proteins (Wyatt, Kwong et al. 1998). The 
structure revealed a cavity-laden C D 4-gpl20 interface, a conserved binding site for
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the chemokine receptor, evidence o f conformational change upon CD4 binding, the 
nature o f a CD4-induced antibody epitope, and specific mechanisms for immune 
evasion. Their results provided an insight into the mechanism o f  HIV entry into host 
cells.
CD4 binding orients the gpl20 surface implicated in chemokine receptor binding to 
face the target cell, and also forms and exposes the site itself -  possibly in a single, 
concerted shift in the relative orientation o f  the inner and outer domains. This 
conformational shift may alter the orientation o f  the N and C termini, at the proximal 
end o f the inner domain, perhaps partially destabilizing the oligomeric gpl20 / gp41 
interface (Moore, McKeating et al. 1990). Such a shift would also alter the relative 
placement o f  the V1/V2 stem (in the CD4i site) and the V3 loop, which emanate from 
the inner and outer domains respectively. The next step in HIV-1 entry is the 
interaction o f the gpl20-C D 4 complex with the chemokine receptor. Although 
interactions between CD4 and chemokine receptor may occur, it is most likely that 
direct gpl20 contacts dominate interaction with the chemokine receptor. As most o f 
the chemokine receptor is encased in the host membrane, binding moves the gpl20  
bridging sheet closer to the target membrane, a process requiring some CD4 flexibility 
(Wu, Kwong et al. 1997; Moir, Perreault et al. 1996). Chemokine-receptor binding is 
believed to trigger additional conformational changes in the HIV-1 envelope 
glycoprotein trimer that lead to exposure o f the gp41 ectodomain.
Details o f  the apo state o f core gpl20, the oligomeric structure, the interaction with 
the chemokine receptor, the conformational changes that trigger reorganization o f the 
gp41 ectodomain, and the structural basis for insertion o f  the fusion peptide o f gp41 
into the target membrane have yet to be determined.
Although gpl20 can elicit virus-neutralizing antibodies, HIV eludes the immune 
system. The highly conserved regions o f gpl20 create the structures necessary for 
interaction with the gp41 ectodomain and with receptors on the host cell. In addition 
five variable regions (V1-V5) have been identified within gpl20 (Starcich, Hahn et
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al. 1986). The first four form surface-exposed loops having disulphide bonds at their 
bases (Leonard, Spellman, et al. 1990). All regions o f gpl20  are extensively 
glycosylated (Leonard, Spellman, et al. 1990), and the combination o f variable 
regions and overall glycosylation help minimise the immunogenicity and antigenicity 
o f gpl20 (Profy, Salinas, et al. 1990). Analysis o f the antigenic structure o f gpl20 
shows that most o f the envelope protein surface is hidden from the immune system by 
glycosylation and oligomeric occlusion (Wyatt, Kwong, et al. 1998). Most broadly 
neutralizing antibodies access only two surfaces: one that overlaps the CD4-binding 
site (shielded by the VI/V2 loop), and another that overlaps the chemokine-receptor- 
binding site (shielded by the V2 and V3 loops). Conformational changes in the gpl20 
core provide additional mechanisms for evasion from immune surveillance. In the 
case o f  the CD4-binding surface, which contains a high proportion o f main-chain 
atoms in the complex, the conformation without CD4 bound may expose underlying 
side-chain variability. Escape may also be provided by the recessed nature o f the 
binding pocket (steric occlusion) and by a topographical surface mismatch, which 
encloses a variational island or ‘antihotspot’. Mechanisms may be similar in the 
chemokine-receptor region: conformational change may hide the conserved epitope 
(unformed before CD4 binding); steric occlusion may take place between the CD4 
anchored viral spike and the proximal target membrane; and an ‘anti-hotspot’ 
equivalent may camouflage chemokine-receptor-binding residues on the V3 loop in 
surrounding variability. Some o f  the means used to elude antibody-based defences 
may also help HIV avoid cellular immunity. The future design o f  an effective vaccine 
against HIV will likely depend on a thorough understanding o f  the means by which 
HIV evades the immune system.
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The development of Renin inhibitors.
The development o f  renin inhibitors is in some ways analogous to the development o f 
retroviral protease inhibitors, especially since both targets are aspartic proteases. 
Consequently it is interesting to consider, briefly, the renin field. Renin catalyses the 
first and rate limiting step in the renin-angiotensin cascade, ultimately leading to the 
production o f angiotensin II (All). It cleaves a single peptide bond in the plasma 
glycoprotein angiotensinogen, and in doing so releases the biologically inactive 
decapeptide angiotensin I (Al or ANGI). This in turn is the substrate for a second 
enzyme, Angiotensin Converting Enzyme (ACE), which releases the octapeptide 
angiotensin II (All or ANGII). All is involved in regulation o f  blood pressure. It is a 
strong vasoconstrictor and also indirectly stimulates the adrenal cortex, resulting in 
sodium and water retention. A ll’s role implicates it in the pathology o f  hypertension -  
a major risk factor for cardiovascular diseases such as stroke, myocardial infarction 
and heart failure. Cardiovascular diseases are the major cause o f  death in the Western 
world; consequently the entire renin-angiotensin cascade has been the subject o f much 
research. Renin’s position in the cascade (at the first, and rate limiting, step) 
combined with its unique substrate specificity (it cleaves only one known substrate -  
angiotensinogen) makes it an ideal target for therapeutic intervention. The renin- 
angiotensin system and its role in heart failure is explored by the reviews o f  Wollert 
and Drexler, and De Mello (Wollert and Drexler 1999; De Mello 2004).
Early renin inhibitors were based on prorenin sequences, pepstatin, or pepstatin 
analogues. Substrate analogues and inhibitors based on the enzyme-substrate 
transition state yielded more potent selective inhibitors o f renin. Studies in humans 
demonstrated that such compounds were effective when administered intravenously. 
However, all the early compounds exhibited poor bioavailability, and rapid 
elimination when administered orally. There are many reviews o f  the early 
developments o f this field (Antonaccio and Cushman 1981; Antonaccio 1982; Geiger 
1984; Luther, Stein, et al. 1989; Kleinert 1989; Wood, Cumin et al. 1994; Lin and 
Frishman 1996). Improvements in the pharmacokinetic properties o f renin inhibitors 
have recently been achieved by employing the structure based rational design 
techniques used to great effect in the retroviral protease field. The development o f a 
new class o f low molecular weight inhibitor, that does not incorporate the peptide 
backbone featured in previous inhibitors, was achieved using computer modelling and
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crystallographic structure analyses. The first compound in this class is Aliskiren, 
which has been shown to inhibit Al and All production in both sodium depleted 
marmosets and healthy human volunteers ((Nussberger, Wuerzner et al. 2002; Wood, 
Maibaum, et al. 2003). Subsequent clinical trials on patients with moderate 
hypertension have demonstrated that it is safe, orally active and effective at lowering 
blood pressure (Stanton 2003 (1); Stanton 2003 (2); Stanton, Jensen et al. 2003).
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Neutron Diffraction
Neutrons are neutral particles each with spin 1/2, a magnetic moment o f 1.9132 
nuclear magnetons, and a half-life o f  approximately 888 s. Having a magnetic 
moment causes them to be sensitive to magnetic ordering within a solid. Relative to 
X-ray diffraction, Neutron diffraction is a fairly new technique - the first neutron 
diffraction analysis o f  a protein structure was completed by Schoenbom in 1969 on 
myoglobin (Schoenborn 1969), and it is still quite uncommon. This is largely because 
it requires the generation o f  high thermal-neutron fluxes (a thermal neutron is defined 
as a neutron possessing a kinetic energy o f  about 0.025 eV). These can only be 
obtained from steady state nuclear reactors or from particle accelerators called 
spallation sources.
Steady State Reactors
A steady-state reactor is essentially a nuclear reactor with a core specially adapted to 
produce a maximum flux o f neutrons. The neutrons are produced by the nuclear 
fission o f  U. In this process more neutrons are released than are needed to maintain 
the reaction. The excess neutrons are very high energy “hot or fast neutrons” and must 
be cooled to generate the “thermal neutrons” suitable for diffraction. The cooling 
process takes place in a D2O or graphite moderator kept at a temperature o f 40°C. A 
monochromator is required to select the desired wavelength, resulting in a large loss 
o f neutron flux reaching the sample. The monochromator also provides a beam stop 
for fast neutrons and gamma-radiation, while a collimator reduces the beam 
divergence.
Spallation Sources
A Spallation source produces pulsed radiation (typically 25 - 50 Hz). When pulses o f 
high energy protons strike a tungsten or uranium target the result is an emission of 
neutrons in the order o f 20 to 25 per proton. The pulses are very short (~ 4 x 10-16 
ns). This allows a high flux and easy cooling. Neutron wavelength is selected by time- 
of-flight methods, by collecting data at a fixed Bragg angle as a function o f  neutron 
energy.
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The role o f Neutron Diffraction in Structural Biology.
Although X-ray diffraction has certain advantages over neutron diffraction - one being 
the much higher intensity o f  the sources available (the greater intensity o f  X-ray 
sources allows the use o f smaller crystals and facilitates solution o f  the phase 
problem) - the principle distinction between X-ray and Neutron diffraction involves 
the location o f  hydrogen atoms. Since X-rays are scattered by the atomic electron 
cloud, atoms with fewer electrons scatter X-rays less effectively. Hydrogen atoms can 
therefore only be detected by high precision experiments -  impossible in the case o f 
macro molecular crystallography. It is also difficult to distinguish neighbouring atoms 
o f the same row o f the periodic table and impossible to distinguish between different 
isotopes o f the same element.
Hydrogen represents half o f  all the atoms in a typical protein, yet a survey o f  the PDB 
revealed that only one percent o f proteins crystallise well enough to provide sufficient 
resolution to detect hydrogen atoms using synchrotron X-ray beams.
The greatest advantage o f neutron diffraction over X-ray diffraction is its ability to 
establish the exact position o f  hydrogen atoms. Since neutron beams interact more 
strongly with nuclei than do x-rays, neutron diffraction is more useful than x-ray 
diffraction for determining proton positions. Neutron diffraction can provide data 
concerning the hydrogen bonds or protonation states o f histidine and acidic residues -  
as demonstrated with lysozyme (Mason, Bentley and McIntyre 1984), the 
conformations o f  methyl groups, the solvent structure o f  the protein, and the degree o f  
protection o f  particular hydrogen atoms within the structure. An accurate analysis o f 
hydrogen bonding is importance for a complete understanding a protein’s structure 
and activity, and erroneous hydrogen bonding schemes can result from X-ray data due 
to incorrect assignment o f histidine or amide group orientation through an inability to 
detect hydrogen. Therefore neutron diffraction’s ability to directly determine 
hydrogen / deuterium positions is o f immense value for protein structure 
determination. However, determination o f  the positions for twice as many atoms - 
usually with less observed data - than in the case o f X-ray diffraction creates 
additional experimental complexity.
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Since neutrons interact with a solid to a much lesser degree than X-rays they therefore 
possess advantages when studying materials that are damaged by X-rays (such as 
protein crystals) and in cases where a large penetration depth is desired. Exposure to 
an X-ray beam leads to radiation induced crystal decay, resulting from the generation 
o f free radicals and their diffusion through the crystal lattice (Blundell and Johnson 
1976). Consequently either several crystals, or cryogenic techniques, may be 
necessary for X-ray protein structure determination. Neutrons, however, do not 
damage protein crystals so that complete data sets can be collected from a single 
crystal, and without the need to freeze it. The use o f a single crystal is desirable 
because it eliminates the possibility o f scaling errors that might lead to the 
introduction o f  artefacts in electron density maps refined using data collected from 
multiple crystals. It is also easier to grow a single good crystal, than multiple good 
crystals. However, since the bulk o f neutrons in a beam will pass through a sample 
without interaction, neutron diffraction requires high flux and large crystals in order to 
produce sufficient data. A larger crystal provides a greater probability o f  interaction 
between the atoms within the crystal and the neutrons passing through it.
Crystal growth remains the bottleneck for protein structure determination by any 
diffraction method, but for neutron diffraction the problem is exacerbated by the 
requirement for much larger crystals than those suitable for X-ray techniques. Recent 
advancements in neutron diffraction methods and instrumentation are beginning to 
allow the use o f much smaller crystals or the determination o f much larger unit cells. 
While the early neutron diffraction experiments used crystals up to 30 mm , single 
crystals with a volume o f  1 mm3 can now be studied. Since the inception o f protein 
crystallisation experiments in space on board the U.S. Space Shuttle Columbia in 
1995 and on the Russian Mir space station in the late 1990s, the growth o f larger 
crystals in low gravity has become more common. Proposals have been submitted to 
NASA to grow large crystals for neutron studies in the International Space Station. 
Techniques for growing crystals under conditions o f microgravity on earth are also 
being developed. For most proteins though, it is still difficult to obtain crystals large 
enough for neutron diffraction measurement.
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An additional complication is that in comparison with X-ray diffraction there is an 
increased contribution o f  solvent scattering effects, and overall scattering is much 
higher for neutron diffraction than for X-ray diffraction. For hydrogen atoms most o f 
the scattering is incoherent and thus does not contribute to the reflection intensity but 
only to the background, and is the major source o f background for neutron diffraction. 
A solution involves replacement o f hydrogen atoms by deuterium atoms to reduce the 
background noise and simultaneously increase the coherent scattering power (i.e. that 
which contributes to reflection intensity) in neutron diffraction. For this reason the 
substitution o f hydrogen with deuterium by soaking crystals in D2O for long periods 
(often many months), and more recently the growth o f  perdeuterated crystals 
(Gamble, Clauser and Kossiakoff, 1994) has been necessary to reduce background. In 
order to obtain fully perdeuterated protein, large quantities are expressed in E. coli 
grown using minimal medium containing deuterated amino acids and deuterated 
water. Crystallisation conditions, space group and cell parameters have been 
demonstrated to be the same for both native and perdeuterated forms o f a protein and 
no significant structural differences between the forms are observed.
X-ray and neutron diffraction techniques are in many senses complementary and used 
together they represent the most effective direct method for the determination o f  
protein structures. Consequently neutron diffraction studies are usually carried out in 
conjunction with X-ray diffraction experiments. The X-ray model can be used as a 
starting point for a separate refinement o f the neutron data - either with or without the 
calculated hydrogen positions (Kossiakoff and Spencer 1981; Phillips and Schoenbom 
1981), or the two data sets can be used for a simultaneous joint refinement 
(Wlodawer, Walter, et al. 1984).
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At present very few protein structures have been solved using neutron diffraction. 
However, with more neutron diffraction facilities becoming available worldwide that 
could soon change. One such new facility, the Spallation Neutron Source (SNS), is 
due to be completed in 2006. It will be ten times brighter than existing neutron 
facilities and ideal for atomic-resolution protein crystallography studies. Neutron 
diffraction studies o f protein structures are also being facilitated by the availability o f 
improved neutron detectors that speed up data collection and by improvements in the 
ability to grow larger crystals. It is estimated that within a decade the number o f 
protein structures determined annually using neutron diffraction could reach 50-100, 
although this is still a very small proportion o f the structures solved by X-ray 
diffraction. It is likely that due to the larger experimental cost and effort required, 
neutron diffraction will remain limited in its use, and will predominantly be applied to 
the resolution o f specific issues, where X-ray diffraction is inappropriate.
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Low Barrier Hydrogen Bonds
The concept o f  a LBHB was introduced by Cleland following observation o f low 
hydrogen fractionation factors for certain enzymes. He suggested that the potential 
energy surface o f some hydrogen bonds is a double well potential with a low barrier 
(~2 kcal/mol) toward hydrogen transfer, which he termed a Low-Barrier Hydrogen 
Bond (Cleland 1992). Gerlt and Gassman (Gerlt and Gassman 1993, Biochemistry) 
also suggested the presence o f special hydrogen bonds, proposing a scenario in which 
the hydrogen resides midway between the proton acceptor and donor. Cleland and 
Kreevoy suggested that LBHBs could prove to be very strong, with bonding energy as 
high as 10-20 kcal/mol, effectively making them covalent bonds (Cleland and Krevoy 
1994), hence the alternative name Short-Strong Hydrogen Bond (SSHB). 
Investigations o f  the presence and properties o f LBHBs have ensued. In general they 
are characterised by great strength, short length, and potential surfaces having a very 
small (if  any) barrier to proton migration. It is proposed that they are formed from a 
conventional hydrogen bond when the proton donor is positively charged, or the 
acceptor is negatively charged, (hence they may also be called positive-ion or 
negative-ion hydrogen bonds). When hydrogen bonds are as short as 2.5 -  2.6 A the 
proximity o f  the donor and acceptor atoms reduces the energy barrier which normally 
prevents transfer o f the hydrogen from the donor to the acceptor group. Theoretical
calculations on the system (O H+ O) suggest that the potential energy barrier
becomes less than 5 kcal mol-1 when the O O distance is less than 2.8A, thus
permitting easy proton transfer. This allows rapid exchange o f  the proton between 
donor and acceptor to occur, and it is this proton mobility that may be o f significance 
mechanistically. LBHBs are o f particular interest to biologists because it has been 
hypothesised that they are involved in enzyme catalysis (Cleland 1992; Cleeland and 
Kreevoy 1994; Frey, Whitt and Tobin 1994), and that their formation may stabilize 
the intermediates and / or transition states o f enzymatic reactions (Cleland 1992; Gerlt 
and Gassman 1993; Cleland and Krevoy 1994; Frey, Whitt and Tobin 1994; Tobin, 
Whitt et a l  1995; Cassidy, Lin and Frey 1997; Zhao, Abeygunawardana et a l  1996; 
Zhao, Abeygunawardana et a l  1997; Tong and Davis 1995; Hur, Leja and Dunn 
1996; Kahyaoglu, Haghjoo et a l  1997) explaining why an enzyme is able to bind 
intermediates or transition states more tightly than the original substrate. While there 
is increasing evidence to support this idea, it has not been without controversy 
(Scheiner 1992; Warshel, Papazyan and Kollman 1995; Warshel and Papazyan 1996).
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Materials and methods - supplementary information.
pRSET vector system for the expression of recombinant proteins.
The pRSET system (fig. 1) from Invitrogen (www. invitro gen.com) is designed to
allow high level expression o f genes in E.coli and subsequent purification o f 
expressed protein by IMAC. The pUC derived vectors contain a strong T7 phage 
promoter and a multiple cloning site which allows genes to be inserted down stream 
o f and in frame with a sequence encoding an N-terminal fusion peptide. This fusion 
consists o f a polyhistidine tag (allowing IMAC), a transcript stabilising sequence from 
gene 10 o f page T7, an Anti-Xpress epitope, and an enterokinase cleavage recognition 
sequence (which allows later enzymatic removal o f the N-terminal fusion peptide). 
Three versions o f the pRSET vector are available (designated A, B, and C) which 
differ only in a single variable region designed to allow cloning into each o f the three 
possible reading frames whilst maintaining the correct fusion sequence. Version B 
was used throughout this project. The T7 promoter is recognised by T7 RNA 
polymerase, which must be expressed by the host strain (either via IPTG induction o f 
the polymerase gene carried on the DE3 bacteriophage lambda lysogen incorporated 
in some strains, or as a result o f  deliberate infection by phage expressing the 
polymerase). Strains incorporating the DE3 lysogen were used for any work involving 
this system described herein (specifically BL21(DE3) unless otherwise stated). Such 
strains always exhibit a basal level o f  T7 RNA polymerase expression, which can 
result in premature expression o f  the target protein. T7 lysozyme is able to bind T7 
polymerase and inhibit transcription, thus the incorporation o f  the pLysS plasmid 
(confering chloramphenicol resistance), which encodes T7 lysozyme, can be used to 
minimise unwanted polymerase activity prior to induction. Additionally the T7 
lysozyme is able to cleave the peptidoglycan layer o f the E.coli cell wall and thus aids 
cell lysis, especially when used in conjunction with freeze thawing o f harvested cells.
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Figure 1 The pRset vector map and polvlinker region sequence.
3 C O oB?
CD -C  CD O ) oo
C Q > < C O C Q Q .Q . iC ^U jO Q 3 ;
RBS ATG 6xHis X press Epitope EK MCS
Comments for pRSET A 
2897 nucleotides
T7 promoter: bases 20-39 
6x His tag: bases 112-129 
T7 gene 10 leader: bases 133-162 
Anti-XpressIM epitopre: bases 169-192 
Multiple cloning site: bases 202-248 
pRSET reverse priming site: bases 295-314 
T7 transcription terminator: bases 256-385 
fl origin: bases 456-911 
hla promoter: bases 943-1047
Ampicillin (bla) resistance gene (ORF): bases 1042-1902 
pUC origin (C): bases 916-2852 
(C) = Complementary strand
♦Version C does not contain Sac I
T7 promoter RBS
AATACGACTC ACTATAGGGA GACCACAACG GTTTCCCTCT AGAAATAATT TTGTTTAACT TTAAGAAGGA
Polyhistidine (6xHis) region
GATATACAT ATG CGG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT 
Met A rg  G ly  S e r  H is  H is  H is  H is  H is  H is  G ly  M et A la  S e r  M et T h r
T7 gene 10 leader Xpress™ Epitope BamH 1
"I t
Xho I Sac I i i
GGT GGA CAG CAA ATG GGT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT qCG AGC TCG 
G ly  G ly  G in  G in  M et G ly  A rg  A sp Leu T y r (A sp A sp A sp A sp L y s jA s p  P ro  S e r  S e r
EK recognition site EK cleavage site 
Bgl II Pstl Pvu II K pnlN col EcoR I BstBl HindUl
I i t  \  1 1 i
AGA TCT GCA GCT GGT ACC ATG GAA TTC GAA GCT TGA TCCGGCTGCT AACAAAGCCC 
A rg  S e r  A la  A la  G ly  T h r  M et G lu  Phe G lu  A la  ***
pRSET reverse priming site 
GAAAGGAAGC TGAGTTGGCT GCTGCCACCG CTGAGCAATA ACTAGCATAA
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Results chapters -  supplementary information.
SPA assay data.
Explanation of appendix tables 1 to 5.
The tables 1-5 show raw data for SPA assays carried out on fractions collected during 
purification o f  H IV -1 and HIV-2 proteases, as described in the text o f chapters 3 and 
4. Tables 1 and 2 relate to the elution o f HIV-1 PR from an S-200 Size exclusion 
column, table 3 to the elution o f HIV-2 PR from the same column. Table 4 refers to 
the elution o f HIV-2 PR from a Phenyl Sepharose column, and table 5 to the elution 
o f HIV-2 PR from an S-Sepharose column. The following abbreviations / symbols 
were used in these tables.
Bg Background counts, data collected from empty vials.
0% Control samples containing buffer and protein but no SPA reagent. Such 
samples produce no scintillation, and any counts are the result o f background
100% The maximum scintillation counts possible, determined by counting vials 
containing buffer and SPA reagent, but no protease sample.
Rep. Repetition (ie. a duplicate sample reading).
Samples were represented by their fraction numbers and were counted in duplicate 
(reps 1 - 2 )  and an average taken. Multiple background counts were made and an 
average taken. 0% and 100% controls were distributed at the start, middle, and end o f  
the run to account for any possible instrumental drift, and an average figure for each 
was calculated. In table 2 the average background count was subtracted from each o f 
the average sample counts and the result expressed as a percentage o f total possible 
scintillation. The higher the value for “% uncut SPA substrate”, the lower the level o f  
activity in the sample. The % relative activity for each sample was obtained by 
subtracting the figure for % uncut SPA substrate from 100. A high value for this 
figure indicates a greater proteolytic activity in the fraction. It can therefor be seen 
that fraction 10 in table 2 contains the most protease activity. In subsequent analyses 
(tables 3-5) a single count was taken for each sample, at the start and end o f  the 
incubation period, and the relative activity was calculated as described here.
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Table 1 HIV-1 PR SPA raw data (Chapter 3 Figure 4).
See page 342 for explanation o f  Appendix tables 1-5, and see also Chapter 3, figure 4, 
page 192.
Detection o f  H IV -1 PR activity by SPA assay.
Scintillation counts for fractions eluted from Sephacryl 200 column.
Fraction no. Rep. 1 Rep 2 Averages
& controls Counts per minute (CPM) CPM
0% 2 5 0 0 161 93.00
100% 10963.16 10976.84 10970.00
1 10283.00 10196 10239.50
2 9576.00 9551 9563.50
3 11808.24 12228.24 12018 24
4 10464.00 9983 10223.50
5 11016.84 10916.84 10966.84
6 9714.00 9817 9765.50
7 6765.00 6868 6816.50
8 3218.00 3331 3274.50
9 2539.00 2665 2602.00
100% 11323.33 11132.22 11227.78
100% 13560.00 13141.25 13350.63
10 2181.00 2233 2207.00
11 3145.00 3069 3107.00
12 2436.00 2314 2375.00
13 2313.00 2335 2324.00
14 3010.00 3029 3019.50
15 3398.00 3267 3332.50
16 4152.00 4117 4134.50
17 4348.00 4242 4295 00
18 5718.00 5975 5846 50
19 7530.00 8133 7831 50
100% 10951.58 10307 10629 29
100% 10808.42 9692 10250.21
20 8629.00 8508 8568.50
21 8575.00 8683 8629.00
0% 15 00 24 19.50
Background (Bg) 33.00 16.00 24.50
Bg 16.00 86.00 51.00
Bg 45.00 39.00 42.00
Bg 118.00 74.00 96.00
Bg 67.00 72 00 69.50
Bg 20.00 31 00 25.50
Bg 38.00 22 00 30.00
Average Bg 48.14 48.57 48.36
Average 0% 20 92.5 56.25
Average 100% 11521.3 11049.86 11285.58
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Table 2 HIV-1 PR SPA relative activity data (Chapter 3 Figure 4).
See page 342 for explanation o f  Appendix tables 1-5, and see also Chapter 3, figure 4, 
page 193.
Detection of HIV-i PR activity by SPA assay.
Calculation of relative protease activity for each fraction.
Fraction CPM CPM - Bg % uncut SPA substrate % relative activity
1 10239.50 10191.14 90.75 9.25
2 9563.50 9515.14 84.73 15.27
3 12018.24 11969.88 106.59 -6.59
4 10223.50 10175.14 90.61 9.39
5 10966.84 10918.48 97.23 2.77
6 9765.50 9717.14 86 53 13.47
7 6816.50 6768.14 60.27 39.73
8 3274.50 3226.14 28.73 71,27
9 2602.30 2553.94 22.74 77.26
10 2207.00 2158.64 19.22 80.78
11 3107.00 3058.64 27.24 72.76
12 2375.00 2326,64 20.72 79.28
13 2324.00 2275.64 20.27 79.73
14 3019.50 2971.14 26.46 73.54
15 3332.50 3284.14 29.25 70.75
16 4134.50 4086.14 36.39 63.61
17 4295,00 4246.64 37.82 62.18
18 5846.50 5798.14 51.63 48.37
19 7831.50 7783.14 69.31 30.69
20 8568.50 8520.14 75.87 24.13
21 8629.00 8580.64 76.41 23.59
100% 11285.58 11237.22 100 0
0% 56.25 7.89 0 100
1% 112.2933 112.2933 1 99
Where:-
1% = (CPM 100% - CPM 0%) /100  
% relative activity = 100 - % uncut SPA substrate
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Table 3 HIV-2 PR SPA raw and relative activity data (Chapter 4 Figure 4).
See page 342 for explanation o f  Appendix tables 1-5, and see also Chapter 4, Figure 
4, page 214.
Detection o f HIV-2 PR activity by SPA assay.
Scintillation counts for fractions eluted from Sephacryl 200 column.
Fraction no. Time zero 12 hrs @ 37 C Difference % activity
& controls Counts / min Counts / min
1 16043.08 14717.15 1325.93 8.1
2 14795.72 12927.51 1868.21 11.3
3 16415.40 15380.01 1035.39 6.3
4 14848.59 13698.68 1149.91 7.0
5 16392.33 15285.74 1106.59 6.7
6 15091.45 12220.02 2871.43 17.4
7 16253.87 14109.36 2144.51 13.0
8 17443.36 13430.69 4012.67 24.4
9 17811.70 13058.78 4752.92 28.9
10 18574.58 11420.02 7154.56 43.5
11 18632.79 10225.02 8407.77 51.1
12 16828.38 9525.03 7303.35 44.4
13 16524.66 8337.02 8187.64 49.7
14 16441.59 8602.03 7839.56 47.6
15 15720.05 10164.03 5556.02 33.7
16 14892.89 13690.71 1202.18 7.3
17 15002.93 14591.48 411.45 2.5
18 15680.08 15972.37 -292.29 -1.8
19 14607.22 15178.63 -571.41 -3.5
Bg 19.00 14.00 15.00 12.00
0% 22.00 21.00 23 20
100% 15430.83 16358.47 16811.74 17343.34
Avg Bg 15.0
Avg. 0% 21.5
Avg. 100% 16486.1
Maximum difference 16464.6
1% activity 164.65
1% = (CPM 100% - CPM 0%) /100  
% relative activity = 100 - % uncut SPA substrate
Table 4 HIV-2 PR SPA raw and relative activity data (Chapter 4 figure 7).
See explanation o f  Appendix tables 1-5, page 342; and Chapter 4, fig. 7, page 218.
Detection of HIV-2 PR activity by SPA assay.
Scintillation counts for fractions eluted from Phenyl Sepharose column.
Fraction Max. CPM Sample CPM Difference % activity
1 8057.79 8542.01 -484.22 -2.9
2 8057.79 7748.01 309.78 1.9
3 8057.79 7208.01 849.78 5.2
4 8057.79 8192.01 -134.22 -0.8
5 8057.79 7099.01 958.78 5.8
6 8057.79 8382.01 -324.22 -2.0
7 8057.79 7499.02 558.77 3.4
8 8057.79 8919.02 -861.23 -5.2
9 8057.79 8590.02 -532.23 -3.2
10 8057.79 8235.02 -177.23 -1.1
11 8057.79 5904.02 2153.77 13.1
12 8057.79 1694.01 6363.78 38.7
13 8057.79 2747.01 5310.78 32.3
14 8057.79 3794.01 4263.78 25.9
15 8057.79 4564.02 3493.77 21.2
16 8057.79 5614.02 2443.77 14.8
17 8057.79 7655.03 402.76 2.4
18 8057.79 7051.03 1006.76 6.1
19 8057.79 7242.03 815.76 5.0
20 8057.79 6911.03 1146.76 7.0
21 8057.79 7229.04 828.75 5.0
Repetitions
Bg 18.00 14.00 16.00
0% 15.00 14.00 16.00
100% 7680.00 9185.05 8164.05 7202.04
Avg Bg 16.00
Avg. 0% 15.00
Avg. 100% 8057.79
Maximum difference 8042.785
1 % activity 80.43
1% = (CPM 100% - CPM 0%) / 100 
% relative activity = 100 - % uncut SPA substrate
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Table 5 HIV-2 PR SPA raw and relative activity data (Chapter 4 figure 9).
See explanation o f  Appendix tables 1-5 page 342, and Chapter 4, figure 9 page 221.
Peak No. Fraction CPM CPM-BG % uncut % relative activity
1 1 7490 7478 101 -1
1 2 7441 7429 100 0
1 3 7646 7634 103 -3
2 4 6636 6624 89 11
2 5 6090 6078 82 18
3 6 2708 2696 36 64
3 7 3085 3073 41 59
3 8 3039 3027 41 59
3 9 2976 2964 40 60
3 10 3492 3480 47 53
3 11 4331 4319 58 42
3 12 5302 5290 71 29
3 13 4796 4784 65 35
3 14 5615 5603 76 24
3 15 4695 4683 63 37
4 16 5132 5120 69 31
4 17 5568 5556 75 25
5 18 5548 5536 75 25
5 19 6357 6345 86 14
6 20 5206 5194 70 30
6 21 4699 4687 63 37
6 22 5383 5371 73 27
7 23 5240 5228 71 29
8 24 6142 6130 83 17
8 25 5467 5455 74 26
8 26 7423 7411 100 0
9 27 7912 7900 107 -7
9 28 6846 6834 92 8
9 29 9517 9505 128 -28
9 30 7006 6994 94 6
Max
Backgd 0% (100%) 1% 
12 23 7406 74.06
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Chromogenic activity assay data.
Explanation of appendix tables 6 to 8.
The content o f tables 6 to 8 (pages 349-351) represents the raw data for chromogenic 
activity assays carried out on both mutant heterodimer HIV-2 PR and native HIV-2 
PR, as described in the text o f Chapter 5 and illustrated in figure 23 (page 266) o f  the 
same chapter.
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Table 6 Analysis of mutant HIV-2 PR for activity (Chapter 5 figure 23).
For explanation see page 348, and see Chapter 5, figure 23, page 266.
His /  Cvs
SimDle Mix activity assav  
HIV-2 PR m utan t heterodim er vs su b s tra te  VII
0 M NaCI
qH Abs 0 hrs Abs 20 hrs Abs. Diff. % Rel. Act. Ava. Rel. Act.
4 0.040 0.047 -0.007 -17 .5 -16.6
4 0.038 0.044 -0.006 -15 .8
5 0.041 0.044 -0.003 -7 .3 -8 .4
5 0.042 0.046 -0 .004 -9.5
6 0.042 0.049 -0.007 -16 .7 -13.0
6 0.043 0.047 -0 .004 -9.3
7 0 .044 0.049 -0.005 -11 .4 -9.3
7 0.042 0.045 -0.003 -7.1
8 0.060 0.069 -0 .009 -15 .0 -13.1
8 0.054 0.060 -0 .006 -11.1
1 M NaCI
m Abs 0 hrs Abs 20 hrs Abs. Diff. % Rel. Act. Ava. Rel. Act.
4 0.042 0.046 -0 .004 -9 .5 -4 .8
4 0.046 0.046 0.000 0.0
5 0.040 0.045 -0.005 -12 .5 -9 .8
5 0.042 0.045 -0.003 -7.1
6 0.039 0.040 -0.001 -2 .6 -5.8
6 0.044 0.048 -0 .004 -9.1
7 0.046 0.052 -0 .006 -13 .0 -8.6
7 0.047 0.049 -0 .002 -4.3
8 0.059 0.063 -0 .004 -6 .8 -9.2
8 0.052 0.058 -0 .006 -11 .5
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Table 7 Analysis of mutant HIV-2 PR for activity (Chapter 5 figure 23).
For explanation see page 348, and see Chapter 5, figure 23, page 266.
Refolded m ixture activity a ssav  
His /  Cvs HIV-2 PR m utan t heterod im er vs su b s tra te  VII
q H
0 M NaCI
A bs 0 hrs Abs 20  hrs Abs. Diff. %  Rel. Act. Ava. Rel. Act.
4 0.059 0.061 -0 .002 -3 .9 -16 .4
4 0.045 0.058 -0.013 -28.9
5 0.047 0.054 -0.007 -15 .8 -13 .9
5 0 .050 0.056 -0 .006 -12.0
6 0.071 0.078 -0.007 -10.5 -8 .2
6 0.068 0.072 -0 .004 -5 .9
7 0 .077 0.079 -0 .002 -2 .6 -2 .6
7 0 .086 0.088 -0 .002 -2 .6
8 0.080 0.081 -0.001 -1.3 -5 .3
8 0.075 0.082 -0.007 -9.3
q H
1 M NaCI
A bs 0 hrs A bs 20  hrs Abs. Diff. %  Rel. Act. Ava. Rel. Act.
4 0.065 0.070 -0 .005 -7 .7 -6 .6
4 0.081 0.085 -0 .004 -5 .5
5 0.062 0.076 -0 .014 -21 .7 -11 .7
5 0.058 0.059 -0.001 -1 .7
6 0.044 0.049 -0 .005 -10 .9 -12 .7
6 0.043 0.049 -0 .006 -14 .6
7 0.049 0.054 -0 .005 -10 .0 -7 .9
7 0.053 0.056 -0.003 -5 .9
8 0.062 0.062 0.000 -0 .2 -4 .4
8 0.058 0.063 -0 .005 -8 .6
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Table 8 Analysis of control HIV-2 PR for activity (Chapter 5 figure 23).
For explanation see page 348, and Chapter 5, figure 23, page 266.
Control activity a s sa v
HIV-2 PR vs s u b s t r a te  VII
0 M NaCI
QtL Abs 0 s Abs 180 s Abs. Diff. % Ret. Act. Ava. Rel. Act.
4 0 .072 0.068 0 .004 5.6 7.6
4 0 .073 0.066 0.007 9.6
5 0 .124 0.110 0 .014 11.3 8.9
5 0 .107 0.100 0.007 6.5
6 0 .097 0.090 0 .007 7.2 5.0
6 0 .071 0.069 0.002 2.8
7 0 .055 0 .054 0.001 1.8 -1 .9
7 0 .053 0.056 -0 .003 -5 .7
8 0 .073 0.075 -0 .00 2 -2 .7 -4 .3
8 0 .068 0.072 -0 .00 4 -5 .9
1 M NaCI
qH Abs 0 s Abs 180 s Abs. Diff. % Rel. Act. Ava. Rel. Act.
4 0.045 0.037 0 .008 17.8 16.3
4 0 .047 0.040 0 .007 14.9
5 0 .055 0.045 0 .010 18.2 16.9
5 0 .051 0.043 0 .008 15.7
6 0 .089 0.084 0 .005 5.6 12.4
6 0 .052 0.042 0 .010 19.2
7 0 .063 0.063 0 .000 0.0 -0 .6
7 0 .078 0.079 -0 .001 -1 .2
8 0 ,112 0.114 -0 .00 2 -1 .8 -1 .5
8 0 .089 0.090 -0 .001 -1 .1
351
Further Reading
Table 9 Some useful crystallography texts
• Crystallography Made Crystal Clear (Rhodes 1993)
•  Crystal Structure Analysis (Glusker and Trueblood 1985)
• Practical Protein Crystallography (McRee 1999)
• Crystallographic Methods And Protocols (Jones, Mulloy et al. 1996)
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